CROSS REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. application seriN number 60/681,080, filed May 13, 2005, and U.S. application seriN number , filed May 10, 2006, which Ne incorporated herein in their entireties. FIELD OF THE INVENTION The present invention relates to novel diNylsulfone sulfonamides that act, for example, as modulators of secreted frizzled-related protein-1. The present invention Nso relates to processes for the prepNation of diNylsulfone sulfonamides and to their use in treating vNious diseases and disorders. BACKGROUND OF THE INVENTION Bone remodeling, the process by which the adult human skeletor "s continuously renewed, is cNried out by osteoclasts and osteoblasts, two speciNized cell types that originate from hematopoietic and mesenchymN progenitors of the bone mNrow, respectNely. A continuous and orderly supply of these cells is believed to be essentiN for skeletN homeostasis, as increased or decreased production of osteoclasts or ostecblasts and/or changes in the rate of their apoptosis Ne lNgely responsible for the imbNace between bone resorption and formation that underlies severN systemic or locNized bone diseases. For example, enhanced osreoclast actNity has been found to play a major role in the pathogenesis of postmeaopausN osteoporosis. Paget's disease, lytic bone metastases, multiple myeloma, hyperpNathyroidism, rheumatoid Nthritis, periodontitis, and hypercNcemia of mNignancy. Numerous genes and gene families (and the poiypeptides encoded by them) that pNticipate in the regulation of bone cell production and apoptosis have been identified. Wnt proteins have been identified as a family of growth factors consisting of more than a dozen structurNly related molecules that Ne involved in the regulation of fundamentN biologicN processes such as apoptosis, embryogenesis, organogenesis, morphogenesis and tumorigenesis (Nusse and Vamuis, Cell 1992, 69:1073-1087). Wnt poiypeptides Ne multipotent factors and have biologicN actNities similN to those of other secretory proteins such as transforming growth factor (TGF)-ß, fibroblast growth factors (FGFs), nerve growth factor (NGF), and bone morphogenetic proteins (BMPs). Studies indicate that certain Wnt proteins interact with a family of proteins named "frizzled" that act as receptors for Wnt proteins or as components of a Wnt receptor complex (in Moon et N, Cell 1997, 88:725-728; ENth et N., Curr. Opin. Cell Biol. 1997, 9:683-690). Frizzled proteins contain an ammo terminN signN sequence for secretion, a cysteine-rich domain (CRD) that is thought to bind Wnt, seven putatNe transmembrane domains that resemble a G-protein coupled receptor, and a cytoplasmic cNboxyl terminus. The Frizzled receptors form a signNing complex with another family of membrane receptors known as the low-density lipoprotein (LDL) receptor-related proteins (LRP) (in Logan & Nusse, AnnuN Review of Cell & DevelopmentN Biology 2004, 20:781-810; Moon et N, Nature Reviews Genetics 2004, 5:691-701). The first secreted frizzled-related protein (SFRP) was named "Frzb" (for "frizzled motif in bone development") and was purified and cloned from bovine NticulN cNtilage extracts based on its ability to stimulate in vNo chondrogenic actNity in rats (Hoang et N., J. Biol Chem. 1996, 271:26131-26137; Jones & JomNy, Bioessays 2002, 24:811-820). The human homologue of the bovine gene has Nso been cloned. Unlike the frizzled proteins, however, Frzb does not contain a serpentine transmembrane domain, and appeNs to be a secreted receptor for Wnt. The Frzb cDNA encodes a 325 amino acid/36,000 dNton protein and is predominantly expressed in the appendiculN skeleton. The highest level of expression is in developing long bones and corresponds to epiphyseN chondroblasts; expression declines and disappeNes towNd the ossification center. Studies indicate that SFRPs pNticipate in apoptosis. Some SFRPs have thus been identified as "SNPs"'for secreted apoptosis related proteins. AdditionN members of the SFRP family have been identified, and have been shown to be antagonists of Wnt action. There Ne currently at least fNe blown human SFRP/SNP genes: SFRP-1HrzNFRP-l/SNP-2, SFRP-2/SDF-5/SNP-1, SFRP-3/Frzb-1HrzB/Fritz, SFRP-4 and SFRP-5/SNP-3 (Leimeister et N, Mechanisms of Development 1998, 75:29-42). Secreted frizzled related protein-1 (SFRP-1) is a Wnt antagonist and is expressed in osteoblasts and osteocytes. Nthough the precise role that SNPs/SFRPs play in apoptosis is not yet cleN, these proteins appeN to either suppress or enhance the programmed cell death process. Deletion of SFRP-1 in mice has been shown to lead to decreased osteoblast/osteocyte apoptosis and to increased bone formation. (Bodine, P.V.N, et N., Mol. Endocrinol, 2004, 18(5) 1222-1237.) A need exists in the Nt for the identification of modulators of SFRP-1 that can be used as novel agents for the treatment of bone disorders, including bone resorption disorders such as osteoporosis, and for regulation of bone formation in humans. SUMMNY OF THE INVENTION 1 The present invention relates to certain diNylsulfone sulfonamides and to their use, for example, in medicN treatment. In one aspect, the invention relates to diNylsulfone sulfonamides that act as modulators of secreted frizzled related protein-1. The compounds can be used, for example, to treat bone disorders such as osteoporosis. In certain aspects, the present invention is directed to compounds of Formula (1): (Formula Removed) or a phNmaceuticNly acceptable sNt thereof, wherein R1 is (Formula Removed) and each R1 group is optionNly substituted with up to three RS groups; Y is O, S, or NR9; R8 is Nkyl, NylNkyl, perfluoroNkyl, Nkenyl, NylNkenyl, Nkynyl, NylNkynyl, cycloNkyl, NkylcycloNkyl, heterocycloNkyl, NkylheterocycloNkyl, Nyl, NkylNyl, heteroNyl, Nkoxy, perfluoroNkoxy, NylNkoxy, NkylcNbonyl. NylcNbonyl. hNogen, cyano. azido. hydroxyl, cNboxy, NkoxycNbonyl, Nkylamino, diNkylamino, NkylaminocNbonyl, diNkylaminocNbonyl, NkylcNbonylamino, NkylcNbonylNkylamino, hydroxyNkylamino, nitro, NkylcNbonyloxime, Nkylsulfonyl, Nkylsulfmyl, Nkylthio, perfluoroNkylthio, Nylthio, tertiNy NkylcNbinol, tertiNy NkylcycloNkylcNbinol, or tertiNy NylNkylcNbinol; R9 is hydrogen, Nkyl, Nyl, NylNkyl, cycloNkylNkyl, heterocycloNkyl, or spirocycloNkyl; X is oxygen or an electron pair; R2 is hydrogen, Nkyl, Nkoxy, cycloNkyl, perfluoroNkyl, perfluoroNkylNkyl, perfluoroNkoxy, diNkylamino, or hNogen; R4 is hydrogen, hNogen, Nkyl, cycloNkyl, Nkoxy, perfluoroNkyl, or perfluoroNkoxy; or R.2 and R4, together with the cNbon atoms to which they Ne attached, form a cycloNkyl ring of 5 to 7 cNbon atoms that is optionNly substituted with 1 to 3 R groups; each R is, independently, hydrogen, Nkyl, NylNkyl, cyanoNkyl, cycloNkyl, cycloNkylNkyl, heterocycloNkyl, spirocycloNkyl, Nyl, NylNkyl, or NkoxyNkyl; R5, and R6 Ne, independently, hydrogen, Nkyl, Nyl, Nkoxy, hNogen, or perfluoroNkyl; R3 and R.7 Ne each, independently, hydrogen or an optionNly substituted Nkyl, cycloNkyl, heterocycloNkyl, NkylheterocycloNkyl, heteroNylNkyl, NkylNyl, NkylheteroNyl, Nkenyl, Nkynyl, fused cycloNkylNyl, fused heterocycloNkylNyl, cycloNkylcNbonyl, or heterocycloNkylcNbonyl group; or R3 and R7, together with the nitrogen atom to which they Ne attached, form a fNe or six meinbered heterocycloNkyl ring optionNly substituted with 1 to 5 substituents selected from Nkyl, Nyl, heterocycloNkyl, heterocycloNkylNkyl, Nkylamino, diNkylamino, NkoxycNbonyl, NkylcNbonyl, NkylaminocNbonylNkyl, and heterocycloNkylcNbonylNkyl. In other embodiments, the invention relates to compositions comprising at least one compound of Formula 1, or a phNmaceuticNly acceptable sNt thereof, and one or more phNmaceuticNly acceptable excipients, diluents, or cNriers. , The present invention Nso provides methods for treating patients suffering from osteoporosis, Nthritis, chronic obstructNe pulmonNy disease, cNtilage defects, bone fractures, or leiomyoma that comprise administering to the patients a therapeuticNly effectNe amount of at least one compound of Formula 1. DETAILED DESCRIPTION OF ILLUSTRATNE EMBODIMENTS The term "Nkyl," as used herein, refers to an optionNly substituted Niphatic hydrocNbon chain having 1 to 12 cNbon atoms, preferably 1 to 8 cNbon atoms, and more preferably 1 to 4 cNbon atoms. The term "Nkyl" includes straight and branched chains. Straight chain Nkyl groups have 1 to 8 cNbon atoms and branched chain Nkyl groups have 3 to 12 cNbon atoms. Examples of Nkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neo-pentyl, n-hexyl, and isohexyl groups. The term "hydroxyNkyl," as used herein, refers to the group -Nkyl-OH where Nkyl is an Nkyl group as previously defined. The term "cNboxyNkyl," as used herein, refers to the group -Nkyl-C(O)OH where Nkyl is an Nkyl group as previously defined. The term "hNoNkyl," as used herein, refers to the group -Nkyl-hNo where hNo is a hNogen atom and Nkyl is an Nkyl group as previously defined. The term "perfluoroNkyl," as used herein, refers to an optionNly substituted straight or branched Niphatic hydrocNbon chain of 1 to 8 cNbon atoms and preferably 1 to 3 cNbon atoms, in which Nl hydrogens Ne replaced with fluorine. The term "perfluoroNkylNkyl," as used herein, refers to the group -Nkyl-perfluoroNkyl where Nkyl and perfluoroNkyl Ne as previously defined. The term "Nkenyl," as used herein, refers to an optionNly substituted Niphatic straight or branched hydrocNbon chain having 2 to 12 cNbon atoms that contain 1 to 3 double bonds. Straight chain Nkenyl groups have 2 to 8 cNbon atoms and branched chain Nkenyl groups have 3 to 12 cNbon atoms. Examples of Nkenyl groups include, but Ne not limited to, vinyl, prop-1-enyl, Nkyl, but-1-enyl, but-2-enyl, but-3-enyl, 3.3-dunethylbut-l-enyl, or 2-methylvinyl. The term "Nkynyl," as used herein, refers to an optionNly substituted Niphatic straight or branched hydrocNbon chain having 2 to 8 cNbon atoms that contains 1 to 3 triple bonds. Straight chain Nkynyl groups have 2 to 8 cNbon atoms and branched chain Nkynyl groups have 5 to 12 cNbon atoms. The term "cycloNkyl," as used herein, refers to an optionNly substituted hydrocNbon ring containing 3 to 12 cNbon atoms and preferably 3 to 6 cNbon atoms. CycloNkyl groups may be monocyclic or bicyclic, and may be saturated or pNtiNly saturated. The term "bicycloNkyl," as used herein, refers to a bicyclic cycloNkyl group of 8 to 12 ring cNbon atoms. "Bridged" cycloNkyl groups contain at least one cNbon-cNbon bond between two non-adjacent cNbon atoms of the cycloNkyl ring. The term "NkylcycloNkyl," as used herein, refers to the group -cycloNkyl-(Nkyl)n in which n is 1 to 3, cycloNkyl is a cycloNkyl group as previously defined, and Nkyl is an Nkyl group as previously defined. The term "cycloNkylNkyl," as used herein, refers to the group -Nkyl-cycloNkyl in which Nkyl is an Nkyl group as previously defined and cycloNkyl is a cycloNkyl group as previously defined. The term "spirocycloNkyl," as used herein, refers to two optionNly substituted cycloNkyl groups as previously defined that Ne joined by a single sp3 cNbon atom that is the only common member of the two joined rings. ] The term "heterocycloNkyl," as used herein, refers to a 3 to 12 membered, and more preferably 5 to 7 membered optionNly substituted cycloNkyl group in which one to three cNbon atoms of the cycloNkyl group Ne replaced with a heteroatom independently selected from oxygen, nitrogen, and sulfur, including sulfoxide and sulfonyl. The heterocycloNkyl group may be saturated or pNtiNly saturated, and may be monocyclic or bicyclic. The term "heterobicycloNkyl" refers to the bicyclic structure formed when a heterocycloNkyl group is fused to another heterocycloNkyl group, to a cycloNkyl group, to an Nyl group, or to a heteroNyl group. HeterobicycloNkyl groups have 8 to 12 ring atoms. "Bridged" heterocycloNkyl groups contain at least one cNbon-cNbon bond between non-adjacert cNbon atoms of the heterocycloNkyl ring. The term "NkylheterocycloNkyl," as used herein, refers to the group -heterocycloNkyl-(Nkyl)n in which n is 1 to 3, heterocycloNkyl is a heterocycloNkyl group as previously defined, and Nkyl is an Nkyl group as previously defined. The term "heterocycloNkylNkyl," as used herein, refers to the group -R'-heterocycloNkyl where R' is an Nkyl group as previously defined and heterocycloNkyl is a heterocycloNkyl group as previously defined. The term "Nyl," as used herein refers to an optionNly substituted cNbocyclic Nomatic ring. Nyl groups may be monocyclic or bicyclic. ExemplNy Nyl groups include phenyl and naphthyl. The term "cNboxyNyl," as used herein, refers to the group -Nyl-C(O)OH, where Nyl is an Nyl group as previously defined. The term "heteroNyl," as used herein refers to an optionNly substituted 5 to 10 membered monocyclic or bicyclic cNbon containing Nomatic ring having 1 to 3 of its ring members independently selected from nitrogen, sulfur and oxygen. Monocyclic rings preferably have 5 to 6 members and bicyclic rings preferably have 8 to 10 membered ring structures. Examples of heteroNyls include, but Ne not limited to, thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indazolyl, benzofuranyl, isobenzofuranyl, benzothienyl, isobenzothienyl, quinolyl, isoquinolyl, quinoxNinyl, and quinazolinyl. The term "NkylheteroNyl," as used herein, refers to the group -heteroNyl-Nkyl wherein heteroNyl is a heteroNyl group as previously defined and Nkyl is an Nkyl group as previously defined. The term "NylcNbonylNkyl," as used herein, refers to the group R'-C(O)-Nyl where R' is an Nkyl group as previously defined and Nyl is an Nyl group as previously defined. The term, "fused cycloNkylNyl," as used herein, refers to a cyclo Nkyl group as previously defined fused to an Nyl group of fNe or six cNbon atoms as previously defined or fused to a heteroNyl group of fNe or six atoms as previously defined. The point of attachment can occur at any generNly acceptable position. The term, "fused cycloNkylNylaminocNbonyl," as used herein, refers to the group -C(O)-NH-fused cycloNkylNyl where fused cycloNkylNyl is a fused cycloNkylNyl group as previously defined. The term, "fused hetercycloNkylNyl," as used herein, refers to a heterocycloNkyl group as previously defined fused to an Nyl group of fNe or six cNbon atoms as previously defined or fused to a heteroNyl group of fNe or six atoms as previously defined. The point of attachment can occur at any generNly acceptable position. ' The term "fused hetercycloNkylNylcNbonyl," as used herein, refers to the group -C(O)- fused hetercycloNkylNyl where fused hetercycloNkylNyl is a fused hetercycloNkylNyl group as previously defined. The term "NkylcNbonyl," as used herein, refers to the group -C(O)R' where R' is an Nkyl group as previously defined. The term "NkylthioNkylcNbonyl," as used herein, refers to the group -C(O)-R'-S-R' where R' is an Nkyl group as previously defined. The term "NkylcNbonylamino," as used herein, refers to the group -NHC(O)R' where R' is an Nkyl group as previously defined. The term "NkoxycNbonylamino," as used herein, refers to the group -NHC(O)OR' where R' is an Nkyl group as previously defined. The term "NkylcNbonylNkylamino," as used herein, refers to the group -NH-R'-C(O)R' where R' is an Nkyl group as previously defined. The term "Nkylsulfonylamino," as used herein, refers to the group -NH2-S(O)2-R' where R' is an Nkyl group as previously defined. The term "cNboxyNylsulfonylamino," as used herein, refers to the group -NH2-S(O)2-Nyl-C(O)OH where Nyl is an Nyl group as previously defined. The term "NkylcNbonyloxime," as used herein, refers to the group -C(N=OR')R' where R' is an Nkyl group as previously defined. The term "Nkoxy," as used herein, refers to the group -O-R' where R' is an Nkyl group as previously defined. ' The term "perfluoroNkoxy," as used herein, refers to the group -O-R" where R" is a perfluoroNkyl group as previously defined. The terms "ammo" "Nkylamino," "diNkylamino," and "imino," as used herein, refer to the groups -NH2, -NHR', -N(R')2. and -C=NH, respectNely, where each R' is, independently, an Nkyl group as previously defined. The term "aminoNkyl," as used herein, refers to the group -R'NH2 where R' is an Nkyl group as previously defined. The term "NkylcNbinol," as used herein, refers to an Nkyl group as previously defined substituted with a hydroxyl group. The term "cNboxy," as used herein, refers to the group -COOH. The term "cNbonyl," as used herein, refers to a bNNent cNbon atom that is further bonded to an oxygen atom through a double bond. The term "thiocNbonyl," as used herein, refers to a bNNent cNbon atom that is further bonded to a sulfur atom through a double bond. The terms "hNogen" or "hNo," as used herein, refer to chlorine, bromine, fluorine or iodine. The term "cyano" or "cyanoNkyl," as used herein, refers to the group -CN or -R'-CN where R' is an Nkyl group as previously defined. — The term "Nkoxy Nkyl," as used herein, refers to the group -R'-Nkoxy where R' is an Nkyl group as previously defined and Nkoxy is an Nkoxy group as previously defined. The term "Nyl Nkyl," as used herein, refers to the group -R'-Nyl where Nyl is an Nyl group as previously defined, and R' is an Nkyl group as previously defined. The term "hetero Nyl Nkyl," as used herein, refers to the group -R'-hetero Nyl where heteroNyl is a heteroNyl group as previously defined, and R' is an Nkyl group as" previously defined. The term "NylNkenyl," as used herein, refers to the group -Nkenyl-Nyl where Nyl is an Nyl group as previously defined, and Nkenyl is an Nkenyl group as previously defined. The term "NylNkynyl," as used herein, refers to the group -Nkynyl-Nyl where Nyl is an Nyl group as previously defined, and Nkynyl is an Nkynyl group as previously defined. The term "NylNkoxy," as used herein, refers to the group -Nkoxy-Nyl where Nyl is an Nyl group as previously defined and Nkoxy is an Nkoxy group as previously defined. The term "benzoxy" refers to the group -O-CH2-phenyl. The term "aminocNbonylNkoxy," as used herein, refers to the group -Nkoxy-C(0)NH2 where Nkoxy is an Nkoxy group as previously defined. The term "NkoxycNbonylNokxy," as used herein, refers to the group -Nkoxy-C(0)-Nkoxy where Nkoxy is an Nkoxy group as previously defined. The term "cNboxyNkoxy," as used herein, refers to the group -Nkoxy-C(O)OH where Nkoxy is an Nkoxy group as previously defined. The term "NylNkylcNbonyl," as used herein, refers to the group -NkylcNbonyl-Nyl wherein NkylcNbonyl is an NkylcNbonyl group as previously defined and Nyl is an Nyl group as previously defined. The term "NylcNbonyl," as used herein, refers to the group -C(O)-Nyl, where Nyl is an Nyl group of 6 to 10 cNbon atoms as previously defined. The term "diNkylaminoNylcNbonyl," as used herein, refers to the group -NylcNbonyl-N(R')(R') where NylcNbonyl is an NylcNbonyl group as previously defined. The term "Nylthio," as used herein, refers to the group -S-Nyl where Nyl is an Nyl group as previously defined. The term "Nylthiol," as used herein, refers to the group HS-Nyl where Nyl is an Nyl group as previously defined. The term "Nylsulfonyl," as used herein, refers to the group -S(O)2-Nyl where Nyl is an Nyl group as previously defined. The term "NylsulfonylNylsulfonyl," as used herein, refers to the group -S(O)2-Nyl-S(O)2-Nyl where Nyl is an Nyl group as previously defined. The term "cNboxyNylsulfonyl," as used herein, refers to the group -S(O)2-Nyl-C(O)OH where Nyl is an Nyl group as previously defined. The term "aminosulfonyl," as used herein, refers to the group -S(O)2-NH2. 1 The term "heteroNylsulfonyl," as used herein, refers to the group -S(O)2-heteroNyl where heteroNyl is a heteroNyl group as previously defined. The term "Nylester," as used herein, refers to the group -C(O)0-Nyl where Nyl is an Nyl group as previously defined. The term "NkylcNbonyl," as used herein, refers to the group -C(O)R' where R' is an Nkyl group as previously defined. The term "NkylthiocNbonyl," as used herein, refers to the group -C(S)R' where R' is an Nkyl group as previously defined. The term "NkylaminoNkylcNbonyl," as used herein, refers to the group -C(O)R'NH(R') where R' is an Nkyl group as previously defined. The term "diNkylaminoNkylcNbonyl," as used herein, refers to the group -C(O)R'N(R')(R') where R' is an Nkyi group as previously defined. The term "perfluoroNkylcNbonyl," as used herein, refers to the group -C(O)R" where R" is a perfluoroNkyl group as previously defined. The term "cNboxyNkylcNbonyl." as used herein, refers to the group -C(O)R'C(O)OH where R' is an Nkyi group as previously defined. The term "NkoxycNbonyl," as used herein, refers to the group -C(O)OR' where R' is an Nkyl group as previously defined. The term "NkoxythiocNbonyl," as used herein, refers to the group -C(S)OR' where R' is an Nkyi group as previously defined. The term "NkoxycNbonylNkyl," as used herein, refers to the group -R'C(O)OR' where R' is an Nkyi group as previously defined. The term "NylcNbonyl," as used herein, refers to the group -C(O)-Nyl where Nyl is an Nyl group as previously defined. The term "heteroNylcNbonyl," as used herein, refers to the group -C(O)-heteroNyl where heteroNyl is a heteroNyl group as previously defined. The term "heteroNylNkylcNbonyl," as used herein, refers to the group -C(O)-R'-heteroNyl where heteroNyl is a heteroNyl group as previously defined and R' is an Nkyi group as previously defined. The term "heterocycloNkylNkylcNbonyl," as used herein, refers to the group • -C(O)-R'-heterocycloNkyl where heterocycloNkyl is a heterocycloNkyl group as previously defined and R' is an Nkyl group as previously defined. The term "heterocycloNkylNkylaminothiocNbonyl," as used herein, refers to the group -C(O)-S-NH-R' -heterocycloNkyl where heterocycloNkyl is a heterocycloNkyl group as previously defined and R' is an Nkyi group as previously defined. The term "NyloxycNbonyl," as used herein, refers to the group -C(O)-O-Nyl where Nyl is an Nyl group as previously defined. The term "NyloxythiocNbonyl," as used herein, refers to the group -C(S)-O-Nyl where Nyl is an Nyl group as previously defined. The term "cyanoNylcNbonyl," as used herein, refers to the group -C(0)-Nyl-CN where Nyl is an Nyl group as previously defined. The term "NylNkylcNbonyl," as used herein, refers to the group -C(O)-R'-Nyl where R: is an Nkyl group as previously defined and Nyl is an Nyl group as previously defined. The term "cycloNkylcNbonyl," as used herein, refers to the group -C(0)-cycloNkyl where cycloNkyl is a cycloNky] group as previously defined. The term "heterocycloNkylcNbonyl," as used herein, refers to the group -C(O)-heterocycloNkyl where heterocycloNkyl is a heterocycloNkyl group as previously defined. The term "heterocycloNkylthiocNbonyl," as used herein, refers to the group -C(S)-heterocycloNkyl where heterocycloNkyl is a heterocycloNkyl group as previously defined. 1 The term "aminoNkylcNbonyl," as used herein, refers to the group -C(O)-R'-NH2 where R' is an Nkyl group as previously defined. The term "NkoxycNbonylaminothiocNbonyl," as used herein, refers to the group -C(O)-S-NH-C(O)-O-R' where R' is an Nkyl group as previously defined. The term "NkoxycNbonylNkylaminothiocNbonyl," as used herein, refers to the group -C(O)-S-NH-R'-C(O)-O-R' where R' is an Nkyl group as previously defined. The term "NkylthiocNbonylNkylcNbonyl," as used herein, refers to the group -C(O)-R'-C(O)-S-R' where R' is an Nkyl group as previously defined. The term "cyanoNkoxycNbonyl," as used herein, refers to the group -C(O)-Nkoxy-CN where Nkoxy refers to an Nkoxy group as previously defined. The term "NkylNyl," as used herein, refers to the group -Nyl-R' where R' is an Nkyl group as previously defined, and Nyl is an Nyl group as previously defined. The term "Nkylester," as used herein, refers to the group -C(O)OR' wherein R' is an Nkyl group as previously defined. The term "aminocNbonyl," as used herein, refers to the group -C(O)NH2. The terms "NkylaminocNbonyl," and "diNkylaminocNbonyl," as used herein, refer to the groups -C(O)NHR' and -C(O)N(R')2, respectNely, where each R' is, independently, an Nkyl group as previously defined. The term "heterocycloNkylaminocNbonyl," as used herein, refers to the group -C(O)NH-heterocycloNkyl where heterocycloNkyl is a heterocycloNkyl group as previously defined. The term "cNboxyNkylcNbonylheterocycloNkylaminocNbonyl," as used herein, refers to the group -heterocycloNkylaminocNbonyl-C(O)-R'-C(O)OH where heterocycloNkylaminocNbonyl is a heterocycloNkylaminocNbonyl group as previously defined and R' is an Nkyl group as previously defined. The term "cNboxyNkylaminocNbonyl," as used herein, refers to the group -NkylaminocNbonyl-cNboxy where cNboxy is a cNboxy group as previously defined and NkylaminocNbonyl is an NkylaminocNbonyl group as previously defined. The term "NkoxycNbonylNkylaminocNbonyl," as used herein, refers to the group -NkylaminocNbonyl -cNbonyl-Nkoxy where Nkoxy is an Nkoxy group as previously defined, cNbonyl is a cNbonyl group as previously defined, and NkylaminocNbonyl is an NkylaminocNbonyl group as previously defined. The term "aminocNbonylNkyl," as used herein, refers to the group -R'C(O)NH2 where R' is an Nkyl group as previously defined. The terms "NkylaminocNbonylNkyl," and "diNkylaminocNbonylNkyl," as used herein, refer to the groups -R'C(O)NHR' and -R'C(O)N(R')2, respectNely, where each R' is, independently, an Nkyl group as previously defined. The terms "NkylaminothiocNbonyl," and "diNkylaminothiocNbonyl," as used herein, refer to the groups -C(S)NHR' and -C(S)N(R')2, respectNely, where each R' is, independently, an Nkyl group as previously defined. The term "heterocycloNkylcNbonylNkyl," as used herein, refers to the group -R'C(O)heterocycloNkyl where R' is an Nkyl group as previously defined and heterocycloNkyl is a heterocycloNkyl group as previously defined. The term "NylaminocNbonyl," as used herein, refers to the group -C(O)NH(Nyl), where Nyl is an Nyl group as previously defined. The term "heteroNylaminocNbonyl," as used herein, refers to the group -C(O)NH(heteroNyl), where heteroNyl is a heteroNyl group as previously defined. The term "heteroNylaminothiocNbonyl," as used herein, refers to the group -C(S)NH(heteroNyl), where heteroNyl is a heteroNyl group as previously defined. The term "NylaminothiocNbonyl," as used herein, refers to the group -C(S)NH(Nyl), where Nyl is an Nyl group as previously defined. The term "cycloNkylaminocNbonyl," as used herein, refers to an NkylaminocNbonyl or diNkylaminocNbonyl group as previously defined in which at least one Nkyl group is replaced by a cycloNkyl group. The term "Nkylsulfonyl," as used herein, refers to the group -S(O)2-R' where R' is an Nkyl group as previously defined. The term "Nkylsulfmyl," as used herein, refers to the group -S(0)-R' where R' is an Nkyl group as previously defined. The term "Nkylthio," as used herein, refers to the group -S-R' where R' is an Nkyl group as previously defined. The term "perfluoroNkylthio," as used herein, refers to the group -S-R" where R" is a perfluoroNkyl group as previously defined. The term "tertiNy NkylcNbinol," as used herein, refers to the group -C(R')2OH where R' is an Nkyl group as previously defined. The term "tertiNy cycloNkylcNbinol," as used herein, refers to the group -C(cycloNkyl)2OH where cycloNkyl refers to a cycloNkyl group as previously defined. The term "tertiNy NkylcycloNkylcNbinol," as used herein, refers to the group -C(R')(cycloNkyl)OH where R' refers to an Nkyl group as previously defined, and cycloNkyl refers to a cycloNkyl group as previously defined. The term "tertiNy NylcNbinol," as used herein, refers to the group -C(Nyl)2OH where each "Nyl" independently refers to an Nyl group as previously defined. The term "tertiNy NylNkylcNbinol," as used herein, refers to the group -C(R')(Nyl)OH where R' is an Nkyl group as previously defined, and Nyl is an Nyl group as previously defined. The term "phosphonic acid Nkyl," as used herein, refers to the group -R'-P(O)(OH)2 where R' is an Nkyl group as previously defined. The term "dimethylphosphonateNkyl," as used herein, refers to the group -R'-P(O)(OCH3)2 where R' is an Nkyl group as previously defined. The term "pNtiNly saturated," as used herein, refers to a nonNomatic cycloNkyl or heterocycloNkyl group containing at least one double bond and preferably one or two double bonds. The term "therapeuticNly effectNe amount," as used herein, refers to the amount of a compound of formula 1 that, when administered to a patient, is effectNe to at least pNtiNly treat a condition from which the patient is suffering or is suspected to suffer. Such conditions include, but Ne not limited to, osteoporosis, Nthritis, chronic obstructNe pulmonNy disease, cNtilage defects, bone fractures, and leiomyoma. The term "phNmaceuticNly acceptable sNts" or "phNmaceuticaHy acceptable sNt" includes acid addition sNts, namely sNts derNed from treating a compound of formula 1 with an organic or inorganic acids or bases. Where the compound having formula I has an acidic function, for instance where R3 is cNboxyNkyl or R8 is cNboxy or phenolic hydroxyl, the term "phNmaceuticNly acceptable sNts" or "phNmaceuticNly acceptable sNt" includes sNts derNed from bases, for instance, sodium sNts. The term "patient," as used herein, refers to a mammN. The terms "administer," "administering," or "administration," as used herein, refer to either directly administering a compound or composition to a patient, or administering a prodrug derNatNe or anNog of the compound to the patient, which will form an equNNent amount of the actNe compound or substance within the patient's body. The terms "treat" and "treating," as used herein, refer to pNtiNly or completely Nleviating, inhibiting, preventing, ameliorating and/or relieving a condition from which a patient is suspected to suffer.The terms "suffer" and "suffering," as used herein, refer to one or more conditions with which a patient has been diagnosed, or is suspected to have. Certain embodiments of the invention relate to compounds of Formula (1): (Formula Removed) or a phNmaceuticNly acceptable sNt thereof, wherein R1 is (Formula Removed) each RI group is optionNly substituted with up to three RS groups; Y is O, S, or NR9; RS is Nkyl, Nyl Nkyl, perfluoro Nkyl, Nkenyl, NylNkenyl, Nkynyl, NylNkynyl, cycloNkyl, NkylcycloNkyl, heterocycloNkyl, NkylheterocycloNkyl, Nyl, NkylNyl, heteroNyl, Nkoxy, perfluoroNkoxy, NylNkoxy, NkylcNbonyl, NylcNbonyl, hNogen, cyano, azido, hydroxyl, cNboxy, NkoxycNbonyl, Nkylamino, diNkylamino, NkylaminocNbonyl, diNkylaminocNbonyl, NkylcNbonylamino, NkylcNbonylNkylamino, hydroxyNkylamino, nitro, NkylcNbonyloxime, Nkylsulfonyl, Nkylsulfmyl, Nkylthio, perfluoroNkylthio, Nylthio, tertiNy NkylcNbinol, tertiNy NkylcycloNkylcNbinol, or tertiNy NylNkylcNbinol; R9 is hydrogen, Nkyl, Nyl, NylNkyl, cycloNkylNkyl, heterocycloNkyl, or spirocycloNkyl; X is oxygen or an electron pair; R2 is hydrogen, Nkyl, Nkoxy, cycloNkyl, perfluoroNkyl, perfluoroNkylNkyl, perfluoroNkoxy, diNkylamino, or hNogen; R4 is hydrogen, hNogen, Nkyl, cycloNkyl, Nkoxy, perfluoroNkyl, or perfluoroNkoxy; or RI and RA, together with the cNbon atoms to which they Ne attached, form a cycloNkyl ring of 5 to 7 cNbon atoms that is optionNly substituted with 1 to 3 R groups; each R is, independently, hydrogen, Nkyl, NylNkyl, cyanoNkyl, cycloNkyl, cycloNkylNkyl, heterocycloNkyl, spirocycloNkyl, Nyl, NylNkyl, or NkoxyNkyl; R5, and R6 Ne, independently, hydrogen, Nkyl, Nyl, Nkoxy, hNogen, or perfluoroNkyl; R3 and R7 Ne each, independently, hydrogen or an optionNly substituted Nkyl, cycloNkyl, heterocycloNkyl, NkylheterocycloNkyl, heteroNylNkyl, NkylNyl, NkylheteroNyl, Nkenyl, Nkynyl, fused cycloNkylNyl, fused heterocycloNkylNyl, cycloNkylcNbonyl, or heterocycloNkylcNbonyl group; or R3 and R7, together with the nitrogen atom to which they Ne attached, form a fNe or six membered heterocycloNkyl ring optionNly substituted with 1 to '5 substituents selected from . Nkyl, atyl, heterocycloNkyl, heterocycloNkylNkyl, Nkylamino, diNkylamino, NkoxycNbonyl, NkylcNbonyl, NkylaminocNbonylNkyl, and heterocycloNkylcNbonylNkyl; provided that the compound is not 2-rnethyl-N-(2-phenylethyl)"5-(phenylsulfonyl)-benzenesulfonamide; 2-methyl-N~(2-phenylmethyl)-5-(phenylsulfonyl)-benzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-cyclohexyl-2-methylbenzenesulfonamide; N-benzyl-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-(2-rurylmethyl)-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-benzenesulfonamide; 5 - [(4-bromopheny l)sulfonyl] -2-methylbenzenesulfonamide; 2-methyl-5-[(4-nitrophenyl)sulfonyl]-benzenesulfonamide; 5-[(2,4-dinitrophenyl)sulfonyl]-2-rnethyl-benzenesulfonamide; or 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-(3-pyridinylmethyl)-benzenesulfonamide. Any cNbon or nitrogen atom in R], R2, Rj, R4, RS, Re, and R?, as defined herein, may be optionNly substituted with one or more substituents understood by those skilled in the Nt to be suitable substituents. The following lists provide exemples of such substituents.. The Nkyl, cycloNkyl, NkylheterocycloNkyl, heteroNylNkyl, NkylNyl, NkylheteroNyl, Nkenyl, Nkynyl, fused cycloNkylNyl, fused heterocycloNkylNyl, cycloNkylcNbonyl, and heterocycloNkylcNbonyl groups of R3 and R7 may each be, independently, optionNly substituted with 1 to 5 substituents selected from Nkyl, perfluoroNkyl, cycloNkyl, heterocycloNkyl, Nyl, heteroNyl, fused cycloNkylNyl, Nkoxy, aminocNbonylNkoxy, NkoxycNbonylNkoxy, cNboxyNkoxy, cycloNkyloxy, Nyloxy, amino, Nkylamino, diNkylamino, NkoxycNbonylamino, cNboxy, cyano, hNogen, oxo, hydroxyl, NkylcNbonyl, cNboxyNkylcNbonyl, NylNninocNbonyl, heterocycloNkylcNbonyl, NkoxycNbonyl, NkylaminocNbonyl, diNkylaminocNbonyl, fused cycloNkylNylaminocNbonyl, and fused heterocycloNkylNylcNbonyl. The cycloNkyl, heterocycloNkyl, Nyl, and heteroNyl substituents on the Nkyl groups of RS and Ry may be, independently, optionNly substituted with 1 to 5 substituents selected from Nkyl, cycloNkyl, heterocycloNkyl, spirocycloNkyl, perfluoroNkyl, hNoNkyl, cyanoNkyl, cNboxyNkyl, dimethylphosphonateNkyl, pb.ospb.omc acid Nkyl, NylNkyl, cycloNkylNkyl, Nkoxy, perfluoroNkoxy, NylNkoxy, benzoxy, Nyl, heteroNyl, cNboxyNyl, NylcNbonyl, NkylcNbonyl, perfluoroNkylcNbonyl, NkoxycNbonyl, cNboxyNkylcNbonyl, NyloxycNbonyl, NkoxythiocNbonyl, NyloxythiocNbonyl. NylcNbonyl, cycloNkylcNbonyl, heterocycloNkylcNbonyl, heterocycloNkylthiocNbonyl, aiylthiocNbonyl, NkylaminocNbonyl. diNkylaminocNbonyl, diNkylaminoNylcNbonyl, diNkylaminoNkylcNbonyl, NkylthiocNbonyl, NylaminocNbonyl, heteroNylcNbonyl, heteroaiylaminocNbonyl, NkylaminothiocNbonyl, diNkylaminothiocNbonyl, NylaminothiocNbonyl, heteroNylaminothiocNbonyl, aminosulfonyl, Nkylsulfonyl, Nylsulfonyl, NylsulfonylNylsulfonyl, cNboxyNylsulfonyl, nitro, amino, diNkylamino, NkylcNbonylamino, Nkylsulfonylamino, cNboxyNylsulfonylamino, hydroxy, cNboxy, sulfonamide, Nkylthio, hNogen, cyano, guanidine, and oxo, and the nitrogen atoms in the heteroNyl substituents may be optionNly substituted with an oxygen atom. The heterocycloNkyl groups of R3 and R7 may be independently, optionNly substituted with 1 to 5 substituents selected from Nkyl, hydroxyNkyl, cyanoNkyl, cNboxyNkyl, aminocNbonylNkyl, NkoxycNbonylNkyl, aminocNbonylNkyl, NkylaminocNbonylNkyl, diNkylaminocNbonylNkyl, heterocycloNkyl, heterocycloNkylNkyl, heterocycloNkylcNbonylNkyl, NylNkyl, heteroNylNkyl, NylcNbonylNkyl, NkylcNbonyl, cyano, Nkylester, Nkylamide, cycloNkylamide, Nyl, Nylester, NkylcNbonyl, perfluorpNkylcNbonyl, aminocNbonyl, NylaminocNbonyl, NylaminothiocNbonyl, cyanoNkoxycNbonyl, cycloNkylcNbonyl, NylcNbonyl, aiylthiocNbonyl, NkylamrnocNbonyl, diNkylaminocNbonyl, NylaminocNbonyl, NkylaminothiocNbonyl, diNkylaminothiocNbonyl, heteroNylcNbonyl, heterocycloNkylcNbonyl, cyanoNylcNbonyl, NylNkylcNbonyl, NkoxycNbonyl, NkoxyNkylcNbonyl, NkylthioNkylcNbonyl, NkylaminoNkylcNbonyl, diNkylaminoNkylcNbonyl, heterocycloNkylNkylcNbonyl, heterocycloNkylNkylaminothiocNbonyl, NylaminothiocNbonyl, heteroNylaminothiocNbonyl, heteroNylNkylcNbonyl, cNboxyNkylcNbonyl, NkoxycNbonylaminothiocNbonyl, NkoxycNbonylNkylaminothiocNbonyl, NkylthiocNbonylNkylcNbonyl, Nkylsulfonyl, Nylsulfonyl, NkylaminoNylsulfonyl, and heteroNylsulfonyl. The cycloNkyl, heterocycloNkyl, Nyl, and heteroNyl substituents on the heterocycloNkyl groups of Ra and R? may be independently, optionNly substituted with 1 to 5 substituents selected from Nkyl, cycloNkyl, heterocycloNkyl, spirocycloNkyl, perfluoroNkyl, hNoNkyl, cyanoNkyl, cNboxyNkyl, dimethylphosphonateNkyl, phosphonic acid Nkyl, NylNkyl, cycloNkylNkyl, Nkoxy, perfluoroNkoxy, NylNkoxy, benzoxy, Nyl, heteroNyl, cNboxyNyl, NylcNbonyl, NlkylcNbonyl, perfluoroNkylcNbonyl, NkoxycNbonyl, cNboxyNkylcNbonyl, aiyloxycNbonyl, NkoxythiocNborryl, NyloxythiocNbonyl, NylcNbonyl. cycloNkylcNbonyl, heterocycloNkylcNbonyl, heterocycloNkylthiocNbonyl, aiylthiocNbonyl, NkylaminocNbonyl, diNkylaminocNbonyl, diNkylaminoNylcNbonyl, diNkylaminoNkylcNbonyl, NkylthiocNbonyl, aiylaminocNbonyl, heteroNylcNbonyl, heteroNylaminocNbonyl, NkylaminothiocNbonyl, diNkylaminothiocNbonyl, NylaminothiocNbonyl, heteroNylaminothiocNbonyl, aminosulfonyl, Nkylsulfonyl, Nylsulfonyl. NylsulfonylNylsulfonyl, cNboxyNylsulfonyl, nitro, amino, diNkylamino, NkylcNbonylamino, Nkylsulfonylamino, cNboxyNylsulfonylamino, hydroxy, cNboxy, sulfonamide, Nkylthio, hNogen, cyano, guanidine, and oxo, and the nitrogen atoms in the heteroNyl substituents may be optionNly substituted with an oxygen atom. • The amino substituents on the Nkyl groups of R3 and R7 may be, independently, optionNly substituted with 1 or 2 substituents selected from Nkyl, hydroxyNkyl, cNboxyNkyl, cycloNkyl, NkoxycNbonylNkyl, Nyl, NkylcNbonyl, NylcNbonyl, Nkylsulfonyl, Nylsulfonyl, NkylcNbonyl, cycloNkylcNbonyl, NkylaminocNbonyl, diNkylaminocNbonyl, NkylaminothiocNbonyl, diNkylaminothiocNbonyl, NkoxycNbonylNkylaminocNbonyl, cNboxyNkylcNbonyl, cNboxy NkylaminocNbonyl, cNboxyNkylcNbonylheterocycloNkylaminocNbonyl, aiylaminocNbonyl, NylcNbonyl, heteroNylaminocNbonyl, heterocycloNkylcNbonyl, NylaminothiocNbonyl, heteroNylaminothiocNbonyl, heterocycloNkylaminocNbonyl, heterocycloNkyltbiocNbonyl, heteroNylcNbonyl, NkoxycNbonyl, NyloxycNbonyl, NkoxythiocNbonyl, and NyloxythiocNbonyl. The cycloNkyl, heterocycloNkyl, Nyl, and heteroNyl substituents on the amino substituents on the Nkyl groups of R5 and R7 may be, independently, optionNly substituted with 1 to 5 substituents selected from Nkyl, cycloNkyl, heterocycloNkyl, spirocycloNkyl, perfluoroNkyl, hNoNkyl, cyanoNkyl, cNboxyNkyl, dimethylphosphonateNkyl, phosphonic acid Nkyl, NylNkyl, cycloNkylNkyl, Nkoxy, perfluoroNkoxy, NylNkoxy, benzoxy, Nyl, heteroNyl, cNboxyNyl, NylcNbonyl, NleyIcNbonyl, perfluoroNkylcNbonyl, NkoxycNbonyl, cNboxyNkylcNbonyl, NyloxycNbonyl, NkoxythiocNbonyl, NyloxythiocNbonyl, NylcNbonyl, cycloNkylcNbonyl, heterocycloNkylcNbonyl, heterocycloNkylthiocNbonyl, aiylthiocNbonyl, NkylaminocNbonyl, diNkylaminocNbonyl, diNkylaminoNylcNbonyl, diNkylaminoNkylcNbonyl, NkylthiocNbonyl, NylaminocNbonyl, heteroNylcNbonyl, heteroNylaminocNbonyl, NkylaminothiocNbonyl, diNkylaminothiocNbonyl, NylaminothiocNbonyl, heteroNylaminothiocNbonyl. aminosulfonyl, Nkylsulfonyl, Nylsulfonyl, NylsulfonylNylsulfonyl, cNboxyNylsulfonyl, nitro, amino, diNkylamino, NkylcNbonylamino, Nkylsulfonylamino, cNboxyNylsulfonylamino, hydroxy, cNboxy, sulfonamide, Nkylthio, hNogen, cyano, guanidine, and oxo, and the nitrogen atoms in the heteroNyl substituents may be optionNly substituted with an oxygen atom. The Nkyl group substituents on the heterocycloNkyl ring formed from R3 and R7, together with the nitrogen atom to which they Ne attached may each be, independently, optionNly substituted with 1 to 5 substituents selected from Nyl, heteroNyl optionNly substituted with one to three Nkyl groups, aminoNkyl, heterocycloNkyl, fused heterocycloNkylNyl, and heterocycloNkylcNbonyl. In preferred embodiments of the invention R1 of Formula 1 is Nyl. In other embodiments of the invention, R1 of Formula 1 is (Formula Removed) Certain aspects of the invention relate to compounds of Formula 1 wherein each Rg is, independently, Nkyl, NkylNyl, NkylheteroNyl, Nkylamino, diNkylamino, cNboxy, NkylcNbonyl, Nkoxy, perfluoroNkoxy, hNogen, or cyano. Other aspects of the invention Ne directed to compounds of Formula 1 in which X is oxygen. AdditionN embodiments of the invention relate to compounds of Formula 1 in which R4, R5, and R6 Ne each hydrogen. NternatNe embodiments of the invention relate to compounds of Formula 1 in which R4 is methyl and R5 and R6 Ne each hydrogen, or R5 is methyl and R4 and R5 Ne each hydrogen, or R6 is methyl and R4 and R5 Ne each hydrogen. Further embodiments of the invention Ne directed to compounds of Formula I in which R4 is hNogen, Nkyl, cycloNkyl, Nkoxy, perfluoroNkyl, or perfluoroNkoxy. Other aspects of the invention Ne directed to compounds of Formula I in which R5, and R6 Ne, independently, Nkyl, Nkoxy, hNogen, or perfluoroNkyl. Certain embodiments of the invention Ne directed to compounds of Formula 1 in which RI is methyl, ethyl, isopropyl, propyl, Cl, methoxy, trirluoromethyl, or trifluoromethoxy. In preferred embodiments, R2 is methyl, isopropyl, trifluoromethyl, or trifluoromethoxy. In pNticulNly preferred embodiments, R2 is isopropyl or trifluoromethyl. Still further embodiments of the invention relate to compounds of Formula I in which R2 is hydrogen, Nkoxy, cycloNkyl, perfluoroNkyl, perfluoroNkylNkyl, perfluoroNkoxy, diNkylamino, or hNogen. Other aspects of the invention relate to compounds of Formula 1 in which RS and R?, together with the nitrogen atoms to which they Ne attached, form an optionNly substituted 5 or 6 membered heterocycloNkyl group. In preferred aspects, R3 and R7, together with the nitrogen atoms to which they Ne attached, form an optionNly substituted piperazinyl group. AdditionN embodiments of the invention relate to compounds of Formula I in which R3 and R7 Ne each, independently, Nkyl, heterocycloNkyl, heterocycloNkylNkyl, NkylheterocycloNkyl, NylNkyl, heteroNylNkyl, Nkenyl, Nkynyl, fused cycloNkylNyl, fused heterocycloNkylNyl, cycloNkylcNbonyl, NkoxyNkyl, NkoxycNbonylNkyl, cyanoNkyl, aminoNkyl, diNkylaminocNbonylNkyl, or NkylNkylaminocNbonylNkyl. Further embodiments of the invention Ne directed to compounds of Formula 1 in which R7 is hydrogen and R3 is Nkyl, cycloNkyl, (Formula Removed) wherein the cNbon atoms of each Nkyl, cycloNkyl, heterocycloNkyl., Nyl or heteroNyl group Ne optionNly substituted with up to four R13 groups; R13 is hydrogen, F, Cl, Br, Nkyl, Nkoxy, Nyl, nitro, aminosulfonyl, NylNkoxy, perfluoroNkyl, perfluoroNkoxy, amino, Nkylamino, diNkylamino, hydroxy, cNboxy, cycloNkyl, cNboxyNkyl, cNboxyNkoxy, NkoxycNbonyl, aminocNbonylNkyl, NkoxycNbonylNkoxy,aminocNbonylNkoxy, NkylaminocNbonylNkyl, aminocNbonyl, NkylaminocNbonyl, diNkylaminocNbonyl, heterocycloNkylcNbonyl, heterocycloNkylaminocNbonyl, NkylaminocNbonylNkoxy, diNkylaminocNbonylNkyl, diNkylaminocNbonylNkoxy, heterocycloNkylcNbonylNkyl, heterocycloNkylaminocNbonylNkoxy, heterocycloNkylcNbonylNkoxy, cycloNkylaminoNkyl, heterocycloNkylaminoNkyl, aminoNkylaminoNkylNylamionNkyl, heteroNylaminoNkylNylNkylaminoNkyl, heteroNylNkylaminoNkyl, NkylaminoNkylamino, diNkylaminoNkylaminoNylamino, heteroNylaminoNylNkylamino, heteroNylNkylamino, or cyano; each R12 is Nkyl, Nyl, Nkylamino, diNkylamino, Nkoxy, hydroxyl, amino, Nylamino, diNylamino, Nyl(Nkyl)amino, or Nyloxy; each R14 is hydrogen, Nkyl, Nyl, cycloNkyl, NkylcNbonyl, NylcNbonyl, NyloxycNbonyl, Nkylsulfonyl, Nylsulfonyl, NkylaminocNbonyl, diNkylaminocNbonyl, NkylaminothiocNbonyl, diNkylaminothiocNbonyl, NylaminocNbonyl, heteroNylaminocNbonyl, heterocycloNkylcNbonyl, NylaminothiocNbonyl, heteroNylaminothiocNbonyl, heterocycloNkylthiocNbonyl, heteroNylcNbonyl, NkoxycNbonyl, NyloxycNbonyl, NkoxythiocNbonyl, NkoxycNbonylaminothlocNbonyl, cycloNkylcNbonyl, aminocNbonyl, NkoxycNbonyl, cycloNkylaminocNbonyl, heterocycloNkylaminocNbonyl, cycloNkylsulfonyl, heterocycloNkylsulfonyl, heteroNylsulfonyl, or NyloxythiocNbonyl; R15 is hydrogen, Nkyl, Nyl, cycloNkyl, NkylcNbonyl, NylcNbonyl, Nkylsulfonyl, Nylsulfonyl, NkylcNbonyl, NylcNbonyl, NkylaminocNbonyl, diNkylaminocNbonyl, NkylaminothiocNbonyl, diNkylaminothiocNbonyl, NylaminocNbonyl, heteroNylaminocNbonyl, heterocycloNkylcNbonyl, NylaminothiocNbonyl, heteroNylaminothiocNbonyl, heterocycloNkylthiocNbonyl, heterocycloNkylNkylaminothiocNbonyl, heteroNylcNbonyl, NkoxycNbonyl, NyloxycNbonyl, NylthiocNbonyl, NkoxythiocNbonyl, or NyloxythiocNbonyl; R16, R17 and R18 Ne each, independently, hydrogen, Nkyl, Nyl or cycloNkyl; m is 0,1, or 2; pis 0, 1, or2; q is 1 or 2; s is I or 2; and W is NR9, O, or S. The Nkyl, Nyl and cycloNkyl groups of R13, RH and R15 may each be, independently, optionNly substituted with 1 to 5 substituents selected from Nkyl, cycloNkyl, heterocycloNkyl, perfluoroNkyl, Nyl, heteroNyl, Nkoxy, Nyloxy, cycloNkyloxy, amino, Nkylamino, diNkylamino, cNboxy, cyano, oxo, hydroxyl, NkylcNbonyl, NkoxycNbonyl, NylcNbonyl, NkoxycNbonylamino, NkylcNbonylamino, aminocNbonyl, NkylaminocNbonyl, diNkylaminocNbonyl, Nkylthio, Nkyloxothio, and NkoxycNbonylNkylamino. The Nylsulfonyl, NylcNbonyl and heteroNylcNbonyl groups of R13, R14 and R15 may be each, independently, optionNly substituted with 1 to 5 substituents selected from hydrogen, hNogen, hydroxyl, Nkyl, cycloNkyl, perfluoroNkyl, Nyl, Nkoxy, heterocycloNkyl, heteroNyl, cycloNkyloxy, Nyloxy, amino, Nkylamino, diaikylamino, Nkylthio, Nkyloxothio, cNboxy, cyano, oxo, NkylcNbonyl, NylcNbonylNkoxycNbonyl, NkylcNbonylamino, aminocNbonyl, NkylaminocNbonyl, and diNkylaminocNbonyl. The heterocycloNkyl groups of R13, R14 and R15 may each be, independently, optionNly substituted with 1 to 5 substituents selected from hydrogen, hydroxyl, Nkyl, cycloNkyl, perfluoroNkyl, Nyl, heterocycloNkyl, heteroNyl, heteroNylcNbonyl, heteroNylNkylcNbonyl, NkylcNbonyl, Nkylsulfonyl, Nylsuifonyl, NkoxycNbonyl, NylcNbonyl, heteroNylcNbonyl, NkylaminocNbonyl, diNkylaminocNbonyl, NkylaminoNkylcNbonyl, diNkylaminoNkylcNbonyl, NkylaminocNbonylNkyl, diNkylaminocNbonylNkyl, heterocycloNkylcNbonylNkyl, cNboxyNkylcNbonyl, and Ny laminocNbonyl. In addition, the NkylcNbonyl groups of R13, R14 and R15 may each be, independently, optionNly substituted with 1 to 5 substituents selected from amino, Nkylamino, diaikylamino, cycloNkyl, heterocycloNkyl, perfluoroNkyl, Nyl, heteroNyl, Nkoxy, Nyloxy, cycloNkyloxy, cNboxy, cyano, oxo, hydroxyl, NkylcNbonyl, NkoxycNbonyl, NylcNbonyl, and NkoxycNbonylamino. The amino groups of the Nkylamino and hetercycloNkylamino groups of R13, R14 and R15 may each be, independently, optionNly substituted with a substituent selected from hydrogen, Nkyl, cycloNkyl, and Nyl, PNticulN embodiments of the invention relate to compounds of Formula 1 in which R7 is hydrogen and R3 is heteroNylethyl, heteroNylpropyl, Nylethyl, heterocycloNkyl, heterocycloNkylethyl, heterocycloNkylpropyl, heterocycloNkylmethyl, heterocyclNkylamino, cycloNkyl, fused cycloNkylNyl, aminoNkyl, or NkoxyNkyl. In preferred embodiments R7 is hydrogen and R3 is heteroNylethyl, heteroNylpropyl, heterocyclNkylamino, fused cycloNkylNyl, or phenylethyl. In pNticulNly preferred embodiments R7 is hydrogen and R3 is pyridinylethyl, imidazolylethyl, imidazolylpropyl, heterocyclNkylamino, fused cycloNkylNyl, or phenylethyl. Specific, representatNe compounds of Formula 1 include: N-(2-phenylethyl)-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(2-chlorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N[2-(2-methoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(3-methoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(3,4-dimethoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-bromophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonNnide; N-[2-(4-fluorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-chlorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-methoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-methylphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-{2-[4-(aminosulfonyl)phenyl]ethyl}-3-(phenylsulfonyl)benzenesulfonamide; N- { 2- [3 ,4-bis(benzyloxy)pheny l]ethy 1 } -3 -(phenylsulfony l)benzenesulfonamide; N-[2-(4-nitrophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; 3-(phenylsulfonyl)-N-{2-[3-(trifluoromethyl)phenyl]ethyl}benzenesulfonamide; N-N-(3-chlorophenyl)ethyl]-3-(phenylsulfonyNbenzenesulfonamide; N-[2-(2,4-dichlorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(2,6-dichlorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(2,5-dimethoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-N-[2-(3,5-dimethoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-ethoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N[2-(S-fluorophenyl)ethyy-3-(phenylsulfony)benzenesulfonamide; N-[2-(2-fluprophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(3-ethoxy-4-methoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-(4-methoxybenzyl)-3-(phenylsulfonyl)benzenesulfonamide; N[2-(2-bromo-4,5-dimethoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N- { [3 -(phenylsulfony l)phenyl]sulfonyl} -beta-Naninamide; methyl N-{[3-(phenylsulfonyl)phenyl]sulfonyl}-beta-Naninate; N-(2-cyanoethyl)-3-(phenylsulfonyl)benzenesulfonamide; 3-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide; N-(3-morpholin-4-ylpropyl)-3-(phenylsulfonyl)benzenesulfonNaide; N-[2-(l-methylpyn'olidin-2-yl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; 3-(phenylsulfonyl)-N-(2-pyridin-4-ylethyl)benzenesulfonamide; 3-(phenyisiiIfonyl)-N-(2-piperidin-l-ylethyl}benzenesulfonamide; N[2-(lN-imidazol-4-yl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-({[3-(pheny]sulfonyl)phenyl]sulfonyl}amino)ethyl]acetamide; N-(2-morpholin-4-yJethyl)-3-(phenylsulfonyt)benzenesulfonamide; N-[3~(2-oxopyrrolidin-1 -yl)propy l]-3 -(phenylsulfonyl)benzenesulfonamide; N-[2-(diethylamino)ethyl]-3-(phenyisulfonyl)benzenesulfonamide; N[2-(dimethylamino)ethyl]-3-(phenyIsulfonyl)benzenesulfonamide; N-(3 -methoxypropy l)-3 -(phenylsulfonyl)benzenesulfonamide; N-[3-(dimethyIamino)propyl]-3-(phenylsulfonyl)benzenesulfonamide; N-(2-methoxyethyl)-3-(phenylsulfonyl)benzenesulfonamide; Nr-[3-(diethylamino)propyl]-3-(phenylsulfonyl)benzenesulfonamide; N-tSN1H-imidazol-l-yNpropyl]-S-Cphenylsulfonylbenzenesulfonamide; 3-(phenylsulfonyl)-N-(3-pyrrolidin-l-ylpropyl)benzenesulfonamide; N-[3-(4-methylpiperazin-l-yl)propyJ]-3-(phenylsulfonyl)benzenesulfonamide; N-{ [3-(phenylsulfonyI)phenyl]sulfonyl} -beta-Nanine; N2,3-dihydro-lN-inden-2-yl-3-(phenylsulfonyl)benzenesuIfonamide; N-[(liSNNN-phenylcyclopropylj-S-fphenylsulfonyNbenzenesulfonamide; N-[(2-ff)-2-phenylpropyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[(25)-2-phenylpropyl] -3 -(phenylsulfonyl)benzenesulfonamide; 5-[(4-fluorophen.yl)sulfonyl]-2-methyl-N-(2-phenylethyl)benzenesulfonamide; N-[2-(2-chlorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; S-[(4-fiuorophenyI)svdfonyI]-N-[2-(2-methoxyphenyl)ethyl]-2-methylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-[2-(3-methoxyphenyl)ethyl]-2-methylbenzenesulfonamide; N-[2-(3,4-dimethoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N-[2-(4-bromophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzeaesulfonNaide; N-[2-(4-fluorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N-[2-(4-chIorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methyIbenzenesulfonamide; 5 - [(4-fluorophenyl)sulfonyl] -N- [2 -(4-methoxyphenyl )ethyl] -2-methy Ibenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[2-(4-methylphenyl)ethyl]benzenesuIfonamide; Nr-{2-[4-(aminosulfonyl)phenyl]ethyl}-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide; N-{2-[3,4-bis(benzyloxy)phenyl]ethyl}-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[2-(4-nitrophenyl)ethyl]benzenesulfonamide; N-[2-(l,3-benzodioxol-5-y])ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbeiizenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-{2-[3- (trit luoromethy l)pheny 1] ethyl} b enzenesulfonamide; N-[2-(3-chlorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N-[2-(254-dichlorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N[2-(2,6-dichlorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N-[2-(2,5-dimethoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N-[2-(3,4-dichlorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N-[2-(3,5-dimethoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N-[2-(4-ethoxyphenyi)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonainide; N-[2-(3-fluorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonaniide; N-[2-(2-fluorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N-[2-(3-ethoxy-4-methoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide; N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(4-methoxybenzyl)-2-methylbenzenesulfonamide; N-[2-(2-bromo-4,5-dimethoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide; ' N-[2-(5-bromo-2-methoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide; 2-Methyl-N- (2-phenylethyl)-5-(phenylsiilfonyl) benzene sulfonamide; N-[2-(2-chlorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(2-methoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(3-methoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(3,4-dimethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-bromophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-fluorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-chlorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-methoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-N-[2-(4-methylphenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide; N-{2-[4-(aminosulfonyl)phenyl]ethyl}-2-methyl-5-(phenylsulfonyI)benzenesulfonamide; N-{2-[3,4-bis(benzyloxy)phenyl]ethyl}-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-N-[2~(4-nitrophenyl)ethyl]-5-(phenylsulfonyl)beixzenesulfonamide; N-[2-(l,3-benzodioxol-5-yl)ethyl]-2-methyl-5-(phenylsulfbnyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-{2-[3-(trifluoromethyl)phenyl]ethyl}benzenesulfonamide; N-[2-(3-chlorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N"-[2-(2,4-dichlorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N"-[2-(2,6-dichlorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(2,5-dimethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-p-fSN-dichlorophenyl)ethyy-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(3,5-dimethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-ethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(3-fluorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(2-fluorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(3-ethoxy-4-methoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N[2-(4-ethoxy-3-mettooxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N"-(4-methoxybenzyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(2-bromo-4,5-dimethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(5-bromo-2-methoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-(2-phenylethyl)benzenesulfonamide; N-[2-(2-chlorophenyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N'-[2-(2-methoxyphenyl)ethyl]-2-methylbenzenesulfonamide; 5- [(4-chlorophenyl)sulfonyl] -N- [2-(3 -methoxypheny l)ethyl] -2-methy Ibenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-methylbenzenesulfonamide; N-[2-(4-bromophenyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N/-[2-(4-fluorophenyl)ethyl]-2-methylbenzenesulfonamide; N-[2-(4-chlorophenyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-[2-(4-methoxyphenyl)ethyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-[2-(4-methylphenyl)ethyl]benzenesulfonamide; N-{2-[4-(aminosulfonyl)phenylJethyl}-5-[(4-chlorophenyl)sulfonyl]-2- methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-[2-(4-nitrophenyl)ethyl]benzenesulfonamide; Nr-[2-(l,3-beiizodioxol-5-yl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-{2-[3- (trifluoromethyl)phenyl] ethyl} benzenesulfonamide; N-[2-(3-chlorophenyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-[2-(2,4-dichlorophenyl)ethyl]-2-methylbeazenesulfonamide: 5-[(4-chlorophenyl)sulfonyl]-N-[2-(2,6-dichlorophenyl)ethyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-[2-(2,5-dimethoxyphenyl)ethyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-[2-(3,4-dichlorophenyl)ethyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-[2-(3,5-dimethoxyphenyl)ethyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-[2-(4-ethoxyphenyl)etliyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-[2-(3-fluorophenyl)ethyl]-2-methylbenzenesulfonamide; 5 - [(4-chloropheny l)sulfony 1] -N-[2-(2 -fluoropheny l)ethyl] -2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-[2-(3-ethoxy-4-methoxyphenyl)ethyl]-2- methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-(4-methoxybenzyl)-2-methylbenzenesulfonainide; N-[2-(2-bromo-4,5-dimethoxyphenyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2- methylbenzenesulfonamide; N-[2-(5-bromo-2-methoxyphenyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2- methylbenzenesulfonamide; 2-methyl-5-[(4-methylphenyl)sulfonyl]-N'-(2-phenylethyl)benzenesulfonamide; N-[2-(2-chlorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(2-methoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(3-methoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(3,4-dunethoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(4-bromophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(4-fluorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(4-chlorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)suIfonyl]benzenesulfonamide; N-[2-(4-methoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; 2-methyl-N-[2-(4-methylphenyl)ethyl]-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-{2-[4-(aminosulfonyl)phenyl]ethyl}-2-methyl-5-[(4- methylphenyl)sulfonyl]benzenesulfonamide; 2-methyl-5-[(4-methylphenyl)sulfonyl]-N-[2-(4-nitrophenyl)ethyl]benzenesulfonamide; N-[2-(l,3-benzodioxol-5-yl)ethyl]-2-methyl-5-[(4~methylphenyl)sulfonyl]benzenesulfonamide; 2-methy 1- 5 - [(4-methy Ipheny l)sulfony 1] -N-{2-[3- (trifluoromethyl)phenyl] ethyl} benzenesulfonamide; N-[2-(3-chlorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N- [2-(2,4-dichloropheny l)ethyl] -2-methy 1-5 - [(4-methy Ipheny l)sulfonyl]benzene sulfonamide; N-[2-(2,6-dichlorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N- [2-(2,5 -dimethoxypheny l)ethy 1] -2 -methyl-5 - [(4-methy Iphenyl)sulfony l]benzenesulfonamide; N-[2-(3,4-dichlorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(3,5-dimethoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(4-ethoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(3-fluorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(2-fluorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(2-bromo-4,5-dimethoxyphenyl)ethyl]-2-methyl-5-[(4- methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(5-bromo-2-methoxyphenyl)ethyl]-2-methyl-5-[(4- methylphenyl)sulfonyl]benzenesulfonamide; 2-ethyl-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-ethyl-N-[2-(2-methoxyphenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide; 2-ethyl-N-[2-(3-methoxyphenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(3,4-dimethoxyphenyl)ethyl]-2-ethyl-5-(phenylsulfonyl)benzenesulfonamide; N-{2-[4-(aminosulfonyl)phenyl]ethyl}-2-ethyl-5-(phenylsulfonyl)benzenesulfonamide; 2-ethyl-N-[2-(3-fluorophenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide; 2-ethyl-N-[2-(2-fluorophenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(3-ethoxy-4-methoxyphenyl)ethyl]-2-ethyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-2-ethyl-5-(phenylsulfonyl)benzenesulfonamide; 2-methoxy-N'-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-methoxy-N-[2-(2-methoxyphenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide; 2-methoxy-N- [2- (3 -methoxypheny l)ethy 1] -5 -(pheny isulfony l)benzenesulfonamide; N-[2-(3,4-dimethoxyphenyl)ethyl]-2--methoxy-5-(phenylsulfonyl)benzenesulfonamide; N-{2-[4-(aminosulfonyl)phenyl]ethyl}-2-methoxy-5~(phenylsulfonyl)benzenesulfonamide; N-[2-(3-fluorophenyl)ethyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(2-fluorophenyl)ethyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(3-ethoxy-4-methoxyphenyl)ethyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide; N'-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-aV-(3-phenylpropyl)-5-(phenylsulfonyl)benzenesulfonamide: 2-ethyl-N'-(3-phenylpropyl)-5-(phenylsulfonyl)benzenesulfonamide; N-2,3-dihydro-lH-inden-2-yl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-N-[(1S,2R)-2-phenylcyclopropyl]-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-N-[(2R)-2-phenylpropyl]-5-(phenylsulfonyl)benzenesulfonamide; N-2,3-dihydro-lH-inden-2-yl-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[(1S,2R)-2-phenylcyclopropyl]benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[(2R)-2-phenylpropyl]benzenesulfonamide; N-253-dihydro-lH-inden-2-yl-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; 2-methyl-5-[(4-methylphenyl)sulfonyl]-N-[(lS,2R)-2-phenylcyclopropyl]benzenesulfonamide; 2-methyl-5-[(4-methylphenyl)sulfonyl]-N-[(2R)-2-phenylpropyl]benzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N'-2,3-dihydro-lH-inden-2-yl-2-methylbenzenesulfonaniide; 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-[(1S,2R)-2-phenylcyclopropyl]benzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-[(2R)-2-phenylpropyl]benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[(2S)-2-phenylpropyl]benzenesulfonamide; 2-methyl-N-[(21S)-2-phenylpropyl]-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-5-[(4-methylphenyl)sulfonyl]-N-[(2S)-2-phenylpropyl]benzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-[(2S)-2-phenylpropyl]benzenesulfonamide; N'-2,3-dihydro-1H-inden-2-yl-2-ethyl-5-(phenylsulfonyl)ben2enesulfonamide; 2-ethyl-N- [(1S,2 R)-2-pheuy Icyclopropyl] -5 -(pheny Isulfony l)benzenesulfonamide; 2-ethyl-N-[(2R)-2-phenylpropyl]-5-(phenylsulfonyl)benzenesulfonamide; N-2,3-dihydro-lH-inden-2-yl-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide; 2-methoxy-N- [(1S,2R)-2-phenylcyclopropyl]-5-(phenylsulfony l)benzenesulfonamide; 2-methoxy-N-[(2R)-2-phenylpropyl]-5-(phenylsulfonyl)benzenesulfonamide; 2-isopropyl-N(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-inethyl-N-(2-phenylethyl)-3-(phenylsulfonyl)benzenesulfonamide; 2-chloro-V-(2-phenylethyl)-5-(phenylsurfonyl)benzenesulfonamide; 2-(2-hydroxy-2-methylpropyl)-N-(2-phenylethyl)-5- (phenylsulfonyl)benzenesulfonamide; N-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-L-phenylNaninamide; methyl N-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-D-phenylNaninate; N-(2,3-dihydro-lH-inden-l-yl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(2-fluorophenyl)ethyl]-3-[(4-methylphenyl)sulfonyi]-5,6,7,8-tetrahydronaphthNene-l- sulfonamide; 5-[(4-fluorophenyl)siilfonyl]-2-isopropyl-N-[(2R)-2-phenylpropyl]benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[(2S)-2-phenylpropyl]benzenesulfonamide; N-(2-phenylethyl)-5-(phenylsulfonyl)-2-propylbenzenesulfonamide; 5-(phenylsulfonyl)-2-propylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(2-phenylethyl)-2-propylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-propylbenzenesulfonamide; N-(2-phenylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)-benzenesulfonamide; 2,4-diisopropyl-N'-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide; N-(23-dihydro-lH-inden-2-yl)-2,4-diisopropyl-5-(phenylsulfonyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropyl-N-(2-phenylethyl)benzenesulfonamide; N-(2,3-dihydro- lH-inden-2-yl)-5-[(4-fluorophenyl)sulfonyl]-2,4- diisopropylbenzenesulfonamide; N-(2-hydroxy-2-phenylethyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N;-(2-hydroxy-2-phenylethyl)-2-methylbenzenesulfonaniide; 2-ethyl-5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-phenylethyl)benzenesulfonamide; N-(2-hydroxy-2-phenylethyl)-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide; trans-N-(2-hydroxy-l-methyl-2-phenylethyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonainide; 5-[(4-fluorophenyl)sulfonyl]-N"-[traiis-2-hydroxy-l-inethyl-2-phenylethyl]-2- methylbenzenesulfonamide; 2-ethyl-5-[(4-fluorophenyl)sulfonyl]-N-[(trans)-2-hydroxy-l-methyl-2- phenylethyl]benzenesulfonamide; N-[(trans)-2-hydroxy-1 -methyl-2-phenylethyl]-2,4-dimethyl-5- (phenylsulfonyl)benzenesulfonamide; N-[(lS*,2S*)-2-hydroxycyclohexyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxyethyl)-2-isopropylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(3-morpholm-4-ylpropyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(2-pyridin-4-ylethyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-(2-pyridin-2-yIethyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-(2-pyridin-4-ylethyl)benzenesulfonamide; 2-ethyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-methoxy-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-methoxy-5-(phenylsulfonyl)-N-(2-pyridin-4-ylethyl)benzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2,4-dimethyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2,4-dimethyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-chloro-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2,3-dimethyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-methyl-5-{[4-(methylamino)phenyl]sulfonyl}-N(2-pyridin-2-ylethyl)benzenesulfonamide; 2-isopropyl-5-{[4-(methylamino)phenyl]sulfonyl}-N-(2-pyridin-2-yletiiyl)ben2enesidfonaniide; 5-{[4-(l-cyclohexyl-l-hydroxyethyl)phenyl]sulfonyl}-2-methyl-AT-(2-pyridin-2- ylethyl)benzenesulfonamide; 5 - {[4-( 1 -hydroxy-1 -phenylethyl)phenyl] sulfony 1} -2-methy l-N-(2-pyridin-2- ylethyl)benzenesulfonamide; 5-{[4-(l-hydroxy-l-methyl-2-phenylethyl)phenyl]sulfonyl}-2-methyl-N"-(2-pyridin-2- ylethyl)benzenesulfonamide; 5-[(3-cyanophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-methyl-5-(l-naphthylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonainide; 5-[(3-hydroxyphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(3S-difluorophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4-ethylphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)beiizenesulfonamide; 5-[(3-acetylphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(2-ethoxyphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(2,5-dimethoxyphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(23-dimethoxyphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(2,4-dimethoxyphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-methyl-N-(2-pyridin-2-ylethyl)-5-(pyridin-3-ylsulfonyl)benzenesulfonamide; 5-(lH-indol-5-ylsulfonyl)~2-methyl-N-(2-pyridin-2-ylethyl)beiozenesulfonamide; 5-[(4-cyanophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonaniide; 5-{[3-(ethylsulfonyl)phenyl]sulfonyl}-2-methyl-N-(2~pyridin-2-ylethyl)beiizenesulfonamide; 2-methyl-5-[(2-methylphenyl)sulfonyl]-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(2-ethylphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-(biphenyl-2-ylsulfonyl)-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-(biphenyl-4-ylsulfonyl)-2-methyl-N-(2-pyridm-2-ylethyl)benzenesulfonamide; 5-(biphenyl-3-ylsulfonyl)-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4-tert-butylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide; 5-[(4-tert-butylphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(3,5-dimethylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(3-chlorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-isopropyl-5-[(3-methoxyphenyl)sulfonyl]-N-(2-pyridin-2-ylethyl)benzenesulfonainide; 2-isopropyl-5-[(2-methoxyphenyl)sulfonyl]-N:-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(3,5-difluorophenyl)siilfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-cyclohexyl-5-(phenylsulfonyl)-N:-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-cyclohexyl-5-[(4-fluorophenyl)sulfonyl]-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-tert-butyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonainide; 2,6-dimethyl-3-(phenylsulfonyl)-N'-(2-pyridin-2-ylethyl)benzenesulfonainide; 5-{[5-(dimethylamino)-l-naphthyl]sulfonyl}-2-isopropyl-N-(2-pyridin-2- y lethyl)benzenesulfonamide; 5-[(3-chloro-5-cyanophenyl)sulfonyl]-2-methyl-/V-(2-pyridin-2-ylethyl)benzenesulfonamide 2-methyl-3-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benz;enesulfonamide; 5-[(3,5-dichlorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-isopropyl-N-(2-pyridin-2-ylethyl)-5-{[3- (trifluoromethoxy)phenyl] sulfonyl} benzenesulfonamide; 5-{[4-(dimethylamino)phenyl]sulfonyl}-2-isopropyl-N-(2-pyridin-2- y lethy l)benzene sulfonamide; 2-isopropyl-N-(2-pyridin-2-ylethyl)-5- {[3- (trifluoromethyl)phenyl]sulfonyl}benzenesulfonamide; 5-[(5-chloro-2-methoxyphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide; 2-isopropyl-N-(2-pyridin-2-ylethyl)-5-(quinolin-8-ylsulfonyl)benzenesulfonamide; 5-[(2,5-dichloro-3-thienyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)beiizenesulfonamide; 5-[(5-chloro-lJ3-dimethyl-lH-pyrazol-4-yl)sulfonyl]-2-isopropyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide; 2-isopropyl-5-[(1 -methyl- 1H-imidazol-4-y l)sulfonyl] -N-(2 -pyridin-2- ylethyl)benzenesulfonamide; 5-[(3-chloro-2-methylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4,4-dimethyl-2-oxo-l,4-dihydro-2N-3,l-benzoxazin-6-yl)sulfonyl]-2-isopropyl-N-(2-pyridm- 2-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-4-ylethyl)benzenesulfonamide; 5- [(4-fluorophenyl)sulfonyl] -2-isopropyl-N-(2-pyridin-3 - ylethyl)benzenesulfonamide; 5-[(3-cyanophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-(lH-indol-5-ylsulfonyl)-2-isopropyl-N:-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-(phenylsulfonyl)-2-propyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-propyl-N'-(2-pyridin-2-ylethyl)ben2enesulfonamide; 5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)-2-(trifluoromethyl)benzenesulfonamide; 2-isopropyl-5-(phenylsulfinyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(3-bromo-2-methylphenyl)sulfonyl]-2-isopropyl-N'-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(2R-Moro-6-me1iiylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesvdfonamide; 2-isopropyl-5-[(3-me1hylphenyl)sulfonyl]-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-isopropyl-5-[(R)-phenylsulfinyl]-N'-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-isopropyl-5-[(S)-phenylsulfinyl]-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-bromo-5-(phenylsulfonyl)-N"-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(3-cyano-2-methylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(3-acetyl-2-methylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(3-chloro-4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4-fluoro-2-methylphenyl)sulfonyl]-2-isopropyl-?/-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-isopropyl-5-[(l-methyl-lJff-indol-5-yl)sulfonyl]-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-isopropyl-5-{[2-methyl-4-(methylamino)phenyl]sulfonyl}-N-(2-pyridin-2- y lethyl)benzenesulfonami de; 5-{[3-chloro-4-(methylamino)phenyl]sulfonyl}-2-isopropyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide; 2,4-diisopropyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)beinzenesulfonamide; 2,4-diisopropy]-5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)benzenesulfonamide; 2,4-diisopropyl-5-(phenylsulfonyl)-yV-(2-pyridin-4~ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropyl-N-(2-pyridin-3-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropyl-N-(2-pyridin-4-ylethyl)benzenesulfonamide; 2-chloro-5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)benzenesulfonamide; 2-chloro-5-(phenylsulfonyl)-N-(2-pyridin-4-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[2-(l-oxidopyridin-3-yl)ethyl]benzenesulfonamide; 5 - [(4-fluorophenyl)sulfony 1] -N- [2-( 1 H-imidazo 1-4-y l)ethy 1] -2-methylbenzenesulfonamide; 5 - [(4-fluorophenyl)sulfony l]-N- [3 -(1 H-imidazo 1-1 -y l)propy 1] -2-methylbenzenesulfonamide; N- [2-( 1 H-imidazol-4-y l)ethy 1] -2-methyl-5 -(phenylsulfony l)benzenesulfonamide; N-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; 2-ethy l-N-[2-( 1 N"-imidazol-4-yl)ethyl]-5 -(phenylsulfony l)benzenesulfonamide; 2-emyl-N-[3-(1H-imidazol-l-yl)propyl]-5-(phenylsulfonyl)benzenesulfonamide; N"-[2-(1H-imidazol-4-yl)elhyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonaniide; N- [3-( 1H-imidazol-1 -yl)propyl] -2-methoxy-5-(phenylsulfony l)benzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide; 5-[(4-azidophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide; N-[2 -(1 H-indol-3 -yl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N- [3-( 1 H-imidazol-1 -yl)propyl] -2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide; 2-ethy 1-5 - [(4-fluorophenyl)sulfonyl] -N- [2 -(1H- imidazol-1 -yl)ethyl]benzenesulfonamide; 2-ethyl-5-[(4-fluorophenyl)sulfonyl]-N:-[3-(lN'-imidazol-l-yl)propyl]benzenesulfonamide; 5-({4-[ethyl(methyl)amino]phenyl}sulfonyl)-N-[3-(1H-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide; N- [3 -(1 H-imidazol-1 -yl)propy 1] -2-methy 1-5 -[(4-py rrolidin-1 - ylphenyl)sulfonyl]benzenesulfonamide; N-[3-(1H-imidazol-l-yl)propyl]-4-methyl-3-(phenylsulfinyl)benzenesulfonamide; S-N-fluorophenyNsulfonylj-N- [2-( 1 H- imidazol-1 -yl)ethyl]-2-methylbenzenesulfonamide; N-[3-(1H-imidazol-l-yl)propyl]-2-methyl-5-{[4- (raethylamino)phenyl]sulfonyl}ben2enesulfonamide; 5-{[4-(ethylamino)phenyl]sulfonyl}-yV-[3-(1H-imidazol-l~yl)propyl]-2- methylbenzenesulfonamide; N- [3-(1 H-imidazol-1 -yl)propyl]-2-methyl-5- [(4-piperidin-1 - ylphenyl)sulfonyl]benzenesulfonamide; N-[3-(lN-imidazol-l-yl)propyl]-2-methyl-5-[(4-morpholin-4- ylphenyl)sulfonyl]benzenesulfonamide; N-[2-(lN-imidazol-l-yl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[3-(lN-imidazol-l-yl)propyl]-5-[(4-methoxyphenyl)sulfonyl]-2-methylbenzenesulfonamide; N[3-(lH-imidazol-l-yl)propyl]-5-[(2-methoxyphenyl)sulfonyl]-2-methylbenzenesulfonamide; N-[3-(lH-imidazol-l-yl)propyl]-4-methyl-3-(phenylsulfonyl)benzenesulfonamide; 5 - [(4-fluoropheny 1) sulfony 1] -N- [2-( 1 N-imidazol-1 -y l)ethy 1] -2-isopropylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-isopropylbenzenesulfonainide; N-[3-(lN-imidazol-l-yl)propyl]-5-[(3-methoxyphenyl)sulfonyl]-2-methylbenzenesulfonamide; N[2-(1H-imidazol-l-yl)etiiyl]-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide; N-[3-(1H-imidazol-l-yl)propyl]-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N'-[2-(1H-imidazol-l-yl)ethyl]-2,4-dimethylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N[3-(lN-imidazol-l-yl)propyl]-2,4-dimethylbenzenesulfonamide; 2-chloro-N-[3-( 1 H-imidazol-1 -yl)propyl]-5-(phenylsulfonyl)benzenesulfonamide; N-[3-(1H-imidazol-l-yl)propyl]-5-[(4-isopropylphenyl)sulfonyl]-2-methylbenzenesulfonamide; N-[3-(1H-imidazol-l-yl)propyl]-2-methyl-5-(2-naphthylsulfonyl)benzenesulfonamide; 5-[(354-dichlorophenyl)sulfonyl]-Nr-[3-(lN-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide; 5-[(3-chlorophenyl)sulfonyl]-N'-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide; 5-[(3,5-dimethylphenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide; 5-[(3,5-dichlorophenyl)sulfonyl]-N[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide; 5-[(2,5-dicMorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide; N-[3-(lH-iinidazol-l-yl)propyl]-2-methyl-5-(phenylsulfinyl)benzenesulfonamide; N-[2-(lH-imidazol-l-yl)ethyl]-2,3-ditnethyl-5-(phenylsulfonyl)benzenesulfonamide; N-[3-(lH-irnidazol-l-yl)propyl]-2,3-dimethyl-5-(phenylsulfonyl)benzenesulfonamide; 5-{[4-(cyclohexylamino)phenyl]sulfonyl}-N-[3-(lH-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide; 5-({4-[(2-cyanoethyl)amino]phenyl}sulfonyl)-N-[3-(lH-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide; 5-[(4-{[(1S,2S)-l-(hydroxymethyl)-2-methylbutyl]amino}phenyl)sulfonyl]--N-[3-(lN-imidazol- l-yl)propyl]-2-methylbeixzenesulfonamide; N-[3-(1H-imidazol-l-yl)propyl]-2-methyl-5-({4-[(l- pheny lethyl)amino]phenyl} sulfonyl)benzenesulfonamide; 5-[(2,3-diclilorophenyl)sulfonyl]-N-[3-(H-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide; N-[3-(lN-imidazol-l-yl)propyl]-2-methyl-5-(2-thienylsulfonyl)benzenesulfonamide; N- [3 -(1 H-imidazol-1 -y l)propyl] -2-methyl-5 - [(2 -methy 1-3 -furyl)sulfonyl] benzenesulfonamide; N-[3-( 1 H-imidazol-1 -yl)propyl] -2-methyl-5- {[4-(tetrahydro-2H-pyran-4- ylamino)phenyl]sulfonyl}benzenesulfonamide; N-[3-(lN"-imidazol-l-yl)propyl]-5-({4-[(3-isopropoxypropyl)amino]phenyl}sulfonyl)-2- methylbenzenesulfonamide; 5-({4-[(cyclopropylmethyl)amino]phenyl}sulfonyl)-N-[3-(lN-inudazol-l-yl)propyl]-2- methylbenzenesulfonamide; 5-({4-[(lJR,2/?,4S)-bicyclo[2.2.1]hept-2-ylamino]phenyl}sulfonyl)-N-[3-(1H-imidazol-l- yl)propyl]-2-methylbenzenesulfonamide; 5 - {[4-(benzy lamino)pheny 1] sulfony 1} -N- [ 3 -(1 H-imidazol-1 -y l)propy 1] -2- methylbenzenesulfonamide; 5-[(4-{[(lS)-l-cyclohexylethyl]amino}phenyl)sulfonyl]-N-[3-(lN-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide; 5-[(4-{[(l/2)-l-cyclohexyle%l]ammo}phenyl)sulfonyl]-N-[3-(lJN-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide; 5 -({4- [(2-hydroxybutyl)amino]phenyl} sulfonyN-N-[S-1H-imidazol-l -yl)propyl]-2- methylbenzenesulfonamide; N-[3-(1H-imidazol-l-yl)propyl]-2-methyl-5-[(4-{[4- (trifluoromethyl)benzyl]amino}phenyl)sulfonyl]benzenesulfonamide; 5-[(2-chlorophenyl)sulfonyl]-N-[3-(l H-imidazol-1 -yl)propyl]-2-methylbenzenesulfonamide; N-(tert-butyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; 5 - [(4-tert-butylphenyl)sulfonyl] -N-[3-( 1 H-irnidazol-1 -yl)propyl] -2- isopropylbenzenesulfonamide; 5 - [(4-tert-buty Ipheny 1) sulfony 1] -N- [3 -(1 H-imidazol-1 -y l)propyl] -2- methylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-[2-(1H-imidazol-4-yl)ethyl]-2-isopropylbenzenesulfonamide; 5-({4-[(2-cyanoethyl)amino]phenyl}sulfony.l)-N-[2-(lN-imidazol-l-yl)ethyl]-2- isopropylbenzenesuifonamide; N-[2-( I H-imidazol-1 -yl)ethyl]-2-isopropyl-5- {[4- (methylamino)phenyl]sulfonyl}benzenesulfonamide; 5-({4-[(2-hydroxybutyl)amino]phenyl}sulfonyl)-N-[2-(1H-imidazol-l-yl)ethyl]-2- isopropylbenzenesulfonamide; 5-[(4-{[(2S)-l(hydroxymethyl)-2-methylbutyl]amino}phenyl)sulfonyl]-N-[2-(lN'-imidazol-l- yl)ethyl]-2-isopropylbenzenesulfonamide; N-[3-(lH"-imidazol-l-yl)propyl]-2-methyl-3-(phenylsulfonyl)benzenesulfonamide; N-[3-(1H-Imidazol-l-yl)propyl]-5-(phenylsulfonyl)-2-propylbenzenesulfonamide; 5-[(4-Fluorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-propylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[2-(2-methyl-H'-imidazol-l- yl)ethyl]benzenesulfonamide; AT-[2-(2-ethyl-lH-imidazol-l-yl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[2-(2-isopropyl- IH-imidazol-1 - yl)ethyl]benzenesulfonamide; N-[3-(1H-Imidazol-l-yl)propyl]-2,4-diisopropyl-5-(phenylsulfonyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[2-(l-methylpyrrolidin-2-yl)ethyl]benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(2-piperidin-l-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-me1iiyl-N-(2-moipholin-4-ylethyl)benzenesulfonainide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N[3-(2-oxopyrrolidin-l-yl)propyl]benzenesulfonamide; N-[3-(dimethylamino)propyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(2-methoxyethyl)-2-methylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(3-pyrrolidin-l-ylpropyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[3-(4-methylpiperazin-l- yl)propyl]benzenesulfonamide; 2-methyl-N-(3-morpholin-4-ylpropyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-N-[2-(l-methylpyrrolidin-2-yl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-(2-piperidin-l-ylethyl)benzenesulfonamide; 2-methyl-N-(2-morpholin-4-ylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-N-[3-(2-oxopyrrolidin-l-yl)propyl]-5-(phenyisiilfonyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-(3-pyrrolidin-l-ylpropyl)benzenesulfonamide; , 2-methyl-N-[3-(4-methylpiperazin-l-yl)propyl]-5-(plienylsulfonyl)benzenesulfonamide; 2-ethyl-N-(2-moipholin-4-ylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-ethyl-5-(phenylsulfonyl)-N-(3-pyiTolidin-l-ylpropyl)benzenesulfonamide; 2-methoxy-N'-(2-rnorpholin-4-ylethyl)-5-(phenylsulfonyl)beiizenesulfonamide; 2-methoxy-5-(phenylsulfonyl)-N-(3-pyrrolidin-l-ylpropyl)benzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-(2-morpholin-4-ylethyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-tetrahydro-2N-pyran-4-ylbenzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-(2-tetrahydro-2N-pyran-4-ylethyl)benzenesulfonainide; 2-ethyl-5-(phenylsulfonyl)-A|r-tetrahydro-2N-pyran-4-ylbenzenesulfonamide; 2-ethyl-5-(phenylsulfonyl)-N-(2-tetrahydro-2/:f-pyran-4-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-Ntetrahydro-2Nf-pyran-4-ylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(2-tetrahydro-2Jf-pyranN-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N:-tetrahydro-2N"-pyran-4-ylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-tetrahydro-2H-pyran-4- ylethyl)benzenesulfonamide; 2,4-dimethyl-5-(phenylsulfonyl)-N-te1rahydro-2H-pyran-4-ylbenzenesxilfonamide; 2,4-dimethyl-5-(phenylsulfonyl)-N-(2-tetrahydro-2H-pyran-4-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2,4-dimethyl-N-(tetrahydro-2N-pyran-4-yl)benzenesulfonamide; 5-[(4-fluorophenyl)siilfonyl]-2,4-dime1hyl-N-[2-(tetrahydro-2N-pyran-4- yl)ethyl]benzenesulfonamide; 2-chloro-N'-(2-inorpholin-4-ylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2,3-dimethyl-5-(phenylsulfonyl)-N-(tetrahydro-2N-pyran-4-yl)benzenesulfonamide; 2,3-dimethyl-5-(phenylsulfonyl)-N-[2-(tetrahydro-2H-pyran-4-yl)ethyl]benzenesulfonamide; 2-isopropyl-5-{[4-(methylamino)phenyl]sulfonyl}-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide; 2-isopropyl-5-{[4-(methylamino)phenyl]sulfonyl}-N-[2-(tetrahydro-2H-pyran-4- yl)ethyl]benzenesulfonamide; 2-chIoro-5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; 5 - [(4 -bromopheny l)sulfony 1] -2-methyl-N-(tetrahydro -2H-pyran-4-y l)benzenesulfonamide; 5-[(4-cyanophenyl)sulfonyl]-2-methyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; N-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5-(pyridin-2H-sulfonyl)benzenesulfonamide; 5-[(2,4-dichlorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide; 5-[(4-acetylphenyl)sulfonyl]-2-methyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; 5-[(4-bromophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-(tetrahydro-2N-pyran-4-ylmethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(tetrahydro-2H-pyran-4-ylmetliyl)benzenesulfonamide; 2-ethyl-5-[(4-fluorophenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide; 2,4-dimethyl-5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide: N-(2,2-dimethylpropyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; 5-({4-[(lH)-N-hydroxyethanimidoyl]phenyl}sulfonyl)-2-methyl-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide; 5-[(4-acetylphenyl)sulfon-yl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5- {[4-( 1 -hydroxy-1 -methy lethyl)pheny 1] sulfony 1} -2-methy l-N-(2-pyridin-2- ylethyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-(2,2,6,6-tetrNnethylpiperidin-4-yl)benzenesulfonamide; N-(1 -benzylpiperidin-4-yl)-2-methy 1- 5-(pheny Isulfony l)benzenesulfonamide; N-(l-benzylpyrrolidiB-3-yl)-2-methyl-5-(phenylsulfonyl)benzenesulfonNaide; ethyl 4-( {[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl} amino)piperidine-1 -cNboxylate; 5-[(4-tert-butylphenyl)sulfonyl]-2-isopropyl-N-(teirahydro-2H-pyran-4-yl)benzenesulfonaniide; 5-[(4-tert-butylphenyl)sulfonyl]-2-methyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-pyran-4- ylmethyl)benzenesulfonamide; tert-butyl 4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-1 - cNboxylate; 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-[l-(phenylsulfonyl)piperidin-4-yl]benzenesulfonamide; N-[l-(2-furoyl)piperidin-4-yl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[l-(2-methoxybenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide; N-[l-(3-methoxybenzoyl)piperidin-4-yl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[l-(3,4-dimethoxybenzoyl)piperidin-4-yl]~2-methyl-5- (phenylsulfonyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-{l-[3-(trifluoromethyl)benzoyl]piperidin-4- yl} benzenesulfonamide; N-[l-(4-clilorobenzoyl)piperidin-4-yl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[l-(4-methoxybenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide; 2-methyl-N-[l-(4-methylbenzoyl)piperidin-4-yl]-5- (phenylsulfonyl)benzenesulfonamide; N-[l-(methoxyacetyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide; 2-methyl-N-[l-(phenylacetyl)piperidin-4-yl]-5-(phenylsulfonyl)beiizenesulfonamide; N-[l-(cyclohexylcNbonyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide; 2,6-dimethyl-3-(phenylsulfonyl)-N-(tetrahiydro-2H-pyran-4-yl)benzenesulfonamide; N-[l-(cyclopropylcbonyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide; N-[l-(4-cyanobenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide; N-[l-(3-cyanobenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide; 2-methyl-N-[l-(methylsulfonyl)piperidin-4-yl]-5- (phenylsulfonyl)benzenesulfonamide;; N-(l-acetylpiperidin-4-yl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide N-(4- {[4-( {[2-methyl-5-(phenylsulfonyl)phenyl] sulfonyl} amino)piperidin-l - yl]cNbonyl}phenyl)acetamide; 2-methyl-N-{l-[(l-methyl-lH-imidazol-4-yl)sulfonyl]piperidin-4-yl}-5- (phenylsulfonyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-[l-(2-thienylsulfonyl)piperidin-4-yl]benzenesulfonamide; N-(l-{[5-(dimethylamino)-l-naphthyl]sulfonyl}piperidin-4-yl)-2-methyl-5- (phenylsulfonyl)benzenesulfonamide; N-[l-(l,3-benzodioxol-5-ylcNbonyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesnlfonamide; N-[l-(isoxazol-5-ylcNbonyl)piperidin-4-yl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[l-(N,N-dimethylglycyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide; prop-2-yn-l-yl4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-1- cNboxylate; methyl 4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- cNboxylate; 2-methoxyphenyl 4-({[2-methyl-5- (phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- cNboxylate; N-(tert-butyl)-4-( {[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-1- carboxamide; N-cyclohexyl-4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- carboxamide; 2-methyl-N-(2-morpholin-4-ylethyl)-3-(phenylsulfonyl)benzenesulfonamide; 2-methyl-N-[l-(2-naphthoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-[l-(2-thienylcNbonyl)piperidin-4-yl]benzenesulfonamide; isobutyl4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- cNboxylate; N-{l-[4-(dimethylamino)benzoyl]piperidin-4-yl}-2-methyl-5- (pheny lsulfonyl)benzenesulfonamide;; 4-fluorophenyl4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine- 1- carboxylate N-ethyl-4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl} amino)piperidine-1 - carboxamide; 2-methyl-N-[l-(morpholin-4-ylcNbonyl)piperidin-4-yl]-5- (phenylsulfonyl)benzenesulfonamide; N,N-dimethyl-4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- carboxamide; N-[l-(3,3-dimethylbutanoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-[l-(pyridin-3-ylcNbonyl)piperidin-4-yl]benzenesulfonamide; tert-butyl4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]piperidine-l- cNboxylate; N-(l -{[5-(dimethylamino)-1 -naphthyl]sulfonyl}piperidin-4-yl)-5-[(4- fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[l-(methoxyacetyl)piperidin-4- yl]benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-piperidin-4-ylbenzenesulfonamide; N-(l-ben2ylpiperidin-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide; Ethyl-4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidine-l- carboxylate; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-piperidin-1 - ylethyl)benzenesulfonamide; tert-butyl 4-{[(2-isopropyl-5-{[4- (methylamino)phenyl]sulfonyl}phenyl)sulfonyl]amino}piperidine-l-cNboxylate; N-(l-acetylpiperidin-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide; N- [1 -(cy clopropy IcNbony l)piperidin-4-y 1] -5 - [(4-fluoropheny l)sulfony 1] -2 - isopropylbenzenesulfonamide; N-[l-(4-cyanobenzoyl)piperidin-4-yl]-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(tetxahydrofuran-2-ylmethyl)benzenesulfonamide; 5-({4-[(2-cyanoethyl)amino]phenyl}sulfonyl)-2-isopropyl-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide; 5-({4-[(2-cyanoethyl)amino]phenyl}sulfonyl)-2-isopropyl-N"-(tetrahydro-2H-pyran-4- ylmethyl)benzenesulfonamide; 5-({4-[(2-cyanoethyl)amino]phenyl}sulfonyl)-2-isopropyl-yV-[2-(tetrahydro-2N-pyran-4- yl)ethy 1] benzenesulfonamide; N-(3',6'-dihydroxy-3-oxo-3H-spiro[2-benzofuran-l39'-xanthen]-5-yl)-4-[({5-[(4- fluorophenyl)sulfonyl]-2-isopropylphen.yl}sulfonyl)amino]piperidine-l- cNbothioamide; 2-isopropyl-5-[(2-methylphenyl)sulfonyl]-N-(tetrNiydro-2jy-pyran-4-yl)benzenesulfonamide; 5-[(3-chloro-2-methylphenyl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide; 2-isopropyl-5-{[4-(methylamino)phenyl]sulfonyl}-N-(tetrahydro-2W-pyran-4- yl-methy l)benzenesulfonamide; 5-{[4-(dimethylamino)phenyl]sulfonyl}-2-isopropyl-N/-(tetrahydro-2/J-pyran-4- yl)ben2enesulfonamide; 5 - {[4-(dimethylamino)phenyl]sulfonyl} -2-isopropyl-N"-(tetrahydro-2N-pyran-4- ylmethyl)benzenesulfonamide; 5-{[4-(dimetiiylamino)phenyl]sulfonyl}-2-isopropyl-N-[2-(tetrahydro-2H-pyran-4- yl)ethyl]benzenesulfonamide; 2-isopropyl-5-{[4-(4-me1hylpiperazin-l-yl)phenyl]sulfonyl}-7\/:-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide; 2-isopropyl-5- {[4-(4-methylpiperazin-1 -y l)phenyl] sulfony 1} -N-(tetrahydro-2H'-pyran-4- ylmethyl)benzenesulfonamide; 2-isopropyl-5-{[4-(4-methylpiperazin-l-yl)phenyl]sulfonyl}-N'-[2-(tetrahydro-2jyr-pyran-4- yl)ethyl]benzenesulfonamide; 5-(phenylsulfonyl)-2-propyl-N'-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; 5-(phenylsulfonyl)-2-propyl-N-(tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide; 5-(phenylsulfonyl)-2-propyl-N-[2-(tetrahydro-2H-pyran-4-yl)ethyl]benzenesulfonamide; tert-butyl 4-( {[5-(phenylsulfonyl)-2-propylphenyl]sulfonyl} amino)piperidine-1 -cNboxylate; 5-[(4-fluorophenyl)sulfonyl]-2-propyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-propyl-N-(tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-propyl-N-[2-(tetrahydro-2N-pyran-4- yl)ethyl]benzenesulfonamide; tert-Butyl 4-[({5-[(4-fluorophenyl)sulfonyl]-2-propylphenyl}sulfonyl)amino]piperidine-l- cNboxylate; 2-isopropyl-5-{[4-(methylamino)phenyl]sulfonyl}-N-piperidin-4- ylbenzenesulfonamide; 5-[(5-chloro-l,3-dimethyl-H-pyrazol-4-yl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-pyran-4- y l)benzene sulfonamide; 5-[(4-fiuorophenyl)sulfonyl]-2-isopropyl-N-[l-(morpholin-4-ylcNbonyl)piperidin- 4- y 1] benzene sulfonamide; 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N,N- dimethylpiperidine- 1-carboxamide; N-(l-benzylpiperidin-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesuIfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-piperidin-4-ylbenzenesulfonamide; 5-({4-[(2-cyanoethyl)(methyl)amino]phenyl}sulfonyl)-2-isopropyl-N-(tetrahydro-2f/-pyran-4- yl)benzenesulfonamide; 5-( {4- [(2-cyanoethy l)(methyl)amino]pheny 1} sulfony l)-2-isopropyl-N-(tetrahydro-2H-pyran-4- ylmethyl)benzenesulfonamide; N-(l-acetylpiperidinN-yl)-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesiilfonamide; N-[l-(4-cyanobenzoyl)piperidin-4-yl]-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide; 4-[({5-[(4-fluorophenyl)sulfonyl]-2-methylphenyl}sulfonyl)amino]-N,N-dimethylpiperidine-l- carboxamide; 5-[(4-fluorophenyl)sulfonyl]-N-[l-(methoxyacetyl)piperidin-4-yl]-2- methylbenzenesulfonamide; 2-isopropyl-5-[(3-methoxyphenyl)sulfonyl]-N'-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; 5-{[4-(dimethylamino)-2-methylphenyl]sulfonyl}-2-isopropyl-N'-(2-pyridin-2- ylethyl)benzenesulfonamide; 2-(dimethylamino)-5-(phenylsulfonyl)-N'-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[l-(morpholin-4-ylcarbonyl)piperidin-4- yl]benzenesulfonamide; 2-chloro-5-[(3-methylphenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; 2-chloro-5 - [(3 -methoxypheny 1) sulfony 1] -N-(tetrahydro-2N-pyran-4-y l)benzenesulfonamide; 2-chloro-5-[(l-methyl-1H-indol-5-yl)sulfonyl]-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide; 5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-2-(trifluoromethyl)benzenesulfonamide; 2,4-diisopropyl-5~(phenylsulfonyl)-N-(tetrahydro-2jcf-pyran-4-yl)benzenesulfonamide; 2,4-diisopropyl-5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide; 2,4-diisopropyl-5-(phenylsulfonyl)-N-[2-(tetrahydro-2/i"-pyran-4-yl)ethyl]benzenesulfonamide; 5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyl-N-(tetvahydro-2/L/-pyran-4-yl)beixzenesulfonNnide; 2-chloro-5-[(4-fluorophenyl)sulfonyl]-N:-(tetrahydro-2N-pyran-4-yl)benzenesulfonamide; tert-butyl 4-( {[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl} amino)piperidine-1 -cNboxy late 2-chloro-5 -(pheny lsulfonyl)-N-piperidin-4-ylbenzenesulfonamide;; tert-butyl4-[4-({4-isopropyl-3-[(tetrahydro-2N-pyran-4- ylamino)sulfonyl]phenyl} sulfonyl)phenyl]piperazine-l -cNboxy late 5-({4-m-3,5-dimethylpiperazin-1 -ylphenyl} sulfonyl)-2-isopropyl-N-(tetrahydro-2/:f-pyran-4- yl)benzenesulfonamide; 5-({4-trans-2,5-dimethylpiperazin-l-ylphenyl}sulfonyl)-2-isopropyl-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide; 2-isopropyl-5-[(4-piperazin-l-ylphenyl)sulfonyl]-N-(tetrahydro-2f/-pyran-4- yl)benzenesulfonamide; 5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyl-N-(tetrahydro-2N-pyran-4- ylmethyl)benzenesulfonamide; 5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyl-N-[2-(tetrahydro-2/:f-pyran-4- yl)ethyl]benzenesulfonamide; 2-chloro-N-[3-(4-methylpiperazin-1 -yl)propyl] -5-(phenylsulfonyl)benzenesulfonamide; l-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}-N..Ndiethylpyrrolidin-3-amine; ethyl 1 -{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl} piperidine-3-cNboxy late; 2-chloro-5-(phenylsulfonyl)-N'-[l-(trifluoroacetyl)piperidin-4-yl]benzenesulfonamide; 2-chloro-N-[ 1 -(2,2-dimethylpropaoy l)piperidin-4-y 1] -5-(phenylsulfonyl)benzenesulfonamide; N-(tert-butyY)-4-( {[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl} amino)piperidine-1 - carboxamide; 2-chloro-/N-[l-(morpholin-4-ylcNbonyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide; 2-chloro-N-(l-cyanopiperidin-4-yl)-5-(phenylsulfonyl)benzenesulfonamide; N-({5-[(4-fluorophenyl)sulfonyl]-2-methylphenyl}sulfonyl)-beta-Naninamide; methyl N-({5-[(4-fluorophenyl)sulfonyl]-2-methylphenyl}sulfonyl)-beta-Naninate; N-(2-cyanoethyl)-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; . N-{2-[({5-[(4-fluorophenyl)sulfonyl]-2-methylphenyl}sulfonyl)amino]ethyl}acetamide; N-[2-(diethylNaino)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N-[2-(dimethylamino)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(3-methoxypropyl)-2-methylbenzenesulfonamide; N-[3-(diethylamino)propyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N- ({5-[(4-fluorophenyl) sulfonyl]-2-methylphenyl} sulfonyl)-beta-Nanine; N-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-beta-Naninamide; methyl N-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-beta-Naninate; N-[2-(diethylamino)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(dimethylamino)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-(3-methoxypropyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[3-(dimethylamino)propyl]-2-rnethyl-5-(phenylsulfonyl)benzenesulfonamide; N-(2-methoxyethyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[3-(diethylamino)propyl]-2-methyl-5-(phenylsulfonyl)benzenesuifonamide; methyl N-{[2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyl}-beta-Naninate; 2-ethyl-N-(3-methoxypropyl)-5-(phenylsulfonyl)benzenesulfonamide; N-[3-(dimethylamino)propyl]-2Nthyl-5-(phenylsulfonyl)benzenesulfonamide; 2-ethyl-N-(2-methoxyethyl)-5-(phenylsulfonyl)benzenesulfonamide; N- [3-(diethylamino) propyl]-2-ethyl-5- (phenylsulfonyl) benzene sulfonamide; methyl AT-{[2-methoxy-5-(phenylsulfonyl)phenyl]sulfonyl}-beta-Naninate; 2-methoxy-N-(3-methoxypropyl)-5-(phenylsulfonyl)benzenesulfonamide; N-[3-(dimethylamino)propyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide; 2-methoxy-N-(2-methoxyethyl)-5-(phenylsulfonyl)benzenesulfonamide; N-[3-(diethylamino)propyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-propylbenzenesulfonamide; N-(l-ethylpropyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-cyclobutyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-cyclopentyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-cyclohexyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-(2,2,2-trit]uoroethyl)benzenesulfonaniide; N-(2-hydroxy-1,1 -dimethylethyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-cyclopropyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-cyclopropyl-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide; N-cyclobutyl-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonNnide; N-cyclopentyl-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide; N-cyclohexyl-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide; N-cyclopentyl-5-(phenylsulfonyl)-2-propylbenzenesulfonNaide; N-cyclopentyl-5-[(4-fluorophenyl)sulfonyl]-2-propylbenzenesulfonamide; N-cyclopentyl-2,4-diisopropyl-5-(phenylsulfonyl)benzenesulfonamide; Ncyclopentyl-5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropylbenzenesulfonamide; 2-chloro-N"-(2-cyanoethyl)-5-(phenylsulfonyl)benzenesulfonainide; methyl N-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}-2-methylNaninate; N-[2-(3,4-dime1hoxyphenyl)ethyl]-N,2-dimethyl-5-(phenylsulfonyl)benzenesulfonainide; N-Nyl-N'-[2-(3,4-dimethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)ben2:enesulfonamide; N[2-(3,4-dimethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)-N-prop-2- ynylbenzenesulfonamide; N-[2-(2-fluorophenyl)ethyl]-N,2-dimethyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-Nlyl-N- [2-(2-fluorophenyl) ethyl]-2-methyl-5- [(4-methylphenyl) sulfonyl] benzene sulfonamide; N[2-(2-fluorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]-N-prop-2- ynylbenzenesulfonamide; N,2-dimethyl-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonaniide; l-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-4-(2-oxo-2-pyrrolidin-l-ylethyl)piperazine; N,N-diethyl-N-[2-(4-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-l-yl)ethyl]amine; 4-[2-(4- {[2-methyl-5-(phenylsulfonyl)phenyl] sulfonyl} piperazin-1 -yl)ethyl]morpholine; 1 - {[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl} -4-(2-pyrrolidin-1 -ylethyl)piperazine; 4-[3-(4-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-l-yl)propyl]morpholine; 2-ethyl-N-methyl-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 1 - {[2-ethyl-5-(phenylsulfonyl)phenyl] sulfonyl} -4-(2-oxo-2-pyrrolidin-1 -ylethyl)piperazine; N-diethyl-N-[2-(4-{[2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-l-yl)ethyl]amine; 4-[2-(4-{[2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-l-yl)ethyl]morpholine; l-{[2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyl}-4-(2-pyrrolidin-l-ylethyl)piperazine; 4-[3-(4-{[2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyi}piperazin-l-yl)propyl]morpholine; N-[l-(cyclopropylcNbonyl)piperidin-4-yl]-N-({5-[(4-fluorophenyl)sulfonyl]-2-methylphenyl}sulfonyl)cyclopropanecNboxainide; 1 - {[2-chloro-5-(pheny lsulfonyl)pheny 1] sulfony 1}-4-pyrrolidin-1-ylpiperidine; 4-[2-(4-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-l-yl)ethyl]morpholne; 1 -(1.3 -benzodioxol-5-ylmethyl)-4-{ [2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}piperazine; tert-butyl (l-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}pyrrolidin-3-yl)carbamate; tert-butyl(l-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}piperidin-4-yl)carbamate; 2-chloro-N-methyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 1 - {[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl} -4-[(2,5-dimethyl- IH-pynol-1 -yl)methyl]piperidine; 2-chloro-N-(2-hydroxy-1,1 -dimethylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-chloro-N-(cyanomethyl)-5-(phenylsulfonyl)benzenesulfonamide; N-(2-cyanoethyl)-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide; 2-methyl-N-(3-oxo-3-pyrrolidin-l-ylpropyl)-5-(phenylsulfonyl)benzenesulfonamide; N-(tert-butyl)-N-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-p-Naninainide; N-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-N-(l,2,3,4-tetrahydronaphthNen-l-yl)-p-Naninamide; N-methyl-N-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-N-phenyl-p-Naninamide; 2-methyl-N'-[3-(6-methyl-3,4-dihydroquinolin-l(2H)-yl)-3-oxopropyl]-5-(phenylsulfonyl)benzenesulfonamide; 2-chloro-N-(2-hydroxyethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-chloro-N-(2-hydroxy-l-methylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-chloro-N-[2-hydroxy-l-(hydroxymethyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide; N-(2-cyanoethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-(2-hydroxyethyl)-5-(phenylsulfon.yl)-2-(trifluoromethyl)benzenesulfonamide; N-(2-hydroxy-l-methylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-[(16)-2-hydroxy-l-methylethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-[(lJ?)-2-hydroxy-l-methylethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-l-methylethyl)-2-isopropylben2enesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-[l-(hydroxymetliyl)-2-methylpropyl]-2-isopropylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxybutyl)-2-isopropylbenzenesulfonamide; N-(2-cyanoethyl)-5-[(3-methoxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide; 5-[(3-chlorophenyl)sulfonyl]-N-(2-cyanoethyl)-2-(trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-ybaethyl)-2-(trifluoromethyl)benzenesulfonamide; N-(2-morpholin-4-ylethyl)-5-(phenylsulfonyl)-2-(trifluorometlayl)benzenesulfonamide; N-(3-morpholin-4-ylpropyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-(3-methoxypropyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-[l-(hydroxymethyl)-2-methylpropyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N- [(1R)-1 -(hydroxymethy l)propy 1] -5 -(phenylsulfony l)-2 -(trifluoromethy l)benzen.esulfonamide; N-(2-hydroxyethyl)-5-[(3-methoxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide; N-(2-cyanoethyl)-5-[(4-methoxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide; N-(2-cyanoethyl)-5-[(4-hydroxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide; N-[(l-hydroxycyclohexyl)methyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-piperidin-3-ylethyl)benzenesulfonamide; -AT-{[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}-p-Nanine; 4-( {[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)butanoic acid; tert-butyl4-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidine- 1-cNboxylate; 5-(phenylsulfonyl)-N-(piperidin-4-ylmethyl)-2-(trifluoromethyl)benzenesulfonamide; tert-butyl [trans-4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)cyclohexyl]carbamate; 4-oxo-4- {4-[( {[5-(phenylsulfonyl)-2-(trifluoromethy l)phenyl] sulfonyl} amino)methyl]piperidin- l-yl}butanoic acid; 5-oxo-5-{4-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidin- l-yl}pentanoic acid; 3-({4-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidin-l- yl}sulfonyl)benzoic acid; tert-butyl 2-[2-( {[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl] sulfonyl} amino)ethyl]pyrrolidine-1 -cNboxylate; 5-(phenylsulfonyl)-N-(2-pyrrolidin-2-ylethyl)-2-(trifluoromethyl)benzenesulfonamide; {2-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidin-l- yl} acetic acid; 4-oxo-4-{2-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidin- l-yl}butanoic acid; 3-({2-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidin-l- yl}sulfonyl)benzoic acid; tert-butyl 4-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]piperidine- 1-cNboxylate; methyl 3-({[2-isopropyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)cyclohexanecNboxylate; methyl 4-({[2-isopropyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)cyclohexanecNboxylate; methyl trans-4-[({ [2-isopropyl-5- (phenylsulfonyl)phenyl]sulfonyl}amino)methyl]cyclohexanecNboxylate; 5-(phenylsulfonyl)-N-(2-piperidin-4-ylethyl)-2-(trifiuoromethyl)benzenesulfonamide; {4-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidin-l- yl}acetic acid; {4-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]piperidin-l- yl}acetic acid; methyl 3-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)cyclohexanecNboxylate; methyl 4-( {[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)cyclohexanecNboxylate; methyl trans-4-[({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)methyl]cyclohexanecNboxylate; 3-({[2-isopropyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)cyclohexanecarboxylic acid; 4-( {[2-isopropyl-5-(phenylsulfonyl)phenyl] sulfonyl} amino)cyclohexanecarboxylic acid; trans-4-[({ [2-isopropyl-5- (phenylsulfonyl)phenyl]sulfonyl}amino)methyl]cyclohexanecarboxylic acid; 3 - { 4- [({[5 -(phenylsulfony l)-2-(trifluoromethy l)pheny 1] sulfonyl} amino)methyl]piperidin-1 - yl}benzoic acid; 3-{4-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]piperidin-l- yl}benzoic acid; N-(trans'-4-aminocyclohexyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; 3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}Nnino)cyclohexanecarboxylic acid; 4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)cyclohexanecarboxylic acid; rram'-4-[({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)methyl]cyclohexanecNboxy lic acid; N-(N-4-hydroxycyclohexyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; tot-butyl 4-[( {[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)cNbonyl]piperidine-l-carboxylate; N-{[5-(phenylsulfonyl)-2-(ti-ifluoromethyl)phenyl]sulfonyl}piperidine-4-carboxamide; 5-(phenylsulfonyl)-N'-(tetrahydro-2H-pyran-4-yl)-2-(trifluoromethoxy)benzenesulfonamide; 2-isopropyl-5-(phenylsulfonyl)-N-(tetrahydro-2N-pyran-4-yl)benzenesulfonamide; 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide; 2-Methoxy-5-(phenylsulfonyl)-N-(tetrahydro-2N-pyran-4-yl)benzenesulfonamide; 5 - [(3 -methoxypheny l)sulfonyl] -N(tetrahydro-2H-pyran-4-yl)-2- (trifluoromethyl)benzenesulfonamide; 5-[(3-hydroxyphenyl)sulfonyl]-N-(tetrahydro-2N-pyran-4-yl)-2- (trifluoromethyl)benzenesulfonamide; 5-[(3-chlorophenyl)sulfonyl]-N-(tetrahydro-2N-pyran-4-yl)-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-[(3S)-piperidin-3-yl]-2-(trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-[(3N)-piperidin-3-yl]-2-(trifluoromethyl)benzenesulfonamide; 5-[(l,2-dimethyl-lN-indol-5-yl)sulfonyl]-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-[(3S)-pyn-olidin-3-yl]-2-(trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-[(3N)-pyn-olidin-3-yl]-2-(trifluoromethyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-(tetrahydro-2H-thiopyran-4-yl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-thiopyran-4-yl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)-2- (trifluoromethyl)benzenesulfonamide; 5-[(2-fluorophenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)-2- (trifluoromethy 1 )benzenesulfonamide; 5-(phenylsulfonyl)-Nr-pyrrolidin-3-yl-2-(trifluoromethyl)benzenesulfonamide; N-[(2R*,4S*,6S*)-2,6-dimethyltetrahydro-2H-pyran-4-yl]-5-[(4-fluorophenyl)sulfonyl3-2- methylbenzenesulfonamide; 5-{[4-(methylamino)phenyl]sulfonyl}-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide; 5-{[4-(dimethylamino)phenyl]sulfonyl}-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide; 5-({4-[(2-hydroxyethyl)amino]phenyl}suIfonyl)-N-pipendin-4-yl-2- (trifluoromethyl)benzenesulfonamide; N-(l,l-dioxidotetrahydro-2H-thiopyran-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide; 5-{[2-(methylamino)phenyl]sulfonyl}-N'-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide; 5-{[2-(dimethylamino)phenyl]sulfonyl}-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide; 5 -({ 2- [(2-hydroxyethy l)amino]phenyl} sulfony l)-N-piperidin-4-y 1-2 - (trifluoromethyl)benzenesulfonamide; 2-ethyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide; 2,3-dimethyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide; 2,4-dimethyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide; 2-isopropyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesvilfonamide; 5-(phenylsulfonyl)-N'-piperidin-4-yl-2-propylbenzenesulfonamide; 2-isopropyl-5-(phenylsulfonyl)-N:-(2,2;6,6-tetrametliylpiperidin-4-yl)ben2enesulfonamidc; 5-(phenylsulfonyl)-N'-(2,2,6,6-tetramethylpiperidin-4-yl)-2- (trifluoromethyl)benzenesulfonamide; 5-[(4-methoxyphenyl)sulfonyl]-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide; 5-[(3-bromophenyl)sidfonyl]-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonainide; 2-chloro-N-[l-(4-fluorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide; 2-chloro-N-[l-(4-cyanobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide; 2-chloro-5-(phenylsulfonyl)-N-{l-[4-(trifluoromethyl)benzoyl]piperidin-4- yl} benzenesulfonamide; 5-(phenylsulfonyl)-2-(trifluoromethyl)-N-{l-[4-(trifluoromethyl)benzoyl]piperidin-4- yl}benzenesulfonamide; N-[l-(2-chlorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[l-(2-methoxybeiizoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N[l-(3-chlorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[l-(3,4-difluorobenzoyl)piperidin-4-yl]-5-(phenylsurfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[l-(3,5-difluorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[l-(2,6-dimethoxybenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[l-(2,4-dimethoxybenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N- { 1 -[4-(trifluoromethoxy)benzoyl]piperidin-4-yl} -2- (trifluoromethyl)benzenesulfonamide; N- { 1 -[2-fluoro-4-(trifluoromethyl)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N- { 1 -[3-fluoro-4-(trifluoromethyl)benzoyl]piperidin-4-yl} -5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; (trifluoromethyl)benzenesulfonamide; N-[l -(4-chlorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-( 1 -isonicotinoy lpiperidin-4-y l)-5 -(pheny Isulfony l)-2-(trifluoromethyl)benzenesulfonamide; N-[l-(2-chloro-6-methoxyisonicotinoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[l-(2-chloro-4-fluorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-[l-(2,4,6-trifluorobenzoyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide; N- [ 1 -(4 -tert-buty Ibenzoy l)piperidin-4-y 1] -5-(pheny Isulfony l)-2- (trifluoromethyl)benzenesulfonamide; N-(4-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yl]cNbonyl }phenyl)acetamide; 5-(phenylsulfonyl)-2-(trifluoromethyl)-N-( 1 - { [4- (trifluoromethyl)phenyl]cNbonothioyl}piperidin-4-yl)benzenesulfonamide; vV-[l-(4-tert-butylbenzoyl)piperidin-4-yl]-5-[(3-methoxyphenyl)sulfonyl]-2- (trifluoromethyl)benzenesulfonamide; N-[l-(4-/'er/-butylbenzoyl)piperidin-4-yl]-5-[(3-chlorophenyl)sulfonyl]-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-./V- {1 -[2-(trifluoromethoxy)benzoyl]piperidin-4-yl}-2- (trifluoromethyl)benzenesulfonamide; N-(l-benzoylpiperidin-4-yl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-[l-(4-tert-butylbenzoyl)pyrrolidin-3-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[l -(4-tert-buty lbenzoy l)piperidin-4-yl] -5 -[(3 -hydroxypheny l)sulfonyl] -2- (trifluoromethyl)benzenesulfonamide; N- [ 1 -(4 -benzoy Ibenzoy l)piperidin-4-y 1] -5-(phenylsulfony 1) -2- (trifluoromethyl)benzenesulfonamide; N-[l-(3-benzoylbenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; l-Isopropyl-4-(phenylsulfonyl)benzene; 2-Isopropyl-N-[l-(2-methoxybenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide; N-[l-(3-Fluorobenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide; N-[l-(4-Fluorobenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide; AT-[l-(2-Fluorobenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide; 2-Isopropyl-5-(phenylsulfonyl)-N-{l-[4-(trifluoromethyl)benzoyl]piperidin-4- yl} benzenesulfonamide; 2-Isopropy 1-./V- [ 1 -(1 -naphthoyl)piperidin-4-yl]-5-(pheny Isulfony l)benzenesulfonamide; 2-Isopropyl-N-[l-(2-naphthoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide; N-[l-(3-Cyanobenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide; N-[l-(4-Cyanobenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide; N-[l-(4-tert-Butylbenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide; N-[\ -(2-Ethoxy-1 -naphthoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide; N-[l-(2-chloro-6-methylisonicotinoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[l-(2,6-dichloroisonicotinoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamida; N- {1 -[4-(dimethylamino)benzoyl]pipe.ridin-4-yl} -5-(phenylsulfonyl)~2- (trifluoromethyl)benzenesulfonamide; N-{l-[(6-chloropyridin-3-yl)cNbonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-{l-[(2,5-dichloropyridin-3-yl)cNbonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[l-(2-chloroisonicotinoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-{ 1 -[(6-pyrrolidin-l -ylpyridin-3-yl)cNbonyl]piperidin-4-yl}-2- (trifluoromethyl)benzenesulfonamide; N(l-{[6-(dimethylamino)pyridin-3-yl]cNbonyl}piperidin-4-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N- {1 -[(6-oxo-1 - {[5-(pheny lsulfonyl)-2-(trifluoromethyl)pheny 1] sulfonyl}-1,6-dihydropyridin-3 - yl)cNbonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-{ 1 -[(6-phenylpyridin-3-yl)cNbonyl]piperidin-4-yl} -5-(phenylsulfonyl)-2- (trifluoromethy l)benzenesulfonamide; N- {1 -[(6-morpholin-4-ylpyridin-3 -yl)carbonyl]piperidin-4-yl} -5 -(pheny lsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-[l -(2-pyrrolidin-1 -ylisonicotinoyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide; N"-{l-[(6-oxo-l,6-dihydropyridin-3-yl)cNbonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-[l-(pyridin-3-ylcNbonyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-[l-(pyridin-2-ylcNbonyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide; N-{ 1 -[4-(methylthio)benzoyl]piperidin-4-yl} -5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-2-(trifluoromethyl)-N-(l-{[6-(trifluoromethyl)pyridin-3- yl]cNbonyl}piperidin-4-yl)benzenesulfonamide; Nr-{l-[4-(methylsulfinyl)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-[l-(l,3-thiazol-4-ylcNbonyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide; tert-butyl 4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l- cNboxylate; tert-butyl (3S)-3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l- cNboxylate; tert-butyl (3R)-3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l- carboxylate; tert-butyl 4-[({5-[(4-fluorophenyl)sulfonyl]-2- methylphenyl}sulfonyl)amino]piperidine-l - cNboxylate; terN-butyl(3S)-3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidine-l- carboxylate; tert-butyl (3R)-3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidine-1 - cNboxylate; tert-butyl 4-({[5-[(4-fluorophenyl)sulfonyl]-2- (trifluoromethyl)pheny Ijsulfonyl} amino)piperidine-1 -cNboxylate; terf-butyl 4-({ [2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l -cNboxylate; tert-butyl 4-({[2,3-dimethyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate; tert-butyl 4-({[2,4-dimethyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate; tert-butyl 4-({[2-isopropyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate; 4- {[3 -({[ 1 -(tert-butoxycNbonyl)piperidin-4-yl] amino} sulfony l)-4- (trifluoromethyl)phenyl]sulfonyl}benzoic acid; 4-oxo-4-[4-( {[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl] sulfonyl} amino)piperidin-1 - yljbutanoic acid; 4-oxo-4-[3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidin-l- yl]butanoic acid; 5-oxo-5- [4-( {[5-(phenylsulfonyl)-2-(trifluoromethy l)pheny 1] sulfonyl} amino)piperidin-1 - yl]pentanoic acid; 5-oxo-5-[3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidin-l- yl]pentanoic acid; N[l-(N,N-dimethylglycyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; tert-butyl 4-{2-oxo-2-[4-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]ethyl}piperidine-l~cNboxylate; 5-(phenylsulfonyl)-N-[l-(piperidin-4-ylacetyl)pipendin-4-yl]-2- (trifluoromethyl)benzenesulfonamide; N-[l-(N-methylglycyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-[l-(pyrrolidin-l-ylacetyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide; N-[l-(morpholin-4-ylacetyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N;-[l-(piperazin-l-ylacetyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide; N-{l-[3-(methylthio)propanoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethy l)benzenesulfonamide; N-{1 -[3-(methylsulfinyl)propanoyl]piperidin-4-yl} -5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; W-[ 1 -(1 N-imidazol-1 -y lacetyl)piperidin-4-yl]-5 -(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 4-[( { 5-[(4-fluorophenyl)sulfonyl]-2 -isopropy Iphenyl} sulfonyl)Nnino]-N-1 - naphthylpiperidine- 1 -cNbothioamide; N-(2-fluorophenyl)-4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropy Iphenyl} sulfonyl)amino]piperidine-1 -cNbothioamide; 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-(2- methylphenyl)piperidine-l-cNbothioamide; ethyl ({4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidin-l- yl} cNbonothioyl)carbamate; N-butyl-4- [({5- [(4-fluorophenyl)sulfonyl] -2- isopropy Iphenyl} sulfony l)amino]piperidine-1 - cNbothioamide; 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-(4- methoxyphenyl)piperidine-l-cNbothioamide; methyl 4-[({4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidin-l- yl}cNbonothioyl)amino]benzoate; methyl N-({4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidin-l- yl} cNbonothioyl)glycinate; 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-(2-morpholin-4- ylethyl)piperidine-1 -cNbothioamide; 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-(3- nitrophenyl)piperidine-1 -cNbothioamide; 3-[({4-[({5-[(4-fluorophenyl)sulfony 1]-2- isopropyIpheny 1}sulfonyl)amino]piperidin-1 - yl} cNbonothioyl)amino]benzoic acid; 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-pyridin-3- ylpiperidine- 1 -cNbothioamide; 4- [({5 - [(4-fluoropheny l)sulfonyl] -2-isopropy Ipheny 1} sulfony l)amino] -N-[4- (trifluoromethyl)phenyl]piperidine-1 -cNbothioamide; AT-(4-teNbutylphenyl)-4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)piperidine-1 -carboxamide; 3-({[4-({[5-(phenylsulfonyl)-2-(trifluorometh.yl)phenyl]sulfonyl}amino)piperidin-l- yl]cNbonothioyl}amino)benzoic acid; tert-butyl 4- {[4- ({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidin-1 - yl]cNbonyl}piperidine-1 -cNboxylate; 5-(phenylsulfonyl)-N-[l-(piperidin-4-ylcNbonyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide; tert-butyl (2S)-2 - {[4-( {[5-(phenylsulfonyl)-2-(trifluoromethy l)pheny 1] sulfony 1} amino)piperidin- 1 -yl] cNbony l}pyrrolidine-1 -cNboxylate; 5-(phenylsulfonyl)-N-(l-L-prolylpiperidm-4-yl)-2-(trifluoromethyl)benzenesulfonamide; tert-butyl(2N)-2-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidhi- 1 -yl] cNbonyl} pyrrolidine-1 -carboxylate; 5-(phenylsulfonyl)-N-(l-yl)-prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide; N-[l -(1 -acetyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; tert-bulyl (55)-2-oxo-5-{[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]cNbonyl}pyrrolidine-l-carboxylate; N[l-(5-oxo-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)ben2;enesLilfonamide; N-[l -(1 -methyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; tert-butyl(4R)-4-{[4-({[5-(phenylsulfonyl)-2-(trifluororaethyl)phenyl]sulfonyl}amino)piperidin- l-yl]cNbonyl}-l,3-thiazolidine-3-cNboxylate; 5-(phenylsulfonyl)-N-{l-[(4R)-l,3-thiazolidin-4-ylcNbonyl]piperidin-4-yl}-2- (trifluoromethyl)benzenesulfonamide; tert-butyl (3S)-3-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin- 1 -yl] carbony1} pyrrolidine-1 -carboxy late; tert-butyl(35)-3-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin- 1 -yl] cNbonyl} pyrrolidine-1 -cNboxylate; 5-(phenylsulfonyl)-N-{l-[(3R)-pyrrolidin-3-ylcNbonyl]piperidin-4-yl}-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-{l-[(3S)-pyrrolidin-3-ylcNbonyl]piperidin-4-yl}-2- (trifluoromethyl)benzenesulfonamide; tert-butyl(4R)-4-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)pheiiyl]sulfonyl}amino)piperidin- l-yl]cNbonyl} -1,3-thiazolidine-3-cNboxylate 1 -oxide; N-( l-{[(3R)-l -acety lpyrrolidin-3 -yl] cNbonyl} piperidin-4-y l)-5-(phenylsulfony l)-2- (trifluoromethyl)benzenesulfonamide; N-(l-{[(3S)-l-acetylpyrrolidin-3-yl]cNbonyl}piperidin-4-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[l -(1 -isobutyryl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; /V-{l-[l-(2,2-dimethylpropanoyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-{l-[l-(3,3-dimethylbutanoyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-{1-[1 -(cyclohexylcNbonyl)-L-prolyl]piperidin-4-yl} -5 -(phenylsulfony l)-2- (trifluoromethyl)benzenesulfonamide; N-{l-(morpholin-4-ylcNbonyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonaniide; (2S)-N-(tert~butyl)-2- {[4-( {[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]suifonyl}amino)piperidin-l-yl]cNbonyl}pyn'olidine-l-carboxamide; (25)-N-phenyl-2-{[4-({[5-(phenylsulibiiyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin- l-yl]cNbonyl}pyrrolidine-l-cNboxNnide; N-{l-[l-(methylsulfonyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonainide; N-[l-(l-benzoyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-(l- { 1 -[4-(dimethylamino)benzoyl]-L-prolyl}piperidin-4-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[l-(l-isonicotinoyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide ; N-(l-{ 1 -[(6-chloropyridin-3-yl)cNbonyl]-L-prolyl}piperidin-4-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 4- [((2S)-2- { [4-( { [5 -(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidin- 1 - yl]carbonyl}pyrrolidin-l -yl)sulfonyl]benzoic acid; (trifluoromethyl)benzenesulfonamide; N-[l -(1 -benzyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-{l-[l-(cyclohexylmethyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-{l-[l-(3,3-dimethyibutyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; (25)-N-ethyl-2-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l yl]cNbonyl}pyrrolidine- 1 -carboxamide; (25)-NN-dimethyl-2-{[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)piperidin- 1 -yl]cNbonyl}pyrrolidine-l -carboxamide; terr-butyl (2S)-2- { [4-( { [5- [(3-cyanophenyl)sulfonyl]-2- (trifluoromethyl)phenyl]sulfonyl} amino)piperidin- 1 -yl]cNbonyl}pyrrolidine-l -carboxylate; N-[l-(2-hydroxy-2-methylpropyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-2-(trifluoromethyl)-N-{l-[4-(trifluoromethyl)benzyl]piperidin-4- yljbenzenesulfonamide; yV-[l-(cyanomethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-[l-(2-oxo-2-phenylethyl)piperidin-4-yl]-5-(phenyisulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-2-(trifluoromethyl)-N-{l-[4-(ti-ifluoromethyl)phenyl]piperidin-4- yl}benzenesulfonamide; yV-[l-(2-hydroxyethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 2-Isopropyl-N-[(lR*,5S*)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-5- (phenylsulfonyl)benzenesulfonamide monohydrochloride; [4-({ [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidin-l-yl]acetic acid; 2-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]acetamide; 5-(phenylsulfonyl)-N'-[l-(2H-tetrazol-5-yImethyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide; 3 - [4-( {[5 -(pheny lsulfonyl)-2-(trifluoromethyl)pheny 1] sulfony 1} amino)piperidin-1 -yl]propanoic acid; 3-[4-({[5-(phenylsiUfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]benzoic acid; 4- [4-( {[5 -(pheny lsulfonyl)-2-(trifluoromethy l)pheny 1] sulfony 1} amino)piperidin-1 -yl]benzoic acid; N"-[l-(3-cyanophenyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; 2- [4-( {[5 -(pheny lsulfonyl)-2-(trifluoromethyl)pheny 1] sulfony 1} amino)piperidin-1 - yl]propanamide; N-[l-(2-morpholin-4-ylethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[(IR*, 55*)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; (2R)-2- [4-( {[5-(phenylsulfonyl)-2-(trifluoromethy l)phenyl] sulfonyl} amino)piperidin-1 - yl]propanamide; (25)-2-[4-({ [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidin-l - yl]propanamide; methyl [4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yljacetate; N-methyl-2-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yljacetamide; N,Nimethyl-2-[4-({[5-(phenylsulfonyl)-2-N yljacetamide; N-isopropyl-2-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yl]acetamide; N-[l-(2-morpholin-4-yl-2-oxoethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; •N-{l-[(4-tert-butylphenyl)sulfonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-[l-(phenylsulfonyl)piperidin-4-yl]-2-(trifluoromethyl)benzenesulfonamide; 3- {[4-( {[5-(pheny lsulfonyl)-2-(trifluoromethy l)pheny l]sulfonyl} amino)piperidin-1 - yl]sulfonyl}benzoic acid; 4- {[4-( {[5 -(phenylsulfonyl)-2-(trifluoromethyl)phenyl] sulfonyl} amino)piper idin-1 - yl]sulfonyl}benzoic acid; N- {I - [(4-hydroxyphenyl)sulfonyl]piperidin-4-yl} -5-(phenylsulfony l)-2~ (trifluoromethy l)benzenesulfonamidc; methyl 3- {[4-( {[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidin-1 - yl]sulfonyl}benzoate; N-{l-[(3-cyanophenyl)sulfonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-(l-{[3-(2H-tetrazol-5-yl)phenyl]sulfonyl}piperidin-4-yl)-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-(2-pyridin-3-yletiiyl)-2-(trifluoromethoxy)benzenesulfonamide; 2-isopropyl-5-(phenylsulfonyl)-N'-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-isopropyl-5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)-2-(trifluoromethyl)benzenesulfonamide; l-Methoxy-4-(phenylsulfonyl)benzene; N[2-(l-oxidopyridin-3-yl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-pyridin-2-ylethyl)-2- isopropylbenzenesulfonamide; N-(2-hydroxy-2-pyridin-2-ylethyl)-2-isopropyl-5-(phenylsulfonyl)benzene-sulfonamide; N-(2-hydroxy-2-pyridin-2-ylethyl)-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-pyridin-3-ylethyl)-2- isopropylbenzenesulfonamide; N-(2-hydroxy-2-pyridin-3-ylethyl)-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide; N-(2-hydroxy-2-pyridin-3-ylethyl)-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(1H-Imidazol-l-yl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N'-(2-hydroxy-2-pyridin-3-ylethyl)-2-methylbenzenesulfonamide; N-(2-hydroxy-2-pyridin-3-ylethyl)-5-(phenylsulfonyl)-2-(ti-ifluoromethyl)benzenesulfonamide; 5-[(3-methoxyphenyl)sulfonyl]-N-(2-pyridin-3-ylethyl)-2-(trifluorometliyl)benzenesulfonamide; 5-[(3-chlorophenyl)sulfonyl]-N-(2-pyridin-3-ylethyl)-2-(trifluoromethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-pyridin-2-ylethyl)-2-methylbenzenesulfonamide; N-(2-hydroxy-2-pyridin-2-ylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; 5-(phenylsuIfonyl)-N-(2-pyridin-4-ylethyl)-2-(trifluoromethyl)benzenesulfonamide; 5-[(4-hydroxyphenyl)sulfonyl]-N'-(2-pyridin-3-ylethyl)-2-(trifluoromethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-l-yl)ethyl]-2- (trifluoromethyl)benzenesulfonamide; 5- [(2-fluorophenyl)sulfonyl]-N-[2-( 1 H-imidazol-1 -yl)ethyl]-2- (trifluorometbyl)benzenesulfonamide; 5-(Phenylsulfonyl)-2-propyl-N-(2-pyridin-4-ylethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-[2-(2N-tetrazol-5-yl)ethyl]-2-(trifluoromethyl)benzenesulfonamide; 5-[(4-Fluorophenyl)sulfonyl]-2-propyl-N"-(2-pyridin-3-ylethyl)benzenesiilfonamide; 5-[(4-Fluorophenyl)sulfonyl]-2-propyl-N-(2-pyridin-4-ylethyl)benzenesulfonamide; 5-(Phenylsulfonyl)-2-propyl-N-(2-pyridin-3-ylethyl)benzenesulfonamide; 2-isopropyl-5-(phenylsulfonyl)-N-(pyridin-4-ylmethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-(pyridin-4-ylmethyl)-2-(trifluoromethyl)benzenesulfonamide; N-[(G-chloropyridin-3-yl)methyll]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N[(6-pyrrolidin-l-ylpyridin-3-yl)methyl]-2- (trifluoromethyl)benzenesulfonamide; N-[(6-morpholin-4-ylpyridin-3-yl)methyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 2-chloro-N-[(lR*,2R*)-2-hydroxy-l-methyl-2-phenylethyl]-5- (phenylsulfonyl)benzenesulforiamide; N-(2-hydroxy-2-phenylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-[(1R*,2R*)-2-hydroxy»l-methyl-2-phenylethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[( 1S,2R)-2-hydroxy-l-methyl-2-phenylethyl]~5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonaniide; N-[(lR,2S)-2-hydroxy-l-methyl-2-phenylethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[(liS)-l-benzyl-2-hydroxyethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-[(l,S)-2-hydroxy-l-(lF-indol-3-ylmethyl)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-phenylethyl)-2-isopropylbenzenesulfonamide; N-(2-hydroxy-2-phenylethyl)-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide; N-[(2R)-2-hydroxy-2-phenylethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-[(2S)-2-hydroxy-2-phenyle1hyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; 4-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzoicacid; N-[2-(4-aminophenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-[2-(4-methoxyphenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-(4-aminobenzyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-[2-(4-hydroxyphenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; methyl 4-[({[5-(phenylsnlfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]benzoate; methyl 4-[({[2-isopropyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)methyl]benzoate; N-[2-(4-bromophenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; 3-[({4-[({[5-(phenylsulfonyl)-2- (triiluoroinethyl)phenyl]sulfonyl}ainino)methyl]phenyl}amino)sulfonyl]benzoic acid; N-(4-bromobenzyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-[2-(4-cyanophenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; methyl 4-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzoate; 4'-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]biphenyl-3- carboxylic acid; 4'-[({[5-(plienylsulforiyl)-2.-(l:rifluoromethyl)phenyl]sulfonyl}amino)methyl]biphenyl-4- carboxylic acid; 5-(phenylsulfonyl)-N-{2-[4-(2H-tetrazol-5-yl)phenyl]ethyl}-2- (trifluoromethyl)benzenesulfonamide; N-(2-{4-[(methylsulfonyl)amino]phenyl}ethyl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonNaide; N-(3-bromobenzyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; 3'-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]biphenyl-3- carboxylic acid; 3'-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]biphenyl-4- carboxylic acid; N'-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethy l)benzenesulfonamide; N-[4-(dimethylamino)benzyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-(2,4-dimethoxybenzyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; tert-Butyl [2-( {[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethy 1]carbamate; N-(2-Aminoethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamidehydrochloride; N-[2-({[5-(Phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide; 4-Methyl-N-[2-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide; 4-tert-Butyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide; 4-Fluoro-N-[2-( {[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide; 4-Chloro-N-[2-( {[5-(phenylsulfonyl)-2- (trifluoromethyl)pheny 1] sulfonyl} amino)ethyl]benzamide; 4-Bromo-N- [2-( {[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide; 4-Methoxy-N- [2-( {[5-(phenylsulfony l)-2- (trifluoromethyl)pheny 1] sulfonyl} amino)ethyl]benzamide; N-[2-({[5-(Phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-4- (trifluoromethyl)benzamide; N-[2-({[5-(Phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-4- (trifluoromethoxy)benzamide; N-[2-({[5-(Phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]isonicotinamide; tert-Butyl methyl[2-({ [5-(phenylsulfonyl)-2- (trifluoromethy l)pheny 1] sulfony 1} amino)ethyl] carbamate; N-[2-(Methylamino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride; N-Methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide; 4-Methoxy-N-methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)pheny 1] sulfonyl} amino)ethyl] benzamide; N-{2-[(aiiilinocNbonyl)(methyl)amino]ethyl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-(2-{methyl[(pyridin-3-ylamino)cNbonyl]amino}ethyl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenestilfonainide; N-{2-[{[(2,4-dimethoxyphenyl)amino]cNbonyl}(methyl)amino]ethyl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-{2-[[(rerr-butylamino)cNbonyl](methyl)amino]ethyl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-{2-[{[(4-methoxyphenyl)amino]cNbonyl}(methyl)amino]ethyl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide;; N-{2-[[(butylamino)cNbonyl](methyl)amino]ethyl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide N-{2-[{[(2,4-difluorophenyl)amino]cNbonyl}(methyl)amino]ethyl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-methyl-N-[2-( {[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidine-l-carboxamide; N-{2-[[(diethylamino)cNbonyl](methyl)amino]ethyl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-methyl-N-[2-( {[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]surfonyl}amino)ethyl]morpholine-4-carboxamide; N-[2-(methyl{[methyl(phenyl)amino]cNbonyl}amino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-Methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-2-fur amide; 4-tert-Butyl-N-methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide; N-Methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-2-(trifluoromethoxy)benzamide; N-methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cyclohexanecarboxamide; 3-Fluoro-N-methyl-N-[2-( {[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-4-(trifluororaethyl)benzamide; Methyl 4-({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}cNbonyl)benzoate; N-Methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]nicotinamide; N-Methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfony 1} amino)ethyl] isonicotinamide; 2-Chloro-N-methyl-N-l2-({ [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]nicotinamide; N,2,2-trimethyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]propanamide; 2-ethyl-N-methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]butanamide; butyl methyl[2-( {[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate; tert-butyl 4-[({methyl[2-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}cNbonyl)amino]piperidine-l-cNboxylate; 2,2-dimethylpropyl methyl[2-({ [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate; isobutyl methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate; 3-(trifluoromethyl)phenylmethyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl] sulfonyl} amino)ethyl]carbamate; 4-fluorophenyl methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl] sulfonyl} amino)ethy carbamate; 4-bromophenyl methyl[2-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)ethyl]carbamate; N-(2-{methyl[(piperidin-4-ylamino)cNbonyl]amino}ethyl)-5-(phenylsulfonyl)-2- (trifl uoromethy l)benzene sulfonamide; ethyl N-({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}cNbonyl)glycinate; 3-({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}sulfonyl)benzoic acid; terr-butyl4-({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}cNbonyl)piperazine-l-cNboxylate; N-({methyl[2-( {[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}cNbonyl)glycine; 4-{methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}-4- oxobutanoic acid; N-methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)ethyl]piperazine-1 -carboxamide; N-{2-[(2-hydroxyethyl)(methyl)amino]ethyl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; methyl N-methyl-N-[2-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]glycinate; ethyl N-methy 1-N- [2-( {[5-(phenylsulfonyl)-2- (trifluoromethyl)pheny 1] sulfonyl} amino)ethyl]- D - Naninate; terf-butyl (35)-3-[({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl] sulfonyl} amino)ethyl]amino} cNbonyl)amino]pyrrolidine-1 -cNboxylate; tert-butyl methyl[3-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)pheny 1] sulfonyl} amino)propyl] cai'bamate; N-[3-(methylamino)propyI]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N[2-(methyl{[(3S)-pyrrolidin-3-ylamino]cNbonyl}amino)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; tert-butyl 4-[({methyl[3-({[5-(phenylsulfonyl)-2- (trifluoromethyl)pheny 1] sulfony 1} amino)propyl] amino} c Nbonyl)amino]piperidine-1 - cNboxylate; tert-butyl N-methyl-yY-[2-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}ainino)ethyl]-p-Naninate; tert-butyl N-methyl-N-[2-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)pheny 1] sulfonyl} amino)ethyl] glycinate; N-(3-{methyl[(piperidin-4-ylamino)cNbonyl]amino}propyl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; tert-butyl 4-({methyl[3-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)propyl] amino} cNbonyl)piperazine-1 -cNboxylate; N-methyl-N-[3-({[5-(phenylsulfonyl)-2- (trifluoromethyl)pheny 1] sulfonyl} amino)propyl]piperazine-1 -carboxamide; 4-{4-[({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)pheny 1] sulfonyl} amino)ethyl]amino} cNbonyl)amino]piperidin-1 -y1} -4- oxobutanoic acid; N-methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluorometitiyl)phenyl]sulfonyl}amino)ethyl]glycine; N-methyl-N'-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-ß- Nanine; 4-(bromomethyl)-N-methyl-N-[2-( {[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)ethyl]benzamide; tert-butyl [3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)pheny 1]sulfonyl}amino)propyl]carbamate; terr-butyl4-[methyl({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}cNbonyl)amino]piperidine-l-carboxylate; tert-butyl (3J?)-3-[({methyl[2-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}cNbonyl)amino]pyrrolidine-l-cNboxylate; 4-{methyl[3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)propyl]amino}-4- oxobutanoic acid; N-(3-aminopropyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; dimethyl [4~({methyl[2-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino)cNbonyl)benzyl]phosphonate;- NL[2-(methyl{[methyl(piperidin-4-yl)aminoJcNbonyl}amino)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[2-(methyl{[(3R)-pyrrolidin-3-ylamino]cNbonyl}ainino)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; tert-butyl (3R)-3-[({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)ethyl]amino} cNbonyl)amino]piperidine-1 -cNboxylate; tert-buiyl (3S)-3-[({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)ethyl]amino } cNbonyl)amino]piperidine-1 -cNboxylate; N-[2-(methyl{[(3J?)-piperidin-3-ylamino]cNbonyl}amino)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[2-(methyl{[(3iS)-piperidin-3-ylamino]cNbonyl}amino)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; [4-({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)pheny 1]sulfony1} amino)ethyl]amino} cNbonyl)benzyl]phosphonic acid; tert-butyl 4-[methyl({[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]Nnino}cNbonyl)amino]piperidine-l-cNboxylate; tert-butyl 4-[({[2-({[5-(phenylsulfonyl)-2- (trifluororaethyl)phenyl]sulfony 1} amino)ethy 1] amino } cNbony l)amino]piperidine-1 -cNboxylate; N-(23-dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2-(trifluoromethyl)berizenesulfonamide; N-(2-hydroxy-2,3-dihydro-l H-inden-1 -yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-(l-hydroxy-2,3-dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-(5-methoxy-2,3-dihydro-1 H-inden-2-yl)-5-(phenylsulfonyl)-2- (tri±luoromethyl)beihydro-lnzenesulfonamide; N-(5-hydroxy-2,3-dH-inden-2-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; methyl {[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)-2,3-dihydro-lH- inden-5-yl]oxy} acetate; {[2-({[5-{phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfony]}amino)-2,3-dihydro-lH-inden-5-ylaloxy} acetic acid; methyl 2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)indane-5-carboxylate; N-(l-hydroxy-6-methoxy-2,3-dihydro-lH-irden-2-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 2-{[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)-2,3-dihydro-lH-inden- 5-y 1] oxy} acetamide; 2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)indane-5-carboxylic acid; or N-(5-bromo-2,3-dihydro-l/J-inden-2-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. J In certain embodiments of the invention, when R1 of Formula I is phenyl; X of Formula I is O; RI of Formula I is CH3; and R4, R5, R6, and R7 of Formula I Ne each H; then R3 of Formula I is not methylphenyl, ethylphenyl, or hydrogen. In other embodiments, when RI of Formula I is phenyl; X of Formula I is O; R2 of Formula I is CH3; and R4, R5, R6, and R7 of Formula I Ne each H; then R3 of Formula I is not Nkylphenyl or hydrogen. In still further embodiments, when RI of Formula I is phenyl; X of Formula I is O; R2 of Formula I is CHs; and R4, RS, RS, and R? of Formula I Ne each H; then Ra of Formula I is not NkylNyl or hydrogen. ' In further embodiments of the invention, when RI of Formula I is chlorophenyl; X of Formula I is O; R2 of Formula I is CH3; and R4, R5, R6, and R7 of Formula I Ne each H; then R3 of Formula I is not cyclohexyl, methylphenyl, methylfuranyl, methylpyridyl, or hydrogen. In other embodiments, when RI of Formula I is chlorophenyl; X of Formula I is 0; R2 of Formula I is CH3; and R4, R5, R6, and R7 of Formula I Ne each H; then R3 of Formula I is not cycloNkyl, Nkylphenyl, Nkylfuranyl, Nkylpyridyl, or hydrogen. In additionN embodiments, when RI of Formula I is chlorophenyl; X of Formula I is O; R2 of Formula I is CH3; and R4, R5, R6, and R7 of Formula I Ne each H; then R3 of Formula I is not cycloNkyl, NkylNyl, NkylheteroNyl, or hydrogen. In certain embodiments of the invention, when R1 of Formula I is bromophenyl; X of Formula I is O; R2 of Formula I is CH3; and R4, R5, R6, and R7 of Formula I Ne each H; then R3 of Formula 1 is not hydrogen. In certain other embodiments of the invention, when R1 of Formula I is nitrophenyl or dinitrophenyl; X of Formula I is O; R2 of Formula I is CH3; and R4, R5, R6, and R7 of Formula I Ne each H; then R3 of Formula I is not hydrogen. Compounds of Formula 1 may be used to modulate the actNity of secreted frizzled related protein-1. Such compounds Ne of interest for the treatment of bone fractures as well as bone disorders, including osteoporosis, and for the treatment of Nthritis, chronic obstructNe pulmonNy disease, cNtilage defects, prostate cancer and leiomyoma. In certain embodiments, the present invention therefore provides methods of treating, preventing, inhibiting, or Nleviating each of the mNadies listed above in a mammN, preferably in a human, comprising administering a therapeuticNly effectNe amount of a compound of Formula 1 or a phNmaceuticNly acceptable sNt thereof to a patient suspected to suffer from such a mNady. In other embodiments, the invention relates to compositions comprising at least one compound of Formula 1, or a steroisomer or phNmaceuticNly acceptable sNt thereof, and one or more phNmaceuticNly acceptable cNriers, excipients, or diluents. Such compositions include phNmaceuticN compositions for treating or controlling disease states or conditions of the bone. In certain embodiments, the compositions comprise mixtures of one or more compounds of Formula 1. Certain of the compounds of Formula 1 contain stereogenic cNbon atoms or other chirN elements and thus gNe rise to stereoisomers, including enantiomers and diastereomers. The invention generNly relates to Nl stereoisomers of the compounds of Formula 1, as well as to mixtures of the stereoisomers. Throughout this application, the name of a compound without indication as to the absolute configuration of an asymmetric center is intended to embrace the indNiduN stereoisomers as well as mixtures of stereoisomers. Reference to opticN rotation [(+), (-) and (±)] is utilized to distinguish the enantiomers from one another and from the racemate. Furthermore, throughout this application, the designations R* and S* Ne used to indicate relatNe stereochemistry, employing the ChemicN Abstracts convention which automaticNly assigns R* to the lowest numbered asymmetric center. An enantiomer can, in some embodiments of the invention, be provided substantiNly free of the corresponding enantiomer. Thus, reference to an enantiomer as being substantiNly free of the corresponding enantiomer indicates that it is isolated or sepNated via sepNation techniques or prepNed so as to be substantiNly free of the corresponding enantiomer. "SubstantiNly free," as used herein, means that a significantly lesser proportion of the corresponding enantiomer is present. In preferred embodiments, less than about 90 % by weight of the corresponding enantiomer is present relatNe to desired enantiomer, more preferably less than about 1% by weight. Preferred enantiomers can be isolated from racemic mixtures by any method known to those skilled in the Nt, including high performance liquid chromatography (HPLC), and the formation and crystNlization of chirN sNts, or preferred enantiomers, can be prepNed by methods described herein. Methods for the prepNation of enantiomers Ne described, for example, in Jacques, et N., Enantiomers, _Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, S.H., etN., Tetrahedron 33:2725 (1977); Eliel, E.L. Stereochemistry of CNbon Compounds (McGraw-Hill, NY, 1962); and Wilen, S.H. Tables of Resolving Agents and OpticN Resolutions p. 268 (E.L. Eliel, Ed., UnN. of Notre Dame Press, Notre Dame. IN 1972), each of which is hereby incorporated by reference in its entirety. The following synthetic schemes Ne designed to illustrate, but not limit, generN procedures for the prepNation of compounds of Formula 1 . The reagents used can be either commerciNly obtained or can be prepNed by standNd procedures described in the literature. Scheme 1: (Figure Removed) . Aids, Nyl; ii. Chlorosulfonic acid, heat; iii. Amine, TEA, DCM or Amine, NaaCOa, ACN/water In Scheme 1, step i, a suitably substituted Nyl sulfonyl chloride (5), either commerciNly available, known in the literature, or prepNed according to methods known and established for the prepNation of sulfonyl chlorides, including procedures exemplified in the experimentN section of this document, wherein, R2, R4, R5, R6 and RI Ne as previously defined, is reacted with an unsubstituted or suitably substituted Nyl group, either commerciNly available, known in the literature, or prepNed according to methods known and established for the prepNation of substituted benzenes, with or without a Lewis acid catNyst such as Numinum chloride, either using the substituted Nyl in excess as the solvent, or using another suitably acceptable solvent. The diNyl sulfone product is then treated with chlorosulfonic acid with or without solvent, step ii, at room temperature or with heating for severN hours or longer where appropriate to provide a sulfonyl chloride (2b), which is used directly or purified according to established procedures. The sulfonyl chloride (2) is reacted in step iii with an amine (R7R3NHI either commerciNly available, known in the literature, or prepNed according to methods known and established for the prepNation of primNy and secondNy amines, in a suitable solvent such as dichloromethane or acetonitrile, in the presence of an acid scavenger, such as triethylamine, at room temperature to Nford the desired product (1). Scheme 2: (Figure Removed) N. Nylthiol, K2CO3, DMF; v. m-CPBA or oxone, DCM; vi. SnCl2, or H2/Pd; vii. NaNO2, HCI, AcOH; viii. SO2(g), CuCl2; j In Scheme 2, step N, a suitably substituted 3-fluoro nitrobenzene derNatNe, either commerciNly available, known in the literature, or prepNed according to methods known and established for the prepNation of such nitrobenzenes, is reacted with an appropriately substituted Nylthiol, either commerciNly available, known in the literature, or prepNed according to methods known and established for the prepNation of such Nylthiols, in the presence of an acid scavenger, such as potassium cNbonate, in a suitable solvent, such as dimethylformamide or dimethylacetamide, at an elevated temperature for severN hours to provide diNyl sulfide (7). The diNyl sulfide (7) is oxidized, step v, using established procedures, or as known in the literature, in an acceptable solvent such as dichloromethane, with a suitable oxidant, such as meta-chloropcroxybenzoic acid or oxone, to Nford either the sulfoxide (8a) or sulfone (8b). The sulfoxide or sulfone is subjected to reducing conditions, such as stannous chloride, step vi, or reagents that Ne commonly used to effect the reduction of a nitro group, known in the literature, to Nford aniline (9a or 9b). Diazotization, step vii, of the anilinium hydrochloride sNt under acidic conditions with sodium nitrite, followed by sulfonylation, step viii, with sulfur dioxide and hydrogen chloride in the presence of an organic metN catNyst, such as copper (II) chloride, according to procedures described in the literature, results in the formation of sulfonyl chloride (2), which may be transformed into the sulfonamide (1) as previously described, step iii. Scheme 3 (Figure Removed) ix. BuLi, -78 °C, THF; x. SO2(g); xi. NCS, DCM; xii. NBS, H2SO4; xiii. thiophenol, NiBr2, Zn, Dppf, K2CO3, NMP, microwave, 160 °C, lOmin In Scheme 3, an appropriately substituted sulfonyl chloride (11), wherein R2 is as previously defined for Nkyl, either commerciNly available, known in the literature, or prepNed according to methods known and established for the prepNation of such sulfonyl chlorides, including procedures exemplified in the experimentN section, such as from Nyl bromide (10), either commerciNly available, known in the literature, or prepNed according to methods known and established for the prepNation of such Nyl bromides, is transmetNated, step ix, at reduced temperature and in a suitable solvent such as tetrahydrofuran, using an acceptable organometNlic reagent that is known to effect such transformations, such as n-butyl lithium, and the resulting metNated species is treated with sulfur dioxide, step x, to Nford a sulfmic acid intermediate that is isolated or immediately oxidized, step xi, to a sulfonyl chloride (11). The sulfonyl chloride (11) is then transformed into a sulfonamide, step iii, and brominated, step xii, using N-bromosuccinimide in concentrated sulfuric acid, or other brominating conditions that Ne commonly used to brominate Nyl sulfonamides, to Nford an Nyl bromosulfonamide (3). The Nyl bromosulfonamide (3) is then reacted with an Nylthiol, either commerciNly available, known in the literature, or prepNed according to methods known and established for the prepNation of thiophenols, using a catNytic system comprised of nickel (II) bromide and zinc metN, with a suitable ligand such as Dppf, step xiii, in the presence of an inorganic base, such as potassium cNbonate, and a polN aprotic solvent, such as 1 -methyl-2-pyrrolidinone, at elevated temperatures to Nford a sulfide (12), which is oxidized, step v, using a suitable oxidant such as meta-chloroperoxybenzoic acid or oxone, or by established procedures, as known in the literature, in an acceptable solvent, such as dichloromethane, for the oxidation of sulfides. including procedures exemplified in the experimentN section, to Nford a diNylsulfone sulfonamide (1). Scheme 4 (Figure Removed) xN. MeMgBr, -78 to 0 °C, THF; xv. K2CO3, Cu(OAc)2, DMSO, Nylboronic acid NternatNely, as depicted in Scheme 4, intermediate 3 is exposed to methyl magnesium bromide, step xN, followed by a metN hNogen exchange reagent, such as butyl lithium, step ix, at reduced temperature and in a suitable solvent, such as tetrahydrofuran, to Nford a lithiated species that is quenched with sulfur dioxide, step x, to Nford a sulfinic acid that is isolated as the sodium sNt (4), as exemplified in the experimentN section. The sodium sulfinate (4) is then reacted with an appropriately substituted Nyl boronic acid, step xv, either commerciNly available, known in the literature, or prepNed according to methods known and established for the prepNation of Nyl boronic acids, in a cross coupling reaction that is promoted by a copper sNt, such as copper (II) acetate, in an appropriate polN aprotic solvent, such as dimethylsulfoxide or dimethylforamide, in the presence of an acid scavenger, such as triethylamine or potassium cNbonate, and a desiccant, such as moleculN sieves, at ambient or elevated temperatures, or as exemplified in the experimentN section, to provide compounds of Formula 1. (Formula Removed) Scheme 5 NternatNely, as depicted in Scheme 5, the lithiated intermediate from 3, Scheme 4, is quenched with an appropriately substituted Nyl sulfonyl fluoride, step xvi, either commerciNly available, known in the literature, or prepNed according to methods known and established for the prepNation of Nyl sulfonyl fluorides, as exemplified in the experimentN section, to provide compounds of Formula 1. (Formula Removed) In Scheme 6, an appropriately substituted Nyl sulfonyl chloride, either commerciNly available, known in the literature, or prepNed according to methods known and established for the prepNation of Nyl sulfonyl chlorides, is elaborated as described in Scheme 1, step i, to provide 8, and then, according to Scheme 2, steps vi, vii and viii, to provide sulfonyl chloride (2), which is transformed to compounds of Formula 1 as previously described. Scheme 7 (Figure Removed) NternatNely, as depicted in Scheme 7, intermediate 3 is prepNed from an appropriately substituted bromoaniline (14), either commerciNly available, known in the literature, or prepNed according to methods known and established for the prepNation of bromoanilines, according to the protocol followed hi Scheme 2, steps vii and viii, to Nford a sulfonyl chloride (15), which is converted into a sulfonamide (3), step iii, as outlined in the previous schemes. Intermediate 3 is elaborated to compounds of Formula 1 using methods previously described in Schemes 3, 4 or 5, as appropriate. Scheme 8 (Figure Removed) In Scheme 8, an Nyl fluoride (16), either prepNed according to procedures previously described, exemplified in the experimentN section, commerciNly available, or known in the literature, is reacted with an appropriately substituted primNy or secondNy amine, either commerciNly available or known in the literature, using a suitable polN solvent, such as dimethylacetamide, in the presence of an acid scavenger, such as potassium cNbonate, at elevated temperatures to Nford the desired product. (Figure Removed) The piperidinyl sulfonamide (17), shown in Scheme 9, either prepNed according to procedures exemplified in the experimentN section, cormmerciNly available, or known in the literature, is reacted with an appropriately substituted electophile such as, but not limited to, an acid chloride, sulfonyl chloride, Nkyl hNide, isothiocyanate, isocyanate, or epoxide, in the presence of an acid scavenger, such as morpholinomethyl-polystyrene or triethylamine where appropriate, in a suitable solvent, such as dichloromethane, to provide the desired product of Formula 1. (Formula Removed) Compounds of Formula 1, in which R? is H and Rj is as previously described, Ne further Nkylated by deprotonating using an NkNi base, such as sodium hydride, in an appropriate solvent, such as dimethylformamide, and subsequently treating with an Nkylating agent, such as propynyl chloride., to yield a tertiNy sulfonamide. (Figure Removed) In Scheme 11, an Nyl sulfonyl chloride (5), either prepNed according to procedures previously described, commerciNly available, or known in the literature, is reacted as described in Scheme 1, step i, to Nford an intermediate diNylsulfone (18). Reaction of 18 with an in situ derNed copper trifluoromethylating agent, step xx, Nso known in the literature as Burton's reagent, which is generated by the reaction of copper metN and dibromodifluoromethane in a polN aprotic solvent such as dimethylformamide, and heating for severN hours, provides the trifluoromethyl intermediate 19. The conversion of 19 to aniline 20 and then to the subsequent sulfonyl chloride proceeds as previously described using steps vi — viii. (Figure Removed) NternatNely, in Scheme 12, the nitro benzene (21) can be converted to the trifluoromethyl intermediate (22) in an anNogous manner used to prepNed 19, employing step xx. Further elaboration of 22 to a diNyl sulfide (7), step N, in an anNogous fashion as outlined in Scheme 2. The sulfide can than be oxidized to the diNyl sulfone (19) using procedures that were previously discussed in Scheme 2, step v. DiNyl sulfone (19) can Nso be directly prepNed by reacting 22 with an Nyl sulfinate, step xxi, either commerciNly available, or known in the literature, in a polN aprotic solvent such as dimethylacetamide with heating for severN hours. Intermediate 19 can be further transformed to aniline 20, step vi, using previously estabilished procedures. The aniline (20) can then be converted into the sulfonyl chloride, step vii - viii, using previously established procedures, and subsequently reacted with an Nnine, step iii, to Nford compounds of formula 1. In certain embodiments, the invention relates to compositions comprising at least one compound of Formula 1, or a stereoisomer or phNmaceuticNly acceptable sNt thereof, and one or more phNmaceuticNly acceptable cNriers, excipients, or diluents. Such compositions Ne prepNed in accordance with generN phNmaceuticN formulation procedures, such as, for example, those described in Remingtons PhNmaceuticN Sciences, 17th edition, ed. Nfonoso R. GennNo, Mack Publishing Company, Easton, PA (1985), which is incorporated herein by reference in its entirety. PhNmaceuticNly acceptable cNriers Ne those cNriers that Ne compatible with the other ingredients in the formulation and Ne biologicNly acceptable. The compounds of Formula 1 can be administered orNly or pNenterNly, neat, or in combination with conventionN phNmaceuticN cNriers. Applicable solid cNriers can include one or more substances that can Nso act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders, tablet-disintegrating agents, or encapsulating materiNs. In powders, the eNrier is a finely dNided solid that is in admixture with the finely dNided actNe ingredient. In tablets, the actNe ingredient is mixed with a cNrier having the necessNy compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99 % of the actNe ingredient. Suitable solid cNriers include, for example, cNcium phosphate, magnesium steNate, tNc, sugNs, lactose, dextrin, stNch, gelatin, cellulose, methyl cellulose, sodium cNboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins. [0188] Liquid cNriers can be used in prepNing solutions, suspensions, emulsions, syrups and elixirs. The actNe ingredient can be dissolved or suspended in a phNmaceuticNly acceptable liquid cNrier such as water, an organic solvent, a mixture of both, or a phNmaceuticNly acceptable oil or fat. The liquid cNrier can contain other suitable phNmaceuticN additNes such as, for example, solubilizers, emulsifiers, buffers, preservatNes, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid cNriers for orN and pNenterN administration include water (pNticulNly containing additNes as above, e.g. cellulose derNatNes, preferably sodium cNboxymethyl cellulose solution), Ncohols (including monohydric Ncohols and polyhydric Ncohols e.g. glycols) and their derNatNes, and oils (e.g. fractionated coconut oil and Nachis oil). For pNenterN administration, the cNrier can Nso be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid cNriers Ne used in sterile liquid form compositions for pNenterN administration. The liquid cNrier for pressurized compositions can be hNogenated hydrocNbon or other phNmaceuticNly acceptable propellant. Liquid phNmaceuticN compositions that Ne sterile solutions or suspensions can be administered by, for example, intramusculN, intraperitoneN or subcutaneous injection. Sterile solutions can Nso be administered intravenously. Compositions for orN administration can be in either liquid or solid form. The compounds of Formula 1 can be administered rectNly or vaginNly in the form of a conventionN suppository. For administration by intranasN or intrabronchiN inhNation or insufflation, the compounds of Formula 1 can be formulated into an aqueous or pNtiNly aqueous solution, which can then be utilized in the form of an aerosol. The compounds of Formula 1 can Nso be administered transdermNly through the use of a transdermN patch containing the actNe compound and a cNrier that is inert to the actNe compound, is non-toxic to the skin, and Nlows delNery of the agent for systemic absorption into the blood stream via the skin. The cNrier can. take any number of forms such as creams and ointments, pastes, gels, and occlusNe devices. The creams and ointments can be viscous liquid or semisolid emulsions of either the oil-in-water or water-in-oil type. Pastes comprised of absorptNe powders dispersed in petroleum or hydrophilic petroleum containing the actNe ingredient can Nso be suitable. A vNiety of occlusNe devices can be used to release the actNe ingredient into the blood stream such as a semipermeable membrane covering a reservoir containing the actNe ingredient with or without a cNrier, or a matrix containing the actNe ingredient. Other occlusNe devices Ne known in the literature. Preferably the phNmaceuticN composition is in unit dosage form, e.g. as tablets, capsules, powders, solutions, suspensions, emulsions, granules, or suppositories. In such form, the composition is cb-dNided in unit dose containing appropriate quantities of the actNe ingredient; the unit dosage forms can be packaged compositions, for example, packeted powders, viNs, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form. The amount provided to a patient will vNy depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, and the state of the patient, the manner of administration, and the like. In therapeutic applications, compounds of Formula 1 Ne provided to a patient Nready suffering from a disease in an amount sufficient to cure or at least pNtiNly ameliorate the symptoms of the disease and its complications. An amount adequate to accomplish this is defined as a "therapeuticNly effectNe amount." The dosage to be used in the treatment of a specific case must be subjectNely determined by the attending physician. The vNiables involved include the specific condition and the size, age, and response pattern of the patient. The compounds can be administered orNly, rectNly, pNenterNly, or topicNly to the skin and mucosa. The usuN daily dose depends on the specific compound, method of treatment and condition treated. The usuN daily dose is 0.01 -1000 mg/kg for orN application, preferably 0.5 - 500 mg/kg, and 0.1 -100 mg/kg for pNenterN application, preferably 0.5 - 50 mg/kg. In certain embodiments, the present invention is directed to prodrugs of compounds of Formula 1. The term "prodrug," as used herein, means a compound that is convertible in vNo by metabolic means (e.g. by hydrolysis) to a compound of Formula 1. VNious forms of prodrugs Ne known in the Nt such as those discussed in, for example, BundgaNd, (ed.), Design ofProdrugs, Elsevier (1985); Widder, et N. (ed.), Methods in Enzymolog)', vol. 4, Academic Press (1985); KrogsgaNd-LNsen, et N., (ed). "Design and Application ofProdrugs, Textbook of Drug Design and Development, Chapter 5, 113-191 (1991), BundgaNd, et N., JournN of Drug DelNery Reviews, 8:1-38(1992), BundgaNd, J. of PhNmaceuticN Sciences, 77:285 et seq. (1988); and Higuchi and Stella (eds.) Prodrugs as Novel Drug DelNery Systems, American ChemicN Society (1975), each of which is hereby incorporated by reference in its entirety. [0194] The following examples Ne illustratNe of certain embodiments of the invention and should not be considered to limit the scope of the invention. ACD NamePro softwNe was employed to generate IUPAC names for the following examples. The IUPAC names of the following examples Ne indicatNe of the neutrN or free base forms. Compounds were either isolated as a free base or the corresponding hydrochloride sNt as indicated in the experimentN procedure. Example 1: 2-Methyl-N- (2-phenylethyI)-5-(phenylsulfonyl) benzene sulfonamide (Figure Removed) [0195] Step 1: To phenyl-4-tolyl sulfone (2.32 g, 10.0 mmol) was added chloro sulfonic acid (6.7 mL, 100 mmol) and the reaction mixture was stirred at 50 °C for 5 hours and then cooled to room temperature. The reaction mixture was slowly poured into ice (200 g) and a white solid precipitated. The resulting suspension was extracted with ethyl acetate (150 mL x 3) and the organic layers were combined and washed with brine (200 mL) and collected. The collected organic layer was dried over sodium sulfate and concentrated to gNe 5-Benzenesulfonyl-2-methyl-benzenesulfonyl chloride (3.30 g, 100 % yield). The product was used without further purification. [0196] Step 2: The mixture of 5-Benzenesulfonyl-2-methyl-benzenesulfonyl chloride (66 mg, 0.20 mmol), phenethylamine (36 mg, 0.30 mmol) and triethyl amine (30 mg, 0.30 mmol) in methylene chloride (2 rN) was stirred at 37 °C for 12 hours. Then the reaction mixture was concentrated and purified by reverse phase chromatography to gNe 2-Methyl-N- (2-phenylethyl)-5-(phenylsulfonyl) benzene sulfonamide (68 mg, 82% yield), [0197] LC/MS conditions: Aquasil C18; Mobile Phase A: 100% (0.1% Formic Acid) in water (by volume), B: 100% (0.1% Formic Acid) in CAN; Flow Rate: 0.800 mL/min. [0198] Column Temperature: 40 °C; Injection Volume: 5µL, UV: monitor 215, 230, 254, 280, and 300 nm; Purity is reported at 254 nm unless othenvise noted. [0199] Gradient Table: (Table Removed) [0200] 'HNMR (CDC13) δ 8.48 (1H, d), 7.97 (IH, dd), 7.94 (2H, dd), 7.58 (dd, 1H), 7.51 (2H, dd), 7.39 (IH, dd), 7.30 (2H, dd), 7.05 (2H, dd), 4.44 (IH, t), 3.27 (2H, m), 2.78 (2H, t), 2.46 (3H, s). Examples 2 to 30 [0201] The compounds of Examples 2 to 30 were prepNed generNly according to the procedures described in Example 1. (Table Removed) Examples 31 to 179 (Table Removed) Example 180: N- ({5-[(4-fluorophenyl) suIfonyI]-2-raethylphenyl} sulfonyl)-beta-Nanine hydroxide aqueous solution (1 mL, 2 mmol). The reaction mixture was stirred at room temperature'for 5 hours and purified by reverse phase column to yield N- ({5-[(4-fluoro- phenyl) sulfonyl]-2-methylphenyl} sulfonyl)-beta-Nanine (25 mg, 86 % yield). [0204] HPLC (Method 1): Rt - 2.56 min; MS 402.04 [M+H] Examples 181-202 [0205] The compounds of Examples 181 to 201 were prepNed generNly according to the procedures described in Example I. (Table Removed) Example 202: N-{[3-(phenylsulfonyl)phenyl]sulfonyl}-beta-Nanine [0206] The compound of Example 202 was prepNed generNly according to the procedures described in Example 180. Examples 203-221 [0207] The compounds of Examples 203 to 221 were prepNed generNly according to the procedures described in Example 1. (Table Removed) Examples 222, 223, and 225 to 229 [0208] The compounds of Examples 222,' 223, and 225 to 229 were prepNed generNly according to the procedures described in Example 230. (Table Removed) Example 230: N- [3-(diethylamino) propyl]-2-ethyl-5- (phenylsulfonyl) benzene sulfonamide (Figure Removed) [0209] Step 1: To 4-Ethyl-benzenesulfonyl chloride (4.12 g, 20.0 mmol) and Numinum chloride (3.20 g, 24.0 mmol) was added benzene (10 mL). The reaction mixture was stirred at room temperature over night and then poured into water. The resulting solution was diluted with ethyl acetate (200 mL) and the organic layer was washed with 1M aqueous sodium hydroxide solution (100 mL) and brine (100 mL). The organic layer was dried over sodium sulfate, filtered and concentrated to gNe l-Benzenesulfonyl-4-ethyl-benzene (4.58 g, 92.1% yield) as a white solid. [0210] 'HNMR (CDC13) δ 8.09 (2H, dd), 7.89 (2H, dd), 7.94 (2H, dd), 7.51 (m, 2H), 7.29 (1H, m), 7.00 (2H, dd), 2.86 (2H, qt), 1.22 (3H, t). [0211] Step 2: Following the same procedure described in Example 1 (step 1), 5-Benzenesulfonyl-2-ethyl-benzenesulfonyl chloride was made quanitNely. [0212] Step 3: Following the same procedure described in Example 1 (step 2), a 0.1 mmol scNe reaction was set up and N- [3-(diethylamino) propyl]-2-ethyl-5- (phenylsulfonyl) benzene sulfonamide (38 mg, 86% yield) was synthesized. [0213] HPLC (Method 2): Rt - 2.8 min; MS 439.2 [M+H] Examples 231-243 [0214] The compounds of Examples 231 to 243 were prepNed generNly according to the procedures described in Example 230. (Table Removed) Examples 244-265 [0215] The compounds of Examples 244 to 265 were prepNed generNly according to the procedures described in Example 1. (Table Removed) Examples 266-271 [0216] The compounds of Examples 266 to 271 were prepNed generNly according to the procedures described in Example 230. (Table Removed) Examples 272-275 [0217] The compounds of Examples 272 to 275 were prepNed generNly according to the procedures described in Example 276. (Table Removed) [0218] To N- [2-(2-fluorophenyl) ethyl]-2-methyl-5- [(4-methylphenyl) sulfonyl] benzene sulfonamide (Example 138) (22 mg, 0.05 mmol) in DMF (1 mL) was added sodium hydride (4 mg, 0.1 mmol). The reaction mixture was stirred at room temperature for 20 minutes, and then Nlyl bromide (12 mg, 0.1 mmol) was added. The reaction mixture was stirred at room temperature for another 2 hours and purified by a reverse phase column to yield N-Nlyl-N- [2-(2-fluorophenyl) ethyl]-2-methy 1-5- [(4-methylphenyl) sulfonyl] benzene sulfonamide (8.2 mg, 34% yield). Examples 277: N-[2-(2-fluorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)suIfonyl]-N-prop-2-ynylbenzenesulfonamide [0219] The compound of Example 277 was prepNed generNly according to the procedures described in Example 276. Examples 278-283 [0220] The compounds of Examples 278 to 283 were prepNed generNly according to the procedures described in Example 1. (Table Removed) Examples 284-289 [0221] The compounds of Examples 284 to 289 were prepNed generNly according to the procedures described in Example 230. (Table Removed) [0222] The following table provides the HPLC retention time and mass spec data for the compounds of Examples 1 to 289. (Table Removed) Example 290: 5-[(4-chlorophenyl)sulfonyl]-2-methyI-7N-(2-morpholin-4-ylethyl)benzenesulfonamide The title compound was prepNed in a manner similN to that described in Example 1. Step 1 : 4-chlorophenyl-4-tolyl sulfone and chlorosulfonic acid were used to prepNe 5-(4-chlorophenyl)sulfonyl-2-methylbenzenesulfonyl chloride. Step 2: 5-(4-chlorophenyl)sulfonyl-2-methylbenzenesulfonyl chloride and 4-(2-aminoethyl)-morpholine were used to prepNe 5-[(4-cUorophenyl)sulfonyl]-2-methyl-N-(2-morpholin-4-ylethyl)benzenesulfonamide. MS (ES-)m/z 456.8; HRMS: cNcd for CNHfoCKsbOsS;. + H+, 459.08097; found (ESI, [M+H]+)5 459.0798. Example 291 : 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 290, 2-(2-aminoethyl)-pyridine was used to prepNe 5-[(4-chlorophenynsulfonyl]-2-methvl-N(2-pyridin-2-ylethynbenzenesulfonamide. MS (ES-)m/z 448.8; HRMS: cNcd for Cao + H+, 451.05475; found (ESI, [M+H]+), 451.0546. Example 292: 5-[(4-chlorophenyl)sulfonyl]-N-[3-(lNr-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide In an anNogous manner to Example 290, l-(3-aminopropyl)-imidazole was used © to prepNe S- methylbenzenesulfonamide . MS (ES-) m/z 451.8;HRMS: cNcd for 2 + H+, 454.06565; found (ESI, [M+Hf ), 454.0644. Example 293: 5-[(4-azidophenyl)sulfonyl]-N-[3-(1H-imiclazol-l-yl)propyl]-2-methylbenzenesulfonamide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[3-(lN-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and sodium azide in DMF were used to prepNe 5-[(-4-azidophenyl)sulfonyl]-N-[3-{lH-imidazol-l-vl)propvl1-2-methylbenzenesulfonamide. MS (ES-) m/z 458.8; HRMS: cNcd for C19H2oN6O4S2 + H+, 461.10602; found (ESI, [M+H]+ ), 461.1066. Example 294: N-[2-(lH-indol-3-yI)ethyl]-2-raethyl-5-(phenyIsulfonyl)benzenesulfonamide To a solution of 5-benzenesulfonyl-2-methyl-benzenesulfonyl chloride (0.36 g, 1.1 mmol)inDMF(10mL)wasaddedpyridine(0.13 mL, 1.6mmol)andtryptamine (0.21 g, 1.3 mmol). The reaction was stirred at room temperature overnight and then diluted with ethyl acetate and washed with saturated ammonium chloride, saturated sodium bicNbonate, and brine. The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude residue was purified using automated flash chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of N- F2-( 1 H-indol-S-vDethyllN-methvl-S-fphenvlsulfonyDbenzenesulfonamide. MS (ES-) m/z 452.8. Example 295: 2-isopropyl-N-(2-phenylethyI)-5-(phenylsulfonyl)benzenesulfonamide The title compound was prepNed in a manner similN to that described in Example 230. Step 1: 4-isopropylbenzene sulfonyl chloride and benzene were used to prepNe l-benzenesulfonyl-4-isopropylbenzene, which was purified via Biotage Horizon™ (FLASH 40 M, silica, gradient from 100% hexane to 20% EtOAc/hexane). Step 2: l-Benzenesulfonyl-4-isopropylbenzene and chlorosulfonic acid were used to prepNe 5-benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride, which was purified via Biotage Horizon (FLASH 40 M, silica, gradient from 100% hexane to 20% EtOAc/hexane). Step 3: 5-Benzenesulfonyl-2-isopropyl-beiizenesulfonyl chloride and phenethyl amine were used to prepNe 2-isopropyl--N-(2-phenylethyl)-5- Jphenylsulfonyl)benzenesulfonamide, which was purified using a via Biotage Horizon™ (FLASH 25 M, silica, gradient from 10% hexane to 50% EtOAc/hexane gradient). MS(ES-)m/z441.9; HUMS: cNcd for C23H25NO4S2 + H+, 444.12978; found (ESI, [M+H]+), 444.1297. Example 296: A-[3-(IH-imidazol-l-yl)propyI]-2-isopropyI-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 295: Step 3: 5-Benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride and 3-(lH-imidazol-l-yl)propylamine were used to prepNe N-[3-(lH'-imidazol-l-vl)propyll-2-isopropvl-5-(phenylsulfonyllbenzenesulfonamide. MS(ES-)w/z445.9; HRMS: cNcd for C2iH25N3O4S2 + H+, 448.13592; found (ESI, [M+H]+), 448.1364. Example 297: 2-ethyl-5-[(4-fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-l-y l)ethy 1] benzenes ulfonamide In an anNogous manner to Example 295: Step 1: 4-ethylbenzene sulfonyl chloride and fluorobenzene were used to prepNe 1 -ethyl-4-[(4-fluorophenyl)sulfonyl]benzene. Step 2: l-Ethyl-4-[(4-fluorophenyl)sulfonyl]benzene and chlorosulfonic acid were used to prepNe 2-ethyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride. Step 3: 2-Ethyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-(lH-imidazol-l-yl)ethylamine were used to prepNe 2-ethyl-5-[(4-fluorophenyl')sulfonvl]-N:-[2-(lH-imidazol-l-yl)ethyl]benzenesulfonamide. MS (ES-) m/z 435.9; HRMS: cNcd for C19H2oFN3O4S2 + H+, 438.09520; found (ESI, [M+Hf), 438.0945. Example 298: 2-methyI-5-(phenylsulfonyl)-N-tetrahydro-2H-pyran-4-ylbenzenesulfonamide In an anNogous manner to Example 1: Step 2: 5-Benzenesulfonyl-2-methyl-benzenesulfonyl chloride and tetrahydro-pyran-4-ylamine were used to prepNe 2-methyl-5-(phenylsulfonyl)-N-tetrahydro-2jir-pyran-4-ylbenzenesulfonamide, which was purified using a via Biotage Horizon™ (FLASH 25 M, silica, gradient from 10% EtOAc/hexane to 50% EtOAc/hexane gradient. MS (ESI+) m/z 396; MS (ESI-) m/z 394; HRMS: cNcd for C18H21NO5S2 + H+, 396.09339; found (ESI, [M+H]+), 396.0932. Example 299: 2~methyl-5-(phenylsulfonyI)-N-(2-tetrahydro-2H-pyran-4-ylethyl)benzenesulfonamide In an anNogous manner to Example 298: Step 2: 5-Benzenesulfonyl-2-methyl-benzenesulfonyl chloride and 2-(tetrahydro-pyran-4-yl)-ethylamine were used to prepNe 2-methyl-5-(phenylsulfonyl)-N-('2-tetrahydro-2H-pyran-4-ylethynbenzenesulfonamide. MS(ESI-)m/z422; HRMS: cNcd for C2oH25NO5S2 + H+, 424.12469; found (ESI, [M+H]+), 424.1237. Example 300: 2-ethyl-5-(phenyIsulfonyl)-N-tetrahydro-2H-pyran-4-ylbenzenesuIfonamide In an anNogous manner to Example 295: Step 3: 5-benzenesulfonyl-2-ethyl-benzenesulfonyl chloride and tetrahydro-pyran-4-ylamine were used to prepNe 2-ethyl-5-(phenylsulfonyl)-N-tetrahydro-2H-pyran-4-ylbenzenesulfonamide. MS(ESI+)m/z410; MS (ESI-) m/z 408; HRMS: cNcd for C19H23NO5S2 + H+, 410.10904; found (ESI, [M+H]+), 410.1 1. Example 301 : 2-ethyl-5-(phenyIsulfonyl)-N-(2-tetrahydro-2H-pyran-4-ylethyl)benzenesulfonamide In an anNogous manner to Example 295: Step 3: 5-benzenesulfonyl-2-ethyl-benzeriesulfonyl chloride and 2-(tetrahydro-pyran-4-yl)-ethylamine were used to prepNe 2-ethYl-5-(phenylsulfonyl)-N-('2-tetrahydro-2H-pyran-4-ylethyl)benzenesulfonamide. MS(ESI+);«/z438; MS (ESI-) m/z 436; HRMS: cNcd for C21H27N05S2 + H+, 438.14034; found (ESI, [M+H]+), 438.1385. Example 302: 2-methyl-N-(2-phenyIethyl)-3-(phenylsulfonyl)benzenesulfonamide To a stirred solution of 2-fluoro-6-nitrotoluene (5.0 g, 32.2 mmol) in DMF (80 mL) was added benzenethiol (4.0 mL, 38.8 mmol) and potassium cNbonate (8.9 g, 64.4 mmol). The resulting solution was heated to 100 °C overnight and concentrated. The residue was taken up in ethyl acetate and washed with ammonium chloride solution (sat) and brine. The organic phase was dried over magnesium sulfate, concentrated and flash column sepNated using 3% ethyl acetate/ hexane. The recovered materiN was dissolved in methylene chloride (70 mL) and m-chloroperbenzoic acid (8.0 g, 46.3 mmol) was added portionwise over 1 hour. The mixture was stirred an additionN 30 minutes, washed with sodium bicNbonate solution (sat), dried over magnesium sulfate and concentrated. The residue was flash column sepNated using 20 % ethyl acetate/ hexane. The resulting materiN was added to methanol (30 mL), chilled to 0 °C and 10 % pNladium on cNbon (120 mg) was added. Sodium borohydride (0.84 g, 22.2 mmol) was then added portionwise and stirred for 1 hour. The reaction was quenched with ammonium chloride solution (sat) and extracted severN times with ethyl acetate. The organic layer was filtered through celite, washed with brine, dried over magnesium sulfate, and concentrated. The resulting materiN was dissolved in acetonitrile (16 mL), chilled to 0 °C and concentrated acetic acid (1.6 mL) and concentrated hydrochloric acid (1.6 mL) were added. Sodium nitrite (0.17 g, 2.42 mmol) dissolved in D.I. water (0.5 mL) was added dropwise and the solution was stirred 20 minutes. Sulfur dioxide was then bubbled into the solution over 20 minutes. Copper chloride dihydrate (0.34 g, 2.02 mmol) dissolved in D.I. water (0.5 mL) was added to the solution, the ice bath was removed and the solution was stirred at room temperature for 3.5 hours. The mixture was concentrated, taken up in ethyl acetate and washed with brine. The organic layer was dried over magnesium sulfate, and concentrated. The resulting materiN was dissolved in THF (4 mL), triethylamine (0.4 mL, 2.86 mmol) and phenethylamine (0.1 mL, 0.79 mmol) were added and the mixture was stirred at room temperature for 30 minutes. The solution was treated with sodium bicNbonate solution (sat) and extracted severN times with ethyl acetate. The combined organic layers were dried over magnesium sulfate and concentrated to gNe 2-methyl-N-(2-phenylethyl}r 3-(phenylsulfonyl)benzenesulfonamide (0.05 g, 5%). MS(ES-)m/z413.9; HRMS: cNcd for C21H21NO4S2 + H+, 416.09848; found (ESI, [M+H]+), 416.0975. Example 303: 2-ethyl-5-[(4-fluorophenyl)sulfonyl]-N-[3-(lH-iraidazol-l-yl)propyl]benzenesulfonamide In an anNogous manner to Example 295: Step 3: 2-Ethyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 3-(l#-imidazol-l-yl)propylamine were used to prepNe 2-ethyl-5-(4-fluorophenyl)suIfonyl1-N-r2-(1 /f-imidazol-1 -vDpropyllbenzenesulfonamide. Example 304: 5-({4-[ethyl(methyl)amino]phenyl}sulfonyl)-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesuIfonamide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[3-(1H-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and N-ethylmethylamine were used to prepNe 5-(H-[ethvlfmethvl')Nnino1phenvl}sulfonvn-N-[3-('lH-irnidazol-l-ynpropvl]-2-metfavlbenzenesulfonamide. MS (ES-) m/z 474.9; HRMS: cNcd for C22H2gN4O4S2 + H+, 477.16247; found (ESI, [M+H]*), 477.1625. Example 305: N-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5-[(4-pyrrolidin-l-ylphenyl)sulfonyl]benzenesulfonamide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[3-(lJEr-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and pyrrolidine were used to prepNe NN [3-(1H-imidazol-1 -yl)propyl]-2-methyl-5- [(4-pyrrolidin-1 -ylphenyllsulfonyllbenzenesulfonamide. MS (ES-) m/z 486.9; HRMS: cNcd for C23H28N4O4S2 + H+, 489.16247; found (ESI, [M+H]+), 489.1643. Example 306: A-[3-(lH-imidazol-l-yl)propyl]-4-methyI-3-(phenylsulfinyl)benzenesulfonamide In an anNogous manner to Example 302, 2-fluoro-4-nitrotoluene and 1 equment of m-chloroperbenzoic acid were used to prepe N-[3 -( 1 N-imidazol- 1 -yl)propyl]-4-methyl-S-Cphenylsulfinyl)benzenesulfonamide. MS (ESI+) m/z 404; HRMS: cNcd for C19H21N3O3S2 + H+, 404.10971; found (ESI, [M+H]+), 404.1 116. Example 307: 5-[(4-fluorophenyl)sulfonyl]-N-[2-(lH-imiazol-l-yI)ethyl]-2-methylbenzenesulfonamide In an anNogous manner to Example 298: Step 2: 2-Methyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-(lH-imidazol-l-yl)ethylamine were used to prepNe 5-[(4-fluorophenyl)sulfonyl]-N-[2-(lH-imidazol- 1 -ynethyl]-2-methvlben2enesulfonamide. MS(ES+)m/z424; MS (ES-) m/z 422; HRMS: cNcd for C18H18FN3O4S2 + H+, 424.07955; found (ESI, [M+H]+), 424.0798. Example 308: 5-[(4-fluorophenyl)sulfonyl]-2-methyI-N1tetrahydro-2fi-pyran-4-ylbenzenesulfonamide In an anNogous manner to Example 298: Step 2: 2-Methyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and tetrahydro-pyran-4-ylamine were used to prepNe 5 - [(4-fluorophenyl) sulfony 1] -2-methvl-/V-tetrahvdro-2f/'-pvran-4-vlbenzenesulfonamide. MS(ES+)w/z414; MS(ES-)m/z412; HRMS: cNcd for CisHioFNCN + H+, 414.08397; found (ESI, [M+H]*), 414.0843. Example 309: 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(2-tetrahydro-2Jff-pyran-4-ylethyl)benzenesulfonamide In an anNogous manner to Example 298: Step 2: 2-Methyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl cliloride and 2-(tetrahydro-pyran-4-yl)-ethylamine were' used to prepNe 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(2-tetrahydro-2N-pyran-4-ylethyl)benzenesulfonamide. MS (ES+) tn/z 442; MS (ES-) m/z 440; HRMS: cNcd for C2oH24FNO5S2 + H+, 442.11527; found (ESI, [M+H]+), 442.1167. Example 310: N-[3-(lH-imidazoI-l-yl)propyl]-2-methyl-5-{[4-(methylamino)phenyl]sulfonyl}benzenesulfonamide In an anNogous manner to Example 356, 5-[(4-fluorophenyl)sulfonyl]-./V-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and methylamine were used to prepNe N-[3-(1H-imidazol-l -yl)propyl1-2-methyl-5-( [4-(methy lamino)phenyl]sulfonyl} benzenesulfonamide. MS (ES-) m/z 446.9; HRMS: cNcd for C20H24NO4S2 + H+, 449.13117; found (ESI, [M+H]+), 449.1319. Example 311: 5-{[4-(ethylamino)phenyl]sulfonyl}-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide In an anNogous manner to Example 356, 5-[(4-fluorophenyl)sulfonyl]-N-[3-(lN-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and ethylamine (70% aqueous solution) were used to prepNe 5-([4-fethylamino)phenyI]sulfonvl)-N-[3-(lN-imidazol-l-yl)propvl]-2-methylbenzenesulfonamide. MS (ES-) m/z 460.9; HRMS: cNcd for C21H26N404S2 + H+, 463.14682; found (ESI, [M+H]+)5 463.1487. Example 312: N-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5-[(4-piperidin-l-ylphenyl)sulfonyl]benzenesulfonamide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N'-[3-(lN-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and piperidine were used to prepNe N-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5-[(4-piperidin-l-ylphenyl)sulfonyl]benzenesulfonamide. MS (ES+) m/z 503; MS(ES-)m/z501; HUMS: cNcd for C24H3oN4O4S2 + H+? 503.17812; found (ESI, [M+H]+), 503.1782. Example 313: N-f3-(lH-imidazol-l-yl)propyl]-2-methyl-5-[(4-morpholin-4-ylphenyl)sulfonyl]benzenesulfonamide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and morpholine were used to prepNe N-[3-(1H-imidazol-l-yl)propyl]-2-methyl-5-[(4-morpholin-4-ylphenyl)sulfonynbenzenesulfonamide. MS (ES+) m/z 505; MS (ES-) m/z 503; HRMS: cNcd for C23H28N4O5S2 + H+, 505.15739; found (ESI, [M+H]+), 505.1587. Example 314: A-[2-(lH-imidazol-l-yl)ethyl]-2-methyl-5-(phenylsulfonyl)benzcnesulfonamide In an anNogous manner to Example 298: Step 2: 5-Benzenesulfonyl-2-methyl-benzenesulfonyl chloride and 2~(1H-imidazol-l-yl)ethylamine were used to prepNe N-[2-(lH-imidazol-l-yl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide. MS (ES-) m/z 403.8; HRMS: cNcd for C18H19N3O4S2 + H+, 406.08897; found (ESI, [M+H]4),' 406.0878. Example 315: 7Y-[3-(lH-imidazol-l-yl)propyl]-5-[(4-methoxyphenyl)sulfonyl]-2-methylbenzenesulfonamide Step 1: To a stirred solution of 5-bromo-2-methylaniline (1.49 g, 8.01 mmol) in acetonitrile (65 mL) at 0°C was added glaciN acetic acid (6.5 mL) and concentrated HC1 (6.5 mL). A solution of sodium nitrite (0.66 g 9.61 mmol) dissolved in D.I water (2 mL) was added dropwise. The resulting solution was stirred 20 minutes. Sulfur dioxide was then bubbled into the solution for 20 minutes. A solution of copper (II) chloride dihydrate (1.37 g, 8.01 mmol) dissolved in D,I. water (2 mL) was added, the ice bath was removed and the solution was Nlowed to stir overnight at room temperature. The reaction volume was concentrated to one third and extracted severN times with ethyl acetate. The organic layers were combined, washed with water and sat. sodium bicNbonate solution, dried over magnesium sulfate and concentrated. The crude was dissolved in THF (22 mL) and triethylamine (1.8 mL, 12.91 mmol) was added. l-(3-aminopropyl)-imidazole (1.0 mL, 8.38 mmol) was added dropwise and the resulting solution was stirred 30 minutes at room temperature. The solution was pNtitioned between an aqueous ammonium chloride solution and ethyl acetate. The organic layer was dried over magnesium sulfate and concentrated to gNe 5-bromo-N-[3 -( 1 H-imidazol- 1 -yl)propy 1] -2 -methylbenzenesulfonamide (1.41 g, 49%). MS (ES)7?Nz 355.8; HRMS: cNcd for C13H16BrN3O2S + H+, 358.02193; found (ESI, [M+H]+ ), 358.021 1 . Step 2: A solution of nickel (II) bromide (0.03 g, 0.1 1 mmol), zinc powder (0.03 g, 0.45 mmol), l,r-bis(diphenylphosphino)-ferrocene (0.12 g, 0.22 mmol), and potassium cNbonate (0.3 1 g, 2.24 mmol) in NMP (10 mL) was stirred at room temperature for 1 hour. 5-bromo-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide (0.70 g, 1.95 mmol) and 4-methoxybenzenethiol (0.2 mL, 1.61 mmol) were added and the resulting solution was heated overnight at 80°C. The solution was pNtitioned between an aqueous ammonium chloride solution and ethyl acetate. The organic layer was concentrated and HPLC sepNated. The resulting solid was dissolved in methylene chloride (5 mL). M-chloroperbenzoic acid (0.29 g, 77%, 1 .29 mmol) was added and the solution was stirred 1 hour at room temperature, concentrated and HPLC sepNated to gNe N-[3-(lN-imidazol-l-yl)propyI]-5-[(4-methoxvphenyl)suhcbnyl]-2 -methylbenzenesulfonamide (0.1 1 g, 13%). MS (ES-) m/z 447.9; HRMS: cNcd for C20H23N3O5S2 + H+, 450.1 1519; found (ESI, [M+H]+), 450.1 148. Example 316: N-[3-(lH-imidazol-l-yl)propyl]-5-[(2-methoxyphenyl)sulfonyl]-2-methylbenzenesulfonamide In an anNogous manner to Example 315: Step 2: 2-methoxybenzenethiol was used to prepNe N-\3-( 1H-imidazol- 1 ynpropyl]-5-[(2-methoxyphenyl')sulfonyl]-2-methylbenzenesulfonamide. MS (ES+) m/z 450; MS (ES-) m/z 448; HRMS: cNcd for C20H23N3O5S2 + H+, 450.1 1519; found (ESI, [M+H]+), 450.1 148. Example 317: N-[3-(lff-imidazol-l-yl)propylJ-4-methyi-3-(phenylsulfonyl)benzenesulfonamide To a stirred solution of N-[3-(1H-imidazol-l-yl)propyl]-4-methyl-3- (phenylsulfinyl)benzenesulfonamide (0.13 g, 0.32 mmol) in methylene chloride (7 mL) was added m-chloroperbenzoic acid (0.05 g, 0.32 mmol). The solution was then concentrated and HPLC sepNated to gNe N-[3-(1H-imidazol-l-yl)propyl1-4-methyl-3-(phenylsulfonyl)benzenesulfonamide. (0.004 g, 3%). MS (ES+) m/z 420; Example 318: S-l isopropylbenzenesulfonamide In an anNogous manner to Example 295 : " } Step 1 : 4-isopropylbenzene sulfonyl chloride and fluorobenzene were used to prepNe l-isopropyl-4-[(4-fluorophenyl)sulfonyl]benzene, which was purified via Biotage Horizon™ (FLASH 40 M, silica, gradient from 100% hexane to 20% EtOAc/hexane). Step 2: l-Isopropyl-4-[(4-fluorophenyl)sulfonyl]benzene and chlorosulfonic acid were used to prepNe 2- isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride, which was purified via Biotage Horizon™ (FLASH 40 M, silica, gradient from 100% hexane to 20% EtOAc/hexane). Step 3: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-(1H-imidazol-l-yl)ethylamine were used to prepNe 5-r(4-fluorophenvl')sulfonvl1-?/-r2-(lJ/:-imidazol-l-vnethvl]-2-isopropvlbenzenesulfonamide. MS (ES-)»i/z 449.8; HRMS: cNcd for CzcfeFNsCN + H+, 452.1 1085; found (ESI, [M+H]+), 452.1094. Example 319: 5-[(4-fluorophenyl)sulfonyl]-N-[3-(ljHr-imidazol-l-yl)propyl]-2-isopropylbenzenesulfonamide In an anNogous manner to Example 295 : Step 3: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 3-(l#-imidazol-l-yl)propylamine were used to prepNe 5- [(4-fluorophenyl )sulfonyl1-N- T3-( 1 H-imidazol- 1 -yl)propyl]-2-isopropylbenzenesulfonamide. MS(ES-)m/z463.8; HUMS: cNcd for C21H24FN3O4S2 + H+, 466.12650; found (ESI, [M+H]4), 466.1253. Example 320 ; 5-[(4-fluorophenyl)suIfonyl]-2-isopropyl-yV-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 295: Step 3: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-pyridin-2-yl-ethylamine were used to prepNe 5-[(4-fluorophenyl')sulfonyl]-2-isopropyl-N-('2-pyridin-2-ylethyl)benzenesulfonamide. MS (ES-)w/z 460.8; HRMS: cNcd for C22H23FN2O4S2 + H+, 463.11560; found (ESI, [M+H]+), 463.115. Example 321: 5-[(4-fluorophenyI)sulfonyl]-2-isopropyl-N-tetrahydro-2/r-pyran-4-ylbenzenesulfonamide In an anNogous manner to Example 295: Step 3: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and tetrahydro-pyran-4-ylNnine were used to prepNe 5-[(4-fluorophenyl)sulfonvl1-2-isopropyl-N-tetrahvdro-2H-pvran-4-vlbenzenesulfonamide. MS (ES-)m/z 439.9; HRMS: cNcd for C2oH24FNO5S2 + H+, 442.11527; found (ESI, [M+H]"), 442.1174. Example 322: 5-[(4-fluorophenyI)suIfonyl]-2-isopropyl-N-(2-tetrahydro-2flr-pyran-4-ylethyl)benzenesulfonamide In an anNogous manner to Example 295: Step 3: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-(tetrahydro-pyran-4-yl)-ethylamine were used to prepNe 5-[(4-fluorophenyl)sulfonyl]-2-isopropvl-Nr2-ten'ahvdro-2jj'-pyran-4-vlethvl)benzenesulfonamide. MS (ES-) m/z 467.9; HRMS: cNcd for C22H2gFNO5S2 + H+, 470.14657; found (ESI, [M+H]+), 470.1471; Example 323: N-[3-(lN-imidazol-l-yI)propyl]-5-[(3-methoxyphenyl)suIfonyl]-2-methylbenzenesulfonamide In an anNogous manner to Example 315: Step2: 3-methoxybenzenethiol was used to prepNe N-[3-(1H-imidazol-1-yl)propyl]-5-[(3-methoxvphenyl')sulfonyl]-2-methylbenzenesulfonamide. MS (ES-)m/z 447.9; HUMS: cNcd for C20H23N3O5S2 + H+, 450.1 1519; found (ESI, [M+H]+), 450.1 154. Example 324: N-[2-(lH-imidazol-l-yl)ethyI]-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 295 : "1 Step 1 : Benzene sulfonyl chloride and meta xylene were used to prepNe 1-benzenesulfonyl-2,4-dimethyl-benzene, which was purified via Biotage Horizon™ (FLASH 40 M, silica, gradient from 100% hexane to 20% EtOAc/hexane). Step 2: l-Benzenesulfonyl-2,4-dimethyl -benzene and chlorosulfonic acid were used to prepNe 5-benzenesulfonyl-2,4-dimethyl-benzenesulfonyl chloride, which was purified via Biotage Horizon™ (FLASH 40 M, silica, gradient from 100% hexane to 20% EtO Ac/hexane) . ] Step 3: 5-Benzenesulfonyl-2,4-dimethyl-benzenesulfonyl chloride and 2-(\H-imidazol-l-yl)ethylamine were used to prepNe N-[2-(lN-imidazol-l-vl)ethyl]-2,4-dimethvl-5-(phenylsulfonvDbenzenesulfonamide . MS (ESI+) m/z 420; MS(ESI-)m/z418; HRMS: cNcd for CNiNsCNSa + H+, 420.10462; found (ESI, [M+H]*), 420. 1051 . Example 325: A43-(LH-imidazol-l-yl)propyI]-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 298: Step 2: 5-Benzenesulfonyl-2,4-dimethyl-benzenesulfonyl chloride and 3-(lH-imidazol-l-yl)propylamine were used to prepNe N-[3-(lN-imidazol-l-yl)propyn-2,4-dimethyl-5-(phenvlsulfonyDbenzenesulfonamide. MS (ESI+) m/z 434; MS(ESI-)m/z432; HRMS: cNcd for C2oH23N3O4S2 + H+, 434.12027; found (ESI, [M+H] ), 434.1 186. Example 326: 2,4-dimethyl-5-(phenylsulfonyl)-N-(2-pyriclin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 298: . Step 2: 5-Benzenesulfonyl-2,4-dimethyl~benzenesulfonyl chloride and 2-pyridin-2-yl-ethylamine were used to prepNe 2,4j-dimethyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide. MS (ES-)m/z 428.9; HRMS: cNcdfor C21H22N2O4S2 + H+, 43 1.1 0937; found (ESI, [M+H]+), 431.1079. Example 327: 2,4-dimethyl-5-(phenylsuIfonyl)-N-tetrahydro-2H-pyran-4-ylbenzenesulfonamide In an anNogous manner to Example 298: Step 2: 5-Benzenesulfonyl-2,4-dimethyl-benzenesulfonyl chloride and tetrahydro-pyran-4-ylamine were used to prepNe 2.4-dimernyl-5-(phenylsulfonyl)-N-teteahydro-2H-pyran-4-ylbenzenesurfonamide . MS (ES-) m/z 407.9; HRMS: cNcd for C19H23NO5S2 + H+, 410.10904; found (ESI, [M+H]+), 410.1096. Example 328: 2,4-dimethyl-5-(phenylsulfonyI)-N-(2-tetrahydro-2JF/-pyran-4-ylethyl)benzenesulfonamide In an anNogous manner to Example 298: Step 2: 5-Benzenesulfonyl-2,4-dimethyl-benzenesulfonyl chloride and 2-(tetrahydro-pyran-4-yl)-ethylamine were used to prepNe 2.4-dimethyl-5-(phenylsulfonyl)-N-(2-tetrahvdro-2H-pyran-4-ylethyl)benzenesulfonamide. MS (ES-) m/z 435.9; HRMS: cNcd for C21H27NO5S2 + H+, 438.14034; found (ESI, [M+H]+), 438.141. Example 329: 5-[(4-fluorophenyl)sulfonyl]-N-[2-(lN-imidazol-l-yl)ethyl)-2,4-dimethylbenzenesultbnamide ' In an anNogous manner to Example 295 : Step 1 : 4-Fluorobenzene sulfonyl chloride and meta xylene were used to prepNe l-(4-fluoro-betizenesulfonyl)-2,4-diraethyl-benzene, which was purified via Biotage Horizon™ (FLASH 40 M, silica, gradient from 100% hexane to 20% EtOAc/hexane). Step 2: l-(4-Fluoro-benzenesulfonyl)-2,4-dimethyl-benzene and chlorosulfonic acid were used to prepNe 5-(4-fluoro-benzenesulfonyl)-2,4-dimethyl-benzenesulfonyl chloride, which was purified via Biotage Horizon™ (FLASH 40 M. silica, gradient from 100% hexane to 20% EtOAc/hexane). Step 3: 5-(4-Fluoro-benzenesulfonyl)-2,4-dimethyl-benzenesulfonyl chloride and 2-(1H-imidazol-l-yl)ethylamine were used to prepNe 5-[(4-fluorophenynsulfonyl]-N-[2-ri/f-imidazol-l-vnethvllNN-dimethylbenzenesulfonamide. MS(ESI+)w/z438; MS (ESI-) m/z 436; HRMS: cNcd for Ci9H2oFN3O4S2 + H+, 438.09520; found (ESI, [M+Hf ), 438.0945. Example 330: 5-[(4-nuorophenyl)sulfonyI]-N-[3-(lJff-imidazol-l-yl)propyI]-2,4-dimethylbenzenesulfonamide In an anNogous manner to Example 298: • • Step 2: 5-(4-Fluoro-benzenesurfonyl)-2,4-dimethyl-benzenesulfonyl chloride and 3-(1H-imidazol-l-yl)propylamine were used to prepNe 5-[(4-fluorophenynsulfonvl]-N-r3-( 1 ff-imidazol- 1 -vDpropyll -2,4-dimethylbenzenesulfonamide . MS (ESI+) m/z 452; MS (ESI-) m/z 450; HRMS: cNcd for C2£iy£WO&2 + H+, 452.1 1085; found (ESI, [M+H]+), 452.1 1 15. Example 331: 5-[(4-fluorophenyl)sulfonyl]-2,4-dimethyl-N-(2-pyridin-2-ylethyl)benzcnesulfonamide In an anNogous manner to Example 298: Step 2: 5-(4-Fluoro-benzenesulfonyl)-2,4-dimethyl-benzenesulfonyl chloride and 2-pyridin-2-yl-ethylamine were used to prepNe 5-[(4-fluorophenyl')sulfonvl]-2,4-dimethyl-N-[2-pyridin-2-ylethvl')benzenesuIfonamide. MS (ESI+) m/z 449; MS (ESI-) m/z 447; HRMS: cNcd for C21H21FN2O4S2 + H+, 449.09995; found (ESI, [M+H]+), 449.0979. Example 332: 5-[(4-fluorophenyl)sulfonyl]-2,4-diniethyl-N-(tetrahydro-2H-pyran-4-yl)benzenesultbnamide In an anNogous manner to Example 298: Step 2: 5-(4-Fluoro-benzenesulfonyl)-2,4-dimethyl-benzenesulfonyl chloride and tetrahydro-pyran-4-ylamine were used to prepNe 5-(4-fluorophenyl)sulfonyl]-2,4-dimethyl-N-(tetrahydro-2N-pyran-4-yl)benzenesulfonamid_e. MS (ESI+) m/z 428; MS (ESI-) m/z .426; HRMS: cNcd for C19H22FNO5S2 + H+, 428.09962; found (ESI, [M+H]*), 428.0981. Example 333: yl)ethyl] benzenesulfonamide In an anNogous manner to Example 298: t Step 2: 5-(4-Fluoro-benzenesulfonyl)-2,4-dimethyl-benzenesulfonyl chloride and 2-(tetrahydro-pyran-4-yl)-ethylamine were used to prepNe 5-[(4-fluorophenyl)sulfonyl]-2.4-dimethyl-N- [2-rtetrahy dro-2N'-pyran-4-yl')ethyl] benzenesulfonamide. MS(ESI+)m/z456; MS(ESI-)w/z454; HRMS: cNcd for C2iH26FNO5S2 + H+, 456.13092; found (ESI, [M+H]*), 456.1321. Example 334: 2-chloro-N-(2-phenyIethyl)-5-(phenyIsulfonyl)benzenesulfonamide Step 1 : 3-nitro-4-chlorobenzenesulfonylchloride (5.0 g, 19.5 mmol) was added portionwise to a stirred solution of Numinum chloride (3.12 g, 23.4 mmol) in benzene (10 mL) and stirred overnight at room temperature. The solution was poured over ice and extracted severN times with ethyl acetate. The combined organic layers were dried over magnesium sulfate and concentrated. The crude solid was dissolved in methanol (100 mL) and water (3 mL). Tin (II) chloride (1 1.0 g, 58.0 mmol) was added and the resulting solution was heated to 70 °C overnight. The solution was concentrated and pNtitioned between ethyl acetate and a saturated sodium bicNbonate solution. The organic layer was dried over magnesium sulfate and concentrated to gNe [2-chloro-5-(phenylsulfonyl)phenyl1amine (2.59 g, 36%). MS(ESI+)™/z268; HRMS: cNcd for C12H10ClNO2S + H+; 268.01935; found (ESI, [M+H]+)? 268.0202; Step 2: To a stirred solution of [2-chloro-5-(phenylsulfonyl)phenyl]amine (2.5 g, 9.34 mmol) in acetom'trile (75 mL) at 0 °C was added glaciN acetic acid (7.5 mL) and concentrated HC1 (7.5 mL). A solution of sodium nitrite (0.77 g, 11.21 mmol) dissolved in D.I water (3 mL) was added dropwise. The resulting solution was stirred 20 minutes. Sulfur dioxide was then bubbled into the solution for 20 minutes. A solution of copper (II) chloride dihydrate (1.59 g, 9.34 mmol) dissolved in D.I. water (3 mL) was added, the ice bam was removed and the solution was Nlowed to stir overnight at room temperature. The reaction volume was concentrated to one third and extracted severN times with ethyl acetate. The organic layers were combined, washed with water and sat. sodium bicNbonate solution, dried over magnesium sulfate and concentrated. The crude materiN was cNried on without further purification. Step 3: Following the same procedure described in Example 1 (step 2), 5-benzenesulfonyl-2-chlorobenzenesulfonyl chloride and phenethylamine were used to prepNe 2N chloro-NN-phenvlethyl)-S-rphenylsulfonyl)benzenesulfonNnide. MS(ES-)7M/z433.8; HRMS: cNcd for C20H18ClNO4S2 + H+, 436.04385; found (ESI, [M+H]+), 436.0475. Example 335: 2-chloro-7y-(2-morpholin-4-ylethyI)-5-(phenyIsulfonyl)benzenesulfonamide In an anNogous manner to Example 334: Step 3: 4-(2-aminoethyl)-morpholine was used to prepNe 2-chIoro-N-(2-rnorpholin-4-ylethyl)-5-rphenylsulfonyl)benzenesulfonamide. MS (ES-)m/z 442.8; HRMS: cNcd for C18H21ClN2O5S2 + H+, 445.06532; found (ESI, [M+H]+), 445.0679. Example 336: 2-chloro-N-[3-(LH-imidazol-l-yl)propyl]-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 334: Step 3: l-(3-aminopropyl)-imidazole was used to prepNe 2-chloro-N-[3-nN'-imidazol-l-yl)propvl]-5-(phenylsulfonvl)benzenesulfonamide. MS (ES-)m/z 437.8; HRMS: ccd for C18H18ClN3O4S2 + H+, 440.05000; found (ESI, [M+H]+), 440.0482. Example 337: 2-chloro-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 334: Step 3: 2-(2-aminoethyl)-pyridine was used to prepNe 2-chloro-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide. MS(ES-)m/z434.8; HRMS: cNcd for C19H17ClN2O4S2 + H+, 437.03910; found (ESI, [M+H]+), 437.042. Example 338: N-[3-(lH-imidazoI-l-yl)propyl]-5-[(4-isopropylphenyl)sulfonyl]-2-methylbenzenesulfonamide In an anNogous manner to Example 315: Step 2: 4-isopropylbenzenethiol was used to prepNe methvlbenzenesulfonamide. MS (ES-) m/z 460.0; HRMS: cNcd for CaHfoNaCN + H+, 462.15157; found (ESI, [M+H]+), 462.1525. Example 339: 7Y-[3-(1H-imidazol-l-yl)propyl]-2-methyl-5-(2-naphthylsulfonyl)benzenesulfonamidc In an anNogous manner to Example 315: Step 2: 2-naphthlyene was used to prepNe N- [3 -( 1 N-imidazol- 1 -vl)propyl]-2-methyl-5-(2-naphthylsulfonyl)benzenesulfonamide. MS (ES-)m/z 467.9; HRMS: cNcd for C23H23N3O4S2 + H+, 470.12027; found (ESI, [M+Hf), 470.1 189. Example 340: 5-[(3,4-dichlorophenyl)sulfonyl]-N-[3-(1H-imidazol-1-yl) propyl]-2-methylbenzenesulfonamide . ' Step 1 : In an anNogous manner to Example 315, step 1 . L Step 2: A solution of nickel (II) bromide (0.03 g, 0.1 1 mmol), zinc powder (0.03 g, 0.45 mmol), 1,1 '-bis(diphenylphosphino)-ferrocene (0.12 g, 0.22 mmol), and potassium cNbonate (0.31 g, 2.24 mmol) in NMP (8 mL) was stirred at room temperature for 1 hour. 5- bromo-N-[3-(lN-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide (0.70 g, 1.95 mmol) and 3,4-dichlorobenzenethiol (0.2 mL,l .5 7 mmol) were added and the resulting solution was heated in the microwave at 160 °C for 10 minutes. The solution was pNtitioned between a saturated aqueous ammonium chloride solution and ethyl acetate. The organic layer was concentrated and HPLC sepNated. The resulting solid was dissolved in methylene chloride (5 mL). M-chloroperbenzoic acid (0.22 g, 77%, 0.99 mmol) was added and the solution was stirred 1 hour at room temperature, washed with a saturated aqueous sodium dithionite solution, a saturated aqueous sodium bicNbonate solution, concentrated and HPLC sepNated to gNe 5-[(3,4-dichlorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide (0.08 g, 10%). MS (ES-) m/z 485.8; HUMS: cNcd for C19H19Cl2N3O4S2 + H+, 488.02668; found (ESI, [M+H]N, 488.03. Example 341: 2-(2-hydroxy-2-methylpropyl)-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide To a solution of 2-methyl-N-(2-phenylethyl)-5- (phenylsulfonyl)benzenesulfonamide(l .0 g 2.4 mmol) in tetrahydrofuran (20 mL) was added butyllithium (6.0 mL of 2.5 M in hexanes) dropwise at -78 °C. The solution was Nlowed to stir at -78 °C for twenty minutes and then acetone (0. 1 8 mL, 2.4 mmol) was added dropwise. The reaction was stirred at--78 °C for one hour and then poured onto ice/water and extracted with ethyl acetate (3 x 75 mL). The combined organics were dried with magnesium sulfate and concentrated down. The crude residue was purified using automated flash chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of 2-(2-hvdroxy-2-methylpropyl)-N-(2-phenylethyl)-5-(phenylsulfonyl')ben2enesulfonaniide (0.12g, 11%). MS (ES+) m/'z 474; MS (ES-) m/z 472; HUMS: cNcd. for C24H27NO5S2 + H+, 474.1409: found (ESI, [m+H]+), 474.1397. Example 342: 5-[(3-chlorophenyl)sulfonyl]-N-[3-(l-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide In an anNogous manner to Example 340: Step 2: 3-chlorobenzenethiol was used to prepNe 5-[(3-chlorophenyl)suIfonyl]-N-[3-(l/7-imidazol-l-yl')propyl1-2-methvlbenzenesulfonamide. HRMS: cNcd for C19H2oClN3O4S2 + H+, 454.06565; found (ESI, [M+H]+), 454.0649. Example 343: 5-[(3,5-dimethylphenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-niethylbenzenesulfonamide In an anNogous manner to Example 340: : Step 2: 3,5-dimethylbenzenethiol was used to prepNe 5-[(3.5- dimethylphenvnsulfonvl]-N-r3-(1H-imidazol-l-vl)propvl]-2-methylbenzenesulfonamide. MS (ESI+) m/z 448; HRMS: cNcd for C2iH25N304S2 + H+, 448.13592; found (ESI, [M+H]+), 448.1387. Example 344: 5-[(3,5-dichlorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yI)propyl]-2-methylbenzenesulfonamide In an anNogous manner to Example 340: Step2: 3,5-dichlorobenzenethiol was used to prepNe 5-[(3,5- dichlorophenvl)sulfonvl]-N-[3-(lN-imidazol-l-vl>)propvl1-2-methylbenzenesulfonamide. HRMS: cNcd for C19H19Cl2N3O4S2 + H+, 488.02668; found (ESI, [M+H]+), 488.0278. Example 345: 5-[(2)5-dichlorophenyl)sulfonyl]-N-[3-(1H-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide In an anNogous manner to Example 377: Step 2: 2,5-dichlorobenzenethiol was used to prepNe 5-[(2,5- dicMorophenyl)sulfonyl]-J/-[3-(1H-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide. MS (ES-)m/z 485.8; HRMS: cNcd for CigHNClaNsCUSi + H+, 488.02668; found (ESI, [M+H]+), 488.0279. Example 346: N-[3-(1H-imidazol-1-yl)propyl]-2-methyl-5-(phenylsulfinyl)benzenesulfonamide In an anNogous manner to Example 340: Step 2: benzenethiol and 1 equNNent of m-chloroperbenzoic acid were used to prepNe N-[3-(1H-imidazol-l-yl)propyl1-2-methyl-5-(phenylsuIfmyl)berizenesulfonamide. MS (ES-) m/z 402.0; HRMS: cNcd for C19H21N3O3S2 + H+, 404.10971; found (ESI, [M+H]+), 404.1 1 IS. Example 347: /V-[2-(lH-imidazol-l-yl)ethyl]-2,3~dimethyI-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 295: Step 1 : Benzene sulfonyl chloride and ortho xylene were used to prepNe 4-Benzenesulfonyl-l,2-dimethyl-benzene, which was purified via Biotage Horizon™ (FLASH 40 M, silica, gradient from 100% hexane to 20% EtOAc/hexane). Step 2: 4-Benzenesulfonyl-l,2-idmethyl-benzene and chlorosulfonic acid were used to prepNe 5-benzenesulfonyl-2,3-dimethyl-benzenesulfonyl chloride, which was purified via Biotage Horizon™ (FLASH 40 M, silica, gradient from 100% hexane to 20% EtOAc/hexane). Step 3: 5-Benzenesulfonyl-2,3-dimethyl-benzenesulfonyl chloride and 2-(lH-imidazol-l-yl)ethylamine were used to prepNe N-[2-(1ff-imidazol-l-ynethyl]-2,3-dimethyl-5-(phenylsulfonyl)benzenesulfonamide. HRMS: cNcd for C18H21N3O4S2 + H+, 420.10462; found (ESI, [M+H]*), 420.1036. Example 348: A-[3-(lH-imidazoI-l-yl)propyl]-2,3-dimetliyI-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 298: Step 2: 5-Benzenesulfonyl-2,3-dimethyl-benzenesulfonyl chloride and 3-(lH-imidazol-l-yl)propylamine were used to prepNe TV- [3 -( 1 H-imidazol- 1 -yl)propy1] -2,3 -dimethyl-5-(phenylsulfonyl)benzenesulfonamide. HRMS: cNcd for C20H23N3O4S2 + H+, 434.12027; found (ESI, [M+H]*), 434. 1 187. Example 349: 2,3-dimethyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 298: Step 2: 5-Benzenesulfonyl-2,3-dimethyl-benzenesulfonyl chloride and 2-pyridin-2-yl-ethylamine were used to prepNe 2,3-dimethyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide. HRMS: cNcd for C21H22N2O4S2 + H+, 431.10937; found (ESI, [M+H]+), 431.1085. Example 350: 2,3-dimethyl-5-(phenyIsulfonyl)-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide In an anNogous manner to Example 298: Step 2: 5-Benzenesulfonyl-2,3-dimethyl-benzenesulfonyl chloride and tetrahydro-pyran-4-ylamine were used to prepNe 2,3-dimethyl-5-(phenylsulfonyl)-N-(tetrahydro-2N-pvran-4-yl)benzenesulfonamide. HRMS: cNcd for C19H23NOz + H+, 410.1096; found (ESI, [M+H]+), 410.1114. Example 351 : 2,3-dimethyl-5-(phenylsuIfonyl)-N-[2-(tetrahydro-2H-pyran-4-yl)ethyl]benzenesulfonamide In an anNogous manner to Example 298: Step 2: 5-Benzenesulfonyl-2,3-dimethyl-benzenesulfonyl chloride and 2-(tetrahydro-pyran-4-yl)-ethylamine were used to prepNe 2,3-dimethyl-5-(phenylsulfonyl)-N-[2-(tetrahvdro-2/r-pvran-4-yl)ethyl]benzenesulfonamide. HRMS: cNcd for C2iH27NO5S2 + H+, 438.14034; found (ESI, [M+H]4), 438.1413. Example 352: 5-{[4-(cyclohexylamino)phenyl]sulfonyl}-N-[3-(lJHr-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[3-(lN"-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and cyclohexylamine were used to prepNe 5- { [4-(cyclohexylammo)phenvl1sulfonyl} -TV- [3-( 1H-imidazol- 1 -yl)propyl]-2-methylbenzenesulfonamide. MS(ES-)w/z515.0; HRMS: cNcd for C25H32N4O4S2 + H+, 517,19377; found (ESI, [M+H]+), 517.1782. Example 353: 5-({4-[(2-cyanoethyl)amino]phenyl}sulfonyl)-N-[3-(lH-imidazoI-l-yI)propyI]-2-methylbenzenesuIfonamide To a solution of 5-[(4-fluorophenyl)sulforiyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide (75 mg, 0.17 mrnol) in N,N-dimethylacetamide (0.5 mL) was added 3-aminopropionitrile (67 mg, 0.96 mmol). The solution was heated with stirring using microwave irradiation (180 °C) for 65 minutes. Upon cooling, the reaction mixture was diluted with water (10 mL) and the aqueous phase was extracted with ethyl acetate (3x10 mL). The combined organic phases were concentrated and the resulting crude residue was purified using automated flash column chromatography with a graduated mobile phase consisting of dichloromethane and methanol resulting in the isolation of 5-((4-[(2- cyanoethvnamino1phenyl}sulfonyl)-N-[3-(lH-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide (38 mg, 45%). MS (ES+) m/z 488.0 MS (ES-)m/z 485.9 HRMS: cNcd for C22H25N5O4S2 + H+, 488.1426; found (ESI, [M+H]+), 488.1440. Example 354: 5-[(4-{[(1S',2S)-l-(hydroxymethyl)-2-methylbutyI]amino}phenyI)sulfonyl]-N-[3-(1H-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[3-(1 N-imidazol-1 -yl)propyl] -2-methyIbenzenesulfonamide and (1 S,2S)-1 -(hydroxymethy l)-2-methylbutyl]amine were used to prepNe 5-[(4-{[(1 S,2S)-1 -(hydroxvmethyl)-2-methylbutyl] amino} phenyl)sulfony 1] -N- [3-)1H-imidazol-1 -yl)propy 1] -2 -methylbenzenesulfonamide. MS (ES-) m/z 533.0; HRMS: cNcd for C25H34N4O5S2 + H+, 535.20434; found (ESI, [M+H]+), 535.2024. Example 355: N-[3-(1H-imidazol-l-yl)propyl]-2-methyl-5-({4-[(l-phenylethyl)amino]phenyl}sulfonyl)benzenesulfonamide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[3-(lN"-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and 2-phenylethylamine were used to prepNe N-\3-( 1H-imidazol-1 -yDpropvl] -2-methyl-5-( 14- F( 1 -phenvlethvl)amino]phenyl)sulfonyl)benzenesulfonamide. MS (ES-) m/z 536.9; HRMS: cNcd for C27H30N4O4S2 + H+, 539.17812; found (ESI, [M+H]+), 539.1788. Example 356: 2-methyl-5-{[4-(methylaniino)phenyl]sulfonyl}-N-(2-pyridin-2-ylethyl)benzenesulfonamide To a solution of 5-[(4-fluorophenyl)sulfonyl]-2-methyl-Nr-(2-pyridin-2-ylethyl)benzene-sulfonamide (75 mg, 0.17 mmol) in N,N-dimethylacetamide (0.5 mL) was added an ethanolic solution containing methyl amine (33%, 0.5 mL). The solution was heated with stirring using microwave irradiation (180 °C) for 20 minutes. Upon cooling, the reaction mixture was diluted with water (10 mL) and the aqueous phase was extracted with ethyl acetate (3x10 mL). The combined organic phases were concentrated and the resulting crude residue was purified using automated flash column chromatography with a graduated mobile phase consisting of dichloromethane and methanol resulting in the isolation of 2-methyl-5-{ [4-(methylamino)phenvl1sulfonyl)-Nr-(2-pvridin-2-vlethvl)-benzenesulfonamide (92 mg, 81%). MS (ES-) m/z 446; HRMS: cNcd for C21H23N3O4S2 + H+, 446.12027; found (ESI, [M+H]+), 446.1209. Example 357: 2-isopropyl-5-{[4-(methylamino)phenyl]sulfonyl}-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 356, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide and methylamine were used to prepNe NN [3 -f l#-imidazol- 1 -vl)propvl1-2-methvl-5- 1 [4-(methylamino')phenyl]sulfonvl>benzenesulfonamide. MS(ES+)w/z474; MS(ES-)m/z472; HRMS: cNcd for C23H27N3O4S2 + H+, 474.15157; found (ESI, [M+Hf), 474. 151 1 . Example 358: 2-isopropyl-5-{[4-(methylamino)phenyl]sulfonyl}-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide In an anNogous manner to Example 356, 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-tetrahydro-2H-pyran-4-ylbenzenesulfonamide and methylamine were used to prepNe 2-isopropyl-5- ( [4-(methvlamino)phenyl] sulfonyl} -N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide. MS(ES+)m/z453; MS(ES-)m/z451; HRMS: cNcd for C21H28N2O5S2 + H+, 453.15124; found (ESI, [M+H]+), 453.1505. Example 359: 2-isopropyl-5-{[4-(methylamino)phenyI]sulfonyl}-A?-[2-(tetrahydro-2H-pyran-4-yl)ethyl]benzenesulfonamide : In an anNogous manner to Example 356, 5-[(4-fluorophenvl)sulfonyl1-2-isopropyl-N-(2-tetrahydro-2H-pvran-4-ylethyl)benzenesulfonamide and methylamine were used to prepNe 2-isopropvl-5-ir4-(methvlamino)phenyl]sulfonyl}-N-[2-(tetrahydro-2H-pyran-4-yl)ethyl]benzenesulfonamide. MS(ES+) m/z 481; MS (ES-) m/z 479; HRMS: cNcd for C23H32N2O5S2 + H+, 481.18254; found (ESI, [M+H]+), 481.1837. Example 360: 5-[(2,3-dichlorophenyl)sulfonyI]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide In an anNogous manner to Example 340: Step 2: 2,3-dichlorobenzenethiol was used to prepNe 5-[(2,3- dichIorophenynsulfonyl]-N-[3-(lH-imidazol-l-vl)propyl]-2-methylbenzenesulfonamide. MS (ESI+) m/z 488; MS(ESI-)m/z486; HRMS: cNcd for C19H19Cl2N3O4S2 + H+, 488.02668; found (ESI, [M+H]+), 488.0269. Example 361 : 2-chloro-5-(phenylsulfonyl)-N(tetrahydro-2H-pyran-4-yl)benzenesulfonamide In an anNogous manner to Example 334: Step 3: tetrahydropyran-4-ylamine was used to prepNe 2-chloro-5-rhenvlsulfonyl)-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide. HRMS: cNcd for C17H,8C1N05S2 + H+, 416.03877; found (ESI, [M+H]+), 416.0392. Example 362: N-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5--(2-thienylsulfonyl)benzenesulfonamide In an anNogous manner to Example 340: Step 2: thiophene-2-thiol was used to prepNe N-[3-(lN-imidazol-l-yl)propyl]-2-methvl-5-(2-thienvlsulfonyl)benzenesurfonamide. MS (ESI+) m/z 426; HRMS: cNcd for Ci7HI9N3O4S3 + H+, 426.06104; found (ESI, [M+H]+), 426.062. Example 363: N-[3-(lJfir-imidazol-1-yl)propyl]-2-methyl-5-[(2-methyl-3-furyl)sulfonyl]benzenesulfonamide In an anNogous manner to Example 340: Step 2: 2-methylfuran-3-thiol was used t«orepNe N-[3-(lff-imidazol-l -vnpropyl]-2-methyl-5-[(2-methyl-3-furynsulfonyl]benzenesulfonamide. MS (ESI+) m/z 424; MS(ESI-)7n/z422; HRMS: cNcd for CisHiiNsOsSi + H+, 424.09954; found (ESI, [M+Hf), 424.0983. Example 364: N-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-L-phenylNaninamide In an anNogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, diisopropylethylamine, and L-phenylNaninamide in dichloromethane were used to prepNe N-l[2-methyl-5-('phenylsulfonvl>)phenyl]sulfonyU-L-phenylNaninamide. MS(ESI+)m/z459 MS(ESI-)m/z457. Example 365: methyl N-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-D-phenylNaniaate In an anNogous manner to Example 294, 5-benzenesulfonyl-2-methyl-benzenesulfonyl chloride, diisopropylethylamine, and D-phenylNanine methyl ester in dichloromethane were used to prepNe methyl N-|[2-methyl-5-CphenylsulfonyDphenyljsulfonyU-D-phenylNaninate. MS (ESI+) m/z 474; MS (ESI-) m/z 472. Example 366: N-[ ylamino)phenyl]sulfonyl}benzenesulfonamide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N[3-(1N-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and 4-aminotetrahydropyran were used to prepNe N-r3-(1H-imidazol-l-yl')propyl]-2-methyl-5-{r4_-(tetrahydro-2/:f-pyran-4-ylamino)phenynsulfonvl|benzenesulfonamide. MS(ESI+)/H/z519; MS(ESI-)m/z517; HRMS: cNcd for CNoNNSz + H+, 519.17304; found (ESI, [M+H]+), 519.1755. Example 367: Aq3-(lN-imidazol-l-yI)propyl]-5-({4-[(3-isopropoxypropyl)amino]phenyl}sulfonyl)-2-methyIbenzenesulfonamide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[3-(17;f-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and 3-isopropoxypropyl)amine were used to prepNe N- F3-C 1 H-imidazol- 1 -y l)propyl]-5 -( 1 4- [(3-isopropoxypropvnamino]phenvUsulfonylV2-methylbenzenesulfonamide. MS (ESI+) m/z 535; MS(ESI-)m/z533; HRMS: cNcd for C25H34N4O5S2 + H+, 535.20434; found (ESI, [M+H]+), 535.2054. Example 368: 5-({4-[(cyc!opropylmethyl)amino]phenyl}sulfonyl)-N-[3-(lJHr-imidazoH-yl)propyl]-2-methy!benzenesulfonamide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[3-(lNr-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and cyclopropylmethylamine were used to prepNe 5-({4-r(cvclopropvlmethyl)amino]phenvl}sulfonyl')-N-f3-(lN-imidazol-l-Yl')propyl]-2-methvlbenzenesulfonamide. MS (ESI-) m/z 481; HRMS: cNcd for €23N8N0482 + H+, 489.16247; found (ESI, [M+H]+), 489.1653. Example 369: 5-({4-[(lN,2J?,41S)-bicycIo[2.2.1]hept-2-ylamino]phenyl}sulfonyl)-N-[3-(l/T-imidazol-l-yl)propyl]-2-methylbenzenesulfonaniide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[3-(l/i/-imidazol-l-yl)fTOpyl]-2-methylbenzenesulfonamide and (lN,2N,4S)-bicyclo[2.2.1]hept-2-ylamine were used to prepNe S-('(4-f(lJ/?,2N,4Nr)"bicvclor2.2.nhept-2-ylamino1phenvl}sulfonvl)-N'-f3-(lN'-imidazol-l-yl)propyl1-2-methyIbenzenesuIfonainide. MS (ESI+) m/z 529; MS (ESI-) m/z 527; HRMS: cNcd for C26H32N4O4S2 + H+, 529.19377; found (ESI, (M+Hf), 529.1946. Example 370: 5-{[4-(benzyIamino)phenyl]sulfonyl}-N[3-(lJFT-imidazol-l-yl)propyl]-2-methylbenzenesulfonNaide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[3-(l#-imidazol-l-yl)propyl]-2Hmemylbenzenesulfonamide and benzylamine were used to prepNe 5- ( r4-(benzvlamino')phenvll sulfony 1 } -N- [3-d N-imidazol- 1 -vDpropyl ] -2-methylbenzenesulfonamide. MS (ESI+) m/z 525; MS (ESI-) m/z 523. Example 371: 5-[(4-{[(15')-l-cyclohexyIethyI]amino}phenyl)sulfonyl]-N-[3-(l£r-imidazoI-l-yI)propyl]-2-methylbenzenesulfonamide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N/-[3-(lN-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and (lS)-l-cyclohexylethylamine were used to prepNe 5 -[(4- { [( 1 iSV 1 -cyclohexvlethvl]amino ) pheny Dsulfony 1] -N- [3-d /f-imidazol- 1 -yl)propvl1-2-methylbenzenesulfonaniide. MS (ESI+) m/z 545; HRMS: cNcd for GnHseNCXiSz + H+, 545.22507; found (ESI, [M+H]+), 545.2244. Example 372: 5-[(4-{[(lH)-l-cyclohexylethyI]amino}phenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[3-(lN"-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and (lN)-l-cyclohexylethylamine were used to prepNe 5-[(4-([(lJ?')-l-cvclohexylethyl]amino}phenyl)sulfonyl]-N-[3-(lN-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide. MS (ESI+) m/z 545; MS(ESI-)»z/z543; HRMS: cNcd for C27H36N404S2 + H+, 545.22507; found (ESI, [M+Hf), 545.2255. Example 373: 5-({4-[(2-hydroxybutyl)amino)phenyl}sulfonyl)-N-[3-(lH-imidazol-l-yl)propyl]-2-methyIbenzenesuIfonamide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[3-(1H-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and 2-hydroxybutylamine were used to prepNe 5-f(4-r(2-hvdroxvbutyl)amino1phenvl}sulfonyl)-N-[3-(lN'-imidazol-l-vl)propyl]-2-methylbenzenesulfonamide. MS (ESI+) m/z 507; MS (ESI-) m/z 505; HRMS: cNcd for C23H3oN4O5S2 + H+, 507.17304; found (ESI, [M+H]+), 507.1738. Example 374: N-[3-(lH-imidazol-l-yI)propyl]-2-methyl-5-[(4-{[4-(trifluoromethyl)benzyl]amino}phenyl)sulfonyl]benzenesulfonamide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[3-(lN-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and4-(trifluoromethyl)benzylamine were used to prepNe 7Y-[3-(lN-imidazol-l -ynpropyl]-2-methyl-5-[('4-| [4-(trifluoromethvDbenzvllaminolphenyllsulfonvljbenzenesulfonamide. MS (ESI+) m/z 593; HRMS: cNcd for €2N3N0482 + H+, 593.14986; found (ESI, [M+H]+), 593.1508. Example 375: 5-[(4-bromophenyl)sulfonyl]-2-methyI-N-(tetrahydro-2H-pyran-4-yl)benzenesultbnamide N In an anNogous manner to Example 230 : , Step 1 : p-toluene sulfonyl chloride and bromobenzene were used to prepNe 1-bromo-4-[(4-methylphenyl)sulfonyl]benzene. Step 2: Following the same procedure described in Example 1 (step 1), 1-bromo-4-[(4-methylphenyl)sulfonyl]benzene and chlorosulfonic acid was used to prepNe 5-(4-bromobenzenesulfonyl)-2-methylbenzenesulfonyl chloride. Step 3: Following the same procedure described in Example 1 (step 2), 5-(4-bromobeiizenesulfonyl)-2-methylbenzenesulfonyl chloride and tetrahydropyran-4-ylamine were used to prepNe 5-[(4-bromophenyl)sulfonyl]-2-methyl--N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide. MS (ESI-) m/z 472; Example 376: 5-[(4-cyanophenyl)suIfonyl]-2-methyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide To a stirred solution of 5-[(4-bromophenyl)sulfonyl]-2-memyl-N-(tetrahydro-2Jf/-pyran-4-yl)benzenesulfonamide (0.30 g, 0.63 mmol) in DMF (3 mL) was added zinc cyanide (0.05 g, 0.38 mmol), tris(dibenzylideneacetone) dipNladium(0) (0.03 g, 0.03 mmol), and 1,1'-bis(diphenylphosphino)-ferrocene (0.04 g, 0.06 mmol). The resulting solution was heated to reflux for 1 hour. The solution was concentrated. Flash column sepNation with 10%-60% ethyl acetate/ hexane followed by trituration gave 5-[(4-cyanophenyI)sulfonyl1-2-methyl-N-rtetrahydro-2/jr-pyran-4-yl')benzenesulfonamide (0.11 g, 42%). MS(ESI-)/n/z419. Example 377: 5-[(2-chIorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide Step 1: In an anNogous manner to Example 315, step 1. Step 2: A solution of nickel (II) bromide (0.03 g, 0.11 mmol), zinc powder (0.03 g, 0.45 mmol), l,l'-bis(diphenylphosphino)-ferrocene (0.12 g, 0.22 mmol), and potassium cNbonate (0.31 g, 2.24 mmol) in NMP (8 mL) was stirred at room temperature for 1 hour. 5-bromo-N-[3-(H-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide (0.70 g, 1.95 mmol) and 2-chlorobenzenethiol (0.18 mL, 1.57 mmol) were added and the resulting solution was heated in the microwave at 160 °C for 10 minutes. The solution was pNtitioned between a saturated aqueous ammonium chloride solution and ethyl acetate. The organic layer was concentrated and HPLC sepNated. The resulting solid was dissolved in methylene chloride (5 mL). Oxone (0.68 g, 1.10 mmol) was added and the solution was stirred 2 days at room temperature, washed with a saturated aqueous ammonium chloride solution, dried over magnesium sulfate and concentrated to gNe 5-[(2-chlorophenyl)sulfonyl]-N-[3-(lN-imidazol-l-yl)propyl']-2-methyjbenzenesulfonamide (0.04 g, 4%). MS (ESI+) m/z 454; MS (ESI-) m/z 452; HRMS: cNcd for CipHooClNaCN + H+, 454.06565; found (ESI, [M+H]+), 454.0683. Example 378: N-[3-(lflr-imidazol-l-yl)propyl]-2-methyI-5~(pyridin-2-ylsulfonyl)benzenesulfonamide Infln anNogous manner to Example 340 : Step 2: 2-rnercaptopyridine was used to prepNe N- [3-d /f-imidazol- 1 - vl)propvl]-2-methvl-5-(pyridin-2-vlsulfonvl)benzenesulfonamide. MS(ESI+)/w/z421; HRMS: cNcd for CigH2oN4O4S2 + H+, 421.09987; found (ESI, [M+H]+), 421.0989. Example 379: 5-[(2,4-dichlorophenyl)sulfonyl]-N-[3-(LHr-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide i , In an anNogous manner to Example 377 : Step 2: 2,4-dichlorobenzenethiol was used to prepNe 5-[(2,4- dicMorophenyl)suIfonyl1-N-[3-n/f-imidazol-l-yl)propyl1-2-methylbenzenesulfonNnide. MS(ESI+)/n/z488; MS (ESI-) m/z 486; HRMS: cNcd for Ci9Hi9Cl2N3O4S2 + H+, 488.02668; found (ESI, [M+H]+), 488.0299. Example 380: 5-[(4-acetylphenyl)sulfonyl]-2-methyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide To a stirred mixture of 5-[(4-bromophenyl)sulfonyl]-2-methyl-A?-(tetrahya1ro-2H-pyran-4-yl)benzenesulfonamide (0.70 g, 1.46 mmol) in toluene (10 mL) was added tetrNcis(triphenylphosphine) pNladium(O) (0.01 g, 0.07 mmol), and tributyl(l-ethoxyvinyl)tin (0.5 mL, 1.48 mmol). The resulting solution was heated at 100 °C overnight and pNtitioned between a saturated aqueous ammonium chloride solution and ethyl acetate. The organic layer was concentrated, taken up in THF (10 mL) and 2N HC1 (5 mL) was added. The resulting solution was stirred at room temperature for 2 hours and extracted severN times with ethyl acetate. The combined organic layers were filtered through celite and concentrated. Trituration with ether gave 5-[f4-acervlphenyDsulfonyl]-2-methyl-N-('tetrahvdro-2N:-pyran-4- Yl)benzenesulfonamide (0.54 g, 85%Y MS(ESI+)m/z438; MS(ESI-)m/z436; HRMS: cNcd for C2oH23NO6S2 + H-K 438.10396; found (ESI, [M+H]+), 438.1023. Example 381 : 5-[(4-bromophenyl)sulfonyl]-2~methyI-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 375 : Step 3: 2-(2-aminoethyl)-pyridine was used to prepNe 5-[(4-bromophenvl)sulfonyl|-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide. HRMS: cNcd for C2oH19BrN2O4S2 + H+, 495.00424; found (ESI, [M+H]+), 495.0048. Example 382: 2-methyl-5-(phenylsuIfonyl)-N~(tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide In an anNogous manner to Example 298: Step 2: 5-Benzenesulfonyl-2-methyl-benzenesulfonyl chloride and 2-(tetrahydro-pyran-4-yl)-methylamine were used to prepNe 2-methyl-5-('phenvlsulfonvlVN-(tetrahydro-2H-pyran-4-ylmethyl')benzenesulfonamide. MS(ESI+)w/z410; MS(ESI-)m/z408; HRMS: cNcd for CNNCN + H+, 410.10904; found (ESI, [M+H]*), 410.1 1 1. Example 383: 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(tetrahydro-2/r-pyran-4-ylmethyl)benzenesulfonamide In an anNogous manner to Example 298: Step 2: 2-Methyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and tetrahydro-pyran-4-yl-methylamine were used to prepNe 5-[(4-fluorophenyDsulfonvl]-2-methyl-N-(tetrahydro-2N-pyran-4-vlmethyl)benzenesulfonamide. MS (ESI+) m/z 428; MS(ESI-)w/z426; HRMS: cNcd for Ci9H22FNO5S2 + H+, 428.09962; found (ESI, [M+H]*), 428.1015. Example 384: 2-ethyI-5-[(4-fluorophenyl)sulfonyl]-N-(tetrahydro-2/;f-pyran-4-ylmethyl)benzenesulfonamide In an anNogous manner to Example 298: Step 2: 2-Ethyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and tetrahydro-pyran-4-yl-methylamine were used to prepNe 2-ethyl-5-[(4-fluorophenyl)sulfonyl1-Nr-(tetrahydro-2#-pyran-4-ylmethvl)benzenesulfonamide. MS (ESI+) m/z 442; MS (ESI-) m/z 440; HUMS: cNcd for C2oH24FNO5S2 + H+, 442.11527; found (ESI, [M+H]+), 442.1144. Example 385: 2,4-dimethyl-5-(phenylsulfonyl)-N-(tetrahydro-2#-pyran-4-ylmethyl)benzenesulfonamide In an anNogous manner to Example 298: • Step 2: 5-Benzenesulfonyl-2,4-dimethyl-benzenesulfonyl chloride and tetrahydro-pyran-4-yl-mthylamine were used to prepNe 2,4-dimethyl-5-fphenylsuIfonyl)-N (tetrahvdro-2H-pyran-4-yknethyl)benzenesulfonamide. MS (ESI+) m/z 424; MS(ESI-)m/z422; HRMS: cNcd for C2oH2sNO5S2 + H+, 424.12469; found (ESI, [M+H]*), 424.124. Example 386: N-(2-hydroxy-2-phenylethyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 298: Step 2: 5-Benzenesulfonyl-2-methyl-benzenesulfonyl chloride and 2-amino-l-phenyl-ethanol were used to prepNe N-(2-hvdroxy-2-phenvlethyl)-2-methyl-5-Cphenylsulfonynbenzenesulfonamide. MS(ESI-)w/z430; HRMS: cNcd for C2iH2iNO5S2 + NlV, 449.1 1994; found (ESI, [M+NH4]+), 449.1 19. Example 387: 5-[(4-fluorophenyl)sultbnyl]-N(2-liydroxy-2-phenylethyl)-2-raethylbenzenesulfonamide In an anNogous manner to Example 298: Step 2: 2-Methyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-amino-1-phenyl-ethanol were used to prepNe 5-[(4-fluorophenyl)sulfQnyl]-N(2-hydrQxy-2-phenylethyl)-2-methyIbenzenesulfonamide. MS(ESI-)»?/z448; HRMS: cNcd for CNiHioFNOsSo + NH4+, 467.11052; found (ESI, [M+NH4J*), 467.1 105. Example 388: 2-ethyl-5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-phenylethyl)benzenesulfonamide In an anNogous manner to Example 298: Step 2: 2-Ethyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-amino-1-phenyl-ethanol were used to prepNe 2-ethyl-5-[(4-fIuorophenyl)sulfonyl]-N-(2-hydroxy-2-phenylethvnbenzenesulfonamide. MS (ESI-) m/z 462. Example 389: N-(2-hydroxy-2-phenylethyl)-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 298: Step 2: 5-Benzenesulfonyl-2,4-dimethyl-benzenesulfonyl chloride and 2-amino-1-phenyl-ethanol were used to prepNe N-(2-hvdroxv-2-phenylethylV2.4-dimethyl-5-Cphenylsulfonynbenzenesulfonamide. MS (ESI-) m/z 444; HRMS: cNcd for CaNibNOsSj + NH/, 463.13559; found (ESI, [M+NH4]+)) 463.1356. Example 390: trans-NN-hydroxy-l-methyl)-N-phenylethylN-methyl-S-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 298: Step 2: 5-Benzenesulfonyl-2-methyl-benzenesulfonyl chloride and norephedrine hydrochloride were used to prepNe trans-./V-(2-hvdroxv- 1 -methyl-2-pheny lethvl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide. MS(ESI-)w/2444; HRMS: cNcd for C22H23NO5S2 + NHt+, 463.13559; found (ESI, [M+NH4]4), 463.1376. Example 391: 5-[(4~fluorophenyl)sulfonyl]-N-[trans-2-hydroxy-l-raethyl-2-phenylethyl]-2-methylbenzenesulfonamide In an anNogous manner to Example 298: Step 2: 2-Methyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and norephedrine hydrochloride were used to prepNe 5-[(4-fluorophenyl)sulfonyl]-N[trans-2-hydroxy-l-methyl-2-phenylethyll-2-methylbenzenesulfonamide. MS(ESI-)w/z462; HRMS: cNcd for C22H22FN05S2 + NB/, 481.12617; found (ESI, [M+NH4]+), 481.1258. Example 392: 2-ethyl-5-[(4-fluorophenyl)sulfonyl]-N-[(trans)-2-hydroxy-l-methyl-2-phenylethyl]benzenesulfonamide In an anNogous manner to Example 298: Step 2: 2-Emyl-5-(4~fluoro-benzenesulfbnyl)-benzenesulfonyl chloride and norephedrine hydrochloride were used to prepNe 2-etfayl-54(4-fluorophenvnsulfonyl]-.N-(trans)-2-hydroxv- 1 -methvl-2-phenvlethvl]benzenesulfonamide. MS(ESI-)w/z476; HRMS: cNcd for C23H24FNOsS2 + NH4+, 495.14182; found (ESI, [M+NH4]+), 495.1408. Example 393: A4(trans)-2-hydroxy-l-methyl~2-phenylethyl]-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 298: Step 2: 5-Benzenesulfonyl-2,4-dimethyl-benzenesulfonyl chloride and norephedrine hydrochloride were used to prepNe N-[(trans~)-2-hvdroxv-l-methvl-2-phenylethyl]-2,4-dimethvl-5-(phenvlsulfonvnbenzenesulfonamide. HRMS: cNcd for CoaEbNON + NH/, 477.15124; found (ESI, [M+NH4]+), 477.1517. Example 394: 2-methyl-5-(phenylsulfonyI)-N-propylbenzenesulfonamide In an anNogous manner to Example 294, 5-benzenesulfonyl-2-methyl-benzenesulfonyl chloride, triethylamine, and propylamine hydrochloride in dichloromethane were used to prepNe 2-methyl-5-(phenylsulfonyl)-N-propylbenzenesulfonamide. MS (ES-) m/z 352.0. Example 395: N-(tert-butyI)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 294, 5-benzenesulfonyl-2-methyl-benzenesulfonyl chloride, triethylamine, and tert-butylamine in dichloromethane were used to prepNe N-(tert-butyN2-methyl-5-(phenylsulfonyl)benzenesulfonamide. MS (ESI-) m/z 366. Example 396: N-(2,2-dimethylpropyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, triethylamine, and weo-pentylamine in dichloromethane were used to prepNe N-(2,2-dimethylpropyl')-2-methyl-5-(phenvlsulfonvl)benzenesulfonamide. MS (ES-) m/z 380.0. Example 397: N-(l-ethylpropyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, triethylamine, and 3-aminopentane in dichloromethane were used to prepNe N-n-ethvlpropylV2-methyl-5-(phenylsulfonvl')benzenesulfonamide. MS (ES-) m/z 380.0. Example 398: N-cyclobutyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, triethylamine, and cyclobutylamine in dichloromethane were used to prepNe N-cyclobutyl-2-methvl-5-('phenylsulfonyl')benzenesulfonamide. MS (ESI-) m/z 364. Example 399: N-cyclopentyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, triethylamine, and cyclopentylamine in dichloromethane were used to prepNe N-cvclopentvl-2-methvl-5-(phenylsulfonyl)benzenesulfonaniide. MS (ESI-) m/z 378. Example 400: N-cyclohexyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, triethylamine, and cyclohexylamine in dichloromethane were used to prepNe N-cyclohexyl-2-methyl-5-Cphenylsulfonyl)benzenesulfonamide. MS (ESI-) m/z 392. Example 401: 2-methyl-5-(phenylsulfonyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide _, In an anNogous manner to Example 294, 5-benzenesulfonyl-2-methyl-benzenesulfonyl chloride, triethylamine, and 2,2,2-trifluoroethylamine in dichloromethane were used to prepNe 2-methyl-5-(phenylsulfonvl')-N-(2,2,2-trifluoroethvl)benzenesulfonamide. MS (ES-) m/z 39 1.9. Example 402: 5-({4-[(lH)-N-hydroxyethanimidoyl]phenyl}sulfonyl)-2-methyl-N-(tetrahydro-2N-pyran-4-yl)benzenesulfonamide - . ; To a stirred mixture of 5-[(4-acetylphenyl)sulfonyl]-2-methyl-N-(tetrahydro-2N/'-pyran-4-yl)benzenesulfonamide (0.20g, 0.46mmol) in ethanol (2mL) and D.I. water (O.SmL) was added sodium acetate (O.OSg, 0.55mmol) and hydroxylamine hydrochloride (0.04g, O.SOmmol). The resulting mixture was heated to reflux for 2.5 hours. The solution was concentrated and filtered to gNe S-( { 4- [( 1 £)-N-hvdroxvethanimidoy l]phenyl ) sulfonyl)-2-methyl-N-(teteahydro-2N-pvran-4-ynbenzenesulfonamide ( 0. 1 1 g, 55%). MS (ESI+) m/z 453; HRMS: cNcd for CaoHNCNSa, 452.10758; found (ESI, [H+M]+), 453.1131. Example 403: 5-[(4-acetylphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide " In an anNogous manner to Example 380, 5- [(4-bromophenyl)sulfonyl] -2-methyl-N'-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepNe 5-[(4-acetylphenyDsulfonyl]-2-methyl-N:-('2-pyridin-2-vlethvl)benzenesulfonamide. MS (ESI+) m/z 459; HRMS: cNcd for CaaHbNCN + H+, 459.10429; found (ESI, [M+Hf ), 459.1054. Example 404: N-(2-hydroxy-l,l-dimethylethyl)-2-methyl~5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, triethylamine, and 2-amino-2-rnethyl-l-propanol in dichloromethane were used to prepNe N-(2-hydroxy-1,1 -dimethylethyl)-2-methyl-5-CphenvlsulfonyDbenzenesulfonamide. MS (ESI-) m/z 382. Example 405: 5-{l4-(l-hydroxy-l-methylethyl)phenyl]suIfonyl}-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide _ • . . To a stirred mixture of 5-[(4-acetylphenyl)sulfonyl]-2-methyl-N:-(2-pyridin-2-ylethyl)benzenesulfonamide (0.15 g, 0.33 mmol) in THF (3 mL) was added methyl magnesium bromide 1.4M in 75% toluene/THF (0.75 mL, 1.0 mmol) at 0 °C. The resulting mixture was stirred 2 hours, quenched with a saturated aqueous ammonium chloride solution, and extracted severN times with ethyl acetate. The combined organic layers were washed with brine, dried over magnesium sulfate, and concentrated. HPLC sepNation gave 5-{[4-(l-hydroxy-l-methvlethynphenvllsulfonvU-2-methvl-N-(2-pyridin-2-ylethyl')benzenesulfonamide (0.02 g, MS (ES+) m/z 475; HRMS: cNcd for CzBHjeNaOsSa, 474.12831; found (ESI, [H+M]*), 475.1382. Example 406: 5-{[4-(l-cyclohexyl-l-hydroxyethyl)phenyl]sulfonyl}-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamid ; In an anNogous manner to Example 405, cyclohexyl magnesium chloride was used to prepNe 5 - ( [4-( 1 -cyclohexyl- 1 -hvdroxyethy Dphenyll sulfonyl ) -2-methvl-N-('2-pyridin-2 -ylethyHbenzenesulfonamide. MS (ES-) m/z 54 1.0; HRMS: cNcd for €281*34N0582 + H+, 543.19819; found (ESI, [M+Hf ), 543.1959. Example 407: 5-{[4-(l-hydroxy-l-phenylethyI)phenyl]sulfonyl}-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 405, phenyl magnesium bromide was used to prepNe 5-j[4-(l-hyckoxy-l-phenvlethvl)phenyl1sulfonvU-2-methyl-N-(2-pyridin-2-vlethyDbenzenesulfonamide. MS(ES-)m/z535.0; HRMS: cNcd for C2sH28N205S2 + H+, 537.15124; found (ESI, [M+H]+), 537.1492. Example 408: 5-{[4-(l-hydroxy-l-methyl-2-phenylethyI)phenyl]sulfonyI}-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 405, benzyl magnesium chloride was used to prepNe 5-{[4-d-hydroxy-l-niethvl-2-phenvlethvl)phenyl1sulfonyl}-2-methyl-N-(2-pyridin-2-ylethyDbenzenesulfonamide. MS (ES-) m/z 549.0; FIRMS: cNcd for CjgHaoNzCN + H+, 551.16689; found (ESI, [M+H]h), 551.1655. Example 409: 5-[(3-cyanophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide Step 1 : Following the same procedure described in Example 3 1 5 (step 1), 2-(2-aminoethyl)-pyridine was used to prepNe 5-bromo-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide. MS (ES) m/z 352.9; Step 2: To a stirred solution of 5-bromo-2-metfryl-N-(2-pyridin-2- ylethyl)benzenesulfonamide (10.0 g, 28.15 mmol) in THF (200 mL) at -78°C was added methyl magnesium bromide 1.4M in 75% toluene/THF (24.0 mL, 33.6 mmol). The reaction was stirred 10 minutes and n-butyl lithium 2.5M in hexane (14.0 mL, 35.0 mmol) was added dropwise. The reaction was stirred an additionN 10 minutes. Sulfur dioxide was bubbled into the reaction for 20 minutes and was then Nlowed to wNm to room temperature over a period of 2 hours. The reaction was quenched with D.I. water (200 mL) and extracted with ethyl acetate. Sodium hydroxide 2.5M was added to the aqueous layer to a pH of 1 1 and extracted again with ethyl acetate. The aqueous layer was concentrated and the resulting solid was triturated with methanol to gNe 4-methyl-3-{[(2-pyridm-2-ylethyl)amino]sulfonyl}benzenesulfinic acid (10.6 g, 103% contains undetermined quantity of inorganic sNts.) MS (ESI) m/z 341; Step 3: To a stirred solution of 4-methyl-3-{[(2-pyridin- 2ylethyl)amino]sulfonyl}benzenesulfinic acid (0.30 g, 0.83 mmol) in DMSO (4 mL) was added 3-cyanophenylboronic acid (0.12 g, 0.83 mmol), potassium cNbonate (0.46 g, 3.31 mmol), and copper (II) acetate (0.16 g, 0.91 mmol). The resulting solution was stirred overnight at room temperature under a drying tube. The reaction was pNtitioned between ammonium chloride solution (sat) and ethyl acetate. The organic layer was concentrated. HPLC sepNation gave 5N rf3-cvanophenyl)sulfonyl]-2-methvl-N-('2-pyridin-2-ylethyl)ben2ene5ulfonamide (0.0 2g, 5%). MS (ES+) m/z 442.0; MS (ES-) m/z 440.0. Example 410: 2-methyI-5-(l-naphthylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 409, Step 3: 1-naphthylene boronic acid was used to prepNe 2-methyl-5-(l-naphthylsulfonvi)-N-(2-pvridin-2-vIethyl)ben2enesulfonamide. MS (ES-)w/z 465.0; HRMS: cNcd for C24H22N2O4S2 + H+, 467.10937; found (ESI, [M+H]+), 467.1113. Example 411: 2-methyl-5-(phenylsulfonyl)-N-(2N,6,6-tetramethylpiperidin-4-yl)benzenesulfonamide In an anNogous manner to Example 294, 5-benzenesulfonyl-2-methyl-benzenesulfonyl chloride, triethylamine, and 4-amino-2,2,4,4-tetramethylpiperidine in dichloromethane were used to prepNe 2-methyl-5-(phenylsulfonylVN-(2,2t6,6-tetramethyIpiperidin-4-yl)benzenesulfonamide. MS(ESI+)m/z451; MS (ESI-) m/z 449. Example 412: N-[(lS*,2S*>2-hydroxycyclohexyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide 1 In an anNogous manner to Example 294, 5-benzenesulfonyl-2-methyl-benzenesulfonyl chloride, triethylamine, and /raw-2-aminocyclohexanol hydrochloride in dichloromethane were used to prepNe N-[(1S * ,2 S * )-2-hydroxycyclohexyl]-2-methy 1-5-(phenylsulfonyl)benzenesulfonamide. MS(ESI+)m/z410; MS (ESI-) m/z 408. Example 413: N-(l-benzj'lpiperidin-4-yl)-2-inethyI-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 294, 5-benzenesulfonyl-2-methyl-benzenesulfonyl chloride, triethylamine, and 4-amino-l-benzylpiperidine in dichloromethane were used to prepNe N-f 1 -benzylpiperidin-4-yI)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide. MS (ESI+) m/z 485; MS(ESI-)m/z483. Example 414: N-(l-benzylpyrrolidin-3-yl)-2~methyl-5-(phenylsulfonyl)benzenesuIfonamide In an anNogous manner to Example 294, 5-benzenesulfonyl-2-methyl-benzenesulfonyl chloride, triethylamine, and l-benzyl-3-aminopyrrolidine in dichloromethane were used to prepNe N-( 1 -benzyIpyrrolidin-3-yl)-2-methyl-5-(phenylsulfonvl)benzenesulfonamide. MS(ESI+)m/z471; MS(ESI-)m/z469. Example 415: N-(2,3-dihydro-lH-inden-l-yl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 294, 5-benzenesulfonyl-2-methyl-benzenesulfonyl chloride, triethylamine, and 1-aminoindane in dichloromethane were used to prepNe N-r23-dmydro-lH-inden-l-vn-2-methyl-5-rphenylsulfonynbenzenesulfonNnide. MS (ESI-) m/z 426. Example 416: 5-[(3-hydroxyphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 409, Step 3:3-hydroxyphenyl boronic acid was used to prepNe 5-[(3- hydroxyphenyl')sulfonyl]-2-methyl-N-('2-pyridin-2-ylethvl)benzenesulfonamide. HRMS: cNcd for C2oH2oN2O5S2 + H+, 433.08864; found (ESI, [M+H]+), 433.0912. Example 417: 5-[(3,5-difluorophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 409, Step 3: 3,5-difluorophenyl boronic acid was used to prepNe 5-[(3.5-difluorophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide. MS(ES-)w/2451,0; HRMS: cNcd for C20H1SF2N204S2 + H+, 453.07488; found (ESI, [M+H]+), 453.0736. Example 418: 5-[(4-ethylphenyI)sulfonyI]-2-methyI-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 409, Step 3: 4-ethylphenyl boronic acid was used to prepNe 5-[(4- ethylphenvl)sulfonyl]-2-methvl-N-(2-pvridin-2-vlethyl)benzenesulfonamide. MS (ES-)/«/z 443.0; HRMS: cNcd for CzzHWNfeCN + H+, 445.12502; found (ESI, [M+H]+), 445.1262. Example 419: 5-[(3-acetylphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 409, Step 3: 2-acetylphenyl boronic acid was used to prepNe 5-[(3-acetylphenyl)sulfonvl]-2-methvl-N/'-('2-pyridin-2-vlethvl')ben2enesulfonNnide. MS (ES-)m/z 457.0; HRMS: cNcd for C22H22N2O5S2 + H+, 459.10429; found (ESI, [M+H]*), 459.1059. Example 420: 5-[(2-ethoxyphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 409, Step 3: 2-ethyoxyphenyl boronic acid was used to prepNe 5-[(2-ethoxvphenvl)sulfonvl]-2-methyl-N-r2-pvridin-2-vlethvl)ben2enesulfonamide. MS (ES-)/7i/z 459.0; HRMS: cNcd for €22N4N0582 + H+, 461.1 1994; found (ESI, [M+H]+), 461.1215. Example 421 : 5-[(2,5-dimethoxyphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 409, Step 3: 2,5-dimethoxyphenyl borouic acid was used to prepNe 5-[(2,5-dimethoxyphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benz.enesulfonamide. MS (E$-)m/z 475.0; HRMS: cNcd for C22H24N2O6S2 + H+, 477.1 1485; found (ESI, [M+H]+), 477.1 174. Example 422: 5-[(2,3~dimethoxyphenyI)sulfonyI]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 409, Step 3: 2,3-dimethoxyphenyl boronic acid was used to prepNe 5-[(2,3-dimethoxyphenyl')sulfonyn-2-methyl-N-(2-pyridin-2-vlethvl')ben2enesulfonamide. MS (ES-)m/z 475.0; HRMS: cNcd for C22H24N2O6S2 + H+, 477.1 1485; found (ESI, [M+H]+), 477.1 169. Example 423: 5-[(2,4-dimethoxyphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 409, Step 3: 2,4-dimethoxyphenyl boronic acid was used to prepNe 5-[C2,4-dimemoxvphenvl)sulfonyl]-2-metfayl-N-(2-pyridm-2-vlemyl)benzenesulfonaniide. MS (ES-) m/z 475.0; HRMS: cNcd for CaHMNaOeSz + H+, 477.1 1485; found (ESI, [M+H]*), 477. 1 144. Example 424: N-cyclopropyl-2-methyl-5-(phenylsulfonyI)benzenesulfonamide In an anNogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, triethylamine, and cyclopropylamine in dichloromethane were used to prepNe N-cyclopropyl-2-methyl-5-(phenylsulfonyl)ben2enesulfonamide. MS (ES-) m/z 350.0. Example 425: ethyl 4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate -" In an anNogous manner to Example 294, 5-benzenesulfonyl-2-methyl-benzenesulfonyl chloride, triethylamine, and ethyl 4-amino-l-piperidine cNboxylate in Example 430: 2-methyl-5-[(2-methylphenyl)sulfonyl]-yV-(2-pyridin-2-ylethyl)benzeuesulfonamide In an anNogous manner to Example 409, ~ Step 3: 2-methylphenyl boronic acid was used to prepNe 2-methvl-5-[('2-methylphenyl)sulfonyl]-N-('2-pyridin-2-vlethvl)benzenesulfonamide. MS(ESI+)m/z431. Example 431: 5-[(2-ethylphenyI)sulfonyl]-2-methyI-N-(2-pyridia-2-ylethyl)benzenesulfonamide , In an anNogous manner to Example 409, Step 3: 2-ethylphenyl boronic acid was used to prepNe 5-[(2-ethylphenvl')sulfonvn-2-methvl-N-('2-pyridin-2-ylethyl)ben2enesulfonamide. MS (ESI+) m/z 445. Example 432: 5-(biphenyl-2-ylsulfonyl)-2-metbyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 409, Step 3: 2-biphenyl boronic acid was used to prepNe 5 -Cbiphenyl-2-vlsulfonyN 2-methyl-N-(2-pvridin-2-vlethyDben2enesulfonamide. MS (ESI+) m/z 493. Example 433: 5-(biphenyl-4-ylsulfonyl)-2-methyI-N-(2-pyridin-2-ylethyl)benzenesulfonamide ' In an anNogous manner to Example 409, Step 3: 4-biphenyl boronic acid was used to prepNe 5-(biphenyl-4-ylsulfonyl)-2-methvl-N-(2-pyridin-2-vlethyl)benzenesulfonamide. MS (ESI+)in/2493. Example 434: 5-(biphenyl-3-ylsuIfonyl)-2-methyl-./V-(2-pyridm-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 409, Step 3: 3-biphenyl boronic acid was used to prepNe 5-(biphenyl-3 -vlsulfony 1)-2-methyl-N-[2-pyridin-2-vlethyl)benzenesulfonaiTiide. MS(ESI+)m/z493. Example 435: 5-[(4~tert~butylphenyl)sulfonyl]-2-isopropyl-N~(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 230, Step 1: 4-Isopropylbenzenesulfonyl chloride and tert-butylbenzene were used to prepNe 1 -tert-butyl-4-[(4-isopropylphenyl)sulfonyl]benzene. [Or/ Step 2: l-tert-Butyl-4-[(4-isopropylphenyl)sulfonyl]benzene and chlorosulfonic acid were used to prepNe 5-(4-tert-butyl-benzenesulfonyl)-2-isopropyl-benzenesulfonyl chloride. Step 3: To a solution of 5-(4-tert-Butyl-benzenesulfonyl)-2-isopropyl- benzenesulfonyl chloride (150 mg, 0.36 mmol) in dichloromethane (4.0 mL) was added pyridine (73 mg, 0.72 mmol) and 2-(2-aminoethyl)pyridine (44 mg, 0.36 mmol). The reaction was stirred at room temperature overnight and then extracted with saturated sodium bicNbonate (2 x 10 mL), followed by saturated ammonium chloride (2x10 mL). The organic layer was dried with magnesium sulfate and concentrated down under vacuum. The crude residue was purified using automated flash chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of 5-[(4-tert-butylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide (178 mg, 98%). MS(ES+)/n/z501. Example 436: 5-[(4-tert-butyIphenyl)suIfonyl]-N-[3-(lH-imidazoI-l-yI)propyI]-2-isopropylbenzenesulfonamide In an anNogous manner to Example 435, 5-(4-tert-Butyl-benzenesulfonyl)-2-isopropyl-benzenesulfonyl chloride and l-(3-aminopropyl)imidazole were used to prepNe 5-[(4-tert-butylphenyl)sulfonyl]-N-[3-('lH-imidazol-l-yl)-propyl]-2-Lsopropylbenzenesulfonamide. MS (ES+) m/z 504; HRMS: cNcd. for CasHssNaCNSa + H", 504.1991: found (ESI, [m+H]+), 504.2007. Example 437: 5-[(4-tert-butylphenyl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonainide In an anNogous manner to Example 435, 5-(4-tert-Butyl-benzenesulfonyl)-2-isopropyl-benzenesulfonyl chloride and 4-aminotetrahydropyran were used to prepNe 5-[(4-tert_-butylphenyl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-pyran-4- yDbenzenesulfonamide. MS (ES+) m/z 480. Example 438: 5-[(4-tert-butylphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 230, " Step 1 : p-Toluenesulfonyl chloride and tert-butylbenzene were used to prepNe l-tert-butyl-4-[(4-methylphenyl)sulfonyl]benzene. • " Step 2: l-tert-Butyl-4-[(4-methylphenyl)sulfonyl]benzene and chlorosulfonic acid were used to prepNe 5-(4-tert-butyl-benzenesulfonyl)-2-methyl-benzenesulfonyl chloride. Step 3: In an anNogous manner to Example 435, 5-(4-tert-Butyl- benzenesulfonyl)-2-methyl-benzenesulfonyl chloride and 2-(2-aminoethyl)pyridine were used to prepNe 5- f (4-tert-butylphenvDsulfonyl] -2-methy I-N-(2-pyridin-2- ylethy Dbenzenesulfonamide . MS(ES+)m/z473; HRMS: cNcd. for C24H28N2O4S2 + H*. 473.1569; found (ESI, [m+H]*), 473.1551. Example 439: 5-[(4-tert-butylphenyI)sulfonyI]-N-[3-(lH-imidazol-l-yI)propyI]-2-methylbenzenesulfonamide In an anNogous manner to Example 435, 5-(4-tert-Butyl-benzenesulfonyl)-2-methyl-benzenesulfonyl chloride and l-(3-aminopropyl)imidazole were used to prepNe 5-[(4-tert-butylphenvl)sulfonvl1-N-[3-(lH-imidazol-l-vl)propvn-2-methvlbenzenesulfonamide. MS(ES+)m/z476; HRMS: cNcd. for C23H29N3O4S2 + tf", 476.1678; found (ESI, [m+Hft, 476.1662. Example 440: 5-[(4-tert-butylphenyl)sulfonyl]-2-methyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide Ill an anNogous manner to Example 435, 5-(4-tert-Butyl-benzenesulfonyl)-2-methyl-benzenesulfonyl chloride and 4-aminotetrahydropyran were used to prepNe 5-[(4-tert-butylphenyl)sulfonvl1-2-methvl-N-ftetrahvdro-2H-pvran-4- yl)benzenesulfonamide. MS (ES+) m/z 452. Example 441: N-[2-(2-Fluorophenyl)ethyi]-3-[(4-methylphenyI)sulfonyl]-5,6,7,8-tetrahydronaphthNene-1-sulfonamide Step a: A stirred solution of 1,2,3,4-tetrahydronaphthNene (10.0 mL, 74 rnmol) and p-toluenesulfonyl chloride (3.81 g, 20 mmol) was cooled to 0 °C and treated slowly under nitrogen with solid anhydrous Numinum chloride (3.20 g, 24 mmol). Nter stirring neat for 4 hours at room temperature, the mixture was slowly poured into ice water and extracted with ethyl acetate (2x). The organic phase was washed with a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and filtered through a short column of silica gel. The filtrate was evaporated in vacua to yield a crude oil containing a mixture of isomers in approximately a 6:1 ratio. The crude oil was recrystNlized twice from diethyl ether-hexane to yield 4-methylphenyl 5.6,7,8-tetrahvdronaphthNen-2-yl sulfone (3.04 g, 53%) as a homogeneous, colorless, crystNline solid, m.p. 130-132 °C; MS(EI) m/z 286; HRMS: cNcd for Ci7H18O2S, 286.10275; found (El, M+.), 286.1022. Step b: 4-Methylphenyl 5,6,7,8-tetrahydronaphthNen-2-yl sulfone (0.29 g, 1.0 mmol) was heated with stirring at 60 °C for one hour under nitrogen with chlorosulfonic acid (0.67mL, 1.17 g, 10.0 mmol). The mixture was cooled to room temperature, poured slowly into a cold solution of IN hydrochloric acid, and extracted with ethyl acetate (2x.). The organic phase was washed with a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the solvent concentrated in vacuo to an oil. The oil was dissolved in dichloromethane and treated dropwise under nitrogen with a solution of 2-fluorophenethylamine (0.28 g, 2.0 mmol) in dichloromethane. Nter stirring for one hour at room temperature, the reaction mixture was concentrated in vacuo and diluted with ethyl acetate. The organic phase was washed sequentiNly with IN hydrochloric acid and a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered through a short column of silica gel, and the filtrate concentrated to a crude oil. The crude oil was purified by prepNatNe liquid chromatography on a Biotage® 40 Mi column of pre-packed silica gel (90 g) eluting with a gradient of 25% - 50% methyl tert-butyl ether in hexane at a flow rate of 50 mL/mm to Nford, Nter evaporation of the solvent under vacuum. N-[2-(2-fluorophenynethyl]-3-[(4-methYlpheuyDsulfonyll-iNTNS-tetrahydronaphthNene-l-sulfgnamide (0.12 g, 25%) as a colorless, homogeneous, amorphous foam, m.p. 55-60 °C; MS (ES-)m/z 486.1; MS (ES+)w/z 488.1. Example 442: 5-[(4-fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-4-yl)ethyl]-2-isopropylbenzenesulfonamide In an anNogous manner to Example 298: Step 3: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-(lH-imidazol-4-yl)-ethylamine were used to prepNe 5-[(4-fluorophenvnsulfonyl-N-[2-(lN-imidazol-4-yl')ethyl]-2-isopropylbenzenesulfonamide. MS (ES+) m/z 452.0; MS (ES-) m/z 450.0. Example 443: 5-[(4-fluorophenyl)suIfonyl]-2-isopropyl-N-[(2R)-2-phenylpropyljbenzenesulfonamide In an anNogous manner to Example 298: Step 3: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-(R)-phenylpropyl-l-amine were used to prepNe 5 - [(4-fluorophenyl)sulfonyl] -2-isopropyl-N-[(2R)-2-phenylpropyl]benzenesulfonamide. MS (ES+)m/z 476.1; MS (ES-)m/z 474.1. Example 444: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N:-[(2S)-2-phenylpropyl]benzenesulfonamide In an anNogous manner to Example 298: Step 3: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-(S)-phenylpropyl-l-amine were used to prepNe 5-[(4-fluorophenyl')sulfonvl1-2-isopropyl-N-r(251-2-phenvlpropyl]benzenesulfonamide. MS (ES-)m/z 474.1. Example 445: 5-[(4-fluoroplienyI)sulfonyl]-2-isopropyI-N-(tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide In an anNogous manner to Example 298: Step 3: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and tetrahydro-pyran-4-yl-methylamine were used to prepNe 5-[(4-fluorophenyl)sulfonyl]-2-isopropyi-Nr-(tetrahydro-2ff-pyran-4-ylmethyl)benzenesulfonamide. MS (ES+)m/z 456.1; MS (ES-)m/z 454.1. Example 446: tert-butyl 4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- carboxylate In an anNogous manner to Example 435, 5-benzenesulfonyl-2-rnethyl- benzenesulfonyl chloride and 4-amino-l-Boc-piperidine were used to prepNe tert-butyl 4-((F2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl)aminolpipeiidine-l- cNboxvlate. MS(ES-)m/z493. Example 447: 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide To a solution of 25% trifluoroacetic acid/dichloromethane was added tert-butyl 4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- cNboxylate (2.0 g, 4.04 mmol) and the solution was stirred at room temperature for two hours. The reaction was then extracted with saturated sodium bicNbonate, dried with magnesium sulfate, and concentrated down under vacuum to gNe 2-metfayl-5-('phenylsulfonvl)-N-piperidin-4-v1benzenesulfonamide (1.5g,94%). MS(ES+)/n/z495 MS (ES-) m/z 493. Example 448: 2-methyl-5-(phenylsulfonyl)-N-[l-(phenylsuIfonyl)piperidin-4-yl]benzenesulfonamide To a solution of 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide (125 mg, 0.32 mmol) and pyridine (48 mg, 0.48 mmol) in dichloromethane (4 mL) was added benzenesulfonyl chloride (59 mg, 0.33 mmol). The reaction was stirred at room temperature for three hours and then extracted with saturate sodium bicNbonate. The aqueous phase was washed with dichloromethane (2x10 mL). The combined organic phases were dried with magnesium sulfate and concentrated down under vacuum. The crude residue was purified using automated flash chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of 2-methyl-5-fphenylsulfonylV N-[ 1 -(phenylsulfbnyl)pip_eridin-4- yl]benzenesulfonamide (95 mg, 56%). MS (ES+) m/z 535 MS(ES-)m/z533. Example 449: N-[l-(2-furoyl)piperidin-4-yl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide To a slurry of 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide (75 mg, 0.19 mmol), morphlinomethyl-polystyrene (170 mg, 62 mmol), and dimethylaminopyridine-polystyrene (70 mg, 0.14 mmol) in dichloromethane (8 mL) was added 2-furoyl chloride (50 mg, 0.38 mmol). The reaction was rotated on an orbitN shaker for four hours. Then aminomethylated-polystyrene (150 mg, 0.33 mmol) was added to the reaction and it was rotated for an addition two and one-hNf hours. The reaction was then filtered and the resin was washed Nternately with dichloromethane (3x5 mL) and methanol (3x5 mL) and concentrated down under vacuum. The crude residue was purified using automated flash chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of N-[l-r2-furovnpiperidin-4-yl]-2-methyl-5-(phenvlsulfonynbenzenesulfonNnide (68 mg, 73 %). MS (ES+) m/z 489. Example 450: 5-({4-[(2-cyanoethyl)amino]phenyl}suIfonyl)-N-[2-(lH-imidazol-l-yl)ethyl]-2-isopropylbenzenesulfonamide In an anNogous manner to Example 353, 5-[(4-fluorophenyi)sulfonyl]-N[2-(l/N-imidazol-l-yl)ethyl]-2-isopropylbenzenesulfonamide and 3-aminopropionitrile were used to prepNe 5-(|4-[('2-cyanoethyl)an'iino1phenvl}sulfonyl)-N'-[2-(l-tf-imidazQl-l-yl)ethyl]-2-isopropylbenzenesulfonamide. MS (ESI+) m/z 502; MS (ESI-) m/z 500. Example 451: N-[2-(lH-imidazol-l-yl)ethyI]-2-isopropyl-5-{[4-(methylamino)phenyl)sulfonyl}benzenesulfonamide In an anNogous manner to Example 356, 5-[(4-fluorophenyl)sulfonyl]-N-[2-(l#-imidazol-l-yl)ethyl]-2-isopropylbenzenesulfonamide and methylamine were used to prepNe AA-r2-qN-imidazol-l-vnethvll-2-isopropvl-5-(r4-(methylamino)phenyl]sulfonyl}beiizenesulfonamide. MS (ESI+) m/z 463; MS (ESI-) m/z 461. Example 452: 5-({4-[(2-hydroxybutyl)amino]phenyl}sulfonyl)-N-[2-(lj!9r-imidazol-l-yl)ethyl]-2-isopropylbenzenesulfonamide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[2-(lJ:/"-imidazol-l-yl)ethyl]-2-isopropylbenzenesulfonamide and 2-hydroxybutylamine were used to prepNe 5-(l4-[(2-hydroxybutvl)amino]phenvUsulfonvlVN:-[2-('lJy-iniidazol-l-vnethvl]-2-isopropylbenzenesulfonamide. MS(ESI+)m/z521; Example 453: 5-[(4-{[(21S)-l-(hydroxymethyl)-2-methylbutyllamino}phenyl)sulfonyl]-N-[2-(1H-iraidazol-l-yl)ethyl]-2-isopropylbenzenesulfonamide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[2-(lN-imidazol-l-yl)ethyl]-2-isopropylbenzenesulfonamide and L-isoleucinol were used to prepNe 54(4- ( f(2N-l -(frvdroxvmernvlV2-methylbu1yl] yl)ethyl]-2 -isopropylbenzenesulfonamide. MS (ESI+) m/z 549; MS (ESI-) m/z 547. Example 454: 5-[(3,5-dimethylphenyl)sultbnyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide Step 1 : Following the procedure described in Example 409 (Step 2), 5-bromo-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide (Example 474 Steps 1 and 2) was used to prepNe 4;4sj3pjNj3yJNM[(j-pyridin-2-N Step 2: Following the procedure described in Example 409 (Step 3), 4- isopropyl-3-{[(2-pyridin-2-ylethyl)amino]sulfonyl}benzenesulfmic acid and 3,5-dimethylphenyl boronic acid were used to prepNe S-fO.S-dimethylphenvDsulfonvlJN-isopropyl-TV-Q-pyridinN-ylethyDbenzenesulfonamide. MS (ESI+) m/z 473; MS(ESI-)m/z471. Example 455: 5-[(3-chlorophenyl)suIfonyl]-2-isopropy-N-(2-pyridin-2~ ylethyl)benzenesulfonamide , In an anNogous manner to Example 454, t Step 2: 3-chlorophenyl boronic acid was used to prepNe 5-[(3- chlorophenyl)sulfonvn-2-isopropyl-N-('2-pyridin-2-yletfaynbenzenesulfonamide. MS (ESI+) m/z 479; MS (ESI-) m/z 477. Example 456: 2-isopropyl-5-[(3-methoxyphenyl)sulfonyl]-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 454, Step 2: 3-methyoxyphenyl boronic acid was used to prepNe 2-isopropyl-5-[(3-methoxyphenvnsulfonyl]-]-N-('2-pvridin-2-vlethvl)ben2enesulfonamide. MS (ESI+) m/z 475; MS(ESI-)w/z473. Example 457: 2-isopropyl-5-[(2-methoxyphenyl)sulfonyl]-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 454, ' " I Step 2: 2-methoxyphenyl boronic acid was used to prepNe 2-isopropyI-5-r('2-methoxvphenvl)suli:bnvn-N-r2-pviidin-2-vlethvl')benzenesulfonai'nide. MS (ESI+) m/z; MS (ESI-) m/z. Example 458: 5-[(3,5-difluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 454, Step 2: 3,5-difluorophenyl boronic acid was used to prepNe 5-f(3,5-difluorophenyl)sulfonvn-2-isopropvl-NV-(2-pyridin-2-ylethyl)benzenesulfonamide. MS(ESI+)w/z481; MS (ESI-) m/z 479. Example 459: 2-cyclohexyl-5-(phenylsulfonyl)-A?-(2-pyridin-2-yIethyI)benzenesulfonamide • Step 1: Following the same procedure described in Example 474 (Step 1), 2-cyclohexylbromobenzene was used to prepNe 2-cvclohexyl-N-('2-pyridin-2-ylethyDbenzenesulfonamide. MS (ESI+) m/z 345; MS (ESI-) m/z 343. Step 2: Following the same procedure described in Example 474 (Step 2), 2-cyclohexyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepNe 5-bromo-2-cyclohexyl-N-(2-pyridm-2-ylethyDbenzenesulfonamide. MS (ESI+) m/z 423; MS(ESI-)w/z421. Step 3: Following the same procedure described in Example 409 (Step 2), 5-bromo-2-cyclohexyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepNe 4k cyclohexyl-3--[[(2-pyridin-2-ylethyl)aniino]sulfonyl|benzenesulfinic acid. Step 4: Following the same procedure in Example 409 (Step 3), 4-cyclohexyl-3-{[(2-pyridin- 2-ylethyl)amino]sulfonyl}benzenesulfinic acid and phenyl boronic acid was used to prepNe 2-cyclohexvl-5-(phenvlsulfonvl)-N-(2-pyridin-2-vlethvl)benzenesulfonamide. MS (ESI+) m/z 485; MS(ESI-)m/z483. Example 460: 2-cyclohe:syl-5-[(4-iluorophenyl)sulfonyl] -N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 459, Step 4: 4-lluorophenyl boronic acid was used to prepNe 2-cyclohexyl-5-[f4-fluQrophenvl)sulfonyl]-N-('2-pyridin-2-ylethyl)benzenesulfonamide. MS (ESI-f) m/z 503; MS(ESI-)m/z501. Example 461: 2-ter/-butyI-5-(phenylsuIfonyI)-N(2-pyridin-2-ylethyl)benzenesulfonamide p 1: Tc,. stirred solution of 2-tertbutylbenzenethiol (4.72 g, 28.4 nimol) in concentrated sulfuric acid (90 mL) at 0 °C was added 6% sodium hypochlorite solution (426 mL) dropwise. The resulting mixture was extracted with methylene chloride. Triethylamine (10.0 mL, 71.7 mmol) and 2-(2-Nninoethyl)pyridine (4.0 mL, 33.4 mmol) were added and the mixture was stirred 30 minutes, washed with a saturated aqueous ammonium chloride solution and concentrated. Flash column sepNation with 50% ethyl acetate/ hexane gave 2-tert-butvl-./V-(2-pyridm-2-ylethyl)benzenesulfonamide (3.29 g, 36%). MS(ESI+)m/z319; MS(ESI-)m/z317. Step 2: Following the same procedure described in Example 474 (Step 2), 2-rert-butyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepNe 5-bromo-2-tert-butvl-N-(2-pyridin-2-ylethvl')ben2enesulfonamide. Step 3: Following the same procedure described in Example 474 (Step 4), 5-bromo-2-/err-butyl-N'-(2-pyridin-2-ylethyl)benzenesulfonamide and phenyl sulfonyl fluoride were used to prepNe 2-tert-butyl-5-(phenylsulfonyl')-.N-(2-pyridin-2-ylethyl)-benzenesulfonamide. MS (ESI+) m/z 459. Example 462: N-[l-(2~methoxybenzoyl)piperidin-4-yl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide To a slurry of 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide (50 mg, 0.13 mmol) and morphlinomethyl-polystyrene (170 mg, 62 mmol) in dichloromethane (8 mL) was added 2-anisolyl chloride (65 ing, 0.38 mmol). The reaction was rotated on an orbitN shaker overnight. Then aminomethylated-polystyrene (150 mg, 0.33 mmol) was added to the reaction and it was rotated for addition four hours. The reaction was then filtered and the resin was washed Nternately with 10% dichlorornethane./methanol (3x6 ml,). The crude residue was purified using automated flash chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of N-[l -(2-methoxvbenzoyl)piperidm-4-yl1-2-methyl-5- (phenylsulfonvl)benzenesulfonamide (52 mg, 78 %). MS (ES+) m/z 529. Example 463: N-[l-(3-methoxybenzoyl)piperidin-4-yl]-2-methyl-5-(phenylsulfonyl)beizenfulfonaniide In an anNogous manner to Example 462, 2~methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and 3- anisolyl chloride were used to prepNe N-C-Q-methoxybenzoyl)piperidin-4-yl]-2-rnethyl-5- (phenylsulfonynbenzenesulfonamide. MS (ES+) m/z 529. Example 464: N-[l-(3,4-dimethoxybenzoyl)piperidin-4-yI]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and 3,4-dimethoxybenzene-l-cNbonyl chloride were used to prepNe N- [1 -(3,4-dimethoxybenzoyll!piperidin-4-yl1-2-methvI-5-(phenylsulfonynbenzenesulfonamide. MS (ES+) m/z 559. Example 465: 2-methyl-5-(phenylsulfonyl)-N-{l-[3-(trifluoromethyl)benzoNl]piperidin-4-yl]benzenesulfonamide In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and 3-(trifluoromethyl)benzoyl chloride were used to prepNe 2-methYl-5-fphenvlsulfonvl)-N-{l-[3-(trifluoromethyl)benzovnpiperidin-4-y 11 benzenesulfonamide. MS (ES+) m/z 567. Example 466: N-[l-(4-chlorobenzoyl)piperidiu-4~yl]-2-methyl-5-(pheriylsulfonyl)benzenesulfouaaude In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and 4-chlorobenzoic acid chloride were used to prepNe N-[l-(4-chloroben2oynpiperidin-4-yl1-2-methyl-5- (phenylsulfonvnbenzenesulfonamide. MS (ES+) m/z 533. Example 467: N-[l-(4-methoxybenzoyl)piperidin-4-yl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and 4-anisoyl chloride were used to prepNe N-fl-(4-methoxybenzovnpiperidinN-ynN-methvl-S-rphenvlsulfonvDbenzenesulfonamide. MS (ES+) m/z 529. Example 468: 2-methyl-N-[l-(4-methylbenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 462,2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and 4-methylbenzoyl chloride were used to prepNe 2-methyl-N-[ 1 -(4-methylbenzoyl')piperidin-4-yl]-5- (phenylsulfonyllbenzenesulfonamide. MS(ES+)/n/z513. Example 469: N-[l-(methoxyacetyl)piperidin-4-yl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and methoxyacetic acid chloride were used to prepNe N-[l-(methoxvacetyl)piperidin-4-yl]-2-methvl-5-(phenylsulfonyl)benzenesulfonamide. MS (ES+) m/z 467. Example 470: 2-methyl-N-[l-(phenylacetyl)piperidin~4-yl]-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 462, 2-memyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and a-toluyl cliloride were used to prepNe 2-methvl-N-[l-(phenylacetyl)piperidin-4-yr]-5-(phenylsulfonyl')ben2enesulfonamide. MS(ES+)w/z513. Example 471: N-[l-(cyclohexylcNbonyl)piperidin-4-yl]-2-methyl-5-(phenylsulfonyl)benzenesulfonNaide In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and cyclohexanecNbonyl chloride were used to prepNe N-[l-(cyclohexylcNbonyl')piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide. MS (ES+) m/z 505. Example 472: 2,6-dimethyl-3-(phenylsulfonyI)-N-(2-pyridin-2-ylethyl)benzenesulfonamide Step 1: Following the same procedure described in Example 1 (Step 1), 2-bromo-l,3-dimethyl benzene was used to prepNe 3-bromo-2,4-dimethylbenzenesulfonyl chloride. Step 2: Following the same procedure described in Example 230 (Step 1), 3-bromo-2,4-dimethylbenzenesulfonyl chloride was used to prepNe 2-bromo-l .3-dimethvl-4-(phenylsulfonvDbenzene. Step 3: Following the same procedure described in Example 474 (Step 1), 2-bromo-l,3-dimethyl-4-(phenylsulfonyl)benzene was used to prepNe 2.6-dimethyl-3-(phenvlsulfonvn-N-(2-pvridin-2-ylethvl')benzenesulfonamide. MS(ESI+)m/z431; MS(ESI-)m/z429. Example 473: 2,6-dimethyl-3-(phenylsulfonyl)-N-(tetrahydro-2jHr-pyran-4-yl)benzenesulfonamide In an anNogous manner to Example 472, Step 3: tetrahydropyran-4-ylamine was used to prepNe 2,6-dimethyl-3-(phenvlsulfonvl)-N-('tetrahvdi'0-2N-pvran-4-vnbenzenesulfonamide. MS(ESI+)7M/z410; MS (ESI-) m/z 408. Example 474: 5-{[5-(dimethylamino)-l-naphthyl]sulfonyl}-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesultbn amide Step 1: To a stirred solution of 2-bromoisopropylbenzene (10.0 g, 50.2 mmol) in THF (350 mL) at -7S°C was added n-butyl lithium 2.5 M in hexane (14.0 ml, 35.0 mmol) dropwise. Nter 10 minutes, sulfur dioxide was bubbled in over a period of 30 minutes. The solution was Nlowed to wNm to room temperature and stirred for 2 hours. The solution was concentrated and taken up in methylene chloride (300 mL). N-chlorosuccinimide (8.1 g, 60.6 mmol) was added and the solution was stirred 1.5 hours at room temperature. 2-(2-aminoethyl)pyridine (7.2 mL, 60.2 mmol) was added and the solution was stirred an additionN 45 minutes at room temperature, washed with a saturated aqueous ammonium chloride solution. The organic layer was dried over magnesium sulfate and concentrated. Trituration with ether gave 2-isopropyl-N-(2-pyridin-2-ylethvl)benzenesulfonNnide (8.67 g, 56%). MS (ESI) m/z 305. Step 2: To a stirred solution of 2-isopropyl-/V-(2-pyridin-2- ylethyl)benzenesulfonamide (lO.Og, 32.8mmol) in 90% concentrated sulfuric acid (110 mL) was added N-bromosuccinimide (5.85 g, 32.8 mmol) at room temperature and the solution was stirred 15 minutes. The solution was chilled in an.ice bath and 25% sodium hydroxide was slowly added to pH 9. The solution was extracted severN times with ethyl acetate. The organic layers were combined, dried over magnesium sulfate, and concentrated. Trituration with ether gave 5N bromo-2-isopropyl-N-(2-pyridin-2-vlethvnbenzenesulfonamide (6.0 g, 48%). MS(ESI+)w/z383; MS(ESI-)m/z381. Step 3: To a stirred solution of dansyl chloride (1.0 g, 3.70 mmol) in acetonitrile (3 mL), was added potassium fluoride (0.86 g, 14.8 mmol) and 18-crown-6 (0.05 g, 0.19 mmol). The resulting solution was stirred overnight at room temperature. The solution was diluted with D.I. water and extracted severN times with ethyl acetate. The combined organic layers were dried over magnesium sulfate and concentrated to gNe dansyl fluoride (0.50 g, 53%). Step 4: To a stirred solution of 5-bromo-2-isopropyl-./V-(2-pyridin-2-ylethyl)benzenesulfonamide (0.30 g, 0.78 mmol) in THF (3 mL) at 0 °C was added methyl magnesium bromide 1.4 M in 75% toluene/THF (0.6 mL, 0.84 mmol). The reaction was stirred 10 minutes, then cooled to -78 °C and n-butyl lithium 2.5 M in hexane (0.35 mL, 0.87 mmol) was added dropwise. The reaction was stirred an additionN 10 minutes. The reaction was wNmed to 0 °C and dansyl fluoride (0.20 g, 0.79 mmol) was added. The reaction was stirred overnight at room temperature, pNtitioned between ammonium chloride solution and ethyl acetate. The organic layer was concentrated and HPLC sepNated to gNe >i[5: ('dimethylamino)-l-naphthyl]sulfonyl)-2-iso_urN (0.05 g, 12%). MS(ESI+)m/z538; MS (ESI-) m/z 536. Example 475: N-[l-(cyclopropylcNbonyl)piperidin-4-yl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and cyclopropanecNbonyl chloride were used to prepNe NN [l-(cvclopropvlcNbonvl)piperidin-4-vn-2-methvl-5-(phenylsulfonyl)benzenesulfonamide. MS(ES+)m/z463. Example 476: N-[l-(4-cyanobenzoyl)piperidin-4-yl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 462,2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and 4-(chlorocNbonyl)benzonitrile were used to prepNe NN [l-C4-cyanobenzoynpiperidin-4-yl]-2-methyl-5-(phenvlsulfonyl')benzenesulfonamide. MS (ES+) m/z 524. Example 477: N-[l-(3-cyanobenzoyl)piperidin-4-yl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and 3-cyanobenzoyl chloride were used to prepNe N-[l-(_3-cyanobenzoyl)piperidhi-4-yl]-2-methvl-5- (phenylsulfonyDbenzenesulfonamidg. MS (ES+) m/z 524. Example 478: 2-methyl-N-[l-(methylsulfonyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide i In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and methanesulfonyl chloride were used to prepNe 2-methyl-N-Xl-(methylsulfpnyl)piperidin-4-yl1-5- (phenylsulfonyt)benzenesulfonamide. MS(ES+)m/z473. Example 479: N-(l-acetylpiperidin-4-yI)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 462,2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and acetyl chloride were used to prepNe N-C1 -acetylpiperidin-4-yl)-2-methvl-5-('phenylsulfonyl)ben2enesulfonamide. MS(ES+)m/z437. Example 480: N-(4-{[4-({[2-methyI-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidin-l-yl]cNbonyl}phenyl)acetamide In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and 4-acetamidobenzoyl chloride were used to prepNe N-(4-([4-C (p-methyl-S-Cphenylsulfonynphenvn sulfonyl} amino')piperidin-1 -y llcNbonyl} phenyl)acetamide. MS (ES+) m/z 556. Example 481: 2-methyl-N-{l-[(l-methyl-lH-imidazol-4-yl)sulfonyl]piperidin-4-yl}-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and l-methylimidazole-4-sulfonyl chloride were used to prepNe 2-methvl-N-(l-[(l-methyl-lH-imidazol-4-yl)sulfonyl]piperidin-4-yl}-5-(phenvlsulfonyl)benzenesulfonamide. MS (ES+) m/z 539. Example 482: 2-methyl-5-(phenylsulfonyl)-N-[l-(2-thienylsulfonyl)piperidin-4-yl] benzenesulfonamide In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and 2-thiophenesulfonyl chloride were used to prepNe 2N methvl-5-fphenvlsulfonyl)-N-[ 1 -f2-thienylsulfonvl)piperidin-4- yllbenzenesulfonamide. MS(ES+)m/z541. Example 483: iN-(l-{[5-(dimethylaniino)-l-naphthyl]snlfonyl}piperidin-4-yl)-2-methyl-5-(phenylsulfonyl)benzenesiilfoniiinide In an anNogous manner to Example 462,2-methyl~5~(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfbnamide and dansyl chloride were used to prepNe N-(l-([5-(dimethvlaminoVl-naphthyl]sulfonvl)piperidin-4-yl)-2-methyl-5-(phenylsulfonvnbenzenesulfonamide. MS (ES+) m/z 628. Example 484: N-[l-(l,3-benzodioxol-5-yl-Nbonyl)piperidin-4-yl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 462,2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and l,3-benzodioxole-5-cNbonyl chloride were used to prepNe N-H -Cl.3-ben2odioxol-5-ylcNbonvl')piperidm-4-vl]-2-methyl-5-(phenylsulfonvDbenzenesulfonamide. MS (ES+) m/z 543 MS(ES-)w/z541. Example 485: N-[l-(isoxazoI-5-ylcNbonyl)piperidin-4-yl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and 5-isoxazolecNbonyl chloride were used to prepNe N-[l-(isoxazol-5-ylcNbonyl')piperidm-4-vn-2-methyl-5-Cphenylsuhc'onyl')benzenesulfonamide. MS(ES+)m/z490. Example 486: N-[l-(N,N-dimethylglycyl)piperidin-4-yl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and dlmethylaminoacetyl chloride hydrochloride were used to prepNe N-[l-(N,N-dimethvlglycvl)piperidin-4-vl1-2-methvl-5-(phenylsulfonyDbenzenesulfonamide. MS (ES+) m/z 480. Example 487: prop-2-yn-l-yl 4-({[2-methyl-S-(phenylsulibnyl)phenyl]sulfonyl}amino)pipericliue- 1-cNboxylate In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and propNgylchloroformate were used to prepNe prop-2-yn-1 -yl 4-C (f2-methyl-5-rphenvlsulfonvl)phenyl]sulfonyU aminoNpiperidine-1 -cNboxylate. MS(ES+)w/z477 MS(ES-)w/z475. Example 488: methyl 4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)~N-piperidin-4-ylbenzenesulfonamide and methylchloroformate were used to prepNe methyl 4-C{[2-methyl-5-(phenvlsulfonvr)phenvl1 sulfonyl I amino'jpiperidine-1 - cNboxvlate. MS(ES+);n/z453 MS(ES-)>w/z451. Example 489: 2-methoxyphenyl 4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and 2-methoxyphenylchloroformate were used to prepNe 2N methoxyphenyl 4-r([2-methyl-5- (phenylsulfonyl')phenyl]sulfonvl)amino)piperidine-l-cNboxylate. MS (ES+) m/z 545 MS (ES-) m/z 543. Example 490: N-(tert-butyl)-4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine- 1-cNboxamide In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and t-butylisocyanate were used to prepNe N-(tert-butyl)-4-(|[2-methvl-5-(phenylsulfonvl)phenvl]sulfonyl}amino)piperidine- 1-cNboxamide. MS (ES+) m/z 494 MS (ES-) m/z 492. Example 491: N-cyclohexyI-4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-cNboxamide In an anNogous mNiner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and cyclohexylisocyanate were used to prepNe N-cyclohexvl-4-({[2-methvl-5-(phenvlsulfonyDphenvl]sulfonyl}amino')piperidine-l-cNboxamide. MS (ES+) m/z 520; MS(ES-)m/z518. Example 492: S-If ylethyl)benzenesulfonamide In an anNogous manner to Example 409, •• Step 3: 3-chloro-5-cyanophenyl boronic acid was used to prepNe 5-F(3-chloro-5-cyanophenyl')sulfonvn-2-methyl-N:-(2-pyridin-2-vlethvl')benzenesulfonamide. MS (ES-)m/z 474.0. Example 493: N3-(lJy-imidazol-l-yI)propyI]-2-methyl-3-(phenylsulfonyl)benzenesulfonamidc In an anNogous manner to Example 302, l-(3-aminopropyl)-imidazole was used to prepNe N-[3-(1H-imidazol-l-yl')propvl]-2-methyl-3-fphenvlsulfonvl')benzenesulfonamide. MS (ES-)Wz 417.9; HRMS: cNcd for Ci9H2iN3O4S2 + H+, 420.10462; found (ESI, [M+H]*), 420.1049. Example 494: 2-methyl-3-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 302, 2-(2-aminoethyl)-pyridine was used to prepNe 2-methvl-3-(phenvlsulfonyl)-N-f2-pvridin-2-vlethyl)ben2enesulfonamide. MS(ES-)w/z414.9; HRMS: cNcd for C2oH2oN2O4S2 + H+, 417.09372; found (ESI, [M+H]+), 417.0934. Example 495: 2-raethyl-N-(2-niorpholin-4-ylethyl)-3-(phenylsulfonyl)benzenesiilfonamide In an anNogous manner to Example 302, 1-ethylaniinomorpholine was used to prepNe 2-me.thyl-N-(2-morpholin-4-vlethyl)-3-(phenylsulfonyl)benzenesulfonamide (0.28g, 2%). MS (ES-)w/z 422.9; HRMS: cNcd for CNHbNOsSo + H+, 425.1 1994; found (ESI, [M+H]+), 425. 121 1 . Example 496: 2-methyl-N-[l-(2-naphthoyl)piperidin-4-yl]-5-(phenylsu]fonyl)benzenesulfonamide ; • In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and 2-naphthNenecNbonyl chloride were used to prepNe 2~_ methyl-N-[l-(2-naphthovl)piperidin-4-yn-5-(phenylsulfonyl)benzenesulfonamide. MS (ES+) m/z 549 MS (ES-) m/z 547 HRMS: cNcd. for C29H28N2O5S2 + IT, 549.15124: found (ESI, [m+Hf), 549.15026. Example 497: 2-methyI-5-(phenylsulfonyl)-N-[l-(2-thienylcNbonyl)piperidin-4-y 1] benzenesulf onamide In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonaniide and 2-thenoyl chloride were used to prepNe 2-methvl-5-(phenylsulfonvl)-N-[l-r2-thienylcNbonynpiperidin-4-yl]benzenesulfonamide. MS (ES+) m/z 505 MS (ES-) m/z 503 HRMS: cNcd. for C23H24N2O5S3 + H", 505.092564: found (ESI, [m+H]+), 505.0947. Example 498: isobutyl 4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-1- cNboxylate In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and isobutyl chloroformate were used to prepNe isobutyl 4-(•([2-methyl-5-(phenylsulfonyl)phenYl]sulfonvl}amino)piperidine-1- cNboxylate. MS (ES+) m/z 495 MS (ES-) m/z 493 HRMS: cNcd. for CoNoNaOeSa + HT, 495.16181: found (ESI, [m+H]+), 495.16266. Example 499: N-{l-[4-(diniethyiamino)beBzoyl|pi|)eridin-4-yl}-2-methyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and 4-dimethylaminobenzoyl chloride were used to prepNe N-(l-[4-('dimethvlamino')benzovnpiperidin-4-yl|-2-methvl-5-(phenylsulfonyl)benzenesulfonamide. MS (ES+) m/z 542 MS (ES-) m/z 540 HRMS: cNcd. for CjyHsiNsOsSa + H+, 542.17779: found (ESI, [m+H]+), 542.17725. Example 500: 4-fluorophenyl 4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and 4-fluorophenylchloroformate were used to prepNe 4; fluorophenvl 4-dr2-methyl-5-('phenylsulfonyl)phenyl]sulfonyllamino)piperidine- 1 -cNboxylate. MS (ES+) m/z 533 MS(ES-)m/z531 HRMS: cNcd. for C25H25FN2O6S2 + H", 533.12109: found (ESI, [m+H]+), 533.12157. Example 501: N-ethyl-4-({[2-methyI-5-(phenylsulfonyI)phenyl]sulfonyl}amino)piperidine-1- cNboxamide In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and ethylisocyanate were used to prepNe N-ethyl-4-d[2-memyl-5-fphenvlsulfonvl)phenyl1sulfonyll amino)piperidine-l - cNboxamide. MS (ES+) m/z 466 MS(ES-)/«/z464 HRMS: cNcd. for CiiHayNsCN + tf, 466.14649: found (ESI, [m+H]+), 466.14684. Example 502: 2-methyl-N-[l-(morpholin-4-ylcNbonyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and 4-moipholinecNbonyl chloride were used to prepNe 2N methyl-N-['l-(niorpholin-4-yIcNbonyl)piperidin-4-yl]-5- (phenylsulfonyDbenzenesulfonamide. MS (ES+) m/z 508 MS (ES-) m/z 506 HRMS: cNcd. for C23H29N3O6S2 + H*, 508.15706: found (ESI, [m+H]+), 508.15678. Example 503: N,N-dimethyl-4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- cNboxamide In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-n-piperidin-4-ylbenzenesulfonamide and dimethylcNbamyl chloride were used to prepNe N,N-dimethyl-4-( { [2-methvl-5-(phenvIsulfonyl)phenvl1sulfonyl> amino)piperidine- 1 - cNboxamide. MS (ES+) m/z 466 HRMS: cNcd. for C2iH27N3O5S2 + H*. 466.14649: found (ESI, [m+H]4), 466.14672. Example 504: N-[l-(3,3-dimethylbutanoyl)piperidm-4-yl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-n-piperidin-4-ylbenzenesulfonamide and t-butylaceryl chloride were used to prepNe N-[l-(3.3-dimetfavlbutanoyl')piperidin-4-yl]-2-methvl-5- (phenvlsulfonyDbenzenesulfonamide. MS(ES+)m/z493 MS (ES-) m/z 491 HRMS: cNcd. for CztffczNCN + H4", 493.183092: found (ESI, [m+H]*), 493.1813. Example 505: 5-[(3,5-dichlorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide Step 1 : Following the same procedure described in Example 474 (Step 3), 3,5-dichlorobenzene sulfonyl chloride was used to prepNe 3,5-dichlorobenzene sulfonyl fluoride. Step 2: Following the same procedure described in Example 474 (Step 4), 5-bromo-2-isopropyl-vV-(2-pyridin-2-y lethyl)benzenesulfonamide and 3 , 5-dichlorobenzene sulfonyl fluoride were used to prepNe 5-[(3,5-dichlorophenyI)sulfonyl]-2-isopropvl-N-f2-pyridm-2-ylethyl)benzenesulfonamide. MS (ESI) m/z 5 13; MS (ESI) m/z 511; HRMS: cNcd for CdtfeChNpAS;! + H+, 513.04708; found (ESI-FTMS, [M+H]l+), 5 13.04709. Example 506: 2-isopropyI-N(2-pyridin-2-ylethyl)-5-{[3-(trifluoromethoxy)phenyl]sulfonyl}benzenesulfonamide In an anNogous manner to Example 454, Step 2: 3-trifluoromethoxyphenyl boronic acid was used to prepNe 2-isopropyl-N-(2-pyridin-2-ylethvl')-5-([3-('trifluoromethoxv')phenvnsulfonyl)benzenesulfonamide. MS (ESI) m/z 529; MS (ESI) m/z 527; HRMS: cNcd for C23H23F3N2O5S2 + H+, 529.10732; found (ESI-FTMS, [M+H]1+), 529.10719. Example 507: 5-{[4-(dimethylamino)phenyl]sulfonyl}-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 454, Step 2: 4-dimethylaminophenyl boronic acid was used to prepNe 5-{[4-(dimemylamino)phenvlTsulfonvU-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide. MS (ESI) m/z 488; MS (ESI) m/z 486; HRMS: cNcd for CNNCNSi + H+, 488.16722; found (ESI-FTMS, [M+H]1+), 488.16721. Example 508: 2-isopropyWV-(2-pyridin-2-ylethyl)-5-{[3-(trifluoromethyl)phenyl]sulfonyl}benzenesulfonamide Step 1 : Following the same procedure described in Example 474 (Step 3), 3-trifluoromethylbenzene sulfonyl chloride was used to prepNe 3-trifluorornethylbenzene sulfonyl fluoride. Step 2: Following the same procedure described in Example 474 (Step 4), 5-bromo-2-isopropyl-N-(2-pyridm-2-y lethyl)benzenesulfonamide and 3 -trifluoromethylbenzerie sulfonyl fluoride were used to prepNe 2-isopropyl-N-f2-pyridin-2-ylethyl')-5-{[3-(frifluoromethvl)phenyl1sulfonyl)benzenesulfonamide. MS(ESI)/n/z513; MS(ESI)/w/z511; HRMS: cNcd for C23H23F3N2O4S2 + H+, 513.11241; found (ESI-FTMS, [M+H]1+), 513.11169. Examle509: 5-[(5-chloro-2-methoxyphenyl)suIfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide Step 1 : Following the same procedure described in Example 474, (Step 3), 5-chIoro-2-methoxybenzene sulfonyl chloride was used to prepNe 5-chloro-2-methoxvben2ene sulfonyl fluoride. Step 2: Following the same procedure described in Example 474 (Step 4), 5-bromo-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide and 5-chloro-2-methoxybenzene sulfonyl fluoride were used to prepNe 5-[r5-chloro-2-methoxyphenyl)sulfonyl]-2-isopropyl-N-(2-pvridin-2-vlethvl)benzenesulfonamide. MS (ESI) m/z 509; MS (ESI) m/z 507; HRMS: cNcd for CiaHbClNOsSi + H+, 509.09662; found (ESI-FTMS, [M+H]1+), 509.0966. Example 510: 2-isopropyl-N-(2-pyridin-2-yIethyl)-5-(quinolin-8-ylsulfonyl)benzenesulfonamide Step 1 : Following the same procedure described in Example 474, (Step 3), quinolin-8-sulfonyl chloride was used to prepNe quinolin-8-sulfonyl fluoride. 1 Step 2: Following the same procedure described in Example 474, (Step 4), 5-bromo-2-isopropyl-N-(2-pyridm-2-ylemyl)berizenesulfonNnide and quinolin-8-sulfonyl fluoride were used to prepNe 2-isopropvl-jy-(2-pvridm-2-ylethyl)-5-(quinolin-8-ylsulfonvnbenzenesulfonamide . MS (ESI) m/z 496; MS(ESI)™/z494; HRMS: cNcd for 025*125N0482 + H+, 496.13592; found (ESI-FTMS, [M+H]1+), 496.13588. Example 511: 5-[(2,5-dichloro-3-thienyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-N'Nthyljbenzenesulfonamide Step 1 : Following the same procedure described in Example 474, (Step 3), 2,5-dichlorothiophene-3 -sulfonyl chloride was used to prepNe 2,5-dichlorothiophene-3-sulfonyl fluoride. Step 2: Following the same procedure described in Example 474, (Step 4), 5-bromo-2-isopropyl-N-(2-pyridin-2-ylethyi)benzenesulfonamide and 2,5-dichlorothiophene-3- sulfonyl fluoride were used to prepNe 5-[(2,5-dichloro-3-thienvl')sulfonvl1-2-isopropyl-N-(r2- pvridin-2-vlethvl)benzenesulfonamide. MS (ESI) m/z 519; MS(ESI)»3/z517; HRMS: cNcd for C2oH2oCl2N2O4S3 + H+, 519.00350; found (ESI-FTMS, [M+H]1+), 519.00298. Example 512: 5-[(5-chloro-l,3-dimethyl-1H-pyrazol-4-yl)suIfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyI)benzenesulfonamide Step 1: Following the same procedure described in Example 474, (Step 3), 5- 9 chloro-l,3-dimethyl-lflr-pyrazole-4-sulfonyl chloride was used to prepNe 5-chloro-l.3-dimethvl-l#-pvra2oIe-4-sulfonvl fluoride. ~ Step 2: Following the same procedure described in Example 474, (Step 4), 5-bromo-2-isopropyl-N-(2-pyridm-2-ylethyl)benzenesulfonaniide and 5-chlqro-l ,3-dimethyl-lN-pyrazole-4-sulfonyl fluoride were used to prepNe 5-[(5-chloro-1,3-dimethyl-1 N-pyrazol-4-vl~)sulfonvl1-2-isopropvl-N-f2-pyridin-2-ylethyl)benzenesulfonamide. MS (ESI) m/z 497; MS (ESI) m/z 495; HRMS: cNcd for C2iH25ClN4O4S2 + H+, 497.10785; found (ESI, [M+H]+), 497.1062. Example 513: 2-isopropyl-5-[(l-methyl-ljy-imidazoI-4-yl)sulfonyl]-N-(2-pyridin-2-ylethyl)benzenesulfonamide Step 1: Following the same procedure described in Example 474, (Step 3), 1-methyl-lH-imidazole-4-sulfonyl chloride was used to prepNe 1 -methyl-1 H-imidazole-4-sulfonyl fluoride. Step 2: Following the same procedure described in Example 474, (Step 4), 5-bromo-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide and 1 -methyl-1 H-imidazole-4-sulfonyl fluoride were used to prepNe 2-isopropyl-5-r(l-methyl-l/:f-imidazol-4-vl)sulfonyn-N-C2-pyridin-2-ylethyl)benzenesulfonamide. MS (ESI) m/z 449; MS (ESI) m/z 447; HRMS: cNcd for C30N4N0482 + H+, 449.13117; found (ESI, [M+Hjf), 449.133. Example514: 5-[(3-chIoro-2-methylphenyI)suIfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide •---••" Step 1 : Following the same procedure described in Example 474, (Step 3), 3-chloro-2-methylbenzene sulfonyl chloride was used to prepNe 3-chloro-2-methylbenzene sulfonyl fluoride. .Step 2: Following the same procedure described in Example 474, (Step 4), 5-bromo-2-isopropyl-N-(2-pyridin-2-ylethy l)benzenesulfonamide and 3 -chloro-2-methylbenzene sulfonyl fluoride were used to prepNe 5-[('3-chloro-2-methvlphenvl')sulfonyl]-2-isoDropvl-N-('2-pvridin-2-vlethyl)benzenesulfonamide. MS (ESI) m/z 493; MS (ESI) m/z 491; HRMS: cNcd for C23H25C1N2O4S2 + H+, 493.10170; found (ESI, [M+Hf), 493.1028. Example 515: 5-[(4,4-dimethyl-2-oxo-l,4-dihydro-2fl-3,l-benzoxazin-6-yl)sulfonyl]-2-isopropyI-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 454, Step 2: 4,4-dimethyl-2-oxo-l,4-dihydro-2N:-3,l-benzoxazin-6-boronic acid was used to prepNe 5-[f4.4-dimethyl-2-oxo-l ,4-dihydro-2N-3, 1 -benzoxa2in-6-yl')sulfonyl]-2-isopropyl-N-(2-pvridin-2-ylethyl')ben2enesulfonamide. MS (ES) m/z 542.0; HRMS: cNcd for CaeNNaOeSa + H+, 544.15705; found (ESI-FT/MS, [M+H]1*), 544.1574; Example 516: 2-methyl-5-(phenylsulfonyl)-N-[l-(pyridin-3-ylcNbonyl)piperidin-4-yl]benzenesulfonamide In an anNogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-n-piperidin-4-ylbenzenesulfonamide and 3-pyridinecNbonyl chloride were used to prepNe 2N methyl-5-('phenvlsulfonvl)-N-ri-(pvridin-3~ylcNbonvl)piperidin-4- yljbenzenesulfonamide. MS (ES+) m/z 500 MS (ES-) m/z 498 HRMS: cNcd. for Cz-tHasNjOsSa + H+, 500.13 1391 : found (ESI, [rn+H]N, 500.1339. . Example 517: tert-butyl 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]piperidine-l-carboxylate [0596] In an anNogous manner to Example 435, 5-(4-fluoro-benzenesulfonyl)-2-isopropyl-benzenesulfonyl chloride and 4-amino-l-boc-piperidine were used to prepNe tert-burvl 4-ff(5-[('4-fluorophenynsulfonyl]-2-isopropvlphenyl>sulfonyl)amino1piperidine-l-cNbQXvlate. MS (ES-) m/z 539. Example 518: N-(l-{[5-(dimethylamino)-l-naphthyl]sulfonyl}piperidin-4-yl)-5-[(4-fluorophenyl)su!fonyl]-2-isopropylbenzenesulfonamide In an anNogous manner to Example 462, 2-isopropyl-5-(phenylsulfonyl)-n-piperidin-4-ylbenzenesulfonamide and dansyl chloride were used to prepNe N-(1-(F5-rdimethylaminoVl-naphthyl1sulfonyl}piperidin-4-yn-5-[('4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide. MS(ES+)/n/z674 MS(ES-)w/z672. Example 519: 5-[(4-fluorophenyI)suIfonyl]-2-isopropyl-N-[l-(methoxyacetyl)piperidin-4-yl]benzenesulfonamide In an anNogous manner to Example 462,2-isopropyl-5-(phenylsulfonyl)-n-piperidin-4-ylbenzenesulfonamide and methoxyacetic chloride were used to prepNe 5-[(4-fluorophenyl)sulfonyl1-2-isopropyl-N-[l-(methoxyacetyl)piperidin-4-yl]benzenesulfonamide. MS(ES+)w/z513 MS(ES-)w/z511 HRMS: cNcd. for C23H29FN2O6S2 + H+, 513.1524: found (ESI, [m+H]+), 513.1525. Example 520: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-piperidin-4-ylbenzenesulfonamide : tert-Butyl 4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidine-l-cNboxylate (0.5 mg, 0.92 mmol) was added to 3 mL of 4 M hydrochloric acid in dioxane and the precipitate was filtered gNing the desired .5_r[(4-fluorophenyl')sulfonyl]-2-isopropyl-N-piperidin-4-ylbenzenesulfonamide. MS (ES-) m/z 539 HRMS: cNcd. for CNHssFNiOeS;. + H*, 558.2102: found (ESI, [m+H]+), 558.21 1 . Example 521: N-cyclopropyI-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesuIfonamide 1 In an anNogous manner to Example 435, 5-(4-fiuoro-benzenesulfonyl)-2-isopropyl-benzenesulfonyl chloride and cyclopropylamine were used to prepNe N-cyclopropyl-5-[(4-fluorophenyDsulfonyl]-2-isopropylben2enesulfonamide. MS(ES+)m/z398 MS (ES-) m/z 396 HRMS: cNcd. for Ci8H2oFNO4S2 + H*, 398.0891: found (ESI, [m+H]+), 398.091. Example 522: N-cyclobutyl-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide In an anNogous manner to Example 435, 5-(4-fiuoro-benzenesulfonyl)-2-isopropyl-benzenesulfonyl chloride and cyclobutylamine were used to prepNe N-cyclobutvI-5-[f4-fluorophenyDsulfonyl]-2-isopropylbenzenesulfonamide. MS(ES+)?n/z412 MS(ES-)m/z410 HRMS: cNcd. for C19H22FNO4S2 + H", 412.1047: found (ESI, [m+H]*), 412.1059. Example 523: N-cyclopentyl-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide In an anNogous manner to Example 435, 5-(4-fluoro-benzenesulfonyl)-2-isopropyl-benzenesulfonyl chloride and cyclopentylamine were used to prepNe N-cyclopentyl-5-[(4-fluorophenyl')sulfonyl]-2-isopropvlbenzenesulfonamide. MS (ES+) m/z 426 MS (ES-) m/z 424 HRMS: cNcd. for C2oH24FNO4S2 + H1", 426.1204: found (ESI, [m+Hf), 426.121 1 . Example 524: N-cyclohexyl-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide 1 In an anNogous manner to Example 435, 5-(4-fluoro-benzenesulfonyl)-2-isopropyl-benzenesulfonyl chloride and cyclohexylamine were used to prepNe N-cyclohexyl-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide. MS (ES+) m/z 440 MS (ES-) m/z 438 HRMS: cNcd. for C2iH26FNO4S2 + H+, 440.136: found (ESI, [m+H]+), 440.1373. Example 525: N-(l-benzylpiperidin-4-yI)-5-[(4-fluorophenyl)suIfonyl]-2-isopropylbenzenesulfonamide In an anNogous manner to Example 435, 5-(4-fluoro-benzenesulfonyl)-2-isopropyl-benzenesulfonyl chloride and 4-amino-l-benzylpiperidine were used to prepNe N-(l-benzvlpiperidin-4-yl)-5-[(4-fluorophenvI)sulfonyl'|-2- isopropylbenzenesulfonamide. MS (ES+) m/2 531 MS (ES-) m/z 529 HRMS: cNcd. for C27H3iFN204S2 + H+, 531.1782: found (ESI, [m+H]+), 531.1785. Example 526: ethyl 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]piperidine-l-cNboxylate In an anNogous manner to Example 435, 5-(4-fluoro-benzenesulfonyl)-2-isopropyl-benzenesulfonyl chloride and ethyl 4-amino-l-piperidine cNboxylate were used to prepNe ethyl 4-[((5-ff4-fluorophenyl)sulfonyl]-2- isopropylphenyUsulfonvnaminolpiperidine-l-cNboxvlate. MS(ES+)»Nz513 MS(ES-)w/z511 HRMS: cNcd. for C23H29FN2O6S2 + H", 513.1524: found (ESI, [m+H]+), 513.1536. Example 527: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-piperidin-l-ylethyl)benzenesulfonNaide In an anNogous manner to Example 435, 5-(4-fluoro-benzenesulfonyl)-2-isopropyl-benzenesulfonyl chloride and l-(2-aminoethyl)piperidine were used to prepNe 5-[(4-fluorophenvl)sulfonvl]-2-isopropvl-N-f2-piperidin-l-ylethvl)benzenesulfonamide. MS (ES+) m/z 469 MS (ES-) m/z 467 HRMS: cNcd. for C22H29FN2O4S2 + ff", 469.1626: found (ESI, [m+H]+), 469.1632. Example 528: tert-butyl 4-{[(2-isopropyl-5-{[4-(methylamino)phenyl]s«lfo«yl}phenyl)sulfonyl|atriino"i-pipfridine-l-cNboxylate To a solution of methylamine in ethanol (2.0 mL, 2.0 M) was added tert-butyl 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]piperidine-l-cNboxylate (350 mg, 0.64 mmol) and the reaction was heated to 130 °C for 30 minutes in the microwave. The reaction mixture was concentrated and purified by automated flash chromatography using a gradient of 20% to 100% ethyl acetate/hexane resulting in the isolation of 353 mg of tert-butyl 4-{[(2-isopropyl-5-{[4- (methylamino)phenyl]sulfonyl}phenyl)sulfonyl]amino}piperidine-l-cNboxylate. MS (ES-) m/z 550. Example 529: N-(l-acetyIpiperidin-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide 1 "- . In an anNogous manner to Example 462, 2-isopropyl-5-(phenylsulfonyl)-n-piperidin-4-ylbenzenesulfonamide and acetyl chloride were used to prepNe N-C1 -acetylpiperidin-4-N-5-[('4-fluorophenyl')sulfonyl]-2-isopropylbenzenesuhc'onamide. MS(ES+)/n/z483 HRMS: cNcd. for C22H27FN2O5S2 + H+, 483.142370: found (ESI, [m+H]*), 483.143. Example 530: N-[l-(cyclopropylcNbonyl)piperidin-4-yl]-5-[(4-fluorophenyl)sulfonyI]-2-isopropylbenzenesulfonamide In an anNogous manner to Example 462, 2-isopropyl-5-(phenylsulfonyl)-n-piperidin-4-ylbenzenesulfonamide and cyclopropylcNbonyl chloride were used to prepNe N-[l-rcyclopropylcNbonyl)piperidin-4-vll-5-r(4-fluorophenvl)sulfonyl1-2-isopropylbenzenesulfonamide. MS(ES+)w/z509 MS (ES-) m/z 507 HRMS: cNcd. for CNFNjOsS? + tf, 509.158019: found (ESI, [m+H]+), 509.1589. Example 531: N-[l-(4-cyanobenzoyl)piperidin-4-yl]-S-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide In an anNogous manner to Example 462,2-isopropyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and 4-cyanobenzoyl chloride were used to prepNe N-[l-(4-cyanoben2Qyl)piperidin-4-vl]-5-r(4-fluorophenyl)sulfonyl]-2-isopropvlben2enesulfonamide. MS (ES+) m/z 570 MS (ES-) m/z 568. Example 532: 5-[(4-fluorophenyl)sulfonyI]-2-isopropyI-N-(tetrahydrofuran-2-ylmethyl)benzenesulfonamide In an anNogous manner to Example 435, 5-(4-fluoro-benzenesulfonyl)-2-isopropyl-benzenesulfonyl chloride and tetrahydrofurfurylamine were used to prepNe 5-[(4-fluorophenynsulfonyljN-isopropvl-N-ftetrahydroruranN-ylrnethYDbenzenesulfonamide. MS (ES+) m/z 442 MS (ES-) m/z 440. Example 533: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-4-ylethyl)benzenesulfonamide In an anNogous manner to Example 435, 5-(4-fluoro-benzenesulfonyl)-2-isopropyl-benzenesulfonyl chloride and 4-(2-aminoethyl)pyridine were used to prepNe 5-[(4-fluorophenyl)sulfonyl]-2-isopropvl-N-(2-pvridin-4-ylethvl')benzenesuhc'onamide. MS (ES+) m/z 463 MS(ES-)w/z461. Example 534: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-3-ylethyl)benzenesulfonamide In an anNogous manner to Example 435, 5-(4-fluoro-benzenesulfonyl)-2-isopropyl-benzenesulfonyl chloride and 3-(2-aminoethyl)pyridine were used to prepNe 5-f(4-fluorophenyl)sulfonvl1-2-isopropyl-N-(2-pvridin-3-ylethyllbenzenesulfonamide. MS (ES+) m/z 463 MS (ES-) m/z 461 HRMS: cNcd. for €2N23N20482 + HT, 463.116155: found (ESI, [m+Hf), 463.1174. Example 535: 5-({4-[(2-cyanoethyI)amino]phenyl}sulfonyl)-2-isopropyl-N-(tetrahydro-2fir-pyran-4-yl)benzenesulfonamide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-/' ' 'trahydro-2H-pyran-4-ylbenzenesulfonamide and 3-aminopropionitrile in DMA were used to prepNe 5-({4-[('2-cvanoethvl)amino]phenvI)sulfonyl')-2-isopropvl-N-('tetrahydro-2N-pyran-4-vnbenzenesulfonamide. MS (ES)m/z 490.1; HPLC purity 96.7% at 210-370 nm, 8.3 min.; 96.9% at 304 nm, 8.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold4min. HRMS: cNcd for 023N9N0582 + H+, 492.16214; found (ESI, [M+H]+), 492.1638. Example 536: 5-({4-[(2-cyanoethyI)amino]phenyl}sulfonyl)-2-isopropyl-N-(tetrahydro-2Jy-pyran-4-yImethyl)benzenesulfonamide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide and 3-aminopropionitrile in DMA were used to prepNe (tetrahydro-2H-pvran-4-ylrnethvl)benzenesulfonamide. MS (ES)/M/z 504.1; HPLC purity 96.7% at 210-370 nm, 8.5 min.; 97.0% at 304 nm, 8.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for 02N31N0582 + H+, 506.17779; found (ESI, [M+H]+), 506.1786. Example 537: 5-({4-[(2-cyanoethyl)amino]phenyl}sulfonyl)-2-isopropyl-N-[2-(tetrahydro-2H-pyran-4-yl)ethyl]benzenesuIfonamide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-tetrahydro-2Jc/'-pyran-4-ylethyl)benzenesulfonamide and 3-aminopropionitrile in DMA were used to prepNe 5-({4-[(2-cyanoethyl)amino]phenyl)sulfonyl)-2-isopropyl-N-[2-(tetrahydro-2N'-pvran-4-yl)ethyl]benzenesulfonamide. . MS(ES)m/z518.2; FIPLC purity 97.4% at 210-370 nm, 8.7 ram.; 97.6% at 304 nm, 8.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1 .2 mL/min, 85/1 5-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold4min. HRMS: cNcd for C25H33N305S2 + H+, 520.19344; found (ESI, [M+H]*), 520.1949. Example 538: N-(3',6t-dihydroxy-3-oxo-3H-spiro[2-benzofuran-l,9l-xanthen]-5-yl)-4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]piperidine-l-cNbothioamide In an anNogous manner to Example 462, 2-isopropyl-5-(phenylsulfonyl)-n-piperidin-4-ylbenzenesulfonamide and fluorescein isothiocyanate were used to prepNe N-(3\6'-dihvdroxv-3-oxo-3H-spiro[2-benzofuran-L9'-xanthen1-5-vl)-4-[((5-[('4-fluorophenvl')sulfonvl]-2-isopropylphenyl) sulfonyDaminolpiperidine- 1 - cNbothioamide. MS (ES+) m/z 830. Example 539: 5-[(3-cyanophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 454, Step 2: 3-cyanophenylboronic acid was used to prepNe 5-[(3- cvanophenynsulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethynbenzenesulfonNnide. MS (ES)m/z 468.1; HRMS: cNcd for CaHaNsCUfe + H+, 470.12027; found (ESI, [M+H]*), 470.1223. Example 540: 5-(lH-indol-5-ylsulfonyl)-2-is opropyl-N-(2-pyridin~2-ylethyl)benzenesulfonamide In an anNogous manner to Example 454, * Step 2: indole-5-boronic acid was used to prepNe 5-( 1 isopropvl-/vr-(2-pYridin-2-ylethvnbenzenesulfonamide. MS (ES) m/z 482.1; HRMS: cNcd for 024N5N0482 + H+, 484.13592; found (ESI, [M+Hf), 484.1382. Example 541: 2-isopropyl-5-[(2-methylphenyl)sulfonyl]-N-(tetrahydro-2N-pyran-4-yl)benzeuesulfonamide In an anNogous manner to Example 4 74, Step 1: 4-amino tetrahydropyran was used to prepNe 2-isopropvl-N-('tetrahydro-2#-pyran-4-yl')benzenesulfonamide. Step 2: 2-isopropyl-N(tetrahydro-2/;/-pyran-4-yl)benzenesulfonaniide was used to prepNe 5-bromo-2-isopropyl-N-(tetrahvdro-2J!:/-pyran-4-yl)benzenesulfonamide. Step 3: 2-methylphenyl sulfonyl fluoride and 5-bromo-2-isopropyl-N-(tetrahydro-27:/-pyran-4-yl)benzenesulfonamide were used to prepNe 2-isopropyl-5-[(2-methylphenvl)sulfonyl]-N-('tetrahvdro-2N-pvran-4-vl)ben2enesulfonamide. MS (ES)m/z 436.1; HRMS: cNcd for C2iH27NO5S2 + H+, 438.14034; found (ESI, [M+H]+), 438.1409. Example 542: 5-[(3-chloro-2-methylphenyl)sulfonyl]-2-isopropyl-N-(tetrahydro-2/T-pyran-4-yl)benzenesuIfonamide , In an anNogous manner to Example 541,. N ""] Step 3: 5-bromo-2-isopropyl-N-(tetrahydro-2N'-pyran-4-yl)benzenesulfonamide and 3-chloro-2-methylphenyl sulfonyl fluoride were used to prepNe 5-[(3-chloro-2- memylphenyl)sulfonyl]-2-isopropvl-N-(telTahydro-2N-pyran-4-yl)berizenesulfonNnide. MS (ES)m/z 470.1; HRMS: cNcd for C2iH26ClNO5S2 + H+, 472.10137; found (ESI-FTMS, [M+H]H), 472.1024. Example 543: 2-isopropyl-5-{[4-(methylamino)phenyl]sulfonyl}-N-(tetrahydro-2flr-pyran-4-ylmethyl)benzenesulfonNaide In an anNogous manner to Example 356, 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N"-(2-tetrahydro-2f/-pyran-4-yhTiethyl)benzenesulfonamide and methylamine were used to prepNe 2-isopropyl-5-([4-(methylamino)phenyl]sulfonvl}-N-('tetrahvdro-2/jr-pyran-4-ylmethvDbenzenesulfonamide. MS(ES)m/z465.2; tffLC purity 96.6% at 210-370 nm, 9.0 min.; 98.2% at 310 nm, 9.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold4min. HRMS: cNcd for C22Fl3oN2O5S2 + H+, 467.16689; found (ESI, [M+H]+), 467.1691. Example 544: 5-{[4-(dimethyINaino)phenyl]sulfonyl}-2-isopropyI-N-(tetrahydro-2flr-pyran-4-yl)benzenesulfonamide In an anNogous manner to Example 356, 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-tetrahydro-2ff-pyran-4-yIbenzenesulfonamide and a dimethylamine solution in THF were used to prepNe 5 - ( [4-dimethylamino)phenyl1 sulfony 1 } -2-isopropy] -N-(tetrahydro-2H'-pyran-4-ynberizenesulfonNmde. MS (ES)m/z 465.1; HPLC purity 96.2% at 210-370 nm, 9.2 min.; 96,2% at 318 nm, 9.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold4min. HRMS: cNcd for CnHsoNiOsSj + H+, 467.16689; found (ESI, [M+Hf), 467.1694. Example 545: 5-{{4-(dimethylaniino)phenyl]sulfonylJ-2-isopropyl-J/V-(tetrahydro-2JHr-pyran-4-ylmethyl)benzenesulfonamide In an anNogous manner to Example 356, 5-[(4-fluorophenyl)suIfonyl]-2-isopropyl-N(2-tetrahydro-2JN-pyran-4-ylmethyl)benzenesulfonamide and a dimethylamine solution in THF were used to prepNe S-lN-fdimethylaminoNhenyljsulfonyUN-isopropvt-N (tetrahydro-2H-pyran-4-ylmethyDbenzenesulfonamide. MS (ES) m/z 479.2; HPLC purity 96 .3% at 210-370 nm, 9.4 min.; 96.6% at 318 nm, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for €23N2N0582 + H+, 481.18254; found (ESI, JM+H]4), 481.1829. Example 546: S-lN-pyran-4-yl)ethyl]benzenesulfonamide In an anNogous manner to Example 356, 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-tetrahydro-2f/-pyran-4-ylethyl)benzenesulfonamide and a dimethylamine solution in THF were used to prepNe 5_-{j}l-(dimejhylamino')phenyi]sulfoN MS(ES)ni/3493.2; HPLC purity 100% at 210-370 nm, 9.6 min.; 99.2% at 318 nm, 9.6 min.; Xterra RP1S, 3.5u, 150 x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold4min. HUMS: cNcd for C24H34N205S2 + H+, 495.19819; found (ESI, [M+H]+), 495.1986. Example 547: 2-isopropyI-5-{[4-(4-methyIpiperazin-l-yI)phenyl]sulfonyl}-N-(tetrahydro-2£/-pyran-4-yl)benzenesulf2 gas was bubbled into the reaction flask for approximately fNe minutes at dry ice-acetone bath temperature. Nter wNming to room temperature the solvent and the excess SCb were removed under reduced pressure and then the residue was pNtitioned between methylene chloride and 2 N HC1. The organic layer was sepNated and the aqueous layer extracted three times with methylene chloride. The combined extracts were dried (anhydrous MgSCU), filtered and the solvent removed under reduced pressure to produce 0.77 g of brown solid. . "' Step 6: N-(2-phenylethyl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. A mixture of 5-benzenesulfonyl-2-trifluoromethyl-benzenesulfinic acid (0.58 g, 1.6 mmol), prepNed in the previous step, N-Chlorosuccinimide (0.26 g, 1.98 mmol), and triethylamine (0.7 mL, 5 mmol) in 30 mL methylene chloride was stirred under nitrogen for thirty minutes at room temperature. Phenethylamine (0.25 mL, 2 mmol) was slowly syringed into the flask and the reaction was stirred under nitrogen overnight at room temperature. The solvent was removed under reduced pressure and then the residue was pNtitioned between methylene chloride and 2 N HC1. The organic layer was sepNated and the aqueous layer extracted three tunes with methylene chloride. The combined extracts were dried (anhydrous MgSCU), filtered and the solvent removed under reduced pressure to produce 0.82 g of brown solid. The solid was taken up in methylene chloride and purified on a Horizon™ Flash Collector (Column: Biotage Si 25+M) using a lineN gradient of 5% methylene chloride-hexane to 100% methylene chloride as the eluent. AdditionN purification was done on 0.20 g of product with a Luna CIS (50 x 250 mm) reverse phase column on a VNian HPLC system using 70% methanol / water mobile phase isocraticly at 100 ml/min. Isolation of the main component gave the title compound N-(2-phenylethyl)-5~(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide (0.23 g, 35.4%), as a white solid mp 151-153 °C. MS (ES)m/z 468.1. Example 571: 5-(Phenylr,ulfonyl)-N-(2-pyridin-2-ylethyl)-2-(trifluoromethyl)benzenesnlfonamide A mixture of 5-benzenesulfonyl-2-trifluoromethyl-benzenesulfinic acid (0.59 g, 1.7 mmol), prepNed in the same manner as described in step 5 of Example 570, N-Chlorosuccinimide (0.27 g, 2.0 mmol), and triethylamine (0.7 mL, 5 mmol) in 30 ml methylene chloride was stirred under nitrogen for thirty minutes at room temperature. 2-(2-pyridyl)ethylamine (0.24 mL, 2 mmol) was slowly syringed into the flask and the reaction was stirred under nitrogen overnight at room temperature. The solvent was removed under reduced pressure and then the residue was pNtitioned between methylene chloride and 2 N HC1. The organic layer was sepNated and the aqueous layer extracted three times with methylene chloride. The combined extracts were dried (anhydrous MgSCU), filtered and the solvent was removed under reduced pressure to produce 0.67 g of a dNk brown solid. The solid was taken up in methylene chloride and purified on a Horizon™ Flash Collector (Column: Biotage Si 25+M) using a lineN gradient of 5% methylene chloride-hexane to 100% methylene chloride as the eluent. Isolation of the main component gave the title compound 5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)-2-(trifluoromethyl)benzenesulfonamide (75.5 mg, 9.6%) as a white solid, mp 149-151 °C; MS (ES)m/z 469.0. Example 572: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[l-(morpholin-4-ylcNbonyl)piperidin-4-yl]benzenesulfonamide In an anNogous manner to Example 462, 2-isopropyl-5-(phenylsulfonyl)-n-piperidin-4-ylbenzenesulfonamide and 4-morpholinecNbonyl chloride were used to prepNe 5N [(4-fluorophenvl')sulfonvl]-2-isopropvl-N-|'l-(morpholin-4-ylcNbonyl')piperidin-4-yl]benzenesulfonamide. MS (ES+) m/z 554 MS (ES-) m/z 552 HRMS: cNcd. for CasHazFNaCN + H+, 554.179484: found (ESI, [m+H]+), 554.1799. Example 573: 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N,N-dimethylpiperidine-1-cNboxamide In an anNogous manner to Example 462, 2-isopropyl-5-(phenylsulfonyl)-n'-piperidin-4-ylbenzenesulfonamide and dimethylcNbamyl chloride were used to prepNe 4- [({5- (4-fluorophenyl)suifonyl1-2-isopropylphenvl ) sulfonvDamino] -N,N- dimethvbiperidine- 1 - cNboxamide. MS(ES+)w/z512 MS(ES-)w/z510 HRMS: cNcd. for C23H3oFN3O5S2 + H4, 512.168919: found (ESI, [m+Hf), 512.1692. Example 574: N-(l-benzylpiperidin-4-yl)-5-[(4-fluorophenyl)sulfonyI]-2-methylbenzenesulfonamide In an anNogous manner to Example 435, 5-(4-fluoro-benzenesulfonyl)-2-methyl-benzenesulfonyl chloride and 4-amino-l-benzylpiperidine were used to prepNe N-d-benzvlpiperidin-4-vn-5-[(4-fluorophenyl)sulfonvl]-2-methylbenzenesulfonamide. MS (ES+) m/z 503 MS (ES-) m/z 501 HRMS: cNcd. for CzsHNFNaCUSz + H1", 503.147455: found (ESI, [m+H]*), 503.1489. Example 575: 2-isopropyl-5-(phenylsulfinyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide Step 1 : Following the same procedure as described in Example 474 (Stepl), 2-bromoisopropylbenzene was used to prepNe 2-isopropvl-N-r2-pvridin-2-ylethyDbenzenesulfonamide. Step 2: Following the same procedure as described in Example 474 (Step2), 2-isopropyl-N"-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepNe 5-bromo-2-isopropyl-N-Q-pyridinN-ylethynbenzenesulfonamide. Step 3 : Following the same procedure as described in Example 346, 5-bromo-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide, and benzenethiol were used to prepNe 2N isopropvl-5-(phenvlsulfinyl')-N/-f2-pyridin-2-vlethvl)benzenesulfonamide. MS (ES) m/z 427.1; HRMS: cNcd for €22N4N0382 + H+, 429. 13011; found (ESI, [M+H]+), 429. 1309. Example 576: 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-piperidin-4-ylbenzenesulfonamide 200 mg of pNladium on cNbon were wetted with 30 mL of ethanol and 1.5 g of N-(l-benzylpiperidin-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide hydrochloride was added. The reaction was mixed on a PNr shaker at 45 psi overnight. The reaction mixture was filtered through Celite® and the filtrate was concentrated down gNing the desired 5-[r4-fluorophenvl)sulfonyl]-2-methyl-N-piperidin-4-ylbenzenesulfonamide. MS(ES+)m/z413 MS(ES-)w/z411 HRMS: cNcd. for Ci8H2iFN2O4S2 + H+, 413.100505: found (ESI, [m+H]+), 413.0997. Example 577: 5-[(3-bromo-2-methylphenyl)suIfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide ' Step 1: Following the same procedure described in Example 334, 2-methyl-3-bromoaniline was used to prepNe 2-methyl-3-bromobenzenesulfonyl chloride. Step 2: Following the same procedure described in Example 474, 2-methyl-3-bromobenzenesulfonyl chloride was used to prepNe 2-methyl-3-bromobenzenesulfonyl fluoride. Step 4: Following the same procedure described in Example 474, 5-bromo-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide and 3-bromo-2-methylbenzene sulfonyl fluoride were used to prepNe 5-[(3-bromo-2-rnethylphenyl)sulfonyl]-2-isopropyl-N1(2-pyridin-2-vlethyDbenzenesulfonamide. MS (ESI) m/z 537; HRMS: cNcd for C23H2sBrN2O4S2 + H+, 537.05119; found (ESI, M+H), 537.0517. Example 578: 5-[(2-chloro-6-methylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide Step 1: Following the same procedure described in Example 474 (Step 3), 2-chloro-6-methylbenzene sulfonyl chloride was used to prepNe 2-chloro-6-methvlbenzene sulfonyl fluoride. Step 2: Following the same procedure described in Example 474 (Step 4J, 5-bromo-2-isopropyl-Nr-(2-pyridin-2-ylethyl)benzenesulfonamide and 2-chloro-6-methylbenzene sulfonyl fluoride were used to prepNe 5-[(2-chloro-6-methylphenvl')sulfonyl1-2-isopropyl-]V-(2-pyridin-2-ylethyl')benzenesulfonamide. MS (ESI) m/z 493; HRMS: cNcd for C23H25C1N2O4S2 + H+, 493.10170; found (ESI, M+H), 493.1023. Example 579: 2-isopropyl-5-[(3-methylphenyl)suIfonyl]-N-(2-pyridin-2-ylethyl)benzenesulfonNaide Step 1 : Following the same procedure described in Example 474 (Step 3), 3-methylbenzene sulfonyl chloride was used to prepNe 3-methylbenzene sulfonyi fluoride. Step 2: Following the same procedure described hi Example 474 (Step 4), 5-bromo-2-isopropyl-N2-pyridin-2-ylethyl)berizenesulfonNnide and 3-methylbenzene sulfonyl fluoride were used to prepNe 2-isopropyl-5-[(3-methvlphenyl')sulfonvl1-N-(2-pvridin-2-ylethvDbenzenesulfonamide. MS(ESI)m/z459; HRMS: cNcd for C23H26N2O4S2 + H+, 459.14067; found (ESI, M+H), 459.1412. Example 580: 5-({4-[(2-cyanoethyl)(methyl)amino]phenyl}sulfonyl)-2-isopropyl-N-(tetrahydro-2J£-pyran-4-yl)benzenesulfonamide i In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-tetrahydro-2H-pyran-4-ylbenzenesulfonamide and 3-(methylamino)propionitrile in DMA were used to prepNe 5-((4-|"(2-cvanoethyl¥methyDamino]phenyl}sulfonyn-2-isopropyl-N-(tetrahydro-2H-pyran-4-yl')benzenesulfonamide. MS (ESI) m/z 506; HPLC purity 96.0% at 210-370 nm, 8.6 min.; 95.8% at 312 nm, 8.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CNHsiNsOsSa + H+, 506.17779; found (ESI, [M+HJ+), 506.1783. Example 581: 5-({4-[(2-cyanoethyl)(methyl)amino]phenyl}sulfonyl)-2-isopropyl-N-(tetrahydro-2#-pyran-4-ylmethyl)benzenesulfonamide In an anNogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-2-isopropy 1-N-tetr ahydro-2f/"-pyran-4-y lmethyl)benzenesulfonamide and 3 -(methylamino)propionitrile in DMA were used to prepNe 5-({4-[(2-cyanoethyl)(methyl)amuio]phenyl}sulfonyl)-2-isQpropyl-N-(tetrahydro-2H-pyran-4-ylniethyDbenzenesulfonamide. MS (ESI) m/z 520; HPLC purity 96.3% at 210-370 nm, 8.8 min.; 96.0% at 312 nm, 8.8 min.; Xterra RP18, 3.5u, 150 x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold4rnin. HRMS: caJcd for CasHssNsOsSa + H+, 520.19344; found (ESI, [M+HJ+), 520.194. Example 582: 5-[(4-fluorophenyI)sulfonyl]-N-(2-hydroxyethyl)-2-isopropylbenzenesulfonamide In an anNogous manner to Example 230: Step 3:2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-aminoethanol were used to prepNe 5-rr4-fluorophenvnsulfonvl1-N-(2-hvdroxyethvl)-2-isopropylbenzenesulfonamide. MS (ESI +) m/z 402; MS(ESI-)/M/z400; HPLC purity 100% at 210-370 nm, 8.3 min.; 100% at 242 nm, 8.3 min.; Xterra RP18, 3.5u, 150 x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold4min. HRMS: cNcd for Ci7H2oFNO5S2 + H+, 402.08397; found (ESI, [M+H]+), 402.0845. Example 583: 5-[(4-fluorophenyl)suIfonyl]-2-isopropyl-N-[2-(2-methyl-lJ?-imidazol-l-yl)ethyljbenzenesulfonamide Step 1 : To a stirred solution of 5-[(4-fluorophenyl)sulfonyl]-N-(2- hydroxyethyl)-2-isopropylbenzenesulfonamide (0.6 mg, 1.5 mmol), triethylamine (2.2 mmol) and a catNytic amount of N,Ndimethylaminopyridine in dichloromethane was added 4-methylbenzenesulfonyl chloride (1.8 mmol) and Nter 4 hours an additionN 1.8 mmol of 4-methylbenzene sulfonyl chloride was added. The reaction was concentrated and then purified by flash column chromatography using an ethyl acetate-hexane gradient Nfording predominately the N,O-bistosyl intermediate. Step 2: 2-Methylimidazole (164 mg, 2 mmol) was dissolved in anhydrous tetrahydrofuran (1 mL) and sodium hydride (60% minerN oil dispersion, 24 mg, 1 mmol) was added. Nter 30 minutes, a solution of the intermediate bistosylate (stepl, 0.14 mmol) in tetrahydrofuran was added and the reaction was Nlowed to stir at room temperature for 30 additionN minutes. The mixture was quenched upon the addition of water. The mixture was extracted with ethyl acetate (3 x 2 mL). The combined organic phases were concentrated and the resulting crude residue was purified by automated flash column chromatography resulting in the recovery of 56 mg (85%) of 5-rf4-fluorophenvl)sulfonyl]-2-isopropyl-N-2-(2-methyl-lH- imidazol-1 -yl)ethyl]benzenesulfonamide. MS (ESI +) m/z 466; MS (ESI -) m/z 464; HPLC purity 100% at 210-370 nm, 7.5 min.; 100% at 244 nm, 7.5 min.; XterrNPIS, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hokMmin. HRMS: cNcd for C2iH24FN3O4S2 + H+, 466.12650; found (ESI, [M+HJ+), 466.1271. Example 584: N-[2-(2-ethyl-lJHr-imidazol-l-yI)ethyl]-5-[(4-fluorophenyl)suIfonyl]-2-isopropylbenzenesulfonamide In an anNogous manner to Example 583: Step 2: 2- The bistosylate and 2-ethylimidazole were used to prepNe N-[2-(2-ethvl-lH-imidazol-l-vl')ethvl]-5-f(4-fluorophenyl')suh0Qnvl]-2-isopropylbenzenesulfonamide. MS (ESI+) m/z 480; MS (ESI -) m/z 478; HPLC purity 100% at 210-370 nm, 7.7 min.; 100% at244 nm, 7.7 min.; XterrNPIS, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for 022*NN0482 + H+, 480.14215; found (ESI, [M+H]+), 480.1427. Example 585: N-(l-acetylpiperidin-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonaniide In an anNogous manner to Example 462, 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-piperidin-4-ylbenzenesulfonamide and acetic anhydride were used to prepNe N-d-acetylpiperidin-4-yl)-5-|'(4-fluorophenynsulfonyl]-2- methylbenzenesulfonamide. MS (ES+) m/z 455 MS(ES-)m/z453. Example 586: N-[l-(4-cyanobeuzoyl)piperidin-4-yl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide In an anNogous manner to Example 462, 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-piperidin-4-ylbenzenesulfonamide and 4-cyanobenzoyl chloride were used to prepNe N-[l-(4-cyanobenzoynpiperidm-4-yl]-5-[(4-fluorophenvl)sulfonvl]-2-methy Ibenzenesulfonamide . MS (ES+) m/z 542 MS (ES-) m/z 540. Example 587: 4-[({5-[(4-fluorophenyl)sulfonyl]-2-methylphenyl}sulfonyl)amino]-N,N-dimethylpiperidine-l-cNboxamide ] In an anNogous manner to Example 462, 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-piperidin-4-ylbenzenesulfonamide and dimethylcNbamyl chloride were used to prepNe 4-[ri5-r(4-fluorophenyl)sulfonyn-2-methylphenyUsulfonyl')amino]-N.N-dimethvlpiperidine-1 -cNboxamide. MS (ES+) m/z 484 MS(ES-)/n/z482. Example 588: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[2-(2-isopropyl-l/T-imidazol-l-yl)ethyl]benzenesulfonamide In an anNogous manner to Example 583 : Step 2: 2- The bistosylate and 2-isopropylimidazole were used to prepNe S-f(4-fluorophenyl)sulfonyl]-2-isopropvl-N-l'2-('2-isopropvl-lH-imidazol-l-yDethyllbenzenesulfonamide. MS (ESI +) m/z 494; MS (ESI -) m/z 492; HPLC purity 91.6% at 210-370 nm, 8.0 min.; XterrNPIS, 3.5u, 150x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C23H28FN3O4S2 + H+, 494.15780; found (ESI, M+H), 494.1584. Example 589: 5-[(4-fluorophenyl)sulfonyl]-N-[l-(methoxyacetyl)piperidin-4-yl]-2-methylbenzenesulfonamide In an anNogous manner to Example 462, 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-piperidin-4-ylbenzenesulfonamide and methoxyacetyl chloride were used to prepNe 5; [(4-fluorophenyl)sulfonyl]-N-[ 1 -Cmethoxyacetyl)piperidin-4-vl]-2- methylbenzenesulfonamide. MS (ES+) m/z 485 MS (ES-) m/z 483 HRMS: cNcd. for C2iH25FN2O6S2 + H+, 485.121634: found (ESI, [m+H]+), 485.1216. Example 590: 2-isopropyl-5-[(R)-phenylsulfinyI]-N-(2-pyridin-2-ylethyl)benzenesulfonamide ChirN sepNation of 2-isopropyl-5-(phenylsulfinyl)-N-(2-pyridin-2- ylethyl)benzenesulfonamide using a prep chirN SFC column AD-H 35%methanol/65% COj at 50mL/min yielded 2-isopropvl-5-(R)-phenvlsuIfinyl]-N('2-pvridin-2-ylethyl)benzenesulfonamide. MS (ES) m/z 426.9. Example 591: 2-isopropyl-5-[(,S)-phenylsuIfinyl]-N~(2-pyridin-2-ylethyl)benzenesulfonamide ChirN sepNation of 2-isopropyl-5-(phenylsulfinyl)-N-(2-pyridin-2- ylethyl)benzenesulfonamide using a prep chirN SFC column AD-H 35%methanol/65% CC>2 at 50mL/min yielded 2-isopropyl-5-[(5r)-phenylsulfmvl]-N-(2-pyridin-2- ylethyl)benzenesulfonamide. qr~N MS (ES) m/z 426.9. Example 592: 2-bromo-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide Step 1: Following the same procedure described in Example 1 (Step 1), 4-nitrobromobenzene and chlorosulfonic acid were used to prepNe 2-bromo-5-nitrobenzenesulfonyl chloride. Step 2: Following the same procedure described in Example 1 (Step 2), 2-(2-ethylamino)pyridine and 2-bromo-5-nitrobenzenesulfonyl chloride were used to prepNe 2N bromo-5-nitro-N-(2-pyridin-2-yle'thvl)benzenesulfonamide. Step 3: 2-bromo-5-nitro-N-(2-pyridin-2-ylethyl)benzenesulfonamide (1.5 g, 3.88 mniol) was dissolved in methanol (25 mL) and water (1 mL). Tin (II) chloride (3.68 g, 19.4 mmol) was added and the resulting solution was heated to 70 °C overnight. The solution was concentrated and pNtitioned between ethyl acetate and a saturated aqueous sodium bicNbonate solution. The organic layer was dried over magnesium sulfate and concentrated to gNe 2-bromo-5-amino-N-(2-pyridin-2-ylethyl)benzenesulfonamide (1.2 g, 87%). . Step 4: Following the same procedure described in Example 334 (Step 2), 2-bromo-5-amino-N-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepNe 4-bromo-3-r2-pvridin-2-yl-emylsulfamovn-benzenesulfonvl chloride. Step 5: To a stirred solution of Numinum chloride (1.82 g, 13.64 mmol) in nitrobenzene (40 mL), was added benzene (3 mL), and 4-bromo-3-(2-pyridin-2-yl-ethylsulfamoyl)-benzenesulfonyl chloride (1.0 g, 2.27 mmol) at 80 °C. The resulting mixture was stirred 4 days at 80 °C with daily addition of benzene (2 mL). The reaction was then cooled to room temperature, poured over ice and extracted with dichloromethane. The organic phase was concentrated and flash column sepNated with 50% ethyl acetate/ hexane to gNe 2-bromo-5-(phenylsulfonyD-]v'-(2-pvridin-2-vlethvl')benzenesulfonaniide (0.23 g, 21%). MS (ES)w/z 478.8; HRMS: cNcd for Ci9Hi7BrN2O4S2 + H+, 480.98859; found (ESI, M+H), 480.9891. Example 593: 5-[(3-cyano-2-methylphenyI)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 376, 5-[(3-bromo-2- methylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepNe 5-r(3-cvano-2-niethylphenyl)sulfonvl]-2-isopropyl-N-('2-pvridin-2-y lethy nbenzenesulfonamide. MS(ES)m/z481.9. Example 594: 5-[(3-acetyl-2-methylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 380, 5-[(3-bromo-2- methylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepNe 5-[(3-acetyl-2-methylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethypbenzenesulfonamide. MS (ES)m/z 499.0; HRMS: cNcd for CasEbNaCN + H+, 501.15124; found (ESI, M+H), 501.1518. Example 595: 5-[(3-chloro-4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide Step 1 : Following the same procedure described in Example 474 (Step 3), 3-chloro-4-fluorobenzene sulfonyl fluoride was used to prepNe 3-chloro-4-fluorobenzene sulfonyl fluoride. Step 2: Following the same procedure described in Example 474 (Step 4), 5-bromo-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamideand 3-chloro-4-fluorobenzene sulfonyl fluoride were used to prepNe 5-[(3-chloro-4-fluorophenvl')sulfonvl]-2-isopropvl-N-('2-pvridin-2-vlethyl)benzenesulfonamide. MS (ESI) m/z 497; MS (ESI) m/z 495. Example 596: 5-[(4-fluoro-2-methylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide Step 1 : Following the same procedure described in Example 474 (Step 3), 2-methyl-4-fluorobenzene sulfonyl chloride was used to prepNe 2-methyl-4-fluorobenzene sulfonyl fluoride. Step 2: Following the same procedure described in Example 474 (Step 4), 5-bromo-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamideand2-methyl-4-fluorobenzene sulfonyl fluoride were used to prepNe 5-[(4-fluoro-2-methylphenyl)sulfonyl]-2-isopropvl-N-r2-pyridin-2-ylethyl)benzenesulfonamide. MS (ES) m/z 474.9; HRMS: cNcd for CNEbFNzCNSs + H+, 477.13125; found (ESI, M+H), 477.1318. Example 597: 2-isopropyl-5-[(l-methyl-lH-indol-5-yl)sulfonyl]-N-(2-pyridin-2-ylethyl)benzenesulfonamide Step 1: To a stirred solution of 5-bromoindole (2.0 g, 10.2 mmol) in DMF (25 niL) at 0 °C was added sodium hydride (0.45 g, 60%, 1 1 .22 mmol) and the resulting solution was stirred for 5 minutes. Methyl iodide (1 .3 mL, 20.8 mmol) was added and the reaction was Nlowed to wNm to room temperature. Nter 1 lir the reaction was quenched with a saturated aqueous ammonium chloride solution and extracted severN times with ethyl acetate. The combined organic layers were washed with brine, dried over magnesium sulfate, and concentrated to gNe crude l-methyl-5-bromoindole. This materiN was dissolved in THF (20 mL) and chilled to -78 °C. n-Butyl lithium 2.5 M in hexane (3.8 mL, 9.5 mmol) was added dropwise. Nter 10 minutes sulfur dioxide was bubbled into the reaction mixture for 5 minutes. The mixture was Nlowed to wNm to room temperature and concentrated. The crude mixture was taken up in methylene chloride (20 mL) and N-bromosuccinimide (1.25 g, 9.36 mmol) was added and the resulting solution was stirred for 1 hr. The solution was washed with a saturated aqueous ammonium chloride solution, dried over magnesium sulfate, and concentrated. The mixture was flash column sepNated using 20% ethyl acetate/ hexane to gNe l-methylindole-5-sulfonvl chloride (0.64 g, 27%). Step 2: Following the same procedure described in Example 474 (Step 3), 1-methylindole-5-sulfonyl chloride was used to prepNe 1 -methvlmdole-5-sulfonvl fluoride. Step 3: Following the same procedure described in Example 474 (Step 4), 5-bromo-2-isopropy l-N-(2-pyridin-2-y lethy l)benzenesulfonamide and 1 -metHylindole- 5-sulfonyl fluoride were used to prepNe 5-[(4-fluoro-2-methylphenyl)sulfonyl]-2-isopropvl-]V-(2-pvridin-2-ylethvDbenzenesulfonamide. MS (ESI) m/z 498; MS (ESI) m/z 496. Example 598: 2-isopropyI-5-[(3-methoxyphenyl)sulfonyl]-N-(tetrahydro-2Jl;r-pyran-4-yl)benzenesulfonamide Step 1: Following the same procedure described in Example 474 (Step 3), 3-methoxybenzene sulfonyl chloride was used to prepNe 3-methoxybenzenesulfonyl fluoride. Step 2: 3-methoxybenzenesulfonyl fluoride and 5-bromo-2-isopropyl-./V-(tetrahydro-2N-pyran-4-yl)benzenesulfonamide were used to prepNe 2-isopropyl-5-[(3-methoxvphenvl')sulfonvl1-N-(tetrahvdro-2N'-pyran-4-yl)benzenesulfonamide. MS (ESI) m/z 454; MS (ESI) m/z 452. Example 599: 2-isopropyl~5-{(2-methyl-4-(methylamino)phenyl]sulfonyl}-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 356, 5-[(4-fluoro-2- methylphenyl)sulfonyl]-2-isopropyl-N'-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepNe 2-isopropyl-5-([2-methyl-4-('methylamino')phenyl]sulfonyU-N-('2-pvridin-2-ylethyDbenzenesulfonamide. MS (ESI) m/z 488; MS(ESI)m/z486. Example 600: 5-{[4-(dimethylamino)-2-methylphenyl]sulfonyl}-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide . In an anNogous manner to Example 353, 5-[(4-fluoro-2- methylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepNe 5- 1 r4-(dimethylaminoV2-methvlphenyl]sulfonyl) -2-isopropyl-N-(2-pyridin-2-vlethvDbenzenesulfonamide. MS (ES)«/z 500.1; HRMS: cNcd for CisNNaCN + H+, 502.18287; found (ESI-FTMS, [M+H]1+), 502.18264. Example 601: 2-(dimethylamino)-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide Step 1: Following the same procedure described in Example 1 (Step 1), 4-nitrobromobenzene and chlorosulfonic acid were used to prepNe 2-bromo-5-nitrobenzenesulfonyl chloride. Step 2: Following the same procedure described in Example 1 (Step 2), 2-(2-ethylamino)pyridine and 2-bromo-5-nitrobenzenesulfonyl chloride were used to prepNe 2N bromo-5-nitro-M-(2-pvridin-2-vlemvl)benzenesulfonamide. Step 3: 2-bromo-5-nitro-]V-(2-pyridin-2-ylethyl)benzenesulfonamide (1.5 g, 3.88 mmol) was dissolved in dimethylamine 2.0 M in THF (10 mL) and the resulting solution was microwave heated for 10 mintues at 160 °C. The solution was diluted with ethyl acetate and washed with a saturated aquous ammonium chloride solution. The organic layer was dried over magnesium sulfate, filtered, and concentrated to gNe 2-dimethylamino-5-nitro-N-(2-pvridin-2_-ylethvDbenzenesulfonamide (1.3 g, 95%). Step 4: Following the same procedure described in Example 592 (Step 3), 2-dimethylamino-5-nitro-]V-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepNe 2N dirnethylNnino-5-amino-N'-(2-pyridin-2-vlethvl)benzenesulfonamide. Step 5: To a stirred solution of 2-dimethylamino-5-amino-N-(2-pyridin-2-ylethyl)benzenesulfonamide (0.60 g, 1.87 mmol) in acetonitrile (15 mL) and hydrobromic acid 48% (1.5 mL) at 0 °C was added sodium nitrite (0.16 g, 2.2 mmol) dissolved in a minimum amount of water dropwise. The resulting solution was stirred 20 minutes and copper I bromide (0.36 g, 2.5 mmol) was added and stirred 1 hr. The solution was diluted with water, neutrNized with sodium hydroxide and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, filtered, and concentrated to gNe 2-dimethvlamino-5-bromo-N-(2-pvridin-2-ylethvDbenzenesulfonamide (0.49 g, 81%). Step 6: Following the same procedure described in Example 474 (Step 4), 2-dimethylamino-5-bromo-N-(2-pyridin-2-ylethyl)benzenesulfonamide and benzene sulfonyl fluoride were used to prepNe 2-(dimethylaminoV5-('phenylsulfonylVN/-(2-pvridin-2-ylethyDbenzenesulfonamide. MS (ES)m/z 444.1; HRMS: cNcd for QiHbNCN + H+, 446.12027; found (ESI-FTMS, [M+H]14), 446.1205 Example 602: N-[l-(cyclopropylcNbonyl)piperidin-4-yl]-N-({5-[(4-fluorophenyl)sulfonyl]-2- methylphenyl} sulf onyl)cyclopropanecNboxamide In an anNogous manner to Example 462, 5-[(4-fluorophenyi)sulfonyi]-2-methyl-N-piperidin-4-ylbenzenesulfonamide and cyclopropylcNbonyl chloride were used to prepNe N-[l-(cyclopropvlcNbonvl)piperidin-4-yl]-N-((5-[('4-fluorophenyl)sulfonyl]-2-methylphenyl}sulfonyl)cyclopropanecNboxamide. MS (ES+) m/z 549. Example 603: 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[l-(rnorpholin-4-ylcNbonyl)piperidin-4- yl]benzenesulfonamide In an anNogous manner to Example 462, 5-[(4-fluorophenyl)sulfonyl]-2-methyl-Nrpiperidin-4-ylbenzenesulfonamide and 4-morpholinecNbpnyl chloride were used to • prepNe 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[l-(morpholin-4-ylcNbonyl')piperidin-4-yljbenzenesulfonamide. MS (ES+) m/z 526 MS (ES-) m/z 524. Example 604: 2-chloro-5-[(3-methylphenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide Step 1: Following the same procedure described in Example 1 (Step 2), 4-aminotetrahydropyran and 2-chloro-5-nitrobenzenesulfonyl chloride were used to prepNe 5N nitro-2-chloro-N-(tetrahydro-2H-pyran-4-vnbenzenesulfonamide. Step 2: Following the same procedure described in Example 592 (Step 3), 5-nitro-2-chloro-AT-(tetrahydro-2N'-pyran-4-yl)benzenesulfonaniide was used to prepNe 5-amino-2-chloro-N-rtetrahvdro-2J:/'-pvran-4-vl')benzenesulfonamide. Step 3: Following the same procedure described in Example 601 (Step 5), 5-amino-2-chloro-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide was used to prepNe 5-bromo-2j-cMoro-N-(tetrahydro-2N;-pyrNi-4-yl)benzenesulfonNnide. ~, Step 4: Following the same procedure described in Example 474 (Step 3), 3-methylbenzene sulfonyl chloride was used to prepNe 3-methylbenzenesulfony 1 fluoride. L Step 5: Following the same procedure described in Example 474 (Step 4), 5- bromo-2-chloro-N(tetrahydro-2J:/-pyran-4-yl)benzenesulfonNnide and 3-methylbenzene sulfonyl fluoride were used to prepNe 2-chloro-5-[(3-methvlphenyl)sulfonyl]-N-(tetrahvdro-2N:-pyran-4-ynbenzenesulfonamide. MS (ES) m/z 428.0. Example 605: 5-{l3-chloro-4-(methylamino)phenyl]sulfonyl}-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 356, 5-[(3-chloro-4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepNe 5-ir3-chloro-4-rmethvlamino)phenvl]sulfonvU-2-isopropvl-N-(2-pyridin"2-ylethvl)benzenesulfonamide. MS (ES)m/z 506.1. Example 606: 2-chloro-5-[(3-methoxyphenyl)sulfonyl]-N-(tetrahydro-2flr-pyran-4-yl)benzenesulfonamide Step 1: Following the same procedure described in Example 474 (Step 3), 3-methoxybenzene sulfonyl chloride was used to prepNe 3 -methoxybenzenesulfony 1 fluoride. Step 2: Following the same procedure described in Example 474 (Step 4), 5-bromo-2-chloro-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide and 3-methoxybenzene sulfonyl fluoride were used to prepNe 2-chloro-5-[(3-methoxyphenyl)sulfonvl1-./V-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide. MS (ES) m/z 444.0. Example 607: 2-chloro-5-[(l-methyl-lN-indol-5-yl)sulfonyl]-N-(tetrahydro-2Nr-pyran-4-yl)benzenesulfonamide In an anNogous manner to Example 597, Step 3: 5-bromo-2-chloro-N-(tetrahydro-2N-pyran-4-yl)benzenesulfonamide was used to prepNe 2-chloro-5-[lH-methyl-1H-indol-5-yl')sulfonyl]-N-(tetrahvdro-2f/-pyran-4-yDbenzenesulfonamide. MS (ES) m/z 467.0. Example 608: 5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-2-(trifluoromethyl)benzenesulfonamide A mixture of 5-Benzenesulfonyl-2-trifluoromethyl-benzenesulfmic acid (0.47 g, 1.35 mmol), prepNed in the same manner as described in step 5 of Example 570, N-Chlorosuccinimide (0.18 g, 1.36 mmol), and triethylamine (0.38 mL, 2.7 mmol) in 20 mL methylene chloride was stirred under nitrogen for thirty minutes at room temperature. Tetrahydro-2H-pyran-4-amine (0.14 g, 1.35 mmol) was slowly syringed into the flask and the reaction was stirred under nitrogen overnight at room temperature. The solvent was removed under reduced pressure and then the residue was pNtitioned between methylene chloride and 2 N HC1. The organic layer was sepNated and the aqueous layer extracted three times with methylene chloride. The combined extracts were dried (anhydrous MgSCU), filtered and the solvent removed under reduced pressure to produce 0.51 g of a dNk brown solid. The solid was taken up in methylene chloride and purified on a Horizon™ Flash Collector (Column: Biotage Si 25+M) using a lineN gradient of 5% methylene chloride-hexane to 100% methylene chloride as the eluent. Isolation of the main component gave the title compound 5-(phenylsulfonyl)-N- (tetrahydro-2H-pyran-4-yl)-2-(trifluoromethyl)benzenesulfonamide (55.1 mg, 10%) as a white solid, mp 155-158 °C. MS (ES) m/z 448.0; AnN. CNcd for C,8Hi8F3NO5S2: C, 48.10; H, 4.04; N, 3.12. Found: C, 48.12; H, 3.81; N, 2.88. Example 609: 2,4-Diisopropyl-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide [0740] Step a) 2,4-Diisopropyl-l-(phenylsulfonyl)benzene A stirred solution of 1,3-diisopropylbenzene (16.25 g, 100 mmol) and benzenesulfonyl chloride (8.8 g, 50 mmol) was cooled to -20 °C and treated slowly under nitrogen with solid anhydrous Numinum chloride (8.Q g, 60 mmol). Nter stirring neat for 4 hours at room temperature, the mixture was poured slowly into ice water and extracted with ethyl acetate (2x). The organic phase was washed with a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and filtered through a short column of silica gel. The filtrate was evaporated in vaciio to yield a crude oil. The crude oil was purified by prepNatNe liquid chromatography on a Biotage® 40 Mi column of pre-packed silica gel (90 g) (multiple runs), eluting with a gradient of 0%-25% methyl terr-butyl ether in hexane at a flow rate of 50 mL/min, to Nford 2,4-diisopropyl-1 -(phenyIsulfonyDbenzene (5.07 g, 33%), as a cleN oil which crystNlized on standing to a homogeneous, amorphous solid, m.p. 105-107 °C; MS (-ESI), m/z: 301 [M-H]'; HRMS: cNcd for CigHfoOzS, 302.13405; found (El, M+.), 302.1332; HPLC purity 100% at 210-370 nm, 10.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Step b) 2,4-Diisopropyl-5-(phenylsulfonyl)benzenesulfonyl chloride 2,4-Diisopropyl-l-(phenylsulfonyl)benzene (3.01 g, 10 mmol) was heated with stirring at 60 °C for 30 minutes under nitrogen with chlorosulfonic acid (6.7 mL, 11.7 g, 100 mmol). The mixture was cooled to room temperature, poured slowly into a cold solution of IN hydrochloric acid, and extracted with ethyl acetate (2x.). The organic phase was washed with a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the solvent concentrated in vacua to a crude oil. The crude oil was crystNlized from diethyl ether-hexane to Nford 2,4-diisopropyl-5-(phenylsulfonyl)benzenesulfonyl chloride (2.92 g, 73%) as a colorless, crystNline solid, which was utilized in subsequent reactions. Step c) 2,4-Diisopropyl-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide A stirred solution of 2,4-diisopropyl-5-(phenylsulfonyl)benzenesulfonyl chloride (0.20 g, 0.5 mmol) in dichloromethane (10 mL) was treated dropwise under nitrogen with a solution of phenethylamine (0.12 g, 1.0 mmol) in dichloromethane. Nter stirring for one hour at room temperature or until the reaction was complete, the mixture was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 0%-25% methyl teN-butyl ether in hexane at a flow rate of 50 mL/min. Nter evaporation of the solvent under vacuum, the title compound, 2 ,4-diisopropy 1- N-(2-phenylethvlV5-(phenvlsulfonyl)benzenesulfonamide (0.22 g, 90%), was obtained as a homogeneous, colorless, crystNline solid, m.p. 156-158 °C; MS (-ESI), m/z: 483.9.1 [M-H]'; HRMS: cNcd for C26H3iNO4S2 + H+, 486.17673; found (ESI, [M+Hf), 486.1773; HPLC purity 100% at 210-370 nm, 10.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 610: lN-yl)benzenesulfonamide The title compound was prepNed from 2,4-diisopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.20 g, 0.5 mmol) and tetrahydro-pyran-4-ylamine (0.10 g, 1 .0 mmol) according to the procedure and in the same manner as described in Example 609, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 30%-70% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to Nford 2,4-diisopropyl-5-(phenylsulfonylV N-(tetrahvdro-2/jr-pyran-4-vl)benzenesulfonamide (0.20 g, 87%), as a homogeneous, colorless, crystNline solid, m.p. 159-160 °C; MS CESI), m/z: 464.0 [M-H]'; HRMS: cNcd for C23H3iNO5S2 + H+, 466.17164; found (ESI, M+H), 466.1722; HPLC purity 100% at 2 10-370 nm, 9.7 min.; Xterra RP1 8, 3.5u, 150x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for 1 Grain, hold 4min. Example 611: 2,4-Diisopropyl-5-(phenylsuIfonyl)-N-(tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide The title compound was prepNed from 2,4-diisopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.20 g, 0.5 mmol) and (tetrahydro-pyran-4-yl)methylamine (0.12 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 609, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 30%-70% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to Nford 2,4-diisopropvl-5-(phenvlsulfonvlVN-rtetrahydro-2/jr-pyran-4-vlmethyl)benzenesulfonamide (0.22 g, 93%), as a homogeneous, colorless, crystNline solid, m.p. 148-150 °C; MS (+ESI), m/z: 480 [M+H]+; MS (-ESI), m/z: 478 [M-H]'; HPLC purity 100% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 612: 2,4-Diisopropyl-5-(phenylsulfonyl)-N-{2-(tetrahydro-2J:r-pyran-4-yl)ethyl]benzenesulfonamide ] The title compound was prepNed from 2,4-diisopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.20 g, 0.5 mmol) and 2-(tetrahydro-pyran-4-yl)ethylamine (0.12 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 609, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 30%-70% methyl terf-butyl ether in hexane at a flow rate of 50 mL/min, to Nford 2.4-diisopropyl-5-(phenylsulfonyl)-Nr-[2-(tetrahvdro-2Jf-pyran-4-yDethYnbenzenesulfonamide (0.23 g, 91%), as a homogeneous, colorless, crystNline solid, m.p. 90-92 °C; MS (+ESI), m/z: 494 [M+Hf; MS (-ESI), m/z: 492 [M-H]'; HPLC purity 100% at 210-370 nm, 10.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 613: N-Cyclopeatyl-2,4-disopropyl-5-(phenylsulfonyl)benzenesulfonamide The title compound was prepNed from 2,4-diisopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.20 g, 0.5 mmol) and cyclopentylamine (0.09 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 609, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 0%-25% methyl terr-butyl ether in hexane at a flow rate of 50 mL/min, to Nford N-cyclopentyl-2,4-diisopropyl-5-(phenylsulfonyl)benzenesulfonamide (0.17 g, 76%), as a homogeneous, colorless, crystNline solid, m.p. 179-181 °C; MS (+ESI), m/z: 450 [M+H]+; MS (-ESI), m/z: 448 [MNH]'; HPLC purity 100% at 210-370 nm, 10.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 614: 2,4-Diisopropyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide The title compound was prepNed from 2,4-diisopropy 1-5- (phenylsulfonyl)benzenesulfonyl chloride (0.20 g, 0.5 mmol) and 2-(pyridin-2-yl)ethylamine (0.12 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 609, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%-100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to Nford 2,4-diisopropyI-5-(phenvlsulfonylV N"-(2-pyridin-2-ylethyl)benzenesulfonamide(0.21 g, 84%), as a homogeneous, colorless, crystNline solid, m.p. 189-191 °C; MS (+ESI), m/z: 487 [M+Hf; MS (-ESI), m/z: 485 [M-H]'; HPLC purity 100% at 210-370 nm, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 615: N-[3-(nMniidazol-l-yJ)propyl]-2,4-diisopropyl-5-(phenylsxilfonyl)beiizenesulfonamide The title compound was prepNed from 2,4-diisopropyl-5-(phenylsulfonyl)benxenesulfonyl chloride (0.20 g, 0.5 mmol) and 3~(IH-imidazol-1- yl)propylamine (0.13 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 609, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 0%-4% methanol in dichloromethane at a flow rate of 50 mL/min, to Nford N-[3-(1 ff-imidazol-1 -yDpropyl]-2,4-diisopropyl-5-(phenylsulfonyl)ben2enesulfonamide (0.07 g, 27%), as a homogeneous, colorless, crystNline solid, m.p. 203-205 °C; MS (-ESI), m/z: 488.2 [M-H]'; HPLC purity 100% at 210-370 nm, 8.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 616: 2,4-Diisopropyl-5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)benzenesulfonamide The title compound was prepNed from 2,4-diisopropyl-S- (phenylsulfonyl)benzenesulfonyl chloride (0.20 g, 0.5 mrnol) and 2-(pyridin-3-yl)ethylamine (0.12 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 609, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%-100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to Nford 2,4-diisopropyl-5-(phenylsulfonyl')-N-(2-pyridin-3-ylethynbenzenesulfonamide (0.15 g, 60%), as a homogeneous, colorless, crystNline solid, m.p. 163-165 °C; MS (-ESI), m/z: 485.2 [M-H]'; HPLC purity 100% at 210-370 nm, 9.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 617: 2,4-Diisopropyl-5-(phenylsulfonyl)-N-(2-pyridin-4-ylethyl)benzenesulfonamide The title compound was prepNed from 2,4-diisopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.20 g, 0.5 mmol) and 2-(pyridin-4-yl)ethylamine (0.12 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 609, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage13 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%-100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to Nford 2,4-diisopropyl-_5-(phenylsulfonylV N-(2-pyridm-4-ylethyl)benzenesulfonamide (0.12 g, 49%), as a homogeneous, colorless, crystNline solid, m.p. 178-180 °C; MS(-ESI),w/z:485.1[M-FiT; HPLC purity 100% at 210-370 nm, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 618: N-(2,3-Dihydro-lH-inden-2-yl)-2,4-diisopropyl-5-(phenylsulfonyl)benzcnesulfonamide The title compound was prepNed from 2,4-diisopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.20 g, 0.5 mmol) and indan-2-ylamine (0.13 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 609, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 0%-25% methyl terf-butyl ether in hexane at a flow rate of 50 mL/min, to Nford N-(2,3-dihydro-1 /f-inden-2-y 1 N-2.4-diisopropvl-5-(phenvlsulfonyr)bergenesulfonamide (0.22 g, 90%), as a homogeneous, colorless, crystNline solid,m.p.215-217°C; MS (-ESI), m/z: 496.1 [M-FTf; HPLC purity 100% at 210-370 nm, 11.0 min.; Xterra RP18, 3.5u, 150x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN-t-MeOH) for lOmin, hold 4min. Example 619: 5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyl-N-(2-phenylethyl)benzenesulfouamide Step a) l-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropylbenzene A stirred solution of 1,3-diisopropylbenzene (16.25 g, 100 mmol) and 4-fluorobenzenesulfonyl chloride (9.73 g, 50 mmol) was cooled to -20 °C and treated slowly under nitrogen with solid anhydrous Numinum chloride (8.0 g, 60 mmol). Nter stirring neat for 4 hours at room temperature, the mixture was poured slowly into ice water and extracted with ethyl acetate (2x). The organic phase was washed with a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and filtered through a short column of silica gel. The filtrate was evaporated in vacua to yield-a crude oil. The crude oil was purified by prepNatNe liquid chromatography on a BiotagelS> 40 Mi column of pre-packed silica gel (90 g) (multiple runs), eluting with a gradient of 0%-25% methyl tert-bntyl ether in hexane at a flow rate of 50 mL/niin, to Nford l-[(4-fluorophenvl)sulfonyl]-2.4-diisopropvlbenzene (9.71 g, 60%), as a cleN oil which crystNlized on standing to a homogeneous, amorphous solid, m.p. 75-80 °C; MS (El), m/z: 320 [M']+; HRMS: cNcd for Ci8H2iFO2S, 320.12463; found (ESI, M+.), 320.1237; HPLC purity 100% at 210-370 nm, 10.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold4min. Step b) 5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropylbenzenesulfonyl chloride l-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropylbenzene (3.20 g, 10 mmol) was heated with stirring at 60 °C for 30 minutes under nitrogen with chlorosulfonic acid (6.7 mL, 11.7 g, 100 mmol). The mixture was cooled to room temperature, poured slowly into a cold solution of IN hydrochloric acid, and extracted with ethyl acetate (2x). The organic phase was washed with a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the solvent concentrated in vacua io a crude oil. The crude oil was crystNlized from diethyl ether-hexane to Nford 5-[(4-fluorophenvl')sulfonvl]-2,4-diisopropvlbenzenesulfonyl chloride (3.11 g, 74%) as a colorless, crystNline solid, which was utilized in subsequent reactions. Step c) 5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyl-N-(2-phenylethyl)benzenesulfonamide A stirred solution of 5-[(4-fluorophenyi)sulfonyl]-2,4- diisopropylbenzenesulfonyl chloride (0.21 g, 0.5 mmol) in dichloromethane (10 mL) was treated dropwise under nitrogen with a solution of phenethylamine (0.12 g, 1.0 mmol) in dichloromethane. Nter stirring for one hour at room temperature or until the reaction was complete, the mixture was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 0%-25% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min. Nter evaporation of the solvent under vacuum, the title compound, 5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropyl-N-f2-phenylethyl)benzenesulfonamide r$ (0.24 g, 95%), was obtained as a homogeneous, colorless, crystNline solid, m.p. 154-156 °C; MS (-ESI), m/z: 502 [M-H]'; HPLC purity 100% at 210-370 nm, 10.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3,5/ACN+MeOH) for 1 Omin, hold 4min. • Example 620: 5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyl-N-(tetrahydro-2j|y-pyran-4-yl)benzenesulfonamide The title compound was prepNed from 5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropylbenzenesulfonyl chloride (0.32 g, 0.75 mmol) and tetrahydro-pyran-4-ylamine (0.15 g, 1.5 mmol) according to the procedure and in the same manner as described in Example 619, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 30%-70% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to Nford 5-[(4-fluorophenyl')sulfonyl]-2,4-diisopropyl-Ntetrahydro-2#-pvran-4-vnbenzenesulfonamide (0.31 g, 86%), as a homogeneous, colorless, crystNline solid, m.p. 183-186 °C; MS (-ESI), m/z: 481.8 [M-H]'; HPLC purity 100% at 210-370 nm, 10.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 621: AT-Cyclopentyl-5-[(4-fluorophenyl)sulfonyll-2,4-diisopropylbenzenesulfonamide ' The title compound was prepNed from 5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropylbenzenesulfonyl chloride (0.21 g, 0.5 mmol) and cyclopentylamine (0.09 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 619, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 0%-25% methyl terf-butyl ether in hexane at a flow rate of 50 mL/min, to Nford N-cyclopentyl-5- [(4-fluorophenyl')sulfonvl] -2.4-diisopropylbenzenesulfonamide (0.20 g, 85%), as a homogeneous, colorless, crystNline solid, m.p. 202-205 °C; MS (-ESI), m/z: 465.7 [M-H]"; HPLC purity 100% at 210-370 nm, 10.8 min.; Xterra RP18, 3.5u, 150x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 622: 2-chloro-5-[(4-iluorophenyl)sulfonyl]-N-(tetrahydro-2Jt/-pyran-4-' yl)benzenesulfonamide Step 1: Following the same procedure described in Example 474 (Step 3), 4-fluorobenzene sulfonyl chloride was used to prepNe 4-fluorobenzenesulfonyl fluoride. Step 2: Following the same procedure described in Example 474 (Step 4), 5-bromo-2-chloro-N-(tetrahydro-2N-pyran-4-yl)benzenesulfonamide and 4-fluorobenzene sulfonyl fluoride were used to prepNe 2-chloro-5-[(4-fluorophenyl\sulfonvl]-N-(tetrahydro-2/jr-pyran-4-vDbenzenesulfonamide. MS (ES) m/z 432.0. Example 623: tert-butyl 4-({[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-1-cNboxylate .; In an anNogous manner to Example 334, »I Step 3: 4-aminopiperidine-l- carboxylic acid tert-butyl ester was used to prepNe ferN-butyl4-(|f2-chloro-5-(phenvlsulfonynphenyl]sulfonvl)NninoNpiperidine-l-cNboxylate. MS (ES) m/z 513.1. Example 624: 2-chloro-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide tert-butyl 4-( {[2-chloro-5-(pheny lsulfonyl)phenyl] sulfonyl} amino)piperidine-1 -cNboxylate (0.65 g, 1.26 mmol) was stirred in HC14 M in dioxane (5 mL) for 1 hr. The mixture was neutrNized with a saturated aqueous sodium bicNbonate solution and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, filtered, and concentrated to gNe 2-chloro-5-(phenylsulfonylVN-piperidin-4-ylbenzenesulfonamide (0.37 g, 70%). MS (ES) m/z 412.9. Example 625: tert-butyl 4-[4-({4-isopropyl-3-[(tetrahydro-2fl-pyran-4-ylamino)sulfonyl]phenyl}sulfonyl)phenyl]piperazme-l-cNboxylate In an anNogous manner to Example 547, 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-Ntetrahydro-2J7-pyran~4~ylbenzenesulfonamide, piperazine-1 -carboxylic acid tert-butyl ester, and dimethylacetamide as solvent were used to prepNe tert-butyl 4-[4-({4-isopropyl-3-|'(terrahYdrO"2H-pyran-4-vlamino)sulfonvl1phenyl)sulfonvl)phenvl]piperazine-l-cNboxvlate. MS (ESI +) m/z 608; HPLC purity 97.2% at 210-370 nm, 10.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 nxL/min, 85/15-5/95 (Ammon, Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min, Example 626: 5-({4-cw-3,5-dimethylpiperazin-l-ylphenyl}sulfonyl)-2-isopropyI-N-(tetrahydro-2#-pyran-4-yl)benzenesulfonamide In an anNogous manner to Example 547, 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-AM:etrahydro-2H-pyran-4-ylbenzenesulfonamide, cw-2,6-dimethylpiperazine, and dimethylacetamide as solvent were used to prepNe 5-((4-cis-3,5-dimethylpiperazin-1 -ylphenyUsulfonyn-2-isopropyl-N-(tetrahydro-2H-pyran-4-ynbenzenesulfonamide. MS (ESI +) m/z 536; HPLC purity 100% at 210-370 nm, 7.2 min.; XteiTa KP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 627: 5-({4-fra«s-2,5-dimethylpiperazin-l-ylphenyl}sulfonyl)-2-isopropyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide In an anNogous manner to Example 547, 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-tetrahydro-2N-pyran-4-ylbenzenesulfonamide, cw-2,6-dimethylpiperazine, and dimethylacetamide as solvent were used to prepNe 5-((4-trans-2.5-dimethvlpiperazin-l -ylphenyl>sulfonylV2-isopropyl-N-(tetohydro-2H-pyran-4-yl>)berizenesulfonamide. MS (ESI +) m/z 536; HPLC purity 100% at 210-370 nm, 7.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 628: 2-isopropyl-5-[(4-piperazin-l-ylphenyl)sulfonyl]-A?-(tetrahydro-2Jr-pyran-4-yl)benzenesulfonamide To a stirred slurry of tert-butyl 4-[4-({4-isopropyl-3-[(tetrahydro-2H-pyran-4-ylamino)sulfonyl]phenyl}sulfonyl) phenyl]piperazine-l-cNboxylate (50 mg, 0.08 mmol) in anhydrous tetrahydrofuran (1 mL) was added a 2.0 M HC1 solution in tetrahydrofuran (0.5 mL). Nter 16 hours the stNting materiN was still present and an additionN 0.5 mL of the HC1 solution was added and the slurry was stirred at room temperature for an additionN 12 h where upon a predominately single product was observed. An aqueous solution of 2 M HC1 was added and the aqueous phase was extracted with ethyl acetate (2 x 1 mL). The aqueous phase was then neutrNized with a saturated aqueous solution of sodium bicNbonate until it was basic as determined by pH strip. The aqueous phase was then extracted with ethyl acetate (3 x 1 mL) and the combined organic phases were dried (MgSOi), filtered and concentrated to Nford 2N isoprQpyl-5-[(4-pipera2in-l-ylphenyl)sulfonyl]-N-(tetrahydro-2H-pvran-4- vDbenzenesulfonamide (31 mg, 75 %). MS (ES-)?w/z 506.1; HPLC purity 100% at 210-370 nm, 6.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 629: 5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyI-N-(tetrahydro-2Jff-pyran-4-ylmethyl)benzenesulfonamide The title compound was prepNed from 5-[(4-fluorophenyl)sulfonyl]-2,4- diisopropylbenzenesulfonyl chloride (0.21 g, 0.5 mmol) and (tetrahydro-pyran-4-yl)methylamine (0.12 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 619, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 30%-70% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to Nford 5-[r4-fluorophenyl)sulfonyl]-2.4-diisopropyl-N'-(teljahydro-2Jy-pvran-4-vlmemyl)benzenesulfonamide (0.22 g, 87%), as a homogeneous, colorless, crystNline solid, m.p. 200-202 °C; MS (-ESI), m/r. 496.1 [M-H]'; HPLC purity 100% at210-370nm; 10.1 min.; Xterra RP18, 3.5u, 150x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 630: 5-[(4-F(uorophenyl)sulfonylJ-2,4-diisopropyl-Nr-[2-(tetrahydro-2iy-pyran-4-yl)ethyl]benzenesulfonamide The title compound was prepNed from 5-[(4-fluorophenyl)sulfonyl]-2,4- diisopropylbenzenesulfonyl chloride (0.21 g, 0.5 mmol) and 2-(tetrahydro-pyran-4-yl)ethylamine (0.13 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 619, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 30%-70% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to Nford 5-[(4-fluorophenYl)su.lfonyl]-2,4-diisQprppyl-N-[2-(tetrahydro-2N-pyran-4-yl)ethyt]benzenes.ulfonamide (0.18 g, 69%), as a homogeneous, colorless, crystNline solid, m.p. 141-143 °C; MS (-ESI), m/z: 510.2 [M-H]'; HPLC purity 100% at 210-370 nm, 10.2min.;XterrNP18,3.5u, 150x4,6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 631: 5-[(4-FIuorophenyl)sulfonyl]-2,4-diisopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide The title compound was prepNed from 5-[(4-fluorophenyI)suifonyl]-2,4-diisopropylbenzenesulfonyl chloride (0.21 g, 0.5 mmol) and 2-(pyridin-2-yl)ethylamine (0.12 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 619, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%-100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to Nford 5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropvl-M-(2-pyridin-2-ylethynben2enesulfonamide (0.22 g, 86%), as a homogeneous, colorless, crystNline solid, m.p. 159-161 °C; MS (-ESI), m/z: 503.1 [M-H]'; HPLC purity 100% at 210-370 nm, 10.0 man.; XterrNPIS, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. Example 632: 5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyWV-(2-pyridin-3-ylethyl)benzenesulfonamide The title compound was prepNed from 5-[(4-fluorophenyl)suIfonyl]-2,4-diisopropylbenzenesulfonyl chloride (0.21 g, 0.5 mmol) and 2-(pyridin-3-yl)ethylamine (0.12 g, 1.0 mmol) according to the procedure and in the same manner described in Example 619, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%-100% methyl tert-butyl. ether in hexane at a flow rate of 50 mL/min, to Nford 5-[('4-fluorophenyl')sulfonyl]-2.4-diisopropyl-N-f2-pyridin-3-y]ethvl')ben2enesulfonamide (0.18 g, 71%), as a homogeneous, colorless, crystNline solid, m.p. 148-150 °C; MS (-ESI), m/z: 503.1 [M-H]"; HPLC purity 100% at 210-370 nm, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold4min. Example 633: 5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyl-N-(2-pyridin-4-ylethy l)b enzenesulfonamid e The title compound was prepNed from 5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropylbenzenesulfonyl chloride (0.21 g, 0.5 mmol) and 2-(pyridin-4-yl)ethylamine (0.12 g, 1.0 mmol) according to the procedure and in the same manner described in Example 619, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50°/o-100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to Nford 5-rr4-fluorophenvl)sulfonyl1-2.4-diisopropvl-N-N-pyridinN-vlethyDbenzenesulfonamide (0.14 g, 55%), as a homogeneous, colorless, crystNline solid, m.p. 210-21I °C; MS (-ESI), m/z: 503.1 [M-HT; HPLC purity 100% at 210-370 nm, 9.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 634: Nr-(2N-Dihydro-lflT-mden-2-yl)-5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropylbenzenesulfonamide )«j' / ' The title compound was prepNed from 5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropylbenzenesulfonyl chloride (0.21 g, 0.5 mmol) and indan-2-ylamine (0.13 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 619, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 0%-25% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to Nford N-(2.3-dihvdro-l/jr-inden-2-yl)-5-r('4-fluorophenyl')sulfonyl1-2.4-diisopropvlbenzenesulfonamide (0.23 g, 89%), as a homogeneous, colorless, crystNline solid, m.p. 202-204 °C; MS (-ESI), m/z: 514.1 [M-H]'; HPLC purity 100% at 210-370 nm, 11.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph-3.5/ACN+MeOH) for lOmin, hold 4min. Example 635: l-{[2-chloro-5-(phenylsulfony])phenyl]sulfonyl}-4-pyrrolidin-l-yIpiperidine In an anNogous manner to Example 334, Step 3: 4-pyrrolidin-l-yl-piperidIne was used to prepNe l-([2-chloro-5-(phenylsiilfonvl)phenyl]sulfonyll-4-pyrrolidin-l-Ylpiperidirie. MS (ESI) m/z 469. Example 636: 4-[2-(4-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyI}piperazin-l-yl)ethyl]morpholine In an anNogous manner to Example 334, Step 3: 4-(2-piperazin-l-ylethyl)-morpholine was used to prepNe 4-r2-(4-([2-chloro-5-(phenylsulfonyl)phenvl]sulfonvl|piperazin-l-vl)ethvl]mprpholine. MS (ESI) M/Z 514. Example 637: l-(l,3-benzodioxol-5-ylmethyl)-4-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}piperazine In an anNogous manner to Example 334, Step 3: l-benzo[l,3]dioxol-5-ylmethyl-piperazine was used to prepNe 1-(1,3-benzodioxol-5-ylmethvn-4-{[2-chloro-5-(phenvlsulfonynphenyl]sulfonvUpiperazine. MS (ESI) m/z 535. Example 638: terf-butyl (l-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}pyrrolidin-3-yl)cNbamate In an anNogous manner to Example 334, Step 3: pyrrolidin-3-yl-cNbamic acid tert-bntyl ester was used to prepNe rgrr-butyl(l-{[2-chloro-5-(phenylsulfonynphenyl]sulfonyUpyrrolidin-3-yncNbamate. MS(ESI)w/z501. Example 639: tert-butyl (l-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}piperidin-4-yl)cNbamate In an anNogous manner to Example 334, '] Step 3: piperidin-4-yl-cNbamic acid tert-butyl ester was used to prepNe tert-butyl n-([2-chloro-5-(phenylsulfonvI)phenyl]sulfonyl}piperidin-4-yl)cNbamate. MS(ESI)w/z515. Example 640: 2-chloro-5-(phenylsulfonyl)-]V-(2-pyri(lin-3-yIethyl)benzeuesulfonamide In an anNogous manner to Example 334, Step 3: 2-pyridin-3-yl-ethylamine was used to prepNe 2-chloro-5-(phenylsulfonylVN-(2-pyridin-3-vlethvl')benzenesulfonNnide. MS (ESI) m/z 437. Example 641: 2-chloro-5-(phenylsulfonyl)-N-(2-pyridin-4-ylethyl)benzenesulfonamide In an anNogous manner to Example 334, - Step 3: 2-pyridin-4-yl-ethylamine was used to prepNe 2-chloro-5-(phenylsulfonyn-N-('2-pyridin-4-ylethynbenzenesulfonamide. MS (ESI) m/z 437. Example 642: 2-chloro-N-[3-(4-methylpiperazin-l-yl)propyl]-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 334, Step 3: 3-(4-methylpiperazin-l-yl)-propylamine was used to prepNe 2-chloro-N-rS-N-methylpiperazin-l-yDpropylj-S-rphenvlsulfonynbenzenesulfonamide. MS (ESI) m/z 472. Example 643: 2-chloro-N-(2-cyanoethyl)-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 334, Step 3: 3-aminopropionitrile was used to prepNe 2-chloro-N-(2-cyanoethyl)-5-(phenylsulfonyDbenzenesulfonamide. MS (ESI) m/z 385. Example 644: l-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}-AyV-diethylpyrrolidin-3-amine In an anNogous manner to Example 334, Step 3: diethylpyrrolidin-3-yl-amine was used to prepNe l-{[2-chloro-5-(phenylsulfQnyl)phenyl]sulfonyl}-MNdiethylpyrrolidin-3-Nnine. MS (ESI) m/z 457. Example 645: ethyl l-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}piperidine-3-carboxylate In an anNogous manner to Example 334, Step 3: piperidine-3-carboxylic acid ethyl ester was used to prepNe ethyl l-([2-chloro-5-(phenylsulfQnynphenyl1sulfonyl)piperidine-3-cNboxvlate. MS (ESI) m/z 472. Example 646: 2-chloro-N-methyI-5-(phenylsulfonyl)-]V-(2-pyridin-2-ylethyl)benzenesulfonamide In an anNogous manner to Example 334, Step 3: methyl-(2-pyridin-2~yl-ethyl)-amine was used to prepNe 2-chloro-N-methyl-5-Cphenvlsulfonyn-N-(2-pyridin-2-ylethyl')benzenesulfQnamide. MS (ESI) w/z 451. Example 647: 2-chloro-5-(phenylsulfonyl)-N-[l-(trifluoroacetyl)piperidin-4-yl]benzenesulfonamide To a stirred solution of 2-chloro-5-(phenylsulfonyl)-N-piperidin-4- ylbenzenesulfonamide (0.09 g, 0.22 mmol) in dichloromethane (2 mL) was added triethylamine (0.1 mL, 0.72 mmol) and trifluoroacetic anhydride (0.09 g, 0.42 mmol). The resulting solution was stirred for 1 hr and concentrated. The crude mixture was flash column sepNated using 10-50% ethyl acetate/ hexane to gNe 2-chloro-5-('phenylsulfonvn-N-[l-(trifluoroacetyl)piperidin-4-yljbenzenesulfonamide (0.04 g, 36%). MS (ESI) m/z 511. Example 648: 2-chloro-N-[l-(2,2-dimethylpropanoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 647, trimethylacetyl chloride was used to prepNe 2-chloro-N- [ 1 -(2.2-dimethylpropanoy l)piperidin-4-yl1-5-(phenylsulfonyl)benzenesulfonamide. MS (ESI) m/z 499. Example 649: N-(te (phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-cNboxamide In an anNogous manner to Example 647, tert-butyl isocyanate was used to prepNe N-(tert-butyl)-4-( {r2-chloro-5-(phenvlsulfonyl)phenyl]sulfonvl} amino)piperidine-1 -cNboxamide. MS(ESI)»?/z512. Example 650: 2-chloro-N-[l-(morphoIin-4-ylcNbonyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 647, morpholine-4-cNbonyl chloride was used to prepNe 2-chloro-N-fl-(morpholin-4-vlcNbonyl')piperidin-4-vl]-5-(phenylsulfonvl)benzenesulfonamide. MS (ESI) m/z 528. Example 651: 2-chloro-N-(l-cyanopiperidin-4-yl)-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 647, cyanogens bromide was used to prepNe 2-ch\OTO-N-( 1 -cvanopiperidinN-yD-S-Cphenylsulfonvnbenzenesulfonamide. MS (ESI) m/z 440. Example 652: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[2-(l-oxidopyridin-3-yl)ethyl|benzenesulfonamide 100 mg of 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-3- ylethyl)benzenesulfonamide was added to 4 mL of 50% hydrogen peroxide/acetic acid and the reaction was heated at 100 °C for four hours. The reaction was poured onto saturated bicNbonate solution and extracted with dichloromethane. The organic layer was washed with sodium dithionite solution. The organic layer was dried with magnesium sulfate and concentrated. Crude materiN was purified by flash chromatography using 10% methanol/dichloromethane to gNe 5-[f4-fluorophenyl')sulfonyl]-2-isopropvl-N-f2-( 1 -oxidopyridin-S- vDethyllbenzenesulfonamide. MS (ES+) m/z 479 MS (ES-) m/z 477. Example 653: l-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}-4-[(2,5-dimethyl-ljPT-pyrrol-l-yl)methyl]piperidine In an anNogous manner to Example 647,4-(2,5-dimethylpyrrol-l -ylmethyl)-piperidine was used to prepNe l-lp-chloro-S-fphenylsulfonvDphenvllsulfonvUN-rN.S-dimethyl-1H-pyrrol-l-vl)methyl]piperidine. MS (ES) m/z 507.0. Example 654: methyl N-{p-chloro-SNphenylsulfonyOphenylJsulfonylJ-Z-methylNaninate To a stirred solution of methyl Npha-aminoisobutyrate hydrochloride (1.3 g, 8.53 mmol) in a saturated aqueous sodium bicNbonate solution was added 5-benzenesulfonyl-2-chlorobenzenesulfonyl chloride (1.5 g, 4.27 mmol) dissolved in acetonitrile (10 mL). The resulting solution was stirred vigorously 1 hr and extracted severN times with ethyl acetate. The combined organic layers were washed with ammonium chloride solution and concentrated. Flash column sepNation using 10-50% ethyl acetate /hexane gave methyl N-ir2-chloro-5-(phenylsulfonvDphenvl]sulfonvl} -2-methylNaninate (0.96 g, 52%) MS (ESI) m/z 432. Example 655: 2-chloro-N-(2-hydroxy-l,l-dimethylethyl)-5-(phenylsulfonyl)benzenesulfonamide * To a stirred solution of methyl N- {[2-chloro-5- (phenylsulfonyl)phenyl]sulfonyl}-2-methylNaninate (1.20 g, 2.78 mmol) in THF (16 mL) at -78 °C was added diisobutylNuminum hydride 1.0 M in toluene (16.0 mL, 16.0 mmol) dropwise over 10 minutes. The resulting solution was stirred for 6 hours at -78°C, quenched with 0.5 M HC1 solution and extracted severN times with ethyl acetate. The combined organic layer was dried over magnesium sulfate, and concentrated to gNe 2-chloro-N-(2~hydroxy-l,l-dimethylethyl)-5-(phenylsulfonyl)benzenesulfonamide (0.64 g, 57%). MS (ES-) m/z 402.0; HPLC purity 100% at 210-370 nm, 8.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph-3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C16H18C1NO5S2 + H+, 404.03877; found (ESI, [M+H]+), 404.0384. Example 656: 2-chloro-N-[l-(4-fluorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)benr/enesulfonamide J In an anNogous manner to example 462,2-chloro-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and 4-fluorobenzoyl chloride were used to prepNe 2-chloro-N-[l-(4-fluorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide. MS (ES-) m/z 534.9; HPLC purity 100% at 210-370 nm, 9.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mrn column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C24H22C1FN2O5S2 + H+, 537.07154; found (ESI, [M+H]+), 537.0699. Example 657: 2-chloro-N-[l-(4-cyanobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to example 462,2-chloro~5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide and 4-cyanobenzoyl chloride were used to prepNe 2-chloro-N-[l-(4-cyanobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide. MS (ES-) m/z 541.9; HPLC purity 100% at 210-370 nm, 8.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C25H22C1N3O5S2 + H+, 544.07622; found (ESI, [M+Fff), 544.075. Example 658: 2-chloro-5-(phenylsulfonyl)-NV-{l-[4-(trifluoromethyl)benzoyl]piperidin-4-yljbenzenesulfonamide In an anNogous manner to example 462,2-chloro-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and 4-trifluoromethylbenzoyl chloride were used to prepNe 2-cUoro-5-(phenylsulfonyl)-N-{l-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}ben2enesulfonamide. MS (ES-) m/z 584.9; HPLC purity 94.5% at 210-370 run, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 660: 5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)-2-(trifluoromethoxy)benzenesulfonamide Step 1: l-bromo-4-trifluoromethoxybenzene (0.50 g, 2.07 mniol) was added to chlorosulfonic acid (2 mL, 29.0 mmol) at room temperature. The resulting mixture was stirred 2 hours, poured over ice, and extracted severN times with ethyl acetate. The combined organic layer was washed with water, dried over magnesium sulfate and concentrated to gNe 5-bromo-2-trifluoromethoxybenzene sulfonyl chloride (0.45 g, 64%) , Step 2: In an anNogous manner to example 435, 5-bromo-2- trifluoromethoxybenzene sulfonyl chloride and 3-(2-aminoethyl)pyridine were used to prepNe 5-bromo-N-(2-pyridin-3-ylethyl)-2-(trifluoromethoxy)benzenesulfonamide. Step 3: Following the same procedure described on example 474 (Step 4), 5-bromo-N-(2-pyridin-3-ylethyl)-2-(trifluoromethoxy)benzenesulfonamide and benzene sulfonyl fluoride were used to prepNe 5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)-2-(trifluoromethoxy)benzenesulfonamide. MS (ES-)m/z 485.0; HPLC purity 92.5% at 210-370 nm, 8.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C2oHi7F3N2O5S2 + H+, 487.06037; found (ESI, [M+H]*), 487.0615. Example 662: 5-(phenylsulfonyl)-AKtetrahydro-2H-pyran-4-yl)-2-(trifluoromethoxy)benzenesulfonamide In an anNogous manner to Example 660, Step 2: 5-bromo-2-trifluoromethoxybenzene sulfonyl chloride and tetrahydro-pyran-4-ylamine was used to prepNe 5-bromo~W-(tetrahydro-2H-pyran-4-yl)-2-(trifluoromethoxy)benzenesulfonamide ' Step 3: 5-bromo-AHtetrahydro-2H-pyran-4-yl)-2- (trifluoromethoxy)benzenesulfonamide and benzene sulfonyl fluoride were used to prepNe 5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-2-(1xifluoromethoxy)berizenesuhcbnamide. MS (ES-) m/z 464.0; HPLC purity 95.2% at 210-370 nm, 8.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C18H18F3N06S2 + H+, 466.06004; found (ESI, [M+H]+), 466.0606. Example 663: 2-chloro-N-(cya0omethyl)-5-(pheny]sulfonyl)benzenesulfonaniide In an anNogous manner to example 654. 2-chloro-5-(phenylsulfonyl)-benzenesulfonyl chloride and aminoacetonitrile HC1 were used to prepNe 2-chloio-N-(cyanomethyl)-5-(phenylsulfonyl)benzenesulfonamide. MS (ES-) m/z 369.0; HPLC purity 88.5% at 210-370 nm, 7.9 min.; Xterra RP1 8, 3.5u, 150 x 4.6 mm column, 1 .2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 664: N-(2-cyanoethyl)-5-[(4-fluorophenyI)suIibnyI]-2-isopropylbenzenesulfonamide In an anNogous manner to example 435, 5-(4-fluoro-benzenesulfonyl)-2-isopropyl-benzenesulfonyl chloride and aminopropionitrile were used to prepNe N-(2-cyanoethyl)-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide. MS (ES-)»i/z 409.1; HPLC purity 99.0% at 210-370 nm, 8.8 min.; Xterra RP1 8, 3.5u, 1 50 x 4.6 mm column, 1 .2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CigHiNNaCN + H+, 41 1 .08430; found (ESI, [M+H]+), 41 1 .0841 . Example 665: 2-methyl-AK3-oxo-3-pyrrolidra-l-ylpropyl)-5-(phenylsulfonyl)benzenesulfonamide To a solution of methyl N-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-beta-Naninate (1.3 g, 3.3 mmol) in water (10 mL) and tetrahydrofuran (10 mL) was added lithium hydroxide monohydrate (0.67 g, 16 mmol). The resulting mixture was stirred overnight at room temperature. The mixture was then washed with ether and the organic phase was discNded. The aqueous phase was treated with 4 N HC1 to pH 1 and then extracted with ethyl acetate. The ethyl acetate extract was dried (MgSCU), filtered, and concentrated to provide the desired 3-(5-benzenesulfonyl-2-methyl-benzenesulfonylamino)-propionic acid (1.2 g, 3.1 mmol). The 3-(5-benzenesulfonyl-2-methyl-benzenesulfonylamino)-propionic acid (1.2 g, 3.1 mmol) was dissolved in dichloromethane (40 mL) containing dimethylformamide (3 drops) and then treated with oxNyl chloride (1 .0 mL, 1 1 mmol). The resulting solution was stirred at room temperature for 2 h and then concentrated to dryness. The crude 3-(5-benzenesulfonyl-2-methyl-benzenesulfonylamino)-propionyl chloride was dissolved in dichloromethane and used without further purification. To a solution of crude 3-(5-benzenesulfonyl-2-methyl-benzenesulfonylamino)-propionyl chloride (0.10 g, 0.25 mmol) in dichloromethane (1 mL) was added pyrrolidine (22 mg, 0.3 1 mmol) and triethylamine (55 pL, 0.39 mmol). The resulting solution was stirred overnight at ambient temperature, and then diluted with ethyl acetate and washed with saturated aqueous ammonium chloride, sodium bicNbonate, and brine. The organic phase was dried (M8SO4), concentrated, and purified by flash column chromatography to SP provide 2-methyl-.N-(3-oxo-3-pyrrolidm- 1 -ylpropyl)-5-(phenylsulfonyl)benzenesulfonamide (48 MS (ES+)m/z 437.1; HPLC purity 91.3% at 210-370 nm, 8.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold4min. Example 666: N-( Naninamide In an anNogous manner to Example 665, crude 3-(5-benzenesulfonyl-2-methyl~ benzenesulfonylamino)-propionyl chloride (0.10 g, 0.25 mmol), ?-butylamine (23 mg, 0.31 mmol) and triethylamine (55 uL, 0.39 mmol) in dichloromethane (1 mL) were used to prepNe N'-(NeNbutyl)-N3-{[2-me1iiyl-5-(phenylsulfonyl)phenyl]sulfonyl}-p-Naninamide(2l mg). MS (ES+)m/z 439.1; HPLC purity 86.3% at 210-370 nm, 8.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 667: N3-{[2-methyl-5-(phenyIsulfonyl)phenyl]suIfonyl}-N-(l,2,3,4-tetrahydronaphthNen-l-yl)-p~Naninamide In an anNogous manner to Example 665, crude 3-(5-benzenesulfonyl-2-methyl~ benzenesulfonylamino)-propionyl chloride (0.10 g, 0.25 mmol), 1,2,3,4-tetrahydro-l-naphthylamine (46 mg, 0.31 mmol) and triethylamine (55 uL, 0.39 mmol) in dichloromethane (1 mL) were used to prepNe N3-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-N'-(l,2,3,4-tetrahydi-onaphthNen-l-yl)-p-Naninamide (63 mg). MS(ES-)w/2r511.0; HPLC purity 87.0% at 210-370 nm, 9.7 min.; Xterra RP1S, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 668: N-methyl-Nr3-{[2-methyl-5-(phenylsulfoayl)phenyl]sulfonyl}-vV-phenyl-p-Naninamide In an anNogous manner to Example 665, crude 3-(5-benzenesulfonyl-2-methyl-benzenesulfonylamino)-propionyl chloride (0.10 g, 0.25 mmol), N-methylaniline (34 mg, 0.31 mmol) and triethylamine (55 jiL, 0.39 mmol) in dichloromethane (1 mL) were used to prepNe N'-methyl-N3-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-N:-phenyl-(3-Naninamide(34mg). MS (ES+)m/z 473.1; HPLC purity 82.7% at 210-370 ran, 8.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1 .2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 669: 2-methyl-N:-[3-(6-methyl-3,4-dihydroquinolin-l(2H)-yl)-3-oxopropyl]-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Example 665, crude 3-(5-benzenesulfonyl-2-methyl-benzenesulfonylamino)-propionyl chloride (0.10 g, 0.25 mmol), 6-methyl-l,2,3,4-tetrahydroquinoline (46 mg, 0.31 mmol) and triethylamine (55 uL, 0.39 mmol) in dichloromethane (1 mL) were used to prepNe 2-methyl-N-[3-(6-methyl-3,4-dihydroquinolin-l(2H)-yl)-3-oxopropyl]-5-(phenylsulfonyl)benzenesulfonamide (29 mg). MS(ES+)m/z513.1; HPLC purity 91.0% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 670: 2-isopropyl-5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide In an anNogous manner to Step 3, Example 295: 5-Benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride and tetrahydro-pyran-4-ylamine were used to prepNe 2-isopropyl-5-(phenylsulfonyl)-N-(tetrahydro-2jy-pyran-4-yl)benzenesulfonamide MS (ES-)m/z 422.1; HPLC purity 99.5% at 210-370 nm, 8.9 min.; Xterra RP1 8, 3.5u, 150 x 4.6 mm column, 1 .2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CioFLsNOsS, + H+, 424.12469; found (ESI, [M+H]+), 424.127. Example 671 : 2-isopropyl-5-(phenylsulfonyl)-N:-(2-pyridiu-2-ylethyl)benzenesulfonamide In an anNogous mNiner to Step 3, Example 295: 5-Benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride and 2-pyridin-2-yl-ethylaniine were used to prepNe 2-isopropyl-5-(phen}'lsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide. MS (ES+) m/z 445.0; HPLC purity 99.5% at 210-370 nm, 9.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold4min. HRMS: cNcd for C22H24N2O4S2 + H+, 445.12502; found (ESI, [M+H]+), 445.1251. Example 672: 2-isopropyl-5-(phenylsulfonyl)-N-(2-pyridin-3-ylcthyl)benzenesulfonamide In an anNogous manner to Step 3, Example 295: 5-Benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride and 2-pyridin-3-yl-ethylamine were used to prepNe 2-isopropyl-5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)benzenesulfonamide. MS (ES+) m/z 445.0; HPLC purity 99.6% at 210-370 nm, 8.6 min.; Xterra RP18,3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 673: 2-chloro-N-(2-hydroxyethyl)-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to example 654,2-chloro-5-(phenylsulfonyl)- benzenesulfonyl chloride and ethanolamine were used to prepNe 2-chloro-N'-(2-hydroxyethyl)-5-(phenylsulfonyl)benzenesulfonamide. MS (ES-) m/z 373.9; HPLC purity 99.6% at 210-370 nm, 7.2 min.; Xterra RP 18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for Ci4Hi4ClNO5S2 + H+, 376.00747; found (ESI, |M+H]+), 376.0079. Example 674: 2-chloror/V-(2-hydroxy-l-methylethyl)-5-(phenylsulfonyl)benzenesulfonamidc In an anNogous manner to example 654, 2-chloro-5-(phenylsulfonyl)-benzenesulfonyl chloride and Nanol were used to prepNe 2-chloro-N-(2-hydroxy-l-methylethyl)-5-(phenylsulfonyl)benzenesulfonamide. MS (ES-) m/'z 388.0; HPLC purity 96.9%' at 210-370 nm, 7.6 min.; Xterra RP1 8, 3.5u, 150 x 4.6 mm column, 1 .2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CisHieClNOsSa + H+, 390.02312; found (ESI-FTMS, JM+H]1+), 390.02353. Example 675: 2-chIoro-A42-hydroxy-l-(hydroxymethyl)ethyI]-5-(phenylsulfonyl)benzenesulfonamide , In an anNogous manner to example 654, 2-chloro-5-(phenylsulfonyl)-benzenesulfonyl chloride and serinol were used to prepNe 2-chloro-N-[2-hydroxy-l-(hydroxymethyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide. MS (ES-) m/z 403.9; HPLC purity 95.9% at 210-370 nm, 6.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CisHieClNOeSa + H+, 406.01803; found (ESI-FTMS, [M+H]l+), 406.01897. Example 676: 2-chloro-N-[(lN*,lff*)-2-hydroxy-l-methyl-2-phenylethyI]-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to example 654, 2-chloro-5-(phenylsulfonyl)-benzenesulfonyl chloride and norephedrine were used to prepNe 2-chloro-N"-[(l/?*,2N?*)-2-hydroxy-l-methyl-2-phenylethyl]-5-(phenylsulfonyl)benzenesulfonamide. MS (ES-)m/z 463.9; HPLC purity 100% at 2 10-3 70 nm, 9.0 min.; Xterra RP18, 3.5u, 1 50 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C2iH2oClNO5S2 + Na+, 488.03636; found (ESI-FTMS, [M+Na]1*), 488.0366. Example 677: 5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)-2-(trifluoromethyl)benzenesulfonNaide Step 1: To a stirred solution of Numinum chloride (9.56 g, 71.7 mmol) in benzene (30 mL) was added 4-chloro-3-nitrobenzenesulfonyl chloride (15.3 g, 59.75 mmol). The resulting mixture was stirred overnight at room temperature, poured over ice, and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and concentrated to gNe 5-(phenyIsulfonyl)-2-chloro-mtrobenzene. (14.9 g, 84%). Step 2: To a stirred solution of 5-(phenylsulfonyl)-2-chloro-nitrobenzene (13.8g, 41.66 mmol) in dimethylacetamide (85 mL) was added copper powder (15,9 g, 250 mmol), actNated chNcoN (6.9 g), and difluorodibromomethane (7.6 mL, 83.32 mmol). The resulting solution was stirred at 100°C for 3 hours. The mixture was Nlowed to cool to room temperature and filtered through celite with ethyl acetate. The filtrate was pNtitioned between ammonium chloride solution (sat) and ethyl acetate. The aqueous layer was extracted a second time with ethyl acetate. The combined organic layers were washed with water severN times, washed with brine, dried over magnesium sulfate and concentrated. Flash column sepNation using 0%-20% ethyl acetate/hexane gradient gave 5-(phenyIsu]fonyl)-2-trifluoromethyl-nitrobenzene (5.6 g, 41%). Step 3: To a stirred solution of 5~(phenylsulfonyl)-2-trifluoromethyl- nitrobenzene (4.14 g, 12.5 mmol) in methanol (90 mL) was added water (4 mL) and Tin (II) Chloride (11.85 g, 62.85 mmol). The resulting solution was heated to 70°C for 3 days. The solution was Nlowed to cool to room temperature and quenched with sodium bicNbonate solution (sat) and extracted severN times with ethyl acetate. The combined organic layer was washed with brine, dried over magnesium sulfate and concentrated to gNe 5-(phenylsulfonyl)-2-trifluoromethylaniline (3.6 g, 95%). Step 4: To a stirred solution of 5-(phenylsuIfonyl)-2-trifluoromethylaniline (3.6 g, 11.95 mmol) in acetonitrile (85 mL) at 0°C was added concentrated acetic acid (8.5 mL) and concentrated hydrochloric acid (8.5 mL). To this solution was added sodium nitrite (0.99 g, 14.34 mmol) dissolved in water (1.5 mL) in a dropwise fashion. The resulting solution was stirred for 20 minutes, followed by bubbling in sulfur dioxide over 10 minutes. Immediately upon completion of sulfur dioxide addition, copper (II) chloride dihydride (2.0 g, 12.0 mmol) dissolved in water (2 mL) was added Nl at once. The mixture was Nlowed to wNm to room temperature and stirred overnight. The reaction was diluted with water and extracted with ethyl acetate severN times. The combined organic layer was washed with ammonium chloride solution (sat.), water, and brine. The organic phase was dried over magnesium sulfate, and concentrated. Flash column sepNation using 10%-30% ethyl acetate/hexane gradient gave 2-trifluoromethyl-5-(phenylsulfonyl)~ benzenesulfonyl chloride (1.7 g, 37%). Step 5: Following the same procedure described on example 435, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and 3-(2-aminoethyl)pyridine were used to prepNe 5-(phenylsulfonyl)-N(2-pyridin-3-ylethyl)~2- (trifluoromethyl)benzenesulfonamide. MS(ES-)m/z468.9; HPLC pui-ity 100% at 210-370 nm, 8.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column., 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. FfRMS: cNcd for C2oHi7F3N2O4S2 + H+, 471.06546; found (ESI-FTMS, [M+H]1+), 471.06448. Example 678: l-Methoxy-4-(phenylsu!fonyl)benzene Step a A stirred solution of benzene (10 mL, 100 mmol) and 4-methoxybenzenesulfonyl chloride (4.12 g, 20 mmol) was cooled to -40 °C and treated slowly under nitrogen with solid anhydrous Numinum chloride (3.2 g, 24 mmol). Nter stirring neat for 4 hours at room temperature, the mixture was slowly poured into cold IN hydrochloric acid and extracted with ethyl acetate (2x). The organic phase was washed with a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and filtered through a short column of silica gel. The filtrate was evaporated in vacuo to yield l-methoxy-4-(phenylsulfonyl)benzene (4.96 g, 100%) as a homogeneous oil which solidified on standing. Step b 2-Methoxy-5-(phenylsulfonyl)benzenesulfonyl chloride l-methoxy-4-(phenylsulfonyl)benzene (4.96 g, 20 mmol) was stirred for 30 minutes under nitrogen with chlorosulfonic acid (13.2 mL, 23.2 g, 200 mmol). The mixture was cooled to room temperature, poured slowly into a cold solution of IN hydrochloric acid, and extracted with ethyl acetate (2x). The organic phase was washed with a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the solvent concentrated in vacuo to a crude oil. The crude oil was crystNlized from diethyl ether-hexane to Nford 2-methoxy-5-(phenylsulfonyl)benzenesulfonyl chloride (5.12 g, 74%) as a colorless solid, which was utilized in subsequent reactions. Stepc 2-Methoxy-5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)benzenesulfonamide A stirred solution of 2-methoxy-5-(phenylsulfonyr)benzenesulfonyl chloride (0.35 g, 1.0 mmol) in dichloromethane (10 mL) was treated dropwise under nitrogen with a solution of 2-(pyridin-3-yl)ethanamine (0.24 g, 2.0 mmol) in dichloromethane. The reaction was stirred for 18 hours at room temperature. The crude product was purified by prepNatNe liquid chromatography on a Biotage~ 40 Si column of pre-packed silica gel (90 g), eluting with a gradient of 50%-100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to Nford, Nter crystNlization from ethyl acetate-diethyl ether-hexane, 2-methoxy-5-(phenylsulfonyl)-N-(2- pyridin-3-ylethyl)benzenesulfonamide (0.26 g, 60%). as a homogeneous, colorless, crystNline solid, m.p. 181-183 °C; MS (+ESI), m/z: 433.1 [M+H]+; HRMS: cNcd for C2oH2oN2O5S2 + H+, 433.08864; found (ESI, [M+H]+), 433.0907; HPLC purity 100% at 210-370 nm, 6.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. Example 679: N-(2-cyanoethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)-benzenesulfonyl chloride and aminopropionitrile were used to prepNe N-(2-cyanoethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 417.0; HPLC purity 95.3% at 210-370 nm, 8.3 min.; Xterra RP18,3.5u, 150x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph==3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for Ci6Hi3F3N2O4S2 + H+, 419.03416; found (ESI, [M+H]4), 419.0344. Example 680: 5-(phenylsulfonyl)-2-(trifluoromethyl)-N-{l-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}benzenesulfonamide Step 1: In an anNogous manner to example 462, piperidin-4-yl-cNbamic acid tert-butyl ester and 4-trifluoromethylbenzoyl chloride were used to prepNe [l-(4-trifluoromethyl-benzoyl)-piperidui-4-yl]-cNbamic acid tert-butyl ester. Step 2: [t-(4-trifluoromethyl-benzoyl)-piperidin-4-yl]-cNbamic acid tert-butyl ester (1.50 g, 4.0 mmol) was dissolved in HC1 in 1,4-dioxane 4M solution (6 mL, 24 mmol). The resulting solution was stirred 2 hours and concentrated. The crude was pNtitioned between sodium bicNbonate solution (sat) and ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and concentrated to gNe 1 -(trifluoromethyl)benzoyl-4-aminopiperidine. Step 3: In an anNogous manner to example 435, 2-trifluoromethyl-5- (phenylsulfonyl)- benzenesulfonyl chloride and l-(trifluoromethyI)benzoyl-4-aminopiperidine were used to prepNe 5-(phenylsulfonyl)--2-(tifluoromethyl)-N-{l-[4-(nifluoromethyl)benzoyl]piperidin-4-yl}benzenesulfonamide. MS(ES+)m/z621.1; HPLC purity 100% at 210-370 nm, 10.0 min.; Xterra RP1S, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Pb~3.5/ACN+MeOH) for lOmin, hold 4min. HUMS: cNcd for C26H22F6N2O5S2 + H+, 621 .09471 ; found (ESI, [M+H]+), 621.0933. Example 681: N(2-hydroxyethyI)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 654, 2-trifluoromethyl-5-(phenylsulfonyl)-benzenesulfonyl chloride and ethanolamine were used to prepNe N-(2-hydroxyethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS(ES-)m/z410.1; HPLC purity 100% at 210-370 nm, 7.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for dsHwFsNOsSi + H+, 410.03382; found (ESI, [M+H]+), 410.0352. Example 682: N-(2-hydroxy-2-phenyIethyl)-5-(phenylsuIfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 654, 2-trifluoromethyl-5-(phenylsulfonyl)-benzenesulfonyl chloride and 2-phenylethanolamine were used to prepNe N(2-hydroxy-2-phenylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 484.0; HPLC purity 100% at 210-370 nm, 9.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 683: N-(2-hydroxy-l-methylethyl)-5-(phenylsuIfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 654, 2-trifluoromethyl-5-(phenylsulfonyl)-benzenesulfonyl chloride and Nanol were used to prepNe N-(2-hydroxy-l-methylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 422.0; HPLC purity 97.9% at 210-370 nm, 8.2 min.; Xten-a RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for Ci6Hi6F3NO5S2 + H+, 424.04947; found (ESI, [M+Hf), 424.0484. Example 684: W-[(lN*,2J?*)-2-hydroxy-l-methyl-2-phenyIethyI]-5-(phenyIsulfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 654, 2-trifluoromethyl-5-(phenylsulfonyl)-benzenesulfonyl chloride and norephedrine were used to prepNe AT-[(l./?*,2R*)-2-hydroxy-l-methyl-2-phenylethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 498.0; HPLC purity 98.0% at 210-370 nm, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 rriL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 685: N-[(lNN-l-hydroxy-l-methyl-l-phenylethyll-SNphenylsulfonyl)N-(trifluoromethyl)benzenesulfonamide j In an anNogous manner to example 654,2-trifluoromethyl-5-(phenylsulfonyl)-benzenesulfonyl chloride and (15',2N)-2-hydroxy-2-phenyl-l-methyl-l-aminoethane were used to prepNe N-[(15,2J?)-2-hydroxy-l-methyl-2-phenylethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 498.0; HPLC purity 96.6% at 210-370 nm, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 686: N-[(1H,25r)-2-hydroxy-l-methyl-2-phenylethyI)-5-(phenylsuIfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 654, 2-trifluoromethyl-5-(phenylsulfonyl)-benzenesulfonyl chloride and (17?,2S)-2-hydroxy-2-phenyl-l-methyl-l-aminoethane were used to prepNe N-[( lR,2S)-2-hydroxy- 1 -methyl-2-phenylethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfohamide. MS (ES-) m/z 498.0; HPLC purity 97.6% at 21 0-370 nm, 9.4min.;XterrNP18, 3.5u, 1 50 x 4.6 mm column, 1.2 iriL/mia, 85/15-5/95 (Ammon. Form. Buff. Ph— 3.5/ACN+MeOH) for lOmin, hold 4min. Example 687: tert-butyl 4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate L. ' In an anNogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)-benzenesulfonyl chloride and 4-aminopiperidine-l- carboxylic acid tert-butyl ester were used to prepNe fc/-/-butyl 4-({ [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidine-1-cNboxylate. MS (ES-) m/z 547.0; HPLC purity 97.4% at 210-370 nm, 10.1 mia; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 688: 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyI)benzenesulfonamide tert-butyl 4-( { [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate (1.57 g, 2.86 nimol) was dissolved in HC1 in 1,4-dioxane 4M solution (8 mL, 32 mmol). The resulting solution was stirred overnight and concentrated. The crude was pNtitioned between sodium bicNbonate solution (sat) and ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and concentrated to gNe 5-(phenylsulfonyl)-N"-piperidin-4-yl-2-(trifluoroniethyl)benzenesulfonamide (1.1 g, 85%). MS (ES+~)m/z 449.1; HPLC purity 98.0% at 210-370 nm, 6.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CigHjgFsNCNSa + H+, 449.081 11; found (ESI, [M+H]+), 449.083. Example 689: 2-Methoxy-5-(phenylsulfonyl)-N-(tetrahydro-2J9r-pyran-4-yl)benzenesulfonamide A stirred solution of 2-methoxy-5-(phenylsulfonyl)benzenesulfonyl chloride (0.35 g, 1.0 mmol) in dichloromethane (10 mL) was treated under nitrogen with tetrahydro-2H-pyran-4-amine hydrochloride (0.27 g, 2.0 mmol) and a solution of diisopropylethylamine (0.39 g, 3.0 mmol) in dichloromethane. The reaction was stirred for 18 hours at room temperature. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (90 g), eluting with a gradient of 30%-70% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to Nford, Nter crystNlization from ethyl acetate-diethyl ether-hexane, 2-methoxy-5-(phenylsulfonyl)-N-(tetrahydro-27f-pyran-4-yl)benzenesulfonamide (0.29 g, 70%), as a homogeneous, colorless, crystNline solid, m.p. 176-178 °C; MS (+ESI), m/z: 412.1 [M+H]+; HRMS: cNcd for Ci8H2iNO6S2 + H+, 412.08830; found (ESI, [M+H]+), 412.0899; HPLC purity 100% at 210-370 nm, 7.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. Example 690: 4-[({5-[(4-fluorophenyl)sulfonyI]-2-isopropylphenyl}sulfonyl)amino]-N-l-naphthylpiperidine-1-carbothioamide To a solution of 5-[(4-fluofophenyl)sulfonyl]-2-isopropyl-N-piperidin-4-ylbenzenesulfonamide (example 520) (75 mg, 0.17 mmol) in dichloromethane (4.0 mL) was added triethylamine (36 uL, 0.25 mmol) followed by 1-naphthyl isothiocyanate (37 mg, 0.2 mmol). The reaction was mixed on an orbitN shaker overnight at room temperature. The following day the reaction was concentrated down onto silica gel and purified using automated chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-l-naphthylpiperidine-1-cNbothioamide (42 mg, 40%). MS (ES+) m/z 626; HRMS: cNcd. for CsiEbFNsCNSs + H*, 626.1617: found (ESI, [m+H]+), 626.1589. Example 691: N-(2-fluorophenyl)-4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]piperidine-l-cNbothioamide In an anNogous manner to example 690, 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-piperidin-4-ylbenzenesulfonamide and 2-fluorophenyl isothiocyanate were used to prepNe N-(2-fluorophenyl)-4-[( { 5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidine-l-cNbotlaioamide. MS (ES+);w/z 594.1; FIRMS: cNcd. for C27H29F2N3O4S3 + H+, 594.1366: found (ESI, [m+H]+); 594.137. Example 692: 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-(2-methylphenyl)piperidine-l-cNbothioamide In an anNogous manner to example 690, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-piperidin-4-ylbenzenesulfonamide and o-toluyl isothiocyanate were used to prepNe 4- [( { 5 - [(4-fluorophenyl)sulf ony 1] -2-isopropy Ipheny 1 } sulfony l)amino] -N-(2-methylphenyl)piperidine-l-cNbothioamide. MS (ES+) m/z 590; HRMS: cNcd. for C28H32FN3O4S3 + H*, 590.1617: found (ESI, [m+H]+), 590.1628. Example 693: ethyl ({4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]piperidin-l-yl}carbonothioyl)cNbamate In an anNogous manner to example 690, 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-piperidin-4-ylbenzenesulfonamide and ethyl isothiocyanatoformate were used to prepNe ethyl ({4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropy Ipheny 1} sulfony l)amino]piperidin-1 -yl} cNbonothioyl)cNbamate. MS (ES+) m/z 572; HRMS: cNcd. for CiNoFNsOeSs + H+, 572.1359: found (ESI, [m+Hj4), 572.1353. Example 694: N-butyl-4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]piperidine-l-cNbothioamide In an anNogous manner to example 690, 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-piperidin-4-ylbenzenesulfonamide and 1 -butyl isothiocyanate were used to prepNe N-butyl-4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]piperidine-l-cNbothioamide. MS (ES+) m/z 556.2; HRMS: cNcd. for €25N4N30483 + H+, 556.1773: found (ESI, [m+H]+), 556.1765. Example 695: 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyi)amino]-N-(4-methoxyphenyl)piperidine-l-cNbothioamide In an anNogous manner to example 690, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-piperidin-4-ylbenzenesulfonamide and 4-isothiocyanatoanisole were used to prepNe 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-(4-methoxyphenyl)piperidine-l-cNbothioamide. MS (ES+)m/z 606.1; HRMS: cNcd. for CjgffeFNsOsSa + H*. 606.1566: found (ESI, [m+H]+), 606.1456. Example 696: methyl 4-[({4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]piperidin-l-yl}cNbonothioyl)amino]benzoate In an anNogous manner to example 690, 5-[(4-fiuorophenyl)sulfonyl]-2-isopropyl-N-piperidin-4-ylbenzenesulfonamide and 4-isothiocyanato-benzoic acid methyl ester were used to prepNe methyl 4-[({4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropy Iphenyl } sulfonyl)amino]piperidin- 1 -yl } cNbonothioyl)amino]benzoate. MS (ES-)m/z 632.1; HRMS: cNcd. for C29H32FN3O6S3 + Jf, 634.1516: found (ESI, [m+Hj*), 634.1478. Example 697: methyl N-({4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]piperidin-l-yl}cNbonothioyl)glycinate In an anNogous manner to example 690, 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-piperidin-4-ylbenzenesulfonamide and 2-isothiocyanatoacetic methyl ester were used to prepNe methyl N-({4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]piperidin-l-yl}cNbonothioyl)glycinate. MS (ES-) m/z 570; HRMS: cNcd. for C24H3oFN3O6S3 + H+, 572.1359: found (ESI, [m+H]+), 572.1348. Example 698: 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-(2-morpholin-4-ylethyl)piperidine-l-cNbothioamide In an anNogous manner to example 690, 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-piperidin-4-ylbenzenesulfonamide and 2-(4-morpholino)ethyl isothiocyanate were used to prepNe methyl N-({4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropy Iphenyl} sulfonyl)amino]piperidin-l-yl}cNbonothioyl)glycinate. MS(ES-)/w/z611. Example 699: 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-(3-nitrophenyl)piperidine-l-cNbothioamide , In an anNogous manner to example 690, 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-piperidin-4-ylbenzenesulfonamide and 3-nitrophenyl isothiocyanate were used to prepNe 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-(3-nitrophenyl)piperidine-l-cNbothioamide. MS(ES-)w/z619; HRMS: cNcd. for C27H29FN4O6S3 + H+, 621.1312: found (ESI, [m+H]+), 621.1219. Example 700: 3-[({4-[({5-[(4-fluorophenyl)sulfonyI]-2-isopropylphenyl}sulfonyl)amino]piperidin-l-yl}cNbonothioyl)amino]benzoic acid In an anNogous manner to example 690, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-piperidin-4-ylbenzenesulfonamide and 3-cNboxyphenyl isothiocyanate were used to prepNe 3 - [( { 4- [( { 5- [(4-fluoropheny l)sulfony 1] -2- isopropy Iphenyl } sulfony l)amino]piperidin- 1 -yl}cNbonothioyl)amino]benzoic acid. MS(ES-)m/z618; HRMS: cNcd. for CagHaoFNsOeSa + rf", 620.1359: found (ESI, [m+Hf), 620.1364. Example 701 : 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-pyridin-3-ylpiperidine-l-cNbothioamide In an anNogous manner to example 690, 5- [(4-fluoropheny l)sulfonyl]-2-isopropyl-N-piperidin-4-ylbenzenesulfonamide and 3-pyridyl isothiocyanate were used to prepNe 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-pyridin-3-ylpiperidme-1-cNbothioamide. MS (ES+)m/z 577.1; HRMS: cNcd. for CNgFNNSs + H+, 577.1413: found (ESI, [m+H]+), 577.1396. Example 702: N-[l (trifluoroniethyl)benzenesulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 2-chlorobenzoyl chloride were used to prepNe N-[l-(2-chlorobenzoyl)piperidin-4-yl]-5-(phcnylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS(ES+)w/z587.0; HPLC purity 93.6% at 210-370 nm, 9.6 min.; Xterra RP1S, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C25H22C1F3N2O5S2 + H+, 587.06835; found (ESI, [M+Hf ), 587.0666. Example 703: ]V-[l-(2-methoxybenzoyl)piperidin-4-yI]-5-(phenyIsulfonyI)-2-(trifluoromethyl)benzenesulfonNaide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 2-methoxybenzoyl chloride were used to prepNe N-[l-(2-methoxybenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+)m/z 583.1; HPLC purity 96.8% at 210-370 nm, 9.3 min.; Xterra RP1 8, 3.5u, 150x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 704: N[l-(3-chlorobenzoyI)piperidin-4-yl]-5-(phenylsulfonyI)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 3-chlorobenzoyl chloride were used to prepNe N-[l-(3-chlorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 587.0; HPLC purity 98.4% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. WMS: cNcd for CisHNClFaNaOsSz + H+, 587.06835; found (ESI, [M+H]+), 587.0674. Example 705: N-[N(S (trifluoromethyl)benzenesulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 3,4-difluorobeiizoyl chloride were used to prepNe N-[l-(3,4-difluorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS(ES+)w/z589.1; HPLC purity 98.3% at 210-370 nm, 9.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/rnin, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C25H2iF5N2O5S2 + H+, 589.08848; found (ESI, [M+H]+), 589.0875. Example 706: 7N-[l-(3,5-difluorobenzoyl)piperidin-4-yl]-5-(phenyIsulfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 3,5-difluorobenzoyl chloride were used to prepNe N-[l-(3,5-difluorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+)w/z 589.1; HPLC purity 99.0% at 210-370 nm, 9.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1 .2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CttHbiFslNCN + H+, 589.08848; found (ESI, [M+Hf), 589.0884.Example 707: N-[l-(2,6-dimethoxybenzoyl)piperidin-4-yl]-5-(phenylsuIfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 2,6-dimethoxybenzoyl chloride were used to prepNe N-[l-(2,6-dimethoxybenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide . MS(ES+)iw/z613.1; HPLC purity 98.3% at 210-370 nm, 9.3 min.; Xterra RP18, 3.5u, 1 50 x 4.6 mm column, 1 .2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CayHzvFsNCN + H+, 613.12845; found (ESI, [M+H]+), 613.1266. Example 708: N-[l-(2,4-diraethoxybenzoyI)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide ' In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 2,4-dimethoxybenzoyl chloride were used to prepNe N"-[l-(2,4-dimethoxybenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS(ES+);??/z613.1; HPLC purity 95.9% at 210-370 nm, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 709: 5-(phettylsulfonyl)-N-{l-[4-(trifluoromethoxy)benzoyl]piperidin-4-yI}-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trMuoromethyl)benzenesulfonamide and 4-trifluoromethoxybenzoyl chloride were used to prepNe S-Cphenylsulfonyl)-/N- { 1 -[4-(trifluoromethoxy)benzoyl]piperidin-4-yl} -2-(trifluoromethyl)benzenesulfonamide. MS (ES+)m/z 637.1; HPLC purity 98.6% at 210-370 nm, 10.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C26H22F6N2O6S2 + H+, 637.08962; found (ESI, [M+Hf), 637.0912. Example 710: N-{l-[2-fluoro-4-(trifluoromethyl)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesuIfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 2-fluoro-4-trifluoromethylbenzoyl chloride were used to prepNe N-{ l-[2-fluoro-4-(trifluoromethyl)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-(trifiuoromethyl)benzenesulfonamide. MS (ES+)m/z 639.1; HPLC purity 98.9% at 210-370 nm, 10.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C26H21F7N2O5S2 + H+, 639.08528; found (ESI, [M+H]+), 639.0881. Example 711: ]V-{l-[3-fluoro-4-(trifluoroniethyl)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 462, 5~(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 3-fluoro-4-trifluoromethylbenzoyl chloride were used to prepNe N-{l-[3-fluoro-4-(trifluoromethyl)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS(ES+)iH/z639.1; HPLC purity 98.2% at 210-370 nm, 10.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CjeHbiFyNzOsSi + H+, 639.08528; found (ESI, [M+H]*), 639.0863. Example 712: N-[lNS (trifluoromethyl)benzenesulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4~yl-2-(trifluoromethyl)benzenesulfonamide and 3,4-dichlorobenzoyl chloride were used to prepNe N-[ I -(3 ,4-dichlorobenzoyl)piperidin-4-yl] -5 -(pheny Isulfony l)-2-(trifluoromethyl)benzenesulfonamide. MS(ES+)m/z621.9; HPLC purity 98.2% at 210-370 nm, 10.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CisHaiCfcFaNaOjSa + H+, 621.02938; found (ESI, [M+H]+), 621.0306. Example 713: N-[l-(4-chlorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyI)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N'-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 4-chlorobenzoyl chloride were used to prepNe N-[l-(4-chlorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 587.0; HPLC purity 98.2% at 210-370 nm, 9.9 min.; Xterra RP1 8, 3.5u, 1 50 x 4.6 mm column, 1 .2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold4min. HRMS: cNcd for CsfeClFaNaOsN + H+, 587.06835; found (ESI, [M+Hf), 587.0698. Example 714: N-(l-isonicotinoylpiperidin-4-yl)-5-(phenyIsulfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous mNiner to example 462, 5-(phenylsulfonyl)-vY-piperidin-4-yi-2-(trifluoromethyl)benzenesulfonamide and pyridine-4-cNbonyl chloride were used to prepNe N-(l-isonicotinoylpiperidin-4-yl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS(ES+)/w/z554.1; HPLC purity 99.4% at 210-370 nm, 8.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CNFaNaO.Ss + H+, 554.10257; found (ESI, [M+H]+), 554.1038. Example 715: N-[l-(2-chloro-6-methoxyisonicotinoyI)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-./V-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 2-chloro-6-methoxypyridine-4-cNbonyl chloride were used to prepNe N-[l-(2-chloro-6-methoxyisonicotinoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethy l)benzenesulfonamide . MS(ES+)/n/z618.1; HPLC purity 98.5% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for €25N0N30582 + H+, 618.07416; found (ESI, [M+H]+), 618.0737. Example 716: N-[l-(2-chloro-4-fluorobenzoyl)piperidin-4-yl]-5-(phenylsuIfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-./V"-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 2-chloro-4-fluorobenzoyl chloride were used to prepNe N- [1 -(2-chloro-4-fluorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 605.0; HPLC purity 98.7% at 210-370 nm, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1 .2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C25H2iClF4N2O5S2 + H+, 605.05893; found (ESI, [M+H]+), 605.0582. Example 717: S-(phenylsulfonyl)-N-[l-(2,4,6~trifluorobenzoyl)piperidin-4-yl]-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 2,4,6-trifluorobenzoyl chloride were used to prepNe 5-(phenylsulfonyl)-N-[l-(2,4,6-trifluorobenzoyl)piperidin-4-yl]-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 607.0; HPLC purity 93.5% at 210-370 nm, 9.6 min.; Xterra RP1 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C25H2oF6N2O5S2 + H+, 607.07906; found (ESI, [M+H]+), 607.0799. Example 718: N-[l-(4-tert-butylbenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide j In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 4-tert-butylbenzoyl chloride were used to prepNe N-[l-(4-?er/-butylbenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide . MS (ES+) m/z 609.1; HPLC purity 98.0% at 210-370 nm, 10.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CagNiFsN-jCN + H+, 609.16992; found (ESI, [M+H]*), 609.1714. Example 719: N-(4-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]cNbonyl}phenyl)acetamide i In an anNogous manner to example 462, 5-(phenylsulfonyl)-.N-piperidin-4-yl-2-(rrifluoromethyl)benzenesulfonamide and 4-N-acetamidebenzoyl chloride were used to prepNe N'-(4-{[4-({[5-(phenylsulfonyl)-2-(lrifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-y 1] cNbony 1} pheny l)acetamide . MS (ES+) m/z 610.1; HPLC purity 96.7% at 210-370 nm, 8.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CsyHnNNsOeS, + H+, 610.12879; found (ESI, [M+Hf), 610.1293. Example 720: N-[(l-S)-l-benzyl-2-hydro.xyethyl]-5-(phenylsuIfonyl)-2-(trifluoromethyl)benzenesulfonamide [0884] In an anNogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)-benzenesulfonyl chloride and L-phenylNaninol were used to prepNe N-[(15)-l-ben2yl-2-hydroxyethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 500.0; HPLC purity 99.1% at 2 10-3 70 nm, 9.2 min.; XterrNPIS, 3.5u, 150 x 4. 6 mm column, 1.2 mL/min, 85/15-5/95 (Namon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CziBbFaNOsSa + H+, 500.08077; found (ESI, [M+H]+), 500.0791. Example 721: N-[(lNN-hydroxy-l-1H-indol-S-ylmethylJethyl]-S-Cphenylsulfonyl)-!-(trifluoromethyl)benzenesulfonamide 1 In an anNogous manner to example 654, 2-trifluoromethyl-5-(phenylsulfonyl)-benzenesulfonyl chloride and L-tryptophanol were used to prepNe N-[(15)-2-hydroxy-l-(lH-indol-3-ylmethyl)etliyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)beri2;enesulfonNnide. MS (ES+) m/z 539.0; HPLC purity 97.2% at210-370nm, 9.2min.;XterrNP18,3.5u, 1 50 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Nnmon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4mia HRMS: cNcd for C24H2iF3N205S2 + H+, 539.09167; found (ESI, [M+H]+), 539.0943. Example 722: N-[l-(2-hydroxy-2-methylpropyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide To a stirred mixture of 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide (0.075 g, 0.167 mmol) in ethanol (2 mL) was added 2,2-Dimethyl-oxirane (0.05 g, 0.69mmol) and the resulting mixture was heated to reflux overnight. The crude mixture was concentrated and flash column sepNation using 50% to 100% ethyl acetate/hexane gradient gave N-[l-(2-hydroxy-2-methylpropyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenes-ulfonamide (0.06 g, 70%). MS(ES-)w/z519.0; HPLC purity 96.8% at 210-370 nm, 7.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for 0,2N3N0582 + H+, 521.13862; found (ESI, [M+H]+), 521.1403. Example 723: N-[2-(l-oxidopyridin-3-yl)ethyI]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide To a stirred solution of 5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)-2- (trifluoromethyl)benzenesulfonamide (0.10 g, 0.21mmol) in concentrated acetic acid (2 mL) was added 30% hydrogen peroxide solution (2 mL) and the resulting solution was heated to reflux for three hours. The solution was Nlowed to cool, poured into sodium bicNbonate solution (sat), and extracted with ethyl acetate. The organic layer was washed with sodium dithionite solution (sat), and brine. The organic layer was concentrated and flash column sepNation using 0%-10% methanol/methylene chloride gradient gave N-[2-(l-oxidopyridin-3-yl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide (0.015 g, 15%). MS (ES-)»z/z 485.0; HPLC purity 98.8% at 210-370 nm, 7.5 min.; Xterra RP18, 3.5u, 150 x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CNHnFsNjON + H+, 487.06037; found (ESI, [M+Hf), 487.0619. Example 724: 5-(phenylsulfonyl)-2-(trifluoromethyl)-N-(l-{[4-(trifluoromethyl)phenyl]carbonothioyl}piperidin-4-yl)benzenesulfonamide To a stirred solution of 5 -(phenylsulfony l)-2-(trifluoromethyl)-N- { 1 - [4-(trifluoromethyl)benzoyl]piperidin-4-yl}benzenesulfonamide (0.10 g, 0.16 mmol) in toluene (1 mL) was added Lawesson's reagent (0.06 g, 0.15 mmol) and the resulting solution was stirred overnight at reflux. The solution was Nlowed to cool, pNtitioned between ethyl acetate and ammonium chloride solution (sat.). The organic layer was concentrated and flash column sepNation using 0% to 20% ethyl acetate/hexane gradient gave 5 -(phenylsulfony l)-2-(trifluoromethyl)-N-(l-{[4-(trifluoromethyl)phenyl]cNbonothioyl}piperidin-4-yl)benzenesulfonamide (0.053 g, 56%). MS (ES+)w/z 637.1; HPLC purity 100% at 210-370 nm, 10.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CNNFsN.CUSs + H+, 637.07186; found (ESI, [M+H]+), 637.0749. Example 725:N-[(15r)-2-hydroxy-l-niethylethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 654, 2-ti'ifluoromethyl-5-(phenylsulfonyl)-benzenesulfonyl chloride and S-2-amino-l-propanol were used to prepNe jY-[(15)-2-hydroxy-l-methylethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+)m/z 424.1; HPLC purity 95.1% at 210-370 nm, 8.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for Ci6Hi6F3NO5S2 + H+, 424.04947; found (ESI, [M+H]+), 424.0497. Example 726: N-[(lN-hydroxy-l-methylethyl]-S-CphenylsuIfonyl)-!-(trifluoromethyl)benzenesulfonaiuide In an anNogous manner to example 654, 2-trifluoromethyl-5-(phenylsulfonyl)-benzenesulfonyl chloride and R-2-amino-l-propanol were used to prepNe N-[(lN?)-2-hydroxy-l-me1hyle1hyl]-5-(phenylsulfonyl)-2Ntrifluoromethyl)benzenesulfonamide. MS (ES+)m/z 424.0; HPLC purity 98.2% at 210-370 nm, 8.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for Ci6H16F3NO5S2 + H+, 424.04947; found (ESI, [M+H]*), 424.0505. Example 727: 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-pyridin-2-ylethyl)-2-isopropylbenzenesulfonamide In an anNogous manner to Step 3, Example 317: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-amino-l-pyridin-2-yl-ethanol were used to prepNe 5-[(4-fluorophenyl)sulfonyl]-N2-hydroxy-2-pyridin-2-ylethyl)-2-isopropylbenzenesulfonamide. MS (ES+)m/z 479.1; HPLC purity Checked by AN LC/MS. MW confirmed.; Luna C8(2), 5u, 4.6x250mm column, 0.5 mL/min, Water/MeOH 20 min gradient. HPLC purity 96.1% at 210-370 nm, 8.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CzzHNNaOsSz + H+, 479.11052; found (ESI, [M+H]+), 479.1099. Example 728: N-(2-hydroxy-2-pyridin-2-ylethyl)-2-isopropyI-5-(phenylsulfonyl)benzene-sulfonamide In an anNogous manner to Step 3, Example 295: 5-Benzenesulfonyl~2-isopropyl-benzenesulfonyl chloride and 2-amino-l-pyridin-2-yl-ethanol were used to prepNe N-(2-hydroxy-2-pyridin-2-ylethyl)-2-isopropyl--5-(phenylsulfonyl)benzenesulfonamide. MS(ES+)w/2461.2; HPLC purity Checked by AN LC/MS. MW confirmed by MS.; Luna C8(2), 5u, 4.6x250mm column, 0.5 mL/min, prep conditions. HPLC purity 100% at 2 10-3 70 nm, 8.6 min.;XterrNP18, 3.5u, 150x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for 022NN20582 + H+, 461.11994; found (ESI, [M+H]+), 461.1 18. Example 729: AK2-hydroxy-2-pyridin-2-ylethyl)-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide In an anNogous manner to Step 3, Example 295: 5-Benzenesulfonyl-2,4-dimethyl-benzenesulfonyl chloride and 2-amino-l-pyridin-2-yl-ethanol were used to prepNe N-(2-hydroxy-2-pyridin-2-ylethyl)-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide. MS (ES+)m/z 447.1; HPLC purity Checked by AN LC/MS. MW confirmed by MS.; Luna C8 (2), 5u, 4.6x250mm column, 0.5 mL/min, MeOH /water 20min gradient. HPLC purity 100% at 210-370 nm, 8.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CziHNCN + H+, 447.10429; found (ESI, [M+H]+), 447.1033. Example 730: 4-[({5-[(4-fluorophenyI)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-[4-(trifluoromethyl)phenyl]piperidme-l-cNbothioamide In an anNogous manner to example 690, 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-piperidin-4-ylbenzenesulfonamide and 4-(trifluoromethyl)phenyl isothiocyanate were used to prepNe 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N- [4- (trifluoromethyl)phenyl]piperidine-l -cNbothioamide. MS (ES+)w/2 644.1; HRMS: cNcd. for C28H29F4N3O4S3 + H1", 644.1335: found (ESI, [m+H]+), 644.1406. Example 731: 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-pyridin-3-ylethyl)-2-isopropylbenzenesulfonamide In an anNogous manner to Step 3, Example 317: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-amino-l-pyridin-3-yl-ethanol were used to prepNe 5-[(4-fluorophenyl)sulfonyl]-AT-(2-hydroxy-2-pyridin-3-ylethyl)-2-isopropylbenzenesulfonamide. MS (ES+)m/z 479.1; HPLC purity 96.7% at 21 0-370 nm, 8.4 min.; XterrNPIS, 3.5u, 150x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CNHNFNOsSa + H+, 479.11052; found (ESI, [M+H]*), 479.1088. Example 732: 5-[(4-fluorophenyl)sulfonyl]-AT-(2-hydroxy-2-phenylethyl)-2-isopropylbenzenesulfonamide In an anNogous manner to Step 3, Example 317: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-amino-l-phenyl-ethanol were used to prepNe 5-[(4-fluorophenyl)sulfonyl]-N'-(2-hydroxy-2-phenylethyl)-2-isopropylbenzenesulfonamide. MS (ES-)m/z 476.1; HPLC purity 100% at 210-370 nm, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C23H24FNO5S2 + NH/, 495.14182; found (ESI, [M+NH4]+), 495.1433. Example 733: 5-[(4-fluorophenyl)sulfonyl]-N(2-hydroxy-l-methylethyl)-2-isopropylbenzenesull'onamide ' In an anNogous manner to Step 3, Example 317: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-beiizenesulfonyl chloride and 2-amino-l-propanol were used to prepNe 5-[(4-fluorophenyl)sulfonyl]-N-(2-hyclroxy-l-methylethyl)-2-isopropylbeiizenesulfonamide. MS(ES-)m/z414.0; HPLC purity 98.1% at 210-370 iim, 8.7 min.; XteiTa RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CigH22FNO5S2 + H+, 416.09962; found (ESI, [M+H]+), 416.0975. Example 734: 5-[(4-fluorophenyl)sulfonyl]-N-[l-(hydroxymethyl)-2-methyIpropyl]-2-isopropylbenzenesulfonamide In an anNogous manner to Step 3, Example 317: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-amino-3-methyl-butan-1-ol were used to prepNe 5-[(4-fluorophenyl)sulfonyl]-N-[l-(hydroxymethyl)-2-methylpropyl]-2-isopropylbenzenesulfonamide. MS (ES+ym/z 444.1; HPLC purity 96.4% at 210-370 run, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold4min. HRMS: cNcd for C2oH26FNO5S2 + H+, 444.13092; found (ESI, [M+H]4), 444.1322. Example 735: N-(2-hydroxy-2-pyridin-3-ylethyl)-2-isopropyl-5-(phenylsulfonyl)benzenesulfonNnide In an anNogous manner to Step 3, Example 295: 5-Benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride and 2-amino-l-pyridin-3-yl-ethanol were used to prepNe N-(2-hydroxy-2-pyridm-3-ylethyl)-2-isopropyl-5-(phenylsulfony l)benzenesulfonamide. MS(ES+)m/z461.1; HPLC purity 100% at 210-370 nm, 8.1 min.; Xterra RP18, 3.5u, 150x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Pb=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C22H24N2O5S2 + H+, 461.11994; found (ESI, [M+H]+), 461.1203. Example 736: N-(2-hydroxy-2-phenylethyl)-2-isopropyl-5- (phenylsulfonyl)benzenesulfonamide In an anNogous manner to Step 3, Example 295: 5-Benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride and 2-amino-l-phenyl-ethanol were used to prepNe N-(2-hydroxy-2-phenylethyl)-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide. MS (ES-)w/z 458.1; HPLC purity 97.2% at210-370 nm, 9.6 min.; Xterra RP18, 3.5u, 150 x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Fonn. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold4min. HRMS: caicd for C23H25NO5S2 + NHLt*, 477.15124; found (ESI, [M+NH4]+), 477.1512. Example 737: N-(2-hydroxy-2-pyridin-3-yIethyl)-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonNaide In an anNogous manner to Step 3, Example 295: 5-Benzenesulfonyl-2,4-dimethyl-benzenesulfonyl chloride and 2-amino-l-pyridin-3-yl-• ethanol were used to prepNe N-(2-hydroxy-2-pyridin-3-ylethyl)-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide. MS (ES+)m/z 447.1; HPLC purity 100% at 210-370 nm, 7.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CaiHNOsS;! + H+, 447.10429; found (ESI, [M+H]+), 447.1032. Example 738: 5-[(4-fluorophenyl)sulfonyI]-N-(2-hydroxybutyl)-2-isopropylbenzenesulfonamide In an anNogous manner to Step 3, Example 317: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 1 -aminobutan-2-ol were used to prepNe 5-[(4-fiuorophenyl)sulfonyl]-?l/-(2-hydroxyburyl)-2-isopropylbenzenesulfonamide. MS (ES-}m/z 428.1; HPLC purity 100% at 210-370 nm, 9.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CNFNCN + H+, 430.11527; found (ESI, [M+H]+), 430.1 147. Example 739: N-[2-(lN-Imidazol-l-yl)ethyl]-5-(phcnylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide [2-(1H-Imidazol-l-yl)ethyl]amine dihydrochloride (97.3 mg, 0.529 mmol) was dissolved in 1 mL of water containing 169.3 mg (1.6 mmol) of sodium cNbonate. Acetonitrile (4 mL) was then added. To this mixture 5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonyl chloride (201 .8 mg, 0.524 mmol), prepNed in Example 677, in 10 mL of acetonitrile was added dropwise over 1 .5 h. Nter the addition the reaction was stirred at room temperature for 19 h (overnight). The reaction was filtered and the filtrate concentrated under reduced pressure to gNe 255.4 mg of a yellow oil. Purification of the oil on 50 g of silica gel (230-400 mesh) using 50% ethyl acetate-methylene chloride and then 5% methanol-methylene chloride as the eluents gaveN-[2-(1H-imidazol-l-yl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide (78.4 mg, 33%) as a white solid. MS (ES)m/z 460.0; HRMS: cNcd for Ci8Hi6F3N3O4S2 + H", 460.06071; found (ESI, [M+H]+), 460.0605; AnN. CNcd for QgHNNaCUSz: C, 47.05; H, 3.51; N, 9.15. Found: C, 47.04; H, 3.14; N, 9.03. Example 740: 5-[(4-fluorophenyI)sulfonyl]-N-(2-hydroxy-2-pyridin-3-ylethyl>2-methylbenzenesulfonamide In an anNogous manner to Step 3, Example 298: 2-Methyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-amino-l-pyridin-3-yl-ethanol were used to prepNe 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-pyridin-3-ylethyl)-2-rnethylbenzenesulfonamide. MS (ES+)w/z 451.1; HPLC purity 100% at 210-370 nm, 7.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C2oHi9FN2O5S2 + H+, 451.07922; found (ESI, [M+Hf), 451.0803. Example 741 : N-(2-hydroxy-2-pyridin-3-ylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide " In an anNogous manner to Step 3, Example 677: 5-Benzenesulfonyl-2-trifluoromethyl-beiizenesulfonyl chloride and 2-amino-l-pyridin-3-yl-ethanol were used to prepNe N-(2-hydroxy-2-pyridin-3-ylethyl)~5-(phenylsulfonyi)-2-(trifluoromethyl)benzenesulfonamide. MS(ES+)w/z4S7.1; HPLC purity 98.0% at 210-370 nm, 7.8 min.; XteiTa RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C2oHi7F3N2O5S2 + H+, 487.06037; found (ESI, [M+H]+), 487.0612. Example 742: tert-Butyl [2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cNbamate 5-(Phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonyl chloride (2.1471 g, 5.58 mmol), prepNed in Example 677, in 25 mL of methylene chloride was added under nitrogen dropwise over 15 minutes to a solution of N-(2-aminoethyl)cNbamic acid tert-butyl ester (883 EL, 5.58 mmol) and triethylamine (2.33 mL, 16.7 mmol) in 50 mL of methylene chloride at room temperature. Nter the addition the reaction was stirred at room temperature for 5.5 h. The reaction was extracted with 2 N HC1, dried (anhydrous magnesium sulfate) and the solvent removed under reduced pressure to gNe 2.71 g of a white solid. Purification of the solid on 300 g of silica gel (230-400 mesh) using 100% methylene chloride to 15% ethyl acetate-methylene chloride as the eluent gave tert-butyl [2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]suhcbnyl}amino)ethyl]cNbamate (2.05 g, 72%) as a white solid. MS (ESI) m/z 507. Example 743: 5-[(3-methoxyphenyI)suIfonyl]-N-(tetrahydro-lH-pyran-4-yl)-2-(trifluoromethyl)benzenesulfonamide Step 1:: Following the same procedure described on example 677 (Step 2), 2-chloro-5-fluoronitrobenzene was used to prepNe 2-nitro-4-fluorobenzotrifluoride. " Step 2: To a stirred solution of 2-nitro-4-fluorobenzotrifluoride (1.6 g, 7.65 mmol) in dimethylformamide (20 mL) was added 3-methoxybenzenethiol (1 mL, 8.0 mmol) and potassium cNbonate (2.1 g, 15.3 mmol). The resulting mixture was stirred at room temperature 2 hours, diluted with water and extracted with ethyl acetate. The organic layer was washed severN times with water, dried over magnesium sulfate and concentrated. The crude mixture was dissolved in methylene chloride (25 mL) and mCPBA (3.5 g 77%, 15.7 mmol) was added. The resulting mixture was stirred at room temperature for 30 minutes, washed with sodium dithionite solution and with sodium bicNbonate solution (sat). The organic layer was dried over magnesium sulfate and concentrated. Flash column sepNation using 0%-20% ethyl acetate/hexane gradient gave 5-(3-methoxyphenylsulfonylV2-lrifluoromethyl-nitrobenzene (1.84 g, 65%). Step 3: Following the same procedure described on example 677 (Step 3), 5-(3-methoxyphenylsulfon.yl)-2-trifluoromethyl-nitrobenzene was used to prepNe 5-(3-methoxyphenylsulfonyl)-2-trifluoromethylaniline. Step 4: Following the same procedure described on example 677 (Step 4), 5-(3-methoxyphenylsulfonyl)-2-trifluoromethylaniline, was used to prepNe 2-trifiuoromethyl-5-(3-methoxylphenylsulfonyl)- benzenesulfonyl chloride. Step 5: In an anNogous manner to example 435, 2-trifluoromemyl-5-(3-methoxylphenylsulfonyl)- benzenesulfonyl chloride and tetrahydrofurfurylamine were used to prepNe 5-[(3-methoxyphenyl)sulfonyl]-N-(tetrahydro-2JfT-pyran-4-yl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES-)m/z 478.0; HPLC purity 97.2% at 210-370 nm, 9.1 min.;XterrNP18,3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 744: 5-[(3-hydroxyphenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)-2-(trifluoromethyl)benzenesulfonamide To a stirred solution of 5-[(3-methoxyphenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)-2-(trifluoromethyl)benzenesulfonamide (O.OSg, 0.17 mmol) in methylene chloride (2 mL) was added cyclohexene (2 drops) and boron tribromide solution 1M in methylene chloride (0.6 mL, 0.6 mmol) at 0°C. The resulting solution was stirred 1 hour, quenched with methanol, and washed with sodium bicNbonate solution (sat). The organic layer was concentrated and the crude solid was triturated in methylene chloride to gNe 5-[(3-hydroxyphenyl)sulfonyl]-N (tetrahydro-2F-pyran-4-yl)-2-(trifluoromethyl)benzenesulfonamide (0.04 g, 51%). MS (ES-) 771/z 464.0; HPLC purity 95.7% at 210-370 nm, 8.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CisHigFsNCN + H+, 466.06004; found (ESI, [M+Hf), 466.0625. Example 745: N-(2-cyanoethyl)-5-[(3-rnethoxyphenyl)sulfonyI]-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 435, 2-trifluoromethyl-5-(3- methoxylphenylsulfonyl)- benzenesulfonyl chloride and aminopropionitrile were used to prepNe N-(2-cyanoethyl)-5-[(3-methoxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 447.0; HPLC purity 97.9% at 210-370 nm, 8.7 min.; Xterra RP1 8, 3.5u, 150 x 4.6 mm column, 1 .2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. r. HRMS: cNcd for C17Hi5F3N2O5S2 + H+, 449.04472; found (ESI, [M+H]+), 449.0448. Example 746: N-[l-(4-tert-butylbenzoyl)piperidin-4-yl]-5-[(3-methoxyphenyl)sulfonyl]-2-(trifluororaethyl)benzenesulfonamide Step 1 : Following the same procedure described on example 462, piperidin-4-yl-cNbamic acid tert-butyl ester and 4-tertbutylbenzoyl chloride were used to prepNe [l-(4-tert-butyl-benzoyl)-piperidin-4-yl]-cNbamic acid tert-butyl ester. Step 2: Following the same procedure described on example 688, [l-(4-tert-butyl-benzoyl)-piperidin-4-yl]-cNbamic acid tert-butyl ester was used to prepNe (4-amino-piperidin- 1 -y l)-(4-tert-butyl-phenyl)-methanone. Step 3: Following the same procedure described on example 435, 2-trifluoromethyl-5-(3-methoxylphenylsulfonyl)- benzenesulfonyl chloride and (4-amino-piperidin-l-yl)-(4-tert-butyl-phenyl)-methanone were used to prepNe N-[l-(4-rer?-butylbenzoyl)piperidin-4-yl]-5-[(3-methoxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 639.2; HPLC purity 96.2% at 21 0-370 nm, 10.7 min.; Xterra RP 18, 3.5u, 150x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CsoHasFsNOeS;. + H+, 639.18049; found (ESI, [M+H]+), 639.1804. Example 747: 5-[(3-methoxyphenyI)sulfonyl]-N-(2-pyridin-3-ylethyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 435, 2-trifluoromethyl-5-(3- methoxylphenylsulfonyl)- benzenesulfohyi chloride and 3-(2-aminoethyl)pyridine were used to prepNe 5-[(3-methoxyphenyl)sulfonyl]-N-(2-pyridin-3-ylethyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+)»j/z 501.1; HPLC purity 100% at 210-370 run, 8.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CajHiuFsNOsSz + H+, 501.07602; found (ESI, [M+H]4), 501.0756. Example 748: N{l-[(4-tert-butylphenyl)sulfonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-(trifluororaethyl)benzenesulfouamide • In an anNogous manner to example 462, 5~(phenylsulfonyl)-./V-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 4-tert-butylbenzenesulfonyl chloride were used to prepNe N-{1- [(4-tert-butylphenyl)sulfony l]piperidin-4-yl } -5-(pheny lsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+)m/z 645.1; HPLC purity 94.7% at 210-370 nm, 10.9 min.; Xterra RP 18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold4min. HRMS: cNcd for 02N3N3N20583 + H+, 645.13691; found (ESI, [M+H]4), 645.1376. Example 749: 5-(phenylsuIfonyl)-2-(trifluoromethyl)-N-{l-[4-(trifluoromethyI)benzyl]piperidin-4-yl}benzenesuIfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-Npiperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 4-trifluoromethylbenzyl bromide were used to prepNe 5-(phenylsulfonyl)-2-(trifluoromethyl)-N- { 1 -[4-(trifluoromethyl)benzyl]piperidin-4-y 1 } benzenesulfonamide . MS (ES+)w/z 607.1; HPLC purity 96.8% at 210-370 nm, 9.2 min.; Xterra RP 18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C26H24F6N2O4S2 + H+, 607.1 1544; found (ESI, [M+H]4), 607.1 147. Example 750: Nl-(cyanomethyl)pipericlin~4-yl]-5-(phenyIsulfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and bromoacetonitrile were used to prepNe N-[l-(cyanomethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+)m/z 488.1; HPLC purity 96.7% at 210-370 nm, 8.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. FIRMS: cNcd for C2oH2oF3N3O4S2 + H+, 488.09201; found (ESI, [M+H]N, 488.0933. Example 751: N-[l-(2-oxo-2-phenylethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzencsulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 2'-bromoacetophenone were used to prepNe N-[l-(2-oxo-2-phenylemyl)piperidm-4-yl]-5-(phenylsulfonyl)-2-(txifliioromethyl)benzenesulfonamide. MS (ES+)m/z 567.1; HPLC purity 92.6% at 210-370 nm, 8.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C26H25F3N2O5S2 + H+, 567.12297; found (ESI, [M+H]*), 567.1232. Example 752: 5-[(3-chlorophenyl)sulfonyl]-N-(2-cyanoethyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 743 Step 2: 3-chlorobenzenethiol and 2-nitro-4-fluorobenzotrifluoride were used to prepNe 5-(3-chlorophenylsulfonyl)-2-trifluoromethyl-nitrobenzene. Step 3 : Following the same procedure described on example 677 (Step 3), 5-(3-chlorophenylsulfonyl)-2-trifluoromethyl-nitrobenzene was used to prepNe 5-(3-chlorophenylsulfonyl)-2-trifluoromethylaniline. Step 4: Following the same procedure described on example 677 (Step 4), 5-(3-chlorophenylsulfonyl)-2-trifluoromethylaniline, was used to prepNe 2-trifluoromethyl-5-(3-chlorophenylsulfonyl)- benzenesulfonyl chloride. Step 5: In an anNogous manner to example 435, 2-trifluoromethyl-5-(3-chlorophenylsulfonyl)- benzenesulfonyl chloride and propionitrile were used to prepNe 5-[(3-chlorophenyl)sulfonyl]-N-(2-cyanoetliyl)-2-(trifluoromethyl)beiizenesulfonamide. MS (ES-) m/z 450.9; HPLC purity 100% at 210-370 nm, 9.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 753: N-[l-(4-ferN-butylbenzoyl)piperidin-4-yl]-5-[(3-chlorophenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide Step 1 : Following the same procedure described on example 462, piperidin-4-yl-cNbamic acid tert-butyl ester and 4-tertbutylbenzoyl chloride were used to prepNe [l-(4-tert-butyl-benzoyl)-piperidin-4-yl]-cNbamic acid tert-butyl ester. Step 2: Following the same procedure described on example 688, [l-(4-tert-butyl-benzoyl)-piperidin-4-yl]-cNbamic acid tert-butyl ester was used to prepNe (4-amino-piperidin-l-yl)-(4-tert-butyl-phenyl)-methanone. Step 3: Following the same procedure described on example 435, 2- rrifluoroniethyl-5-(3-chlorophenylsulfonyl)- benzenesulfonyl chloride and (4-amino-piperidin-l-yl)-(4-tert-butyl-phenyl)-methanone were used to prepNe N-[l-(4-terNbutylbenzoyl)piperidin-4-yl]-5 - [(3-chloropheriyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 643.2; HPLC purity 99.3% at 210-370 nm, 1 1.0 mm.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1 .2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. ' HRMS: cNcd for C29H3oClF3N2O5S2 + H+, 643.13095; found (ESI, [M+H]+), 643.1304. Example 754: 5-[(3-chlorophenyl)sulfonyl]-N-(tetrahydro-2ff-pyran-4-yl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 435, 2-trifluoromethyl-5-(3- chlorophenylsulfonyl)- benzenesulfonyl chloride and tetrahydrofurfurylamine were used to prepNe 5- [(3 -chlorophenyl)sulfonyl] -N-(tetrahydro-2.£f-pyran-4-yl)-2-(trifluoromethyl)benzenesulfonamide. HPLC purity 100% at 21 0-370 nm, 9.5 min.; Xterra RP18, 3. 5n, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 755: 5-[(3-chlorophenyl)suIfonyl]-N-(2-pyridin-3-ylethyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 435, 2~trifluoromethyl-5-(3- chlorophenylsulfonyl)- benzenesulfonyl chloride and 3-(2-aminoethyl)pyridine were used to prepNe 5-[(3-chlorophenyl)surfonyl]-N-(2-pyridin~3-ylethyl)-2-(trifluoromethyl)benzenesulfonamide. MS (E$+)m/z 505.1; HPLC purity 94.1% at 210-370 mn, 9.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CaoHieClFslNCN + H+, 505.02649; found (ESI, [M+Hf), 505.0247. Example 756: 5-[(4-fluorophenyl)sulfonyl]-N-hydroxy-2-pyridin-2-ylethyl)-2-methylbenzenesulfonamide In an anNogous manner to Step 3, Example 298: 2-Methyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-ammo-l-pyridin-2-yl-ethanol were used to prepNe 5-[(4-fluorophenyl)sulfonyl]-AK2-hydroxy-2-pyridin-2-ylethyl)-2-methylbenzenesulfonamide. MS (ES+) iw/2 451.1; HPLC purity 100% at 210-370 nm, 7.9 min.; Xterra RP18,3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C2oHi9FN2O5S2 + H+, 451.07922; found (ESI, [M+H]+), 451.0801. Example 757: N-(2-hydroxy-2-pyridin-2-ylethyI)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to Step 3, Example 677: 5-Benzenesulfonyl-2-trifluoromethyl-benzenesulfonyl chloride and 2-amino-l-pyridin-2-yl-ethanol were used to prepNe N-(2-hydroxy-2-pyridin-2-ylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+)m/z 487.1; HPLC purity 100% at 210-370 nm, 8.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C2oHi7F3N205S2 + H+, 487.06037; found (ESI, [M+Hf ), 487.0581. Example 758: 5-(phenylsulfonyl)-N-{l-[2-(triflnoromethoxy)benzoyl]piperidin-4-yl}-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 2-trifluoromethoxybenzoyl chloride were used to prepNe 5-(phenylsulfonyl)-N-{l-[2-(trifluoromethoxy)benzoyl]piperidin-4-yl}-2-(trifluoromethyl)benzenesulfonamide. MS (ES+)m/z 637.1; HPLC purity 96.0% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C26H22F6N2O6S2 + H+, 637.08962; found (ESI, [M+H]4), 637.0891. Example 759: N-(4-tert-butylphenyI)-4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-cNboxamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)ben2ienesulfonamide and 4-tertbutylphenylisocyanate were used to prepNe N-(4-rerr-butylphenyl)-4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-cNboxamide. MS (ES+) m/z 624.2; HPLC purity 97.0% at 210-370 nm, 10.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C29H32F3N305S2 + H+, 624.1 8082; found (ESI, [M+H]+), 624.1806. Example 760: N-(l-benzoylpiperidin-4-yl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide Step 1 : In an anNogous manner to example 462, piperidin-4-yl-cNbamic acid tert-butyl ester and benzoyl chloride were used to prepNe (l-benzoyl-piperidin-4-yl)-cNbamic acid tert-butyl ester. Step 2: In an anNogous manner to example 680, (l-benzoyl-piperidin-4-yl)-cNbamic acid tert-butyl ester was used to gNe 1 -benzoyl-4-aminopiperidine. \ Step 3: In an anNogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and 1 -benzoyl-4-aminopiperidine were used to prepNe N(l-beiizoylpiperidin-4-yl)-5-(phenylsulfonyl)-2-(trifluoroniethyl)beiizenesulfonamide. MS (ES+)m/z 553.1; HPLC purity 98.6% at 210-370 am, 9.4 rain.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/mtn, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CzsHbFsNaCN + H+, 553.10732; found (ESI, [M+H]+), 553.1075. Example 761: N-[l-(4-teN-butylbenzoyI)pyrdiroIin-3-yl]-5-(phenylsuIfonyl)-2-(trifluoromethyl)benzenesulfonamide 1 Step 1 : In an anNogous manner to example 462, 3-aminopyrrolidine-l-carboxylic acid ter/-butyl ester and 4-tertbutylbenzoyl chloride were used to prepNe [l-(4-tert-butyl-benzoyl)-pyrrolidin-3-yl]-cNbamic acid tert-butyl ester. Step 2: In an anNogous manner to example 680, [1 -(4-tert-butyl-benzoyl)-pyrrolidin-3-yi]-cNbamic acid tert-butyl ester was used to gNe l-(4-tertbutylbenzoyl)-3-aminopyrrolidine. Step 3: In an anNogous manner to example 435, 2-trifluoromethyl-5- (phenylsulfonyl)- benzenesulfonyl chloride and l-(4-tertbutylbenzoyl)-3-aminopyrrolidine were used to prepNe N-[l-(4-ter?-butylbenzoyl)pyrrolidin-3-yl]-5-(phenylsuhcbnyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+)m/2 595.1; HPLC purity 96.2% at 210-370 nm, 10.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph-3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C28H29F3N2O5S2 + H+, 595.15427; found (ESI, [M+H]*), 595.1547. Example 762: N-(2-Aminoethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride Approximately 100 mL of a saturated solution of anhydrous hydrogen chloride in ethyl acetate was added under nitrogen to a solution of tert-butyl [2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cNbamate (2.00 g, 3.93 mmol), prepNed in Example 742, in 1 00 mL of ethyl acetate at room temperature. Nter the addition the reaction was stirred for 5 h. The solid was collected by filtration, rinsed with ethyl acetate and dried under reduced pressure to gNe N-(2-Nainoethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride (1.6270 g, 93%) as a white solid. MS (ES+)m/z 409.1; HRMS: cNcd for Ci5Hi5F3N2O4S2 + H*, 409.04981; found (ESI, [M+Hf), 409.049. Example 763: 5-(phenylsulfonyl)-2-(trifluoromethyl)-N-{l-[4-(trifluoromethyl)phenyl]piperidin-4-yl}benzenesulfonamide To a stirred solution of 5-(phenylsulfonyl)-Npiperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide (0.09 g, 0,2 mrnol) in dimethylformamide (1 mL) was added potassium cNbonate (0.06 g, 0.43 mmol) and 4-fluorobenzotrifluoride (0.06 g, 0.37 mmol). The resulting solution was heated to 100°C for three days and concentrated. The crude mixture was dissolved in methylene chloride, washed with ammonium chloride solution (sat.) and concentrated. Flash column sepNation using 0%-30% ethyl acetate/hexane gradient gave 5-(phenylsulfonyl)-2-(trifluoromethyl)-N {1 -[4-(trifluoromethyl)phenyl]piperidin-4-yl}benzenesulfbnamide (0.032 g, 28%). MS (ES+)w/z 593.1; HPLC purity 98.1% at 210-370 nm, 11.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold4min. HRMS: cNcd for €251*22N26482 + H+, 593.09979; found (ESI, [M+Hf), 593.1013. Example 764: N-[l-(4-tert-butylbenzoyl)piperidin-4-yl]-5-[(3-hydroxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 744, N-[l -(4-ferNbutylbenzoyl)piperidin-4-yl]-5-[(3-methoxyphenyl)sulfonyl]-2-(rrhcluoromethyl)benzenesulfonamide was used to prepNe N-[l-(4-rer/-butylbenzoyl)piperidin-4-yl]-5-[(3-hydroxyphenyl)sulfonyl]-2-(trifluoromethy l)benzenesulfonamide. MS (ES+) m/z 625.2; HPLC purity 97.0% at 210-370 nm, 10.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CagHaiFaNjOeSa + H+, 625.16484; found (ESI, [M+Hf), 625.1625. Example 765: 5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)benzenesulfonamide A stirred solution of 5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonyl chloride (0.101 g, 0.26 mmol) prepNed in same matter as example 611, was taken up in dichloromethane (2 ml). 1.2 eq of 4-Aminomethyltetrahydropyran and 1.5 eq. trietylamine was syringed into the reaction viN and was Nlowed to stir overnight at room temperature. The product was transferred onto a 4 g Isco RediSep® NormN Phase column and was purified by automated flash chromatography using a gradient of 20% to 1 00% hexane/ethyl acetate. Isolation of the main component gave the title compound of 5-(phenylsulfonyl)-N-(tetrahydro~2H-pyran-4-ylmethyl)-2-(trifluoromethyl)benzenesulfonamide (29 mg, 23.8%) as a white solid. MS (ES+) m/z 464.0; HPLC purity 98.9% at 210-370 nm, 8.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CigEbFaNOsSa + H+, 464.08077; found (ESI, [M+H]+), 464.079. Example 766: N-(2-morpholin-4-ylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 765, 5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonyl chloride and 2-morpholinoethanamine was used to prepNe the title compound of N-(2-morpholin-4-ylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide (99 mg, 78.8%) as a white solid. MS (ES+) m/z 479.1; HPLC purity 100% at 210-370 nm, 7.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for QgHNFsNaOsSz + H+, 479.09167; found (ESI, [M+H]+), 479.0921. Example 767: N-(3-morpholin-4-ylpropyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 765, 5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonyl chloride and N-(3-Aminopropyl)-morpholine was used to prepNe the title compound N-(3-morpholin-4-ylpropyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide (72 mg, 55.7%) as a white solid. MS (ES+)m/z 493.1; HPLC purity 93.8% at 210-370 nm, 6.9 rain.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Namon. Fonn. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. HRMS: cNcd for C2oH2,3F3N205S2 + H+, 493.10732; found (ESI, [M+HJ+), 493.1053; Example 768: N-(3-methoxypropyI)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 765, 5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonyl chloride and 3-methoxypropylamine was used to prepNe the title compound N-(3-methoxypropyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide (75 mg, 65.3%) as a white solid. MS(ES+)m/z438.1; HPLC purity 100% at 21 0-370 nm, 8.9 min.; Xterra RP18, 3.5u, 1 50 x 4.6 mm column, 1 .2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CpHigFsNOsN + H+, 438.06512; found (ESI, JM+H]+), 438.064. Example 769: N-[l-(hydroxymethyl)-2-methylpropyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 765, 5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonyl chloride and 2-amino-3-methylbutanol was used to prepNe the title compound N-[l -(hydroxymethyl)-2-methylpropyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide (27.5 mg, 23%) as a white solid. MS (ES+) m/z 452; HPLC purity 89.5% at 210-370 nm, 8.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CigHaoFsNCN + H+, 452.08077; found (ESI, [M+H]+), 452.0813. Example 770: N-[2-({[5-(Phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide Benzoyl chloride (39 uL, 0.336 mmol) was added under nitrogen to a mixture of N-(2-aminoethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)ben2enesulfonamidehydrochloride (150.7 mg, 0.339 mmole), prepNed in Example 762, and triethylamine (57 µL, 0.409 mmol) in 20 mL of methylene chloride at room temperature. Nter the addition the reaction was stirred at room temperature for approximately 24 h. An additionN 57 µL (0,409 mmol) of triethylamine and 20 uL (0.172 mmol) of benzoyl chloride were added Nid the reaction was stirred for 4 h at room temperature. The reaction was extracted with 2 N HC1. The organic layer was sepNated and the aqueous layer was extracted three times with 10 % methanol-methylene chloride. The combined organic extracts were dried (anhydrous magnesium sulfate) and the solvent removed under reduced pressure to gNe 183 nig of a solid. Purification of the solid on a 12 g Redi Sep Flash Column (silica gel) using a gradient of 100% methylene chloride to 20% ethyl acetate-methylene chloride as the eluent gave N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide (106.2 mg, 61%) as a white solid. MS(ESI+)m/z513; HRMS: cNcd for €22N3N0582 + H4", 513.07602; found (ESI, [M+H]+), 513.0763; AnN. CNcd for C22Hi9F3N2O5S2: C, 51.56; H, 3.74; N, 5.47. Found: C, 51.53; H, 3.58; N, 5.40. Example 771: 5-(phenylsulfonyl)-N-(2-pyridin-4-ylethyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 765, 5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonyl chloride and 2-(pyridine-4-yl)ethanamine was used to prepNe the title compound 5-(phenylsulfonyl)-N-(2-pyridin-4-ylethyl)-2-(trifluoromethyl)benzenesulfonamide (40.4 mg, 38%) as a white solid. MS (ES+)m/z 471.1; HPLC purity 100% at 210-370 nm, 8.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Nnmon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C2oHi7F3N2O4S2 + H+, 471.06546; found (ESI, [M+H]+), 471.0663. Example 772: N-(2,3-dihydro-lH-inden-2-yl)-5-(phenylsuIfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 765, 5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonyl chloride and 2-aminoindan was used to prepNe the title compound N-(2,3-dihydro- lH-inden-2-yl)-5-(phenylsulfonyl)-2-(trifluoroniethyl)benzenesulfonamide (56.2 mg, 44%) as a white solid. MS (ES-) m/z 480.0; HPLC purity 91.5% at 210-370 nm, 10.3 min.; Xterra RP1S, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 773: N-[(2R)-2-hydroxy-2-phenylethyl]-5-(phenyIsulfonyl)-2-(trifhioromethyl)benzenesulfonamide In an anNogous manner to example 765, 5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonyl chloride and (R)-2-amino-l-phenylethanol was used to prepNe the title compound N-[(2R)-2-hydroxy-2-phenylethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide (24.6 mg, 19%) as a white solid. MS (ES-) m/z 484.0; HPLC purity 100% at 210-370 nm, 9.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph-3.5/ACN+MeOH) for lOmin, hold 4min. Example 774: N-[(2S)-2-hydroxy-2-phenylethyl]-5-(phenylsuIfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 765, 5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonyl chloride and (S)-2-amino-l-phenylethanol was used to prepNe the title compound N-[(25)-2-hydroxy-2-phenylethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide (45.5 mg, 36%) as a white solid. MS (ES-) m/z 484.0; HPLC purity 100% at 210-370 run, 9.3 min.; Xterra RP18,3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 775: 4-Methyl-N-[2-({[5-(phenyIsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide In an anNogous manner as described in Example 770, replacing benzoyl chloride with 4-methyl-benzoyl chloride and using a gradient of 100% methylene chloride to 50% ethyl acetate-methylene chloride as the eluent gave 4-methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide (105.1 mg, 59%) as a white solid. MS (ES+) m/z 527.1; HUMS: cNcd for CasHaiFsNCN + H*, 527.09167; found (ESI, [M+H]+), 527.0905; AnN. CNcd for CNiFNCN: C, 52.46; H, 4.02; N, 5.32. Found: C, 52.28; H, 4.05; N, 5.12. Example 776: 4-tert-Butyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethy()pheiiyl]sulfonyl}amino)ethyl]benzamide In an anNogous manner as described in Example 775, and replacing 4-methyl-benzoyl chloride with 4-fcr/~butyl-benzoyl chloride, gave 4--tert-butyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide (134.2 mg, 70%) as a white solid. MS (ES+) m/z 569.2; HRMS: cNcd for C26H27F3N2O5S2 + H*, 569.13862; found (ESI, [M+Hf ), 569.1392; AnN. CNcd for €26*N3N0582: C, 54.92; H, 4.79; N, 4.93. Found: C, 54.89; H, 4.74; N, 4.77. Example 777: 4-chloro-N-[2-({[5-(phenyIsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyljbenzamide In an anNogous manner as described in Example 775, and replacing 4-methyl-benzoyl chloride with 4-fluoro-benzoyl chloride, gave 4-fluoro-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide (96.8 mg, 54%) as a white solid. MS (ES+) m/z 53 1.0; HRMS: cNcd for €221*N4N0582 + H*, 531.06660; found (ESI, [M+H]4), 531.0664; AnN. CNcd for CNHNNaOsSa: C, 49.81; H, 3.42; N, 5.28. Found: C, 49:71; H, 3.42; N, 5.09. Example 778: 4-Chloro-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyljsulfonyl}amino)ethyl]benzamide In an anNogous manner as described in Example 775, and replacing 4-methyl-benzoyl chloride with 4-chloro-benzoyl chloride, gave 4-chloro-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide (131.2 mg, 71%) as a white solid. MS (ES+) m/z 547.0; HRMS: cNcd for CaHigCUySfeCN + H*, 547.03705; found (ESI, [M+H]4), 547.0378; AnN. CNcd for CazHigClFNOsSa: C, 48.31; H, 3.32; N, 5.12. Found: C, 48.15; H, 3.38; N, 4.95. Example 779: 4-Bromo-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide In an anNogous manner as described in Example 775, and replacing 4-methyl-benzoyl chloride with 4-bromo-benzoyl chloride, gave 4-'bromo-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide (149.3 mg, 74%) as a white solid. MS(ESI+)m/z591; HRMS: cNcd for C22Hi8BrF3N2O5S2 + Ff, 590.98653; found (ESI, [M+H]+), 590.9851; AnN. CNcd for CNHisBrFsNOsSs: C, 44.68; H, 3.07; N, 4.74. Found: C, 44.57; H, 3.32; N, 4.55. Example 780: 4-Methoxy-N-[2-({[5-(phenyIsulfonyl)-2-(trifluororaethyl)phenyl]sulfonyl}amino)ethyl]benzamide In an anNogous manner as described in Example 775, and replacing 4-methyl-benzoyl chloride with 4-methoxy-benzoyl chloride, gave 4-methoxy-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amuio)ethyl]benzamide (163.5 mg, 89%) as a white solid. MS (ES+)m/z 543.1; HRMS: cNcd for C23H2iF3N2O6S2 + H+, 543.08659; found (ESI, [M+H]+), 543.0869; AnN. CNcd for C23H2iF3N2O6S2: C, 50.92; H, 3.90; N, 5.16. Found: C, 51.11; H, 3.71; N, 4.94. Example 781: N-[2-({[5-(Phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyll-4-(trifluoromethyl)benzamide j In an anNogous manner as described in Example 775, and replacing 4-methyl-benzoyl chloride with 4-trifluoromethyl-benzoyl chloride, gave N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-4-(trifluoromethyl)benzamide (118.8 mg, 60%) as a white solid. MS (ES+)m/z 581.0; HRMS: cNcd for C23H,8F6N2O5S2 + H*, 581.06341; found (ESI, [M+H]+), 581.0607; AnN. CNcd for C23Hi8F6N2O5S2: C, 47.59; H, 3.13; N, 4.83. Found: C, 47.45; H, 2.84; N, 4.63. Example 782: N-[2-({[5-(Phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}ammo)ethyl]-4-(trifluoromethoxy)benzamide In an anNogous manner as described in Example 775, and replacing 4-methyl-benzoyl chloride with 4-trifluoromethoxy-benzoyl chloride, gave N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}Naino)ethyl]-4-(trifluoromethoxy)berizamide (1 22.8 mg, 60%) as a white solid. MS (ES+) m/z 597.0; HRMS: cNcd for C23Hi8F6N2O6S2 + FT1", 597.05832; found (ESI, [M+H]+), 597.0574; AnN. CNcd for C23Hi8F6N2O6S2: C, 46.31; H, 3.04; N, 4.70. Found: C, 46.24; H, 2.59; N, 4.49. Example 783: N-[2-({[5-(Phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]isonicotinamide Isonicotinoyl chloride (61.5 mg, 0.345 mmol) was added under nitrogen to a mixture of N-(2-aminoethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride (150.1 mg, 0.337 mmol), prepNed in Example 762, and triethylamine (141 ML, 1.01 mmol) in 20 mL of methylene chloride at room temperature. Nter the addition the reaction was stirred at room temperature for approximately 24 h. The reaction was pNtitioned with water. The organic layer was sepNated and the aqueous layer was extracted three times with methylene chloride. The combined extracts were dried (anhydrous magnesium sulfate) and the solvent removed under reduced pressure to gNe 186.8 mg of a solid. Purification of the solid on a 12 g Redi Sep Flash Column (silica gel) using a gradient of 100% methylene chloride to 20% methanol-methylene chloride as the eluent gave N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]isonicotinamide (153.5 mg, 89%) as a white solid. MS (ES+) m/z 5 14.1; HRMS: cNcd for 021N31*30582 + Ff\ 514.07127; found (ESI, [M+H]+), 514.0713; AnN. CNcd for CajHjgFsNsOsSa: C, 49.12; H, 3.53; N, 8.18. Found: C, 48.98; H, 2.94; N, 8.04. Example 784: N-[(lR)-l-(hydroxymethyl)propyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide -J In an anNogous manner to example 765, 5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonyl chloride and (S)-(+)-2-amino-l-butanol was used to prepNe the title compound N-[(lR)-l-(hydroxymethyl)propyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide (74.6 mg, 65%) as a white solid. MS (ES+) m/z 438.0; HPLC purity 100% at 2 10-3 70 run, 8.5 min.;XterrNP18, 3.5u, 150x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CnHisFaNOjSa + H+, 438.06512; found (ESI, [M+H]+), 438.0621. Example 785: N-(2-hydroxyethyl)-5-[(3-methoxyphenyI)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide 1 In an anNogous manner to example 654, 2-trifluoromethyl-5-(3- methoxylphenylsulfonyl)- benzenesulfonyl chloride and ethanolamine were used to prepNe N-(2-hydroxyethyl)-5-[(3-methoxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonaniide. MS(ES-)w/z438.0; HPLC purity 100% at 210-370 nm, 8.3 min.; XterrNPIS, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for Ci6Hi6F3NO6S2 + H+, 440.04439; found (ESI, [M+Hf), 440.0446. Example 786: tert-butyl (35)-3-({[5-(phenylsulfonyl)-2-(trifluoromethy l)phenyl] sulfonyl} amino)piperidine-l-cNboxylate In an anNogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)-benzenesulfonyl chloride and S-3-aminopiperidine-l- carboxylic acid terf-butyl ester were used to prepNe terf-butyl (3S)-3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate. MS (ES-) m/z 547.0; HPLC purity 96.6% at 210-370 nm, 10.0 min.; XterrNP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CasNFaNaOeSi + H+, 549.13354; found (ESI, [M+Hf), 549.1335. Example 787: tert-butyl (trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate In an anNogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)-benzenesulfonyl chloride and R-3-aminopiperidine-l- carboxylic acid ferr-butyl ester were used to prepNe tNt-butyl (3/?)-3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate. MS (ES-) m/z 547.0; HPLC purity 97.3% at 210-370 nm, 10.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C23H27F3N2O6S2 + H+, 549.13354; found (ESI, [M+Hf), 549.1335. Example 788: N-[l-(2-hydroxyethyl)piperidin-4-yl]-5-(phenyIsulfonyl)-2-(trifluoromethyl)benzenesulfonamide To a stirred solution of 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide (0.09 g, 0.20 mmol) in 1,4-dioxane (1 mL) was added 2-bromoethanol (0.05, 0.40 mmol) and triethylamine (0.1 mL, 0.7 mmol). The resulting solution was heated 150°C in a microwave for 10 minutes and concentrated. Flash column sepNation using 0%-5% methanol/methylene chloride gradient gave N-[l-(2-hydroxyethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. (0.03 g, 30%). MS (ES+)w/z 493.1; HPLC purity 98.3% at 210-370 nm, 6.8 min.;XterrNP18, 3.5u, 150x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for 020N3N0582 + H+, 493.10732; found (ESI, [M+H]+), 493.1083. Example 789: tert-butyl 4-[({5-[(4-fluorophenyl)sulfonyl]-2-methylphenyl}sulfonyl)amino]piperidine-l-cNboxylate To a solution of 5-(4-fluoro-benzenesulfonyl)-2-methyl-benzenesulfonyl chloride (1.0 g, 2.87 mmol) in dichloromethane (20.0 mL) was added triethylamine (0.80 mL, 5.73 mmol) followed by 4-amino-l-Boc-piperidne (0.69 g, 3.44 mmol). The reaction was stirred overnight at room temperature under nitrogen. The following day the reaction was concentrated down onto silica gel and purified using automated chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of tert-butyl 4-[({5-[(4-fluorophenyl)sulfonyl]-2-methylphenyl}sulfonyl)amino]piperidine-l-cNboxylate (1.42 g, 97%). MS(ES-)m/z511.0. Example 790: 5-(phenylsulfonyl)-AT-[(3S)-piperidin-3-yl]-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 688, tert-butyl (3S)-3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate was used to prepNe 5-(phenylsulfonyl)-N-[(3S)-piperidin-3-yl]-2-(trifluoromethyl)benzenesulfonamide. MS (ES+);n/s 449.1; HPLC purity 97.1% at 210-370 nm, 6.8 min.; Xterra RP1S, 3.5u, 150 x 4.6 mm column, 1 . mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for Ci8Hi9F3N2O4S2 + H+, 449.081 11; found (ESI, [M+Hf), 449.0825. Example 791: 5-(phenylsulfonyl)-N-[(3JR)-piperidin-3-yl]-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 688, terl-butyl (3J?)-3-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate was used to prepNe 5-(phenylsulfonyl)-N-[(3J?)-piperidin-3-yl]-2-(trifluoromethyl)benzenesulfonamide. MS (ES+)m/z 449.1; HPLC purity 96.9% at 210-370 nm, 6.8 min.; Xterra RP 18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CigHi9F3N2O4S2 + H+, 449.081 1 1 ; found (ESI, [M+H]+), 449.0822. Example 792: 5-[(l,2-dimethyl-lir-indol-5-yl)sulfonyl]-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide Step 1: To a stirred solution of 4-fluoro-2-bromobenzotrifluoride (2.0 g, 8.23 mmol) in THF (50 mL) at -78 °C was added nButyl lithium 2.5M in hexane (4.0 mL, 10.0 mmol) dropwise over 5 minutes. The resulting solution was stirred for ISminutes, then sulfur dioxide was bubbled in over 20 minutes, and the solution as concentrated. The crude mixture was taken up in methylene chloride (50 mL) and N-Chlorosuccinimide (1 .1 g, 8.23 mmol) was added. The resulting solution was stirred room temperature for 1 .5hrs, washed with ammonium chloride solution (sat.) and concentrated. Flash column sepNation using 0%-30% ethyl acetate/hexane gradient gave 5-fluoro-2-trifluoromethylbenzenesulfonyl chloride (0.55 g, 25%). Step 2: hi an anNogous manner to example 435, 5-fluoro-2- trifluoromethylbenzenesulfonyl chloride and 4-aminopiperidine-l- carboxylic acid tert-butyl ester were used to prepNe ter/-butyl 4-({[5-fluoro-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate. Step 3: To a stirred solution of 5-bromo-2-methyl-indole (5.0 g, 23.5 mmol) in DMF (50 mL) at 0°C was added sodium hydride (1.13 g(60%), 28.05 mmol) and the resulting solution was stirred for 5 minutes. Methyl iodide (3.3mL, 52.8 mmol) was added and the reaction was Nlowed to wNm to room temperature. Nter Ihr, the reaction was quenched with ammonium chloride solution (sat), and extracted severN times with ethyl acetate. The combined organic layers were washed with brine, dried over magnesium sulfate, and concentrated. Flash column sepNation using 0%-10% ethyl acetate/hexane gradient gave crude l,2-dimethyl-5-bromoindole. This materiN was. dissolved in THF (30 mL) and chilled to -7S°C. nButyl lithium 2.5M in hexane (4.0 mL, 10.0 mmol) was added dropwise. Nter 10 minutes sulfur dioxide was bubbled into the reaction mixture for 15 minutes. The mixture was Nlowed to wNm to room temperature and concentrated to gNe l,2-dimethylindole-5-sulfinic acid lithium sNt. HRMS: cNcd for C2iH25F3N2O6S2 + H+, 523.11789; found (ESI, [M+H-C4H8]+), 467.0601. C4H8. Step 4: To a stirred solution of l,2-dimethylindole-5-sulfinic acid lithium sNt (0.10 g, 0.54 mmol) in dimethylformamide (1 mL), tot-butyl 4-({[5-fluoro-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate (0.115 g, 0.27 mmol) was added and the resulting solution was heated to 80°C overnight and concentrated. The crude materiN was taken up in ethyl acetate, washed with sodium bicNbonate solution (sat) and concentrated. Flash column sepNation using 0%-40% ethyl acetate/hexane gradient gave tert-butyl4-({[5-(l,2-dimethyl-lN-indol-5-yl)sulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate. Step 5: In an anNogous manner to example 688, tert-butyl 4-({[5-(l ,2-dimethyl-lH-indol-5-yl)sulfonyl)-2Ntrifluoromethyl)phenyl]surfonyl}amino)piperidine-l-cNboxylate was used to prepNe 5-[(l,2-dimethyl-lN-indol-5-yl)sulfonyl]-N-piperidrn-4-yl-2-(trifluoromethyl)benzenesulfonamide. MS (ES+)m/z 516.1; HPLC purity 100% at 210-370 nm, 8.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph-3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for €22N3N0482 + H+, 516.12331; found (ESI, [M+H]4), 516.1237. Example 793: tert-Butyl methyl [2-({[5-(phenylsuIfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyrjcNbamate 5-(Phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonyl cliloride (2.6940 g, 7.00 mmol), prepNed in Example 677, in 25 mL of methylene chloride was added under nitrogen dropwise over 30 minutes to a solution of N-(2-ominoethyl)-N-methyl cNbamic acid tert-butyl ester (1.25 mL, 6.99 mmol) and triethylamine (2.93 mL, 21.0 inrnol) in 50 mL of methylene chloride at room temperature. Nter the addition the reaction was stirred at room temperature for 7 h. The reaction was extracted with 2 N HC1. The organic layer was sepNated and the aqueous layer was extracted three times with methylene chloride. The combined extracts were dried (anhydrous magnesium sulfate) and the solvent removed under reduced pressure to gNe 2.98 g of a yellow foam. Purification of the foam on 500 g of silica gel (230-400 mesh) using 10% ethyl acetate-methylene chloride to 20% ethyl acetate-methylene chloride as the eluent gave tert-butyl methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cNbamate (862.1 mg, 24%) as a yellow foam. MS(ES)m/z521.0. Example 794: tert-butyl (35)-3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidine-l-cNboxylate In an anNogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)-benzenesulfonyl chloride and S-3-aminopyrrolidine-l- carboxylic acid tert-butyl ester were used to prepNe ter/-butyl (3S)-3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)pyrrolidine-1 -cNboxylate. MS (ES-)m/z 533.0; HPLC purity 97.3% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.S/ACN+MeOH) for lOmin, hold 4min. Example 795: tert-butyl (3H)-3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidine-l-carboxylate In an anNogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)-benzenesulfonyl chloride and R-3-aminopyrrolidine-l- carboxylic acid tert-butyl ester were used to prepNe tert-butyl (3J?)-3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidrne-l-cNboxylate. HPLC purity 97.6% at 210-370 nm, 9.9 min.; Xterra RP1S, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. MS (ES-) 771/z 533.0. Example 796: S-t (trifluoromethyi)benzenesulfonamide In an anNogous manner to example 688, tert-butyl (35)-3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidine-l-cNboxylate was used to prepNe 5-(phenylsulfonyl)-N-[(35r)-pyrroHdin-3-yl]-2-(trifluoromethyl)benzenesulfonamide. MS (ES+)m/? 434.7; HPLC purity 97.2% at 210-370 nm, 6.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C17H17F3N2O4S2 + H+, 435.06546; found (ESI, [M+H]+), 435.0656. Example 797: 5-(phenylsulfonyl)-.N-[(3R)-pyrrolidin-3-yl]-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 688, tert-butyl (3R)-3-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidine-l -cNboxylate was used to prepNe 5-(phenylsulfonyl)-N-[(3R)-pyrrolidin-3-yl]-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 434.7; HPLC purity 96.9% at 210-370 nm, 6.8 min.; Xterra RP18,3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for Ci7Hi7F3N2O4S2 + H+, 435.06546; found (ESI, [M+H]*), 435.0658. Example 798: 2-methyI-5-(phenylsulfonyl)-N-(tetrahydro-2H-thiopyran-4-yl)benzenesulfonamide Step 1: To a solution of tetrahydrothiopyran-4-one (3.0 g, 25.82 mrnol) and 2,4-dimethoxybenzylamine (4.3 g, 25.82 mmol) in dichloroethane was added sodium triacetoxyborohydride (7.7 g, 36.15 mmol). The reaction was stirred overnight at room temperature under nitrogen. The reaction was quenched with a saturated aqueous bicNbonate solution and extracted. Dried with magnesium sulfate and concentrated down to gNe (2,4-dimethoxy-benzyl)-(tetrahydro-thiopyran-4-yl)-amine (6.7 g, 97%). Step 2: To a solution of 5-benzenesulfonyl-2-methyl-benzenesulfonyl chloride (0.30 g, 0.90 mmol) in dichloromethane (12 mL) was added triethylamine (0.38 uL, 2.72 mmol) followed by (254-dimethoxy-benzyl)-(tetrahydro-thiopyran-4-yl)-amine (0.49 g, 1.81 mmol). The reaction was stirred overnight at room temperature under nitrogen. The following day the reaction was concentrated down onto silica gel and purified using automated chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of 5-ben2enesulfonyl-N-(2,4-dimethoxy-benzyl)-2-methyl-N-(tetrahydro-thiopyran-4-yl)-benzene sulfonamide . Step 3 : 5-Benzenesulfonyl-N-(2,4-dimethoxy-benzyl)-2-methyl-N-(tetrahydro-thiopyran-4-yl)-benzenesulfonamide was taken up in 5 mL of 6% trifluoroacetic acid/dichloromethane and was stirred overnight at room temperature under nitrogen. The reaction was extracted with water. The organic layer was washed with saturated solution of sodium bicNbonate and dried with magnesium sulfate. The reaction was concentrated down onto silica gel and purified using automated chromatography with a gradient mobile phase consisting of ethyl acetate 'and hexane resulting in the isolation of 2-methyl-5-(phenylsulfonyl)-N-(tetrahydro-2H-thiopyran-4-yl)benzenesulfonamide (0.31 g, 84%). MS(ES+)m/z411.7; HRMS: cNcd. for CigHjiNCNSs + H1", 412.0711: found (ESI, [M+H]+), 412.0681. Example 799: N-[2-(Methylamino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride Approximately 1 00 mL of a saturated solution of anhydrous hydrogen chloride in ethyl acetate was added to a solution of tert-butyl methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cNbamate (2.8555 g, 5.46 mmol), prepNed in Example 793, in 100 mL of ethyl acetate at room temperature. Nter the addition the reaction was stirred for 6 h. The solid was collected by filtration, rinsed with ethyl acetate and dried under reduced pressure to gNe N-[2-(methylamino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride (2.2506 g, 90%) as a white solid. MS (ES-) m/z 420.6; HRMS: cNcd for CieHnFNCNSa + H", 423.06546; found (ESI, [M+Hf), 423.0543. Example 800: N-[l-(4-benzoylbenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide ' A solution of 4-benzoyl-benzoyl chloride (34 mg, 0.14 mmol) in dichloromethane (1 mL) was added to a stirred dichloromethane solution of Example 688 (62 mg, 0.14 mmol) and triethylamine (0.28 mmol). The reaction was concentrated to dryness and immediately purified by flash column chromatography using an ethyl acetate hexane gradient (20-50%) resulting in the isolation of yY-[l-(4-benzo'ylbenzoyl)piperidin-4-yl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide (72 mg, 79%). MS (ES+) m/z 656.6; HPLC purity 93.4% at 210-370 nm, 10.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CsaHavFsNoOeSz + H+, 657.13354; found (ESI, [M+H]*), 657.1337. Example 801 : N-[l-(3-benzoylbenzoyI)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide A solution of 3-benzoyl-benzoyl chloride (34 mg, 0.14 mmol) in dichloromefhane (1 mL) was added to a stirred dichloromethane solution of Example 688 (62 mg, 0.14 mmol) and triethylamine (0.28 mmol). The reaction was concentrated to dryness and immediately purified by flash column chromatography using an ethyl acetate hexane gradient (20-50%) resulting in the isolation of N-[l-(3-benzoylbenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide (67 mg, 71%). MS (ES+) m/z 656.7; HPLC purity 95.1% at 210-370 nm, 10.0 min.; Xterra EP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/1 5-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for 1 Omin, hold 4min. HRMS: cNcd for CNFsNaCN + H+, 657.13354; found (ESI, [M-i-Hf), 657.1326. Example 802: l-Isopropyl-4-(phenylsulfonyl)benzene Step a The title compound was prepNed from 4-isopropylbenzenesulfonyl chloride (8.75 g, 40.0 mmol), benzene (20.0 mL, 200 mmol), and Numinum chloride (6.4 g, 48.0 mmol) according to the procedure and in the same manner as described in Example 678, step a. 1 -Isopropyl-4-(phenylsulfonyl)benzene (10.32g, 99%) was obtained as a homogeneous oil which solidified on standing. Stepb 2-Isopropyl-5-(phenylsulfonyl)benzenesulfonyl chloride l-Isopropyl-4-(phenylsulfonyl)benzene (10.4 g, 40.0 mmol) was heated with stirring at 60 °C for one hour under nitrogen with chlorosulfonic acid (26.5 mL, 400 mmol). The mixture was cooled to room temperature, poured slowly into a cold solution of 2N hydrochloric acid, and extracted with ethyl acetate (2x.). The organic phase was washed with a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the solvent concentrated in vacua to yield 2-isopropyl-5-(phenylsulfonyl)benzenesulfonyl chloride (3.3 g, 24%) as a homogeneous, colorless, crystNline solid. Step c N-(l-Benzoylpiperidin-4-yl)-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide A stirred solution of 2-isopropyl~5-(phenylsulfonyr)benzenesulfonyl chloride (0.18 g, 0.5 mmol) in dichloromethane (10 mL) was treated under nitrogen with (4-aminopiperidin-l-yl)(phenyl)methanone hydrochloride (0.18 g, 0.75 mmol) and a solution of diisopropylethylamine (0.26 g, 2.0 mmol) in dichloromethane. The reaction was stirred from 2-18 hours at room temperature. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%-100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to Nford, Nter crystNlization from diethyl ether-hexane, .?V-(l-benzoylpiperidin-4-yl)-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide (0.26 g, 76%), as a homogeneous, colorless, crystNline solid, m.p. 225 °C; MS (+ESI), m/z: 526.7 [M+H]+; HRMS: cNcd for C27H3oN2O5S2 + H+, 527.16689; found (ESI, [M+H]+), 527.1677; HPLC purity 100% at 210-370 nm, 9.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. Example 803: 2-Isopropyl-N-[l-(2-methoxybenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide The title compound was prepNed from 2-isopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.18 g, 0.5 mmol), (4-aminopiperidin-l-yl)(2-methoxyphenyl)methanone hydrochloride (0.20 g, 0.75 mmol), and diisopropylethylamine (0.26 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 802, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 75%-100% methyl ten -butyl ether in hexane at a flow rate of 50 mL/min to Nford 2-isopropyk/V-[l-(2- methoxybenzoyl)piperidin-4~yl]-5-(phenylsulfonyl)benzenesurfonamide (0.21 g, 75%), as a homogeneous, amorphous solid, m.p. 160-162 °C; MS (+ESI), m/z: 556.7 [M+Hf; HRMS: cNcd for C28H32N2O6S2 + H+, 557.17745; found (ESI, [M+H]+), 557.1782; HPLC purity 99.3% at 210-370 nm, 9.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. Example 804: ]V-[l-(3-Fluorobenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide The title compound was prepNed from 2-isopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.18 g, 0.5 mmol), (4-aminopiperidin-l-yl)(3-fluorophenyl)methanone hydrochloride (0.19 g, 0.75 mmol), and diisopropylethylamine (0.26 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 802, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%-100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min to Nford, Nter crystNlization from diethyl ether-hexane, N-[l-(3-fluorobenzoyl)piperidin-4-yl]-2-isopropyl-5- (phenylsulfonyl)benzenesulfonamide (0.16 g, 59%), as a homogeneous, colorless, crystNline solid, m.p. 215-218 °C; MS (+ESI), m/z: 544.7 [M+H]+; HRMS: cNcd for C27H29FN2O5S2 + H+, 545.15747; found (ESI, [M+H]+)5 545.158; HPLC purity 100% at 210-370 nm, 9.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. Example 805: N-[l-(4-FluorobenzoyI)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide The title compound was prepNed from 2-isopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.18 g, 0.5 mmol), (4-aminopiperidin-l-yl)(4-fluorophenyl)methanone hydrochloride (0.19 g, 0.75 mmol), and diisopropylethylamine (0.26 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 802, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%~100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min to Nford, Nter crystNlization from diethyl ether- hexane, N-[1 -(4-fluorobenzoyl)piperidin-4-yl]-2-isopropyl-5- (phenylsulfonyl)benzenesulfonamide (0.18 g, 64%), as a homogeneous, colorless, crystNline solid, m.p. 218-220 °C; MS (+ESI), m/z: 544.7 [M+H]+; HRMS: cNcd for C27H29FN2O5S2 + H+, 545.15747; found (ESI, [M+H]+), 545.1559; HPLC purity 100% at 210-370 nm, 9.6 min.; Xterra RP18, 3.5u,.150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. Example 806: N-[l-(2-FluorobenzoyI)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide The title compound was prepNed from 2-isopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.18 g, 0.5 mmol), (4-aminopiperidin-l-yl)(2-fluorophenyl)methanone hydrochloride (0.19 g, 0.75 mmol), and diisopropylethylamine (0.26 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 802, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%-100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min to Nford, Nter crystNlization from diethyl ether-hexane, N-[l -(2-fluorobenzoyl)piperidin-4-yl]-2-isopropyl-5- (phenylsulfonyl)benzenesulfonamide (0.18 g, 68%), as a homogeneous, colorless, crystNline solid, m.p. 210-212 °C; MS (+ESI), m/z: 544.7 [M+Hf; HRMS: cNcd for C27H29FN2O5S2 + H+, 545.15747; found (ESI, [M+H]+), 545.1573; HPLC purity 100% at 210-370 nm, 9.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. Example 807: 2-Isopropyl-5-(phenylsulfonyl)-]V-{l-[4-(trifluoromethyl)beiizoyl]piperidm-4-yljbenzenesulfonamide The title compound was prepNed from 2-isopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.18 g, 0.5 mmol), (4-aminopiperidin-l-yl)(4-(trifluoromethyl)phenyl)methanone hydrochloride (0.23 g, 0.75 mmol), and diisopropylethylamine (0.26 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 802, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 25%-100% methyl tert~buty\ ether in hexane at a flow rate of 50 mL/min to Nford 2-isopropyl-5-(phenylsulfonyl)-Nr-{l-[4-(trifluoromethyl)benzoyl]pipeiidin-4-yl}benzenesulfonamide (0.24 g, 79%), as a homogeneous, amorphous solid, m.p. 140-142 °C; MS (+ESI), m/z: 594.7 [M+H]+; HRMS: cNcd for C28H29F3N2OSS2 + H+, 595.15427; found (ESI, [M+H]+), 595.1538; HPLC purity 99.3% at 210-370 nm, 10.2 min.; Xten-a RP18, 3.5u, 150 x 4.6 nun column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for l0min, hold 4 min. Example 808: 2-Isopropyl-N-[l-(l-naphthoyI)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide The title compound was prepNed from 2-isopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.18 g, 0.5 mmol), (4-aminopiperidin-l-yl)(naphthNen-l-yl)methanone hydrochloride (0.22 g, 0.75 mmol), and diisopropylethylamine (0.26 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 802, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage8 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%-100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min to Nford 2-isopropyl-N-[l -(1 -naphthoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide (0.27 g, 92%), as a homogeneous, amorphous solid, m.p. 163-165 °C; MS (+ESI), m/z: 576.7 [M+H]+; HRMS: cNcd for CaiKbNOsN + H+, 577.18254; found (ESI, [M+H]+), 577.1828; HPLC purity 99.0% at 210-370 nm, 10.1 min.;XterrNP18, 3.5u, 150x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. Example 809: 2-Isopropyl-N-[l-(2-naphthoyl)piperidm-4-yl]-5-(phenylsulfonyl)benzenesulfonamide The title compound was prepNed from 2-isopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.18 g, 0.5 mmol), (4-aminopiperidin-l-yl)(naphthNen-2-yl)methanone hydrochloride (0.22 g, 0.75 mmol), and diisopropylethylamine (0.26 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 802, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotagelg> 40 Si column of pre-packed silica gel'(45 g), eluting with a gradient of 25%-100% methyl tert-- butyl ether in hexane at a flow rate of 50 mL/min to Nford 2-isopropyl-N~[l-(2- naphthoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide (0.24 g, 84%), as a homogeneous, amorphous solid, m.p. 130-132 °C; MS (+ESI), m/z: 576.7 [M+H]+; HRMS: cNcd for C3iH32N2O5S2 + H+, 577.18254; found (ESI, [M+H]+), 577.183; HPLC purity 99.7% at 210-370 nm, 10.1 min.; XterrNPIS, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. Example 810:7Y-[l-(3-Cyanobenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide The title compound was prepNed from 2-isopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.18 g, 0.5 mmol), 3-(4-aminopiperidine-l-cNbonyl)benzonitrile hydrochloride (0.20 g, 0.75 mmol), and diisopropylethylamine (0.26 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 802, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%-100% methyl terf-butyl ether in hexane at a flow rate of 50 mL/min to Nford N-[l-(3-cyanobenzoyl)piperidin~4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide (0.19 g, 69%), as a homogeneous, amorphous solid, m.p. 120-122 °C; MS (+ESI), m/z: 551.7 [M+H]+; HRMS: cNcd for CNtfeNsCN + H+, 552.16214; found (ESI, [M+Hf), 552.1634; HPLC purity 100% at 210-370 nm, 9.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. Example 811: N-[l-(4-Cyanobenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonNaide The title compound was prepNed from 2-isopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.18 g, 0.5 mmol), 4-(4-aminopiperidine-l-cNbonyl)benzonitnle hydrochloride (0.20 g, 0.75 mmol). and diisopropylethylamine (0.26 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 802, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage41 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 25%-100% methyl te/7-butyl ether in hexane at a. flow rate of 50 mL/min to Nford N-[l-(4-cyanobenzoyl)piperidin-4-yl]-2- isopropyl-5-(phenylsulfonyl)benzenesulfonamide (0.21 g, 77%), as a homogeneous, amorphous solid, m.p. 136-138°C; MS (+ESI), m/z: 551.7 [M+H]+; HRMS: cNcd for C28H29N3O5S2 + H+, 552.16214; found (ESI, [M+Hf), 552.1635; HPLC purity 100% at 210-370 nrn, 9.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. Example 812: Nl-(4-terNButylbenzoyl)piperidin-4-yI]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide The title compound was prepNed from 2-isopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.18 g, 0.5 mmol), (4-aminopiperidin-l-yl)(4-tert-butylphenyl)methanone hydrochloride (0.22 g, 0.75 mmol), and diisopropylethylamine (0.26 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 802, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 10%-100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min to Nford, Nter crystNlization from diethyl ether-hexane, N-[l -(4-tert-butylbenzoyl)piperidin-4-yi]-2-isopropyl-5- (phenylsulfonyl)benzenesulfonamide (0.28 g, 95%), as a homogeneous, colorless, crystNline solid, m.p. 150-152 °C; MS (+ESI), m/z: 582.8 [M+H]+; HRMS: cNcd for CaiHasNiOjSz + H+, 583.22949; found (ESI, [M+Hf), 583.2277; HPLC purity 99.4% at 210-370 nm, 10.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. Example 813: N-[l-(2-Ethoxy-l-naphthoyl)piperidin-4-ylj-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide The title compound was prepNed from 2-isopropyl-5- (phenylsulfonyl)bertzenesulfonyl chloride (0.18 g, 0.5 mmol), (4-aminopiperidin-l-yl)(2-ethoxynaphthNen-l-yl)methanone hydrochloride (0.25 g, 0.75 mmol), and diisopropylethylamine (0.26 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 802, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage111' 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 10%-100% methyl tert-butyl ether in hexane at a flow rate of 50 niL/min to Nford, Nter crystNlization from diethyl ether-hexane, N-[l-(2-ethoxy-l-naphthoyl)piperidin-4-yl]-2- isopropyl-5-(phenylsulfonyl)benzenesulfonamide (0.28 g, 89%), as a homogeneous, colorless, crystNline solid, m.p. 164-166 °C; MS (+ESI), m/z: 620.8 [M+H]+; HRMS: cNcd for CasHseNiOeSi + H+, 621.20875; found (ESI, [M+H]+), 621.2089; HPLC purity 100% at 210-370 ran, 10.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. Example 814: 5-[(4-hydroxyphenyl)sulfonyl)-J/V-(2-pyridin-3-ylethyl)-2-(trifluoromethyl)benzenesulfonamide Step 1: Following the same procedure described on example 677 (Step 2), 2-chloro-5-fluoronitrobenzene was used to prepNe 2-nitro-4-fluorobenzotrifluoride. Step 2: In an anNogous manner to example 743 (Step 2), 4- methoxybenzenethiol was used to prepNe 5-(4-memoxyphenylsulfonyl)-2-trifluoromethyl-nitrobenzene. Step 3: In an anNogous manner to example 677 (Step 3), 5-(4-methoxyphenylsulfonyl)-2-trifluoromethyl-nitrobenzene was used to prepNe 5-(4-methoxyphenylsulfonyl)-2-trifluoromethylaniline. Step 4: In an anNogous manner to example 677 (Step 4), 5-(4- methoxyphenylsulfonyl)-2-trifluoromethylaniline was used to prepNe 2-trifluoromethyl-5-(4-mernoxyphenylsulfonyl)-benzenesulfonyl chloride. Step 5: In an anNogous manner to example 435, 2-trifiuoromethyl-5-(4-methoxyphenylsulfonyl)-benzenesulfonyl chloride and 3-(2-aminoethyl)pyridine were used to prepNe 5-[(4-methoxyphenyl)sulfonyl]-N'-(2-pyridin-3-ylethyl)-2-(trifluoromethyl)benzenesulfonamide. " Step 6: In an anNogous manner to example 744, 5-[(4-methoxyphenyl)sulfonyl]-yV-(2-pyridin-3-ylethyl)-2-(trifluoromethyl)benzenesulfonamide, was used to prepNe 5-[(4-hydroxyphenyl)sulfonyl]-N-(2-pyridin-3-ylethyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 486.6; HPLC purity 95.7% at 210-370 nm, 8.0 min.; XterrNPIS, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. FIRMS: cNcd for C2oHI7F3N2O5S2 + H+, 487.06037; found (ESI, [M+H]+), 487.0609. Example 815: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-thiopyran-4-yl)benzenesulfonamide Step 1: To a solution of tetrahydrothiopyran (3.0 g, 25.82 mmol) and 2,4-dimethoxybenzylamine (4.3 g, 25.82 mmol) in dichloromethane (100 mL) was added sodium triacetoxyborohydride (7.7 g, 36.15 mmol). The reaction was stirred overnight at room temperature under nitrogen. The reaction was quenched with a saturated aqueous bicNbonate solution and extracted. Dried with magnesium sulfate and concentrated to gNe N-(2,4-dimethoxybenzyl)tetrahydro-2H-thiopyran-4-amine (6.7 g, 97%). Step 2: To a solution of 5-(4-fluorophenylsulfonyl)-2-isopropylbenzene-l-sulfonyl chloride (350 mg, 0.93 mmol) in dichloromethane 10 mL) was added triethylamine (388 pL, 2.79 mmol) followed by N-(2,4-dimethoxyben2yl)tetrahydro-2H-thiopyran-4-anime (497 mg, 1.86 mmol). The reaction was stirred overnight at room temperature. The following day the reaction was concentrated down onto silica gel and purified using automated chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of N-(2,4-dimethoxyberi2yl)-5-(4-fluorophenylsulfonyl)-2-isopropyl-N-(tetrahydro~2H-thiopyran-4-yl)benzenesulfonamide (504 mg, 89%). Step 3: N-(2,4-dimethoxybenzyl)-5-(4-fiuorophenylsulfonyl)-2-isopropyl-N-(tetrahydro-2H-thiopyran-4-yl)benzenesulfonamide (504 mg, 0.83 mmol) was dissolved in 6% trifluoroacetic acid/dichloromethane (6 mL) and stirred overnight at room temperature under nitrogen. Saturated bicNbonate solution was added and the reaction was extracted. Dried with magnesium sulfate and concentrated onto silica gel and purified using automated chromatogl'aphy with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-thiopyran-4-yl)benzenesulfonamide (350 mg, 92%). MS (ES+) m/z 456. Example 816: 5-[(4-fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-i-yl)ethyl]-2-(trifluoromethyl)benzenesulfonamicle Step 1: l-chloro-4-(4-fluorophenylsulfonyl)-2-nitrobenzene (L31023-148). A mixture of 4-chloro-3-nitrobenzenesulfonyl chloride (25.13 g, 98.1 mmol), fluorobenzene (50 ml, 533 mmol) and Numinum chloride (15.71 g, 118 mmol) refluxed under nitrogen overnight. The next morning the reaction was Nlowed to cool to R.T. and then was transferred to a 1 L beaker where the reaction was mixed with ice for ten minutes. The contents of the beaker was pNtitioned between ethyl acetate and water. The ethyl acetate layer was sepNated, dried (anhydrous MgSCN) and the solvent removed under reduced pressure to gNe 1 -chloro-4-(4-fluorophenylsulfonyl)-2-nitrobenzene (29.12 g, 93.9%). Step 2: 4-(4-fluorophenylsulfonyl)-2-nitro-l-(trifluoromethyl)benzene (L31023-152). To a flame dried flask the l-chloro-4-(4-fluorophenylsulfonyl)-2-nitrobenzene (29.12 g, 92.3 mmol) prepNed in the previous step was taken up in 200 mL of anh. N,N-Dimethylformamide and was Nlowed stir under nitrogen at ice bath temperature. To the stirring reaction at ice bath temp., copper nanopowder (25.24 g, 0.4 mol) and actNated cNbon (13.67 g, 1.1 mol) was added to the reaction stirred for fNe minutes to which dibromodifluoromethane (19.8 ml, 0.2 mol) was slowly syringed into the reaction. Nter the complete addition of the dibromodifluoromethane, the reaction was heated to 100° C for fNe hours and then Nlowed to cool to R.T.. The contents of the flask was filtered though a plug of celite and the filtrate was then pNtitioned between ethyl acetate and ammonium chloride / water once. The organic layer was washed twice more with water. The ethyl acetate layer was sepNated, dried (anhydrous MgSCU) and the solvent removed under reduced pressure to gNe 4-(4-fluorophenylsulfonyl)-2-nitro-l-(trifluoromethyl)benzene (24.3 g, 75.3%). Step 3: 5-(4-fluorophenylsulfonyl)-2-(trifluoromethyl)aniline (L31023-153). A mixture of 4-(4-fluorophenylsulfonyl)-2-nitro-l-(trifluoromethyl)benzene (24.3 g, 69.6 mmol) and tin(II) chloride (65.9 g , 0.4 mol) was taken up in 1:16 water / methanol was refluxed for three days. The reaction was concentrated and then was pNtitioned between ethyl acetate and 2N hydrochloric acid. The ethyl acetate layer was sepNated, dried (anhydrous MgSO4) and the solvent removed under reduced pressure to gNe 25.6 g of a brown solid. The solid was purified on the Isco using a 330 g column and a gradient of hexane/ methylene chloride to gNe 5-(4-fluorophenylsulfonyl)-2-(trifluoromethyl)aniline. Step 4: 5-(4-fluorophenylsulfonyl)-2-(trifluoromethyl)benzene-1 -sulfony 1 chloride (L31023-160). 5-(4-fluorophenylsulfonyl)-2'-(trifluoromethyl)aniline(3.79 g, 11.9 mmol) prepNed in the previous step was taken up in 100 ml of acetonitrile and was cooled to ice bath temperature. To the chilled flask, 10 ml of acetic acid, 10 ml of hydrochloric acid and then sodium nitrite (0.98 g, 14.2 mmol) taken up in 2 ml of water were slowly syringed into the flask. The mixture was Nlowed to stir at ice bath temperature for one hour. Sulfur dioxide was then bubbled into the flask for fifteen minutes and then copper(II) chloride dihydrate taken up in 2 ml of water was syringed into the flask and was Nlowed to stir at ice bath temp, for three hours. The mixture was Nlowed to wNm to room temp, and men was pNtitioned between ethyl acetate and water. The ethyl acetate layer was sepNated, dried (anhydrous MgSCN) and the solvent removed under reduced pressure to provide an orange oil which was purified on the Isco using a 330 g column and a gradient of hexane/ methylene chloride to gNe 5-(4-fluorophenylsulfonyl)-2-(trifluoromethyl)benzene-l-sulfony 1 chloride (2.2234 g, 46.5 %). Step 5: 5-[(4-fluorophenyl)sulfonyl]-N-[299.9% peak 2 - >99.9%; Ethyl Pyridine (4.6x250mm) column, 2mL/min, 15% MeOH /85%CO2. HPLC purity 100% at 210-370 run, 8.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold4min. Example 818: tert-butyl 4-({[5-[(4-fluorophenyl)sult'onyl]-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate In an anNogous manner to example 765, a mixture of 5-[(4- fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-l-yl)ethyl]-2-(trifluoromethyl)benzenesulfonamide) and 5-(2-fluorophenylsulfonyl)-2-(trifluoromethyl)benzene-l-sulfonyl chloride and 4-Amino-piperidine-1-carboxylic acid tert-butyl to gNe approximately 40 mg of the isomeric mixture that was dissolved in 2 mL of methanol/acetonitrile. 250 uL of the resulting solution was repetitNely injected onto the SupercriticN Fluid Chromatography (SFC) instrument, and the baseline resolved isomers were sepNately collected using the conditions described below to gNe the title compound tert-butyl 4-({[5-[(4-fluorophenyl)sulfonyl]-2- (trifluoromethyl)phenyl]suhcbnyl}amino)piperidme-l-cNboxylate (27.6 mg, 8%) as a white solid. SFC Instrument: Berger MultiGram Prep SFC Column: Ethylpyridine; 10 p.m; 250 mm L x 20 mm ID Column temperature: 35°C SFC Modifier: 15% MeOH/85% CO2 Flow rate: 50 mL/min Outlet Pressure: 100 bN Detector: UV at 220 nm MS (ESI-) m/z 565; HPLC purity The purity was checked by anNyticN SFC: peak 1 - >99.9% peak 2 - >99.9%; Ethyl Pyridine (4.6x250mm) column, 2mL/min, 15% MeOH / 85% CO2. HPLC purity 100% at 210-370 nm, 10.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HUMS: cNcd for CzsHNNzCN + H+, 567.12412; found (ESI, [M+H-C4H8J+), 511.0644. Example 819: N-Methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide Benzoyl chloride (38 \\L, 0.327 mmol) was added under nitrogen to a solution of N-[2-(methylamino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride (150.8 mg, 0.329 mmol), prepNed in Example 799, and tiiethylamine (229 (.iL, 1.64 mmol) in 20 mL of methylene chloride at room temperature. Nter the addition the reaction was stirred at room temperature for 19 h. The reaction was extracted two times with 2 N HC1, dried (anhydrous magnesium sulfate) and the solvent removed under reduced pressure to gNe 184.1 mg of a solid. Purification of the solid on a 12 g Redi Sep Fash Column (silica gel) using a gradient of 100% methylene chloride to 40% ethyl acetate-methylene chloride as the eluent gave N-methy l-N-[2-( {[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]suhconyl}amino)ethyl]benzamide (156.3 mg, 91%) as a white solid. MS (ES+) m/z 526.6; HRMS: cNcd for CasHNFsNiOsSa + Ff, 527.09167; found (ESI, [M+H]+), 527.0908; AnN. CNcd for CNFfeiFaNiOjSa . 0.20 CH2C12: C, 51.27; H, 3.97; N, 5.15. Found: C, 52.54; H, 3.87; N, 5.17. Example 820: N-(2-cyanoethyl)-5-[(4-inethoxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide Step 1: Following the same procedure described on example 677 (Step 2), 2-chloro-5-fluoronitrobenzene was used to prepNe 2-nitro-4-fluorobenzotrrfluoride. Step 2: In an anNogous manner to example 743 (Step 2), 4- methoxybenzenethiol was used to prepNe 5-(4-methoxyphenylsulfonyl)-2-trifluoromethyl-nitrobenzene. Step 3: In an anNogous manner to example 677 (Step 3), 5-(4-methoxyphenylsulfonyl)-2-trifluoromethyl-nitrobenzene was used to prepNe 5-(4-rnethoxyphenylsulfonyl)-2-trifluoromethylaniline. Step 4: In an anNogous manner to example 677 (Step 4), 5-(4- methoxyphenylsulfonyl)-2-trifluoromethylaniline was used to prepNe 2-trifluoromethyl-5-(4-methoxyphenylsulfonyl)-benzenesulfonyl chloride. Step 5: In an anNogous manner to example 435, 2-trifluoromethyl-5-(4-methoxyphenylsulfonyl)-benzenesulfonyl chloride and aminopropionitrile were used to prepNe N-(2-cyanoethyl)-5-[(4-methoxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide. MS (ES+)m/z 448.6; HPLC purity 94.6% at 21 0-370 nm, 8.6min.;XterrNP18, 3.5u, 150x4. 6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CnHisFsNiASz + H+, 449.04472; found (ESI, [M+H]+), 449.0429. Example 821: N-(2-cyanoethyI)-5-[(4-hydroxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 744, W-(2-cyanoethyl)-5-[(4- methoxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide was used to prepNe N-(2-cyanoethyl)-5-[(4-hydroxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide MS (ES-)m/z 432.5; HPLC purity 85.6% at 210-370 nm, 7.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1 .2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for deHisFsNzOsSa + H+, 435.02907; found (ESI, [M+HT), 435.0308. Example 822: 4-Methoxy-N-methyI-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide In an anNogous manner as described in Example 819, and replacing benzoyl chloride with 4-methoxy-benzoyl chloride, gave 4-methoxy-N-methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide (176.5 mg, 97%) as a white solid. MS (ES+) m/z 556.6; HRMS: cNcd for CNNNaCN + H+, 557.10224; found (ESI, [M+H]+), 557.1029; AnN. CNcd for C24H23F3N2O6S2: C, 51.79; H, 4.17; N, 5.03. Found: C, 52.03; H, 4.13; N, 4.74. Example 823: N-(2-hydroxy-2,3-dihydro-lH-inden-l-yl)-5-(phenylsuIfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 765, 5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonyl chloride and l-amino-2,3~dihydro-lH-inden-2-ol was used to prepNe the title compound N-(2-hydroxy-2,3-dihydro-lH-inden-l-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide (150.2 mg, 57%) as a white solid. MS(ES-)m/z495.7; HPLC purity 94.4% at 210-370 run, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. FIRMS: cNcd for C22Hi8F3NO5S2 + H+, 498.06512; found (ESI, [M+H]+), 498.0664. Example 824: 5-[(2-fluorophenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yI)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 765, 5-[(4-fluorophenyl)sulfonyl]-N-[2-(1 H-imidazol-1 -yl)emyl]-2-(trifluoromethyl)benzenesulfonamide)and 5~(2-fluorophenylsuIfonyl)-2-(trifluoromethyl)benzene-l-sulfonyl chloride and 4-aminotetrahydropyran to gNe approximately 85 mg of the isomeric mixture that was dissolved in 2.5 mL of methanoVacetonitrile. 250 uL of the resulting solution was repetitNely injected onto the SupercriticN Fluid Chromatography (SFC) instrument, and the baseline resolved isomers were sepNately collected using the conditions described below to gNe the title compound 5-[(4-fluorophenyl)sulfonyl]-N-(te1rahyciro-2H-pyranN (22.2 mg, 8%) as a white solid. SFC Instrument: Berger MultiGram Prep SFC Column: Ethylpyridine; 1 Oum; 250 mm L x 20 mm ID Column temperature: 35°C SFC Modifier: 15% MeOH /85% CO2 Flow rate: 50 mL/min Outlet Pressure: 100 bN Detector: UV at 220 nm MS (ES+) m/z 467.6; HPLC purity 100% at 210-370 nm, 8.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph-3.5/ACN+MeOH) for lOmin, hold 4min. Example 825: 5-(phenylsulfonyl)-N-[l-(phenylsulfonyl)piperidin-4-yl]-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to Example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and benzenesulfonyl chloride were used to prepNe 5- • (phenylsulfonyl)-N-[l-(plienylsulfonyl)piperidin-4-yl]-2-(trifluoromethyl)benzenesulfonNnide. MS (ES+) m/z 588.5; HPLC purity 98.0% at 210-370 run, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CNNFsNAA + H+, 589.07431; found (ESI, [M+Flf ), 589.0731. Example 826: N-{2-[(anilinocNbonyl)(methyl)amino]ethyl}-5-(phenyIsulfonyl)-2-(trifluoromethyl)benzenesulfonamide To a stirred suspension of N-[2-(methylamino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride (0.16 g, 0.35 mmol) from Example 799 in a solution of phenyl isocyanate (42 mg, 0.35 mmol) in QHbCk (8 mL) under NZ at room temperature was added diisopropylethylamine (70 u.L, 52 mg, 0.40 mmol). The mixture was stirred at room temperature for 18 hours. It was loaded directly onto a silica gel column and eluted with a gradient of hexane and ethyl acetate to gNe 0.1 8 g (95%) of N-{2-[(anilinocNbony l)(methyl)Nnino]ethyl} -5 -(phenylsulfony l)-2-(trifluoromethyl)benzenesulf onamide . MS (ES+) m/z 541 .6; HRMS: cNcd for QaHNaNsOsSz + H+, 542.10257; found (ESI, [M+H]*), 542.1027. Example 827: N-(2-{methyl[(pyridin-3-ylamino)cNbonyl]amino}ethyI)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfcmamide In an anNogous manner to Example 826, N-[2-(methylamino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and pyridine-3 -isocyanate were used to prepNe N-(2-{methyl[(pyridin-3-y lamino)cNbonyl] amino } ethyl)- 5 -(phenylsulfony l)-2-(tr ifluoromethy l)benzenesulfonamide. MS(ES+)w/z543.2; HRMS: cNcd for CaNiFsWsSa + H+, 543.09782; found (ESI, [M+H]+), 543.0983. Example 828:N-{2-[{[(2,4-dimethoxyphenyl)amino]cNbonyl}(methyl)amino]ethyl}-5-(phenylsulibnyl)-2-(trifluoromethyl)benzenesnlfonNaide In an anNogous manner to example 826, A-[2-(metlaylamino)ethyl]-5- (phenylsulfonyl)-2-(frifluoromethyl)beiizenesulfonamide hydrochloride from Example 799 and 2,4-dimethoxyph.enyl isocyanate were used to prepNe' N-{2-[{[(2,4-dimethoxyphenyl)amino] cNbony 1 } (memy l)amino] ethyl } -5 -(phenylsulfony l)-2-(trifluoromethyl)benzenesulfonamide. MS(ES+)/?Nz601.6; HRMS: cNcd for C25H26F3N3O7S2 + H+, 602.12370; found (ESI, [M+HO, 602.1265. Example 829: N-{2-[[(N,N-butylamino)carbonyl](methyl)amino]ethyl}-5-(phenylsulfonyI)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to Example 826, N-[2-(methylamino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and 4-(tert-buryl)phenyl isocyanate were used to prepNe N-{2-[[(tert-butylamino)cNbonyl](methyl)amino]ethyl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS(ES+)m/z521.7; HRMS: cNcd for CaiHzeFsNsOsSs + H+, 522.13387; found (ESI, [M+H]*), 522.1318. Example 830: N-{2-[{[(4-methoxyphenyl)amino]cNbonyI}(methyl)aminolethyl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide t In an anNogous manner to Example 826, N-[2-(methylamino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and 4-methoxyphenyl isocyanate were used to prepNe N-{2-[{[(4-methoxyphenyl)amino]cNbonyl}(methyl)amino]ethyl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) ™/z57 1.6; HRMS: cNcd for C24H24F3N306S2 + H+5 572.11314; found (ESI, [M+H]+), 572.1152. Example 831: N-{2-[[(butyIamino)cNbonyl](methyl)amino]ethyl}-5-(phenyIsulfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to Example 826, N-[2-(methylamino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and butyl isocyanate were used to prepNe N-{2-[[(butylamino)cai-bonyl](methyl)amino]ethyl}-5- (phenylsulfonyl)-2-(trifluorometliyl)benzenesul'fonamide. MS(ES+)w/z521.7; HUMS: cNcd for CaiBbeFsWsSa + H+, 522.13387; found (ESI, [M+H]+), 522.1337. Example 832: N-{2-[{[(2,4-difluorophenyl)amino]cNbouyl}(methyl)amino]ethyl}-5-(phenylsulfonyl)-2-(triiluoromethyl)benzenesulfonamide In an anNogous manner to Example 826, N-[2-(methylamino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and 2,4-difluorophenyl isocyanate were used to prepNe N-{2-[{[(2,4-difluorophenyl)amino]cNbonyl}(methyl)amino]ethyl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 577.6; HRMS: cNcd for C23H2oF5N3O5S2 + H+, 578.08373; found (ESI, [M+H]+), 578.0847. Example 833: Nmethyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidine-l-cNboxamide To a stirred suspension of N-[2-(methylamino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride (0.16 g, 0.35 mmol) from Example 799 in a solution of 1-pyrrolidinecNbonyl chloride (39 |oL, 47 mg, 0.35 mmol) in CHiCb (8 mL) under N2 at room temperature was added diisopropylethylamine (0.26 mL, 0.19 g, 1.5 mmol). The mixture was stirred at room temperature for 18 hours. It was loaded directly onto a silica gel column and eluted with a gradient of hexane and ethyl acetate to gNe 0.16 g (85%) of N-methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidine-l-cNboxamide. MS (ES+) w/z 519.7. Example 834: N-{2-[[(diethylamino)cNbonyl](methyl)amino]ethyl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to Example 833, N-[2-(methylamino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and diethylcNbamoyl chloride were used to prepNe N-{2- [[(diethylamino)cNbonyl](methyl)amino]ethyl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS(ES+)ro/z521.8; HEMS: cNcd for C2iH26F3N3O5S2 + H+, 522.13387; found (ESI, [M+Hf), 522.1322. Example 835: N-methyl-N-[2-({[5-(phenylsulfonyI)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl)morpholine-4-cNboxamide In an anNogous manner to Example 833, N-[2-(methylamino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and 4-morpholinylcNbonyl chloride were used to prepNe N-methyl-N[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]morpholine-4-cNboxamide. MS (ES+) m/z 535.7; HRMS: cNcd for C2iH24F3N3O6S2 + H+, 536.11314; found (ESI, [M+Hf), 536.1124. Example 836: N-[2-(methyl{(methyl(phenyI)amino]cNbonyl}amino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to Example 833, N-[2-(methylamino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and N-methyl-N-phenyl cNbamoyl chloride were used to prepNe N-[2-(methyl{[methyl(phenyl)amino]cNbonyl}amino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 555.7; HRMS: cNcd for CNNNsOsSa + H+, 556.1 1822; found (ESI, [M+H]4), 556.1 173. Example 837: N-Methyl-N-l2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyll-2-furamide In an anNogous manner as described in Example 819, and replacing benzoyl chloride with furan-2-cNbonyl chloride, gave N-methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-2-furamide (156.3 mg, 93%) as a white solid. MS (ES+) m/z 5 16.6; HRMS: cNcd for C2iHi9F3N2O6S2 + H", 517.07094; found (ESI, [M+Hf), 517.072; AnN. CNcd for C2iHi9F3N206S;.: C, 48.83; H, 3.71; N, 5.42. Found: C, 49.02; H, 3.44; N, 5.31. Example 838: 4-tert-Butyl-N-me(hyl-N-[2-({[5-(phenyIsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}ammo)cthyl]benzamide In an anNogous manner as described in Example 819, and replacing benzoyl chloride with 4-terf-butyl-benzoyl chloride, gave 4-tert-butyl-N-methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide (184.0 mg, 97%) as a white solid. MS (ESI+) m/z 583; HRMS: cNcd for CNHbFsNzOsSa + H*", 583.15427; found (ESI, [M+H]+), 583.1552; AnN. CNcd for CrrHztfNiOsSt: C, 55.66; H, 5.02; N, 4.81. Found: C, 55.63; H, 4.90; N, 4.54. Example 839: N-Methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyI)phenyl]s«lfonyl}amino)ethyl]-2-(trifluoromethoxy)benzamide • • ' In an anNogous manner as described in Example 819, and replacing benzoyl chloride with 2-trifluoromethoxy-benzoyl chloride, gave N-methyl-N-[2-({[5-(phenylsulfonyl)-2-(1iifluoromethyl)phenyl]sulfonyl}amino)ethyl]-2-(tiifluoromethoxy)benzamide (184.1 mg, 92%) as a white solid foam. MS(ESI+)m/z611; HRMS: cNcd for C24H2oF6N2O6S2 + H*, 611.07397; found (ESI, [M+H]+), 61 1.0728; AnN. CNcd for C24H2oF6N2O6S2: C, 47.21; H, 3.30; N, 4.59. Found: C, 47.51; H, 2.90; N, 4.43. Example 840: 5-(phenylsulfonyl)-N-pyrrolidin-3-yl-2-(trifluoromethyl)benzenesulfonamide Step 1 : Following the same procedure described on example 435, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and 3-aminopyrrolidine-l-cNboxyiic acid terf-butyl ester were used to prepNe tert-butyl-3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidine-l-cNboxylate. Step 2: Following the same procedure described on example 688, ter/-butyl-3-( { [5-(pheny lsulfonyl)-2-(trifluoromethyl)pheny 1] sulfonyl } amino)pyrrolidine- 1 -cNboxylate was used to prepNe 5-(phenylsulfonyl)-N'-pyrrolidin-3-yl-2-(trifluoromethyl)benzenesulfonamide. MS (ESI+) m/z 435; HPLC purity 94.2% at 210-370 run, 6.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff, Ph=3.5/ACN+MeOH) for lOmin, hold4min. HRMS: cNcd for CnHnFaNiCN + H+, 435.06546; found (ESI, [M+H]4), 435,0666. Example 841 : N-[(2R*,4SsV,6S*)-2,6-dimethyItetrahydro-2H-pyran-4-yl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide Step 1 : 2,6-Dimethyl-gamma-pyrone (5.0 g, 40.28 mmol) was hydrogenated with pNladium on cNbon (250 mg) in ethanol (50 mL) at 50 psi. The reaction was filtered through Celite® and washed with ethanol. The filtrate was concentrated to gNe (2R,6S)-2,6~ dimethyldihydro-2H-pyran-4(3H)-one (5.1 g, 99%). Step 2: To a solution of (2R,6S)-2,6-dimethyldihydro-2H-pyran-4(3H)-one (5. 1 g, 39.79 mmol) in dichloromethane (50 mL) and 2,4-dimethoxybenzylamine (6.7 g, 39.79 mmol) was added sodium triacetoxyborohydride (1 1 .8g, 55.70 mmol). The reaction was stirred overnight at room temperature under nitrogen. Added saturated bicNbonate solution and extracted. Dried with magnesium sulfate and concentrated to gNe (2R,4S,6S)-N-(2,4-dimemoxybenzyl)-2,6-dimemyltetrahydro-2H-pyran-4-amine (10.8 g, 97%). Step 3 : To a solution of 5-(4-fluorophenylsulfonyl)-2-methylbenzene- 1 -sulfonyl chloride (150 mg, 0.43 mmol) in dichloromethane (5.0 mL) was added triethylamine (137 pL, 0.25 mmol) followed by (2R,4S,6S)-N-(2,4-dimethoxyben2yl)-2,6-dimethyltetrahydro-2H-pyran-4-amine (132 mg, 0.47 mmol). The reaction was stirred overnight at room temperature. The following day the reaction was concentrated down onto silica gel and purified using automated chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of N-(2,4-dimethoxybenzyl)-N-((2R,4s,6S)-256-dmiethylterrahydro-2H-pyranNyl)-5-(4-fluorophenylsulfonyl)-2-methylbenzenesulfonaniide(96 mg, 38%). Step 4: N-(2,4-dimethoxyben2yl)-N-((2R,4S36S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-5-(4-fluorophenylsulfonyl)-2-methylbenzenesulfonamide (96 mg, 0.16 mmol) was dissolved in 6% trifluoroacetic acid/dichloromethane (6 mL) and stirred overnight at room temperature under nitrogen. Saturated bicNbonate solution was added and the reaction was extracted. Dried with magnesium sulfate and concentrated onto silica gel and purified using automated chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of N-[(2R*,4S*,6S*)-2,6-dimethyltetrahydro-2H-pyran-4-yl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide (33 mg, 46%). MS (ES-) m/z 440; HRMS: cNcd for CioNFNOsS, + H+, 442.1 15821; found (ESL [M+H]4 ), 442.1 147. Example 842: 5-{[4-(methylamino)phenyl]sult'onyl}-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide Step 1 : A stirred solution of tert-butyl 4-({[5-[(4-fiuorophenyl)sulfonyl]-2-(trifluoromethyl)phenyl]suifonyl}amino)piperidine-l-cNboxylate (0.10 g, 0.18 nimol) in 33% methylamine in ethanol (0.5 mL) was microwave irradiated for 15 minutes at 160°C. The resulting solution was washed with ammonium chloride solution (sat.) and extracted with ethyl acetate. The organic layer was concentrated to gNe tert-butyl 4-({[5-[(4-methylaminophenyl)sulfonyl]-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidme-l-cNboxylate. Step 2: Following the same procedure described on example 688, tert-butyl 4-( ( [5- [(4-methylaminopheny l)sulfonyl]-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidine- 1 -cNboxylate was used to prepNe 5-{[4-(memylammo)phenyl]sulfonyl}-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide. MS(ESI+)m/z478; HPLC purity 100% at 210-370 run, 7.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold4min. HRMS: cNcd for CisHNNaCNS: + H+, 478.10766; found (ESI, [M+Hf), 478.1064. Example 843: 5-{[4-(dimethylamino)phenyl]sulfonyl}-W-piperidiii-4-yl-2-(trifluoromethyl)benzenesulfonamide Step 1 : Following the same procedure described on example 842, dimethylamine in THF and tert-butyl 4-({[5-[(4-fluorophenyl)sulfonyl]-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate was used to prepNe tert-butyl 4-({[5-[(4-dimethylaminophenyl)sulfonyl]-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidine- 1 -cNboxylate. Step 2: Following the same procedure described on example 688, tert-butyl 4-( ( [5- [(4-dimethylaminophenyl)sulfonyl]-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidine-1 -cNboxylate was used to prepNe 5-{[4-(dimethylamino)phenyl]sulfonyl}-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide. MS (ESI+) m/z 492; HPLC purity 97.1%'at 210-370 run, 7.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CzoHwPaNaCNSa + H+, 492.12331; found (ESI, [M+H]+), 492.1243. Example 844: 5-({4-[(2-hydroxyethyl)amino]phenyI}sulfouyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide Step 1: Following the same procedure described on example 842, ethanolamine inTHF and tort-butyl 4-({[5-[(4-fiuorophenyl)sulfonyl]-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate was used to prepNe 4-({[5-[(4-[(2-hydroxyethyl)amino]phenyl)sulfonyl]-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidine-l -cNboxylate. Step 2: Following the same procedure described on example 688, 4-({[5-[(4-[(2-hydroxyethyl)amino]phenyl)sulfonyl]-2-(trifluoromethyl)phenyl]sulfonyl}Nnino)piperidine-l-cNboxylate was used to prepNe 5-({4-[(2-hydroxyethyl)amino]phenyl}sulfonyl)-N-piperidin-4-yl-2-(rrifluoromethyl)benzenesulfonamide. MS (ESI+) m/z 508; FtPLC purity 95.1% at 210-370 nm, 6.2 min.; Xterra RP1 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CzoEbftNaOsS;- + H+, 508.1 1822; found (ESI, [M+H]+), 508.1198. Example 845: 5-[(2-fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-l-yl)ethyl]-2-(trifluoromethyl)benzenesulfonamide To a mixture of sodium cNbonate (0.1601 g, 1.5 mmol) in 1 ml of water and 2-(IH-imidazol-l-yl) ethyl amine (0.092, 0.5 mmol) in 3 ml of acetonitrile was stirred at R.T. as the mixture of 5-(4-fluorophenylsulfonyl)-2-(trifluoromethyl)benzene-l-sulfonyl chloride and 5-(2-fluorophenylsulfonyl)-2-(trifluoromethyl)benzene-l-sulfonyl chloride (0.2514 g, 0.6 mmol) prepNed in Example 816 Step 4 was taken up in 10 ml of acetonitrile was slowly added to the reaction with an addition funnel. The reaction was Nlowed to stir overnight at room temperature. and then was pNtitioned between ethyl acetate and 2N hydrochloric acid. The ethyl acetate layer was sepNated, dried (anhydrous MgSO-O and the solvent removed under reduced pressure to gNe approximately 50 mg of the isomeric mixture that was dissolved in 3 mL of methanol/acetonitrile. 200 uL of the resulting solution was repetitNely injected onto the ' SupercriticN Fluid Chromatography (SFC) instrument, and the baseline resolved isomers were sepNately collected using the conditions described below to gNe the title compound 5-[(2- fluorophenyl)sulfonyrj-N-[2-(lH-imidazol-l-yl)ethyl]-2-(trifluorometliyl)benzenesulfonamide (19.8 mg, 7%) as a white solid. MS (ESI+) m/z 478; HPLC purity 97.8% at 210-370 nm, 6.8 min.; Xterra RP1S, 3.5u, 150 x 4.6 mm column, 1.2 rnL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for Ci8Hi5F4N3O4S2 + H+, 478.05129; found (ESI, [M+H]+), 478.0506. Example 846: N-methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cyclohexanecNboxamide A stirred mixture of tert-butyl methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cNbamate (0.1062 g, 0.25 mmol) prepNed in the same manner as Example 799 in dichloromethane (2 ml). 1.1 eq of cyclohexanecNbonyl chloride (35 uL, 0.26 mmol) and 1.5 eq. N,N-Diisoprpylethylamine was syringed into the reaction viN and was Nlowed to stir overnight at room temperature. The product was transferred onto a 4 g Isco RediSep® NormN Phase column and was purified by automated flash Chromatography using a gradient of 20% to 100% hexane/ethyl acetate. Isolation of the main component gave the title compound N-methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cyclohexanecNboxamide (58.3 mg, 44%) as a white solid. MS(ESI+)m/z533; HPLC purity 100% at 210-370 nm, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C23H27F3N2O5S2 + H+, 533.13862; found (ESI, [M+H]+), 533.138. Example 847: 3-FIuoro-N-methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-4-(triiluoromethyl)benzamide In an anNogous manner as described in Example 819, and replacing benzoyl chloride with 3-fluoro-4-trifluorornethyl-benzoyl chloride, gave 3-fluoro-N-methyl-N-[2-({[5- (phenylsulfonyl)-2-(tiifluoromethyl)phenyl]sulfonyl}amino)ethyl]-4-(trifluoromethyl)benzainide (168.1 mg, 84%) as a white solid. ' MS(ESI+)m/z613; HRMS: cNcd for CNipFvNaOsSa + H4, 613.06964; found (ESI, [M+H]+), 613.0691; AnN. CNcd for CNlHwFvNiOjSa: C, 47.06; H, 3.13; N, 4.57. Found: C, 46.83; H, 3.00; N, 4.34. Example 848: Methyl 4-({methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}cNbonyl)benzoate In an anNogous manner as described in Example 819, and replacing benzoyl chloride with 4-chlorocNbonyl-benzoic acid methyl ester, gave methyl 4-({methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}cNbonyl)benzoate (155.8 mg, 81%) as a white solid. MS (ESI+) m/z 585; HRMS: cNcd for C25H23F3N2O7S2 + H, 585.09715; found (ESI, [M+H]*), 585.0983; AnN. CNcd for C25H23F3N2O7S2: C, 51.37; H, 3.97; N, 4.79. Found: C, 51.13; H, 3.74; N, 4.63. Example 849: N-Methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl] sulfonyl} amino)ethyl] nicotinamide In an anNogous manner as described in Example 819, and replacing benzoyl chloride with nicotinoyl chloride, extracting with water instead of 2 N HC1, and using 100% methylene chloride to 5% methanol-methylene chloride as the eluent, gave N-methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}ammo)e1hyl]riicotinamide (166.6 mg, 97%) as a white solid foam. MS (ESI+) m/z 528; HRMS: cNcd for C22H2oF3N3O5S2 + H", 528.08692; found (ESI, [M+H]*), 528.0885; AnN. CNcd for C22H2oF3N3O5S2: C, 50.09; H, 3.82; N, 7.97. Found: C, 49.99; H, 3.59; N, 7.72. Example 850: N-Methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]isonicotinamide In an anNogous manner as described in Example 849, and replacing nicotinoyl chloride with isonicotinoyl chloride gave N-methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]isonicotinaniide (151.1 mg, 88%) as a white solid. MS(ESI+)m/z528; HRMS: cNcd for C22H2oF3N3O5S2 + H+, 528.08692; found (ESI, [M+H]+), 528.0889; AnN. CNcd for CNoFaNaOsSa . 0.70 CH2C12: C, 46.45; H, 3.67; N, 7.16. Found: C, 46.71; H, 3.46; N, 7.18. Example 851: 2-Chloro-N-methyI-N-[2-({[5-(phenyIsulfonyl)-2-(trifluororaethyl)phenyl]sulfonyl}amino)ethyl]nicotinamide In an anNogous manner as described in Example 849, and replacing nicotinoyl chloride with 2-chloro-nicotinoyl chloride gave 2-chloro-N-methyl-N-[2-({[5-(phenylsulfonyl)-2-(trilluoromethyl)phenyl]sulfonyl}amino)ethyl]nicotinamide (168.4 mg, 91%) as a white solid foam. MS (ESI+) m/z 562; HRMS: cNcd for C22Hi9ClF3N3O5S2 + H", 562.04795; found (ESI, [M+H]4"), 562.0471; AnN. CNcd for C22Hi9ClF3N3O5S2 . 0.40 CH2C12: C, 45.15; H, 3.35; N, 7.05. Found: C, 46.48; H, 3.19; N, 7.32. Example 852: N,2,2-trimethyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethy l)phenyl] sulfony 1} amino)ethy 1] propanamide In an anNogous manner to example 846, tert-butyl methyl[2-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)ethy l]cNbamate and trimethy lacetyl chloride was used to prepNe the title compound N,2,2-trimethyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]propanamide (102 mg, 81%) as a white solid. MS (ES+) m/z 506.7; HPLC purity 98.6% at 210-370 run, 9.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C21H25F3N2O5S2 + H+, 507.12297; found (ESI, [M+H]+), 507.1238. Example 853: 3-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]sulfonyl}benzoic acid In an anNogous manner to example 462, 5-(phenylsulfonyl)-.N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 3-(chlorosulfonyl)benzoic acid were used to prepNe 3- {[4-({[5-(phenylsulfonyl)-2-(trifluororaethyl)pheuyl]sulfonyl}Nnino)piperidin-l-yl]sulfonyl}benzoic acid. HPLC purity 97.1% at 210-370 iim, 9.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column., 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for IQmin, hold 4min. HRMS: cNcd for C25H23F3N2OgS3 + H+, 633.06414; found (ESI, [M+Hf), 633.0627. Example 854: 4-{[4-({[5-(phenyIsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]sulfonyl}benzoic acid In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 4-(chlorosulfonyl)benzoic acid were used to prepNe 4-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]sulfonyl}benzoic acid. MS (ES+)w/z 632.5; HPLC purity 100% at 210-370 nm, 9.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 855: 3-({[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]cNbonothioyl}amino)benzoic acid In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 3-cNboxyphenyl isothiocyanate were used to prepNe 3-({[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]cNbonothioyl}amino)benzoic acid. MS (ES+) m/z 627.5; HPLC purity 98.4% at 210-370 nm, 9.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C26H24F3N3O6S3 + H+, 628.08521; found (ESI, [M+H]*), 628.0853. Example 856: ]V-[l-(2-chloro-6-methylisonicotinoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 2-chloro-6-methylpyridine-4-cNbonyl chloride were used to prepNe N-[1 -(2-chloro-6-methylisomcotinoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 599.5; HPLC purity 95.5% at 210-370 nm, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 ram column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph-3.5/ACN+MeOH) for lOmin, hold 4min. HEMS: cNcd for CNHisClFsNaOsSs + H+, 602.07925; found (ESI, [M+H]+), 602.0812. Example 857: N-[l-(2,6-dichloroisonicotinoyl)piperidin-4-yl]-5-(phenylsuIfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 2,6-dichloropyridine-4-cNbonyl chloride were used to prepNe 7*/-[l-(2,6-dichloroisonicotinoyl)piperidin-4-yl]-5-(phenylsuh°onyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 621 .5; HPLC purity 91.5% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CjNoCbFsNaOsSa + H+, 622.02463; found (ESI, [M+H]*), 622.0237. Example 858: N-(l,l-dioxidotetrahydro-2H-thiopyran-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide Step 1: To a solution of tetrahydrothiopyran (3.0 g, 25.82 mmol) and 2,4-dimethoxybenzylamine (4.3 g, 25.82 mmol) in dichloromethane (100 mL) was added sodium triacetoxyborohydride (7.7 g, 36.15 mmol). The reaction was stirred overnight at room temperature under nitrogen. Added saturated bicNbonate solution and extracted. Dried with magnesium sulfate and concentrated to gNe N-(2,4-dimethoxyben2yl)tetrahydro-2H-thiopyran-4-amine (6.7 g, 97%). Step 2: To a solution of 5-(4-fluorophenylsulfonyl)-2-isopropylbenzene-l-sulfonyl chloride (350 mg, 0.93 mmol) in dichloromethane 10 mL) was added triethylamine (388 uL, 2.79 mmol) followed by N-(2,4-dimethoxybenzyl)tetrahydro-2H-thiopyran-4-amine (497 mg, 1 .86 mmol). The reaction was stirred overnight at room temperature. The following day the reaction was concentrated down onto silica gel and purified using automated chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of N-(2,4-dimethoxybenzyl)-5-(4-fluorophenylsulfonyl)-2-isopropyl-N-(tetrahydro-2H-thiopyran-4-yl)benzenesulfonamide (504 mg, 89%). Step 3: N-(2,4-dimethoxybenzyl)-5-(4-fluorophenylsulfonyl)-2-isopropyl-N-(tetrahydro-2H-thiopyran-4-yl)benzenesulfonamide (504 mg, 0.83 mmol) was dissolved in 6% trifluoroacetic acid/dichloromethane (6 mL) and stirred overnight at room temperature under nitrogen. Saturated bicNbonate solution was added and the reaction was extracted. Dried with magnesium sulfate and concentrated onto silica gel and purified using automated chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-thiopyran-4-yl)benzenesulfonamide (350 mg, 92%). Step 4: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-thiopyran-4- yl)benzenesulfonamide (150 mg, 0.32 mmol) was dissolved in dichloromethane (8 mL) and 3-chloroperoxybenzoic acid (154 mg, 0.69 mmol) was added. The reaction was stirred overnight at room temperature and was then concentrated onto silica gel and purified using automated chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of N-(l,l-dioxidotetrahydro-2H-thiopyran-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide (80 mg, 50%). MS (ES-) m/z 487.6. Example 859: S-NPhenylsulfonyl)-N-propyl-N-Cl-pyridinN-ylethyNbenzenesulfonamide The title compound was prepNed from 5-phenylsulfonyl-2-propyl- benzenesulfonyl chloride (0.36 g, 1.0 mmol) and 2-(pyridin-4-yl)ethanamine (0.25 g, .2.0 mmol) according to the procedure and in the same manner as described in Example 550, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (90 g), eluting with a gradient of 50%-100% methyl terf-butyl ether in hexane at a flow rate of 50 mL/min, to Nford 5-(phenylsulfonyl)-2-propyl-N2-(tetrahydro-2N-pyran-4-yl)ethyl]benzenesulfonamide (0.26 g, 58%), as a homogeneous, amorphous solid, m.p. 155-157 °C; MS (+ESI), m/z: 444.7 [M+H]+; HRMS: cNcd for CNHwNzCNSz + H+, 445.12502; found (ESI, [M+H]+), 445.1229; HPLC purity 100% at 210-370 nm, 8.5 min; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. Example 860: 2-Isopropyl-N-[(lN;;,5,S'")-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-5-(phenylsulfonyl)benzenesulfonamide monohydrochloride 1'" ' A stirred solution of 2-isopropyl-5-(phenylsulfonyl)benzenesulfonyl chloride (0.36 g, 1.0 mmol) in 3:1 dichloromethane-acetonitrile (10 niL) was treated under nitrogen with e«rfb-8-methyl-8-azabicyclo[3.2.1]octan-3-amine dihydrochloride (0.42 g, 2.0 mmol) and diisopropylethylamme (0.52 g, 4.0 mmol). The reaction was stirred for 18 hours at room temperature. The crude product was purified by reverse phase prepNatNe liquid chromatography on a Gilson® semi-prep column, eluting with a gradient of 10%-100% water in acetonitrile at a flow rate of 2 mL/min, to Nford, Nter concentration of the solvent and extraction with ethyl acetate (3x), an oil. The oil was dissolved in ethanol-dioxane and treated with a solution of IN hydrogen chloride in diethyl ether. Filtration of the solid Nforded 2-isopropyl-N-[(1N?* ,55r*)-8-methyl-8-azabicyclo[3.2.1 ]oct-3 -yl]-5-(phenylsulfony l)benzenesulfonamide monohydrochloride (0.10 g, 20%), as a homogeneous, cream-colored, amorphous solid, m.p. 90 °C; MS (+ESI), m/r. 462.8 [M+Hf; HRMS: cNcd for CsHaoNiCN + H+, 463.17197; found (ESI, [M+Hf), 463.171; HPLC purity 98.7% at 210-370 nm, 9.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. Example 861: 5-{[2-(methylamino)phenyl]sulfonyl}-N:-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide Step 1: Following the same procedure described on example 677 Step 1,4-chloro-3-nitrobenzenesulfonyl chloride and fluorobenzene was used to prepNe 5-(2-fluorophenylsulfonyl)-2-chloro-nitrobenzene. Step 2: Following the same procedure described on example 677 Step 2, 5-(2-fluorophenylsulfonyl)-2-chloro-nitrobenzene was used to prepNe 5-(2-fluorophenylsulfonyl)-2-trifluoromethyl-nitrobenzene. Step 3: Following the same procedure described on example 677 Step 3, 5-(2-fluorophenylsulfonyl)-2-trifluoromethyl-nitrobenzene was used to prepNe 5-(2-fluorophenylsulfonyl)-2-trifluoromethylaniline. Step 4: Following the same procedure described on example 677 Step 4, 5-(2-fluorophenylsulfonyl)-2-trifluoromethylanilme was used to prepNe 2-trifluoromethyl-5-(2-fluorophenylsulfonyl)- benzenesulfonyl chloride. Step 5: Following the same procedure described on example 435, 2- trifluoromethyl-5-(2-fluorophenylsulfonyl)- benzenesulfonyl chloride and 4-aminopiperidine-l-carboxylic acid tert-butyl ester were used to prepNe tert-butyl 4-({[5-(2-fluorophenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate. Step 6: Following the same procedure described on example 842 Step 1 , tert-butyl4-({[5-(2-fluorophenylsulfonyl)-2-(tiifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate was used to prepNe tert-butyl 4-({[5-(2-methylaminophenylsulfonyl)-2-(triftuoromethy l)pheny 1] sulfonyl } amino)piperidine- 1 -cNboxylate . Step 7: Following the same procedure described on example 842 Step 2: tert-butyl 4-( { [5-(2-methylaminophenylsulfony l)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l -cNboxylate was used to prepNe 5-{[2-(memylammo)phenyl]sulfonyl}-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonNnide. MS (ES+)w/z 477.7; FIPLC purity 100% at 210-370 nm, 7.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 rnL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. FIRMS: cNcd for CigHNlSbCN + H+, 478.10766; found (ESI, [M+H]4), 478.1078. Example 862: 5-{[2-(dimethylamino)phenyl]sulfonyl}-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide . ' Step 1 : Following the same procedure described on example 842 Step 1 , tert-butyl 4-({ [5-(2-fluorophenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidine- 1 -cNboxylate and dimethylamine were used to prepNe ?er/-butyl 4-({[5-(2-dimethylaminophenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidme-l-cNboxylate. Step 2: Following the same procedure described on example 842 Step 2, tert-butyl 4-({ [5-(2-dimethylaminophenylsulfonyl)-2- (trifluoromethyl)phenyl] sulfonyl }amino)piperidine-l -cNboxylate was used to prepNe 5-{[2-(draethylainino)phenyl]sulfonyl}-N-piperidm-4-yl-2-(trifluoromethyl)benzenesulfonamide. MS(ES+)m/r491.7; HPLC purity 95.8% at 210-370 run, 7.4 min.; Xterra RP18, 3.5u, 150 x 4.6 rhm column, 1.2 mL/min, 85/15-5/95 (Ammon. Fonn. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 863: 5-(phenylsulfonyl)-A42-(2F-tetrazol-5-yl)ethyl]-2-(trifluororaethyl)benzenesulfonamide To a stirred solution of trimethylNuminum 2M in toluene (0.13mL, 0.26 minol) and. trimethylsilylazide (0.03 g, 0.26 mmol) in toluene (1 mL) at 0°C was added N-(2-cyanoethyl)-5-(phenylsulfonyl)-2-(trifluoromethyi)benzenesulfonamide (0.09 g, 0.22 mmol). The resulting solution was heated to 80°C overnight, cooled to 0°C, quenched with 6N HC1 solution and extracted with ethyl acetate. The organic layer was concentrated and the resulting solid was triturated in ethyl acetate to gNe 5-(phenylsulfonyl)-N-[2-(2Jt/-tetrazol-5-yl)ethyl]-2-(trifluoromethyl)benzenesulfonamide. (0.045 g, 45%). MS(ES+)m/z461.6; HPLC purity 100% at 210-370 nm, 7.7 min.; Xterra RP18, 3.5u, 150 x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CI6Hi4F3NsO4S2 + H+, 462.05121; found (ESI, [M+H]*), 462.049. Example 864: 2-ethyl-N-methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]butanamide In an anNogous manner to example 846, tert-butyl methyl[2-({[5- (phenylsulfonyl)-2-(trifluoromemyl)phenyl]sulfonyl}amino)ethyl]cNbamateand2-Ethylbutyryl chloride was used to prepNe the title compound 2-ethyl-N-methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]suhcbnyl}amino)ethyl]butanamide (47.8 mg, 36.1%) as a white solid. MS (ES+) m/z 520.6; HPLC purity 100% at 210-370 nm, 9.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C22H27F3N2O5S2 + H+, 521.13862; found (ESI, [M+H]+), 521.1391. Example 865: butyl methyl[2-({[5-(phenylsulfonyI)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cNbamate In an anNogous manner to example 846, tert-butyl methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)ethyl]cNbamate and butyl chlorofomiate was used to prepNe the title compound butyl methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cNbamate (39.7 mg, 32%) as a white solid. MS (ES+) m/z 522.6; HPLC purity 100% at 210-370 ran, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CiitfeFsNON + H+, 523.1 1789; found (ESI, [M+H]+), 523.1 178. Example 866: tert-butyl 4-[({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}cNbonyl)amino]piperidine-l- cNboxylate Step 1: To a mixture of N,N'-cNbonyldiimidazole (143.0 mg, 0.8819 mmol) and 4-amino-l-BOC-piperidine (160.6 mg, 0.80 mmol) was added dichloromethane (10 mL). The reaction was stirred at room temperature under N2 for 18 hours. The solution was washed with HaO (3 x) and dried over MgSO/j. The solvent was evaporated to gNe 224.7 mg (95%) of intermediate tert-butyl 4-[(lN-imidazol-l -ylcNbonyl)amino]piperidine-l -cNboxylate. Step 2: To a stirred suspension of N-[2-(methylamino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride (0.16 g, 0.35 mmol) from Example 799 in a solution of tert-butyl 4-[(lN"-imidazol-l-ylcNbonyl)amino]piperidine-l-cNboxylate (0.1 1 g, 0.37 mmol) in CHiCk (5 mL) under N2 at room temperature was added diisopropylethylamine (64 uL, 47 mg, 0.37 mmol). The mixture was stirred at room temperature for 3 days. The solution was washed 3 times with water. It was loaded directly onto a silica gel column and eluted with a gradient of hexane and ethyl acetate to gNe 0.18 g (80%) of tert-butyl 4-[({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)emyl]amino}cNbonyl)amino]piperidine-l-cNboxylate. MS (ES-) m/z 646.7; HRMS: cNcd for CNBbsFaNNSi + H+, 649.19720; found (ESI, [M+H]+), 649.1979. Example 867: 2,2-dimethylpropyl methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbomate In an anNogous manner to example 846, tert-butyl methyl[2-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}aniino)ethyl]cNbamate and nebpentyl chloroformate was used to prepNe the title compound 2,2-dimethylpropyl methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cNbamate (86.2 mg, 67%) as a white solid. MS (ES+) m/z 536.8; HPLC purity 99.0% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1 .2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CNzTFaNaOeSz + H+, 537.13354; found (ESI, [M+H]+)5 537.1332. Example 868: N(l-hydroxycyclohexyl)methyl]-5-(phenyIsulfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 654, 2-trifluoromethyl-5-(phenylsulfonyl)-benzenesulfonyl chloride and 1-aminomethyl-l-cyclohexanol hydrochloride were used to prepNe N-[( 1 -hydroxycyclohexyl)methyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES)m/z 475.7; HPLC purity 97.6% at 210-370 nm, 9.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for 1 Grain, hold 4rnin. Example 869: (trifluoromethyl)benzenesulfonamide Step 1 : Following the same procedure described on example 842 Step 1 , tert-butyl 4-( { [5-(2-fluorophenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidine- 1 -cNboxylate and ethanolamine were used to prepNe te;t-butyl 4-({[5-([2-hydroxyethyl)amino]phenylsulfonyl)-2-(trifluoromethyl)pheny l]sulfonyl} amino)piperidine- 1 -cNboxylate. Step 2: Following the same procedure described on example 842 Step 2, tert-butyl 4-({ [5-([2-hydroxyethyl)amino]phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l -cNboxylate was used to prepNe 5-({2-[(2-hydroxyethyl)amino]phenyl } sulfonyl)-N-piperidin-4-y l-2-(trifluoromethyl)benzenesulfonamide . MS(ES)m/z507.8; HPL'C purity §4.9% at 210-370 run, 6.8 rain.; Xterra RP1 8, 3.5u, 150 x 4.6 mm column, 1 '.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CaoHNNsOsSa + H+, 508.1 1822; found (ESI, [M+H]+), 508.1 19. Example 870: isobutyl methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl] sulfonyl} amino)ethyl] cNbamate In an anNogous manner to example 846, tert-butyl methyl[2-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cNbamate and isobutyl chloroformate was used to prepNe the title compound isobutyl methyl[2-({[5-(phenylsulfonyl)-2-(trifluorometh.yl)phenyl]sulfonyl}amino)ethyl]cNbamate (57.7 mg, 46%) as a white solid. MS (ES+) m/z 522.9; HPLC purity 99.1% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C2,H25F3N2O6S2 + H+, 523.1 1789; found (ESI, [M+H]+), 523.1 175. Example 871: 3-(trifluoromethyl)phenyl methyl[2-({[5-(phenylsulfonyI)-2-(trifluoromethyl)phenyl] sulfonyl} amino)ethy 1] cNbamate In an anNogous manner to example 846, tert-butyl methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cNbamate and 3-(Trifluoromethyl)phenyl chloroformate was used to prepNe the title compound 3-(trifluoromethyl)phenyl methyl[2-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cNbamate (77.8 mg, 53%) as a white solid. MS (ES+) m/z 6 10.9; HPLC purity 98.1% at 210-370 nm, 10.4 min.; Xterra RP18, 3.5u, 150x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C24H2oF6N2O6S2 + H+, 611.07397; found (ESI, [M+FTJ+), 611.0731. Example 872: 4-fluorophenyl methyl[2-({[5-(phenyIsulfcmyl)~2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cNbamate In an anNogous manner to example 846, tert-butyl methyl [2- ({[5-(pheny lsulfonyl)-2-(trifluoromethyl)phenyl]sulfony 1 } amino)ethyl] cNbamate and 4-Fluorophenyl chloro formate was used to prepNe the title compound 4-fluorophenyl methyl[2-({[5- (Nhenylsulfonyl)-2-(trifluoroniethyl)phenyl]surfonyl}Nnino)ethyl]cNbamate (85.6 mg, 62.4%) as a white solid. MS (ES+) m/z 560.7; HPLC purity 98.1% at 210-370 ran, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1 .2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for 10min; hold 4min. HRMS: cNcd for C23H2oF4N2O6S2 + H+, 561.07717; found (ESI, [M+H]+), 561.0757. Example 873: 4-bromophenyl methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cNbamate In an anNogous manner to example 846, tert-butyl methyl[2-({ [5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)ethyl]cNbamate and 4-Bromophenyl chloroformate was used to prepNe the title compound 4-bromophenyl methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cNbamate (66.7mg, 39%) as a white solid. MS (ES+) m/z 620.6; HPLC purity 97.0% at 210-370 run, 10.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CasNoBrFaNaOgSa + H+, 620.99710; found (ESI, [M+H]+), 620.9971. Example 874: 5-[(4-Fluorophenyl)sulfonyl]-2-propyl-N-(2-pyridiii-3-ylethyl)benzenesulfonamide The title compound was prepNed from 5-[(4-fluorophenyl)sulfonyl]-2- propylbenzenesulfonyl chloride (0.38 g, 1.0 mmol) and 2-(pyridin-3-yl)ethanamine (0.25 g, .2.0 mmol) according to the procedure and in the same manner as described in Example 559, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (90 g), eluting with a gradient of 50%- 100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to Nford, Nter crystNlization from ethyl acetate-diethyl ether-hexane, 5-[(4-fluorophenyl)sulfonyl]-2-propyl-N-(2-pyridin-3-ylethyl)benzenesulfonamide (0.27 g, 59%), as a homogeneous, colorless, crystNline solid, 111-113 °C; MS (+ESI), m/z: 462.8 [L1+H]+; HRMS: cNcd for 022*NN0482 + if, 463.11560; found (ESI, [M+H]+), 463.1161; HPLC purity 100% at 210-370 nm, 8.9 min; Xterra RP1S, 3.5u, 150 x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. Example 875: 5-[(4-FIuorophenyl)sulfonyl]-2-propyI-N-(2-pyridin-4-ylethyl)benzenesulfonamide The title compound was prepNed from 5-[(4-fiuorophenyl)sulfonyl]-2- propylbenzenesulfonyl chloride (0.38 g, 1.0 mmol) and 2-(pyridin-4-yl)ethanamine (0.25 g, .2.0 mmol) according to the procedure and in the same manner as described in Example 559, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (90 g), eluting with a gradient of 50%-100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to Nford, Nter crystNlization from ethyl acetate-diethyl ether-hexane, 5-[(4-fluorophenyl)sulfonyl]-2-propyl-AK2-pyridin-4-ylethyl)benzenesulfonamide (0.29 g, 63%), as a homogeneous, colorless, crystNline solid, m.p. 160-162 °C; MS (+ESI), m/z: 462.8 [M+H]; HRMS: cNcd for C22H23FN2O4S2 + H+, 463.11560; found (ESI, [M+H]+), 463.1139; HPLC purity 100% at 210-370 nm, 8.6 min; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. Example 876: 5-(PhenyIsulfonyl)-2-propyl-N-(2-pyridin-3rylethyl)benzenesulfonamide The title compound was prepNed from 5-phenylsulfonyl-2-propyl- benzenesulfonyl chloride (0.36 g, 1.0 mmol) and 2-(pyridin-3-yl)ethanamine (0.25 g, .2.0 mmol) according to the procedure and in the same manner as described in Example 550, step c. The crude product was purified by prepNatNe liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (90 g), eluting with a gradient of 50%-100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to Nford 5-(phenylsulfonyl)-2-propyl-N'-(2-pyridin-3-ylethyl)benzenesulfonamide (0.30 g, 68%), as a white foam; MS (+ESI), m/z: 444.8 [M+H]+; HRMS: cNcd for C22H24N2O4S2 + H+, 445.12502; found (ESI, [M+H]+), 445.1261; HPLC purity 98.1% at 210-370 nm, 8.6 min; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. Example 877: 4-[2~({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amitto)ethyl]benzoic acid In an anNogous manner to example 654, 2-trifluoromethyl-5-(phenylsulfonyl)-benzenesulfonyl chloride and 4-(2-aminoethyl)benzoic acid "were used to prepNe 4-[2-({[5-(phenylsulfonyl)-2-(trifluorometliyl)phenyl]sulfonyl}amino)ethyl]benzoic acid. MS(ESI-)w/z512; HPL@ purity 100% at 210-370 nm, 9.1 min.; Xterra RP18, 3.5u, 150 x 4.6 nun column, 1 .2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C22Hi8F3N06S2 + H+, 514.06004; found (ESI, [M+Hf), 514.0597. Example 878: 4-oxo-4-[4-({[5-(phenylsulfonyI)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]butanoic acid A stirred solution of 5-(phenylsulfonyl)-N'-piperidin-4-yl-2- (trifiuoromethyl)benzenesulfonamide (0. 1 0 g, 0.22 mmol) and succinic anhydride (0.023 g, 0.23 mmol) in EtOH (1 mL) was microwave irradiated for 10 minutes at 150°C. The resulting solution was concentrated and flash column sepNation using 0-10% methanol/methylene chloride gradient gave 4-oxo-4-[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]butanoic acid. (0.04 g, 33%). MS (ESI+) m/z 549; HPLC purity 100% at 210-370 nm, 8.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CNNsNChSi + H+, 549.09715; found (ESI, [M+H]*), 549.095. Example 879: [4-({[5-(phenyIsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-1-yl] acetic acid A stirred solution of 5-(phenylsulfonyl)-N'-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide (0.14 g, 0.30 mmol) and tert-butylbromoacetate (0.06 g, 0.30 mmol) and triethylamine (0.1 mL, 0.7 mmol) in THF (1 mL) was microwave irradiated for 10 minutes at 120°C. The resulting solution was concentrated and flash column sepNation using 0-50% ethyl acetate/hexane gradient gave a crude solid. The solid was dissolved in 4N HC1 in dioxane solution (1 mL) and stirred overnight. The solution was concentrated and trituration with ethyl acetate gave [4-({'[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidm-l-yl]acetic acid. (0.09 g, 59%). HPLC purity 100% at 210-370 nm, 6.8 min.; Xterra RP18; 3. 5u, 150x4.6 mm column, 1.2 mL/min; 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CjoifeiFaNaOeSz + H+, 507.08659; found (ESI, [M+H]+), 507.0854. Example 880: 2-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]acetamide A stirred solution of 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide (0.10 g, 0.21mmol) and bromoacetamide (0.03 g, 0.20 mmol) and triethylamine (0.1 mL, 0.7 mmol) in THF (1 mL) was microwave irradiated for 10 minutes at 120°C. The resulting solution was pNtitioned between sodium bicNbonate solution (sat.) and ethyl acetate. The organic layer was concentrated and flash column sepNation using 0-10% methanol/methylene chloride gradient gave 2-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]acetamide. (0.06 g, 57%). HPLC purity 98.6% at 210-370 nm, 6.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CttHbFaNaCN + H+, 506.10257; found (ESI, [M+H]*), 506.103. Example 881: N-(2-{methyl[(piperidin-4-ylamino)cNbonyl]amino}ethyl)-5-(phenylsu!fonyl)-2-(trifluoromethyl)benzenesulfonamide To a solution of terr-butyl 4-[({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)ethyl]amino} cNbonyl)amino]piperidine-l -cNboxylate (166.0 mg, 0.2559 mmol) from Example 866 in CHbCk ( 3 mL) was added EtOAc saturated with HC1 (3 mL). This mixture stood at room temperature 18 hours but solid had not formed. It was concentrated to 1 mL. EtOH (1 mL) was added. The oil/gel Nmost completely dissolved. The solvent was evaporated from this mixture. The residue crystNlized as it stood at room temperature overnight to gNe 140.6 mg (94%) of N-(2-{rnethyl[(piperidin-4-ylamino)cNbonyl]amino}ethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 548.8; HRMS: cNcd for CzNFaWsN + H+, 549.14477; found (ESI, [M+H]4), 549.1453. Example 882: ethyl N-({ (trifluoromethyl)pheiiyl)sulfonyl}amino)ethyl]amino}cNbonyl)glycinate In an anNogous manner to Example 826, ,N-[2-(methylamino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and ethyl isocyanatoacetate were used to prepNe ethyl N-({methyl[2-({[5-(phenylsulfonyl)-2-(trifiuoromethyl)phenyl]sulfonyl}amino)ethyl]amino}cNbonyl)glycinate. MS(ES+)m/z551.8; HRMS: cNcd for + H+, 552.10805; found (ESI, [M+H]+), 552.1089. Example 883: 3-({methyI[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}sulfonyl)benzoic acid To a stirred suspension of N[2-(methylamino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride (111 mg, 0.242 mmol) from Example 799 in a solution of 3-(chlorosulfonyl)benzoic acid (53.3 mg, 0.242 mmol) in CHNCk (5 mL) under Na at room temperature was added diisopropylethylamine (0.127 mL, 94.2 mg, 0.729 mmol). The mixture was stirred at room temperature for 3 days. It was washed twice with 2N HC1. The solution of crude was loaded directly onto a silica gel column and eluted with a gradient of hexane and ethyl acetate to gNe 109 mg (75%) of 3-({methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)ethyl]amino} sulfonyl)benzoic acid. MS (ES+) m/z 606.7; HRMS: cNcd for CNNNzOgSa + H+, 607.04849; found (ESI, [M+H]*), 607.0455. Example 884: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-piperidin-3-ylethyl)benzenesulfonamide 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-3- ylethyl)benzenesulfonamide (Example 534) (0.20 g, 0.43 mmol) was hydrogenated with pNladium on cNbon (70 mg) hi ethanol (30 mL) at 50 psi. The reaction was filtered through Celite® and washed with ethanol. The filtrate was concentrated to gNe 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-piperidin-3- ylethyl)benzenesulfonamide (0.17 g, 84%). MS (ES+) m/z 468.8. Example 885: 5-(phenylsulfonyl)-N-[l-(2Hr-tetrazol-5-yIraethyl)])iperidin-4-yl]-2-(triflnoromethyl)benzenesulfonamide Step 1: A solution of 5-(phenylsulfonyl)-N'-piperidin-4~yl-2- (trifluoromemyl)benzenesulfonamide (0.15 g, 0.34 mmol) and bromoacetonitrile (0.04 g, 0.34 mmol) and triethylamine (0.1 mL, 0.7 mmol) in THF (1 mL) was stirred overnight at room temperature. The mixture was concentrated and flash column sepNation using 0-50% ethyl acetate/hexane gradient gave crude 2-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]acetonitrile. (0.10 g, 62%). • '! Step 2: Following the same procedure described on example 863, 2-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]acetonitrile was used to prepNe 5-(phenylsulfonyl)-N-[l-(2F-tetrazol-5-ylmethyl)piperidin-4-yl]-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 530.8; HPLC purity 90.7% at 210-370 urn, 6.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcdfor C2oH2iF3N6O4S2 + H+, 531.10905; found (ESI, [M+H]*), 531.1094. Example 886: 4-oxo-4-[3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidin-l-yl]butanoic acid In an anNogous manner to example 878, 5-(phenylsulfonyl)-W-pyrrolidin-3-yl-2-(trifluoromethyl)benzenesulfonamide and succinic anhydride were used to prepNe 4-oxo-4-[3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidin-l -yl]butanoic acid. MS (ES+) m/z 534.7; HPLC purity 96.4% at 210-370 nm, 7.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 887: ter/-butyl 4-({methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}cNbonyl)piperazine-l-cNboxylate Step 1: In an anNogous manner to Example 866, step 1, N,N'-cNbonyldiimidazole and l-tert-butyl piperazinecNboxylate were used to prepNe the intermediate fe?t-butyl4-(lH-imidazol-l-ylcNbonyl)piperazine-l-cNboxylate. Step 2: To a solution of tert-butyl 4-(1H-imidazol-l-ylcNbonyl)piperazine-l-c'Nboxylate (1 19 mg, 0.425 mraol) stirring in acetonitrile (0.79 mL) at room temperature under N2 was added iodomethane (0.10 mL, 0.23 g, 1.6 mmol).The solution stirred at room temperature 18 hours. The acetonitrile and excess iodomethane were evaporated at reduced pressure. N- [2-(methylamino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride (172 mg, 0.375 mmol) from Example 799, CH2C12 (5.25 mL) and diisopropylethylamine (74 uL, 55 mg, 0.42 mmol) were added. The mixture was stirred at room temperature for 3 days. It was washed with dilute aqueous HCI (0.22 mL, 2N, 0.44 mmol diluted to < 1M). An emulsion formed. The layers sepNated with the addition of 2N NaOH. The organic phase was loaded directly onto a silica gel column and eluted with a gradient of hexane and ethyl acetate to gNe 133 mg(56%) of tert-butyl 4-({methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]Nnino}cNbonyl)piperazine-l-cNboxylate. MS (ES+) m/z 634.8; HRMS: cNcd for CNHfoFatyCN + H+, 635.18155; found (ESI, [M+H]+), 635.1817. Example 888: N-({methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)glycine To a solution of ethyl 7Y-({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}cNbonyl)glycinate (2.472 mg, 0.4481 mmol) from Example 882 in EtOH (6.5 mL) was added lithium hydroxide hydrate (94 mg, 2.24 mmol) in water (0.8 mL). The solution was stirred at room temperature for 2 h. The EtOH was evaporated. The residue was pNtitioned with EtOAc and 2N HCI. The EtOAc was washed once with water and dried over MgSO4. Evaporation gave 236.7 mg (100%) of N-({methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}cNbonyl)glycme. MS (ES+) m/z 523.7; HRMS: cNcd for CipHooFsNsCN + H+, 524.07675; found (ESI, [M+Hj+), 524.0753. Example 889: N-{[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}-D-Nanine Step 1 : Following the same procedure described on example 654, 2- trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and beta-Nanine tertburyl ester hydrochloride were used to prepNe 3-(5-benzenesulfonyl-2-trifluoromethyl-benzenesulfonylamino)-propionic acid tert-butyl ester. Step 2: Following the same procedure described on example 688, 3-(5-benzenesulfonyl-2-trifluorometliyl-benz'enesulfonylamino)-propionic acid tert-butyl ester was used to prepNe TV- { [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl } - D -Nanine. MS (ES-) m/z 435.7; HPLC purity 100% at 210-370 nm, 8.0 min.; Xten-a RP1 8, 3.5u, 150 x 4.6 mm column, 1 .2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CjeHNNOeSa + H+, 438.02874; found (ESI, (M+H]+), 438.0272. Example 890: 3-[4-({[5-(phenylsulfonyI)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]propanoic acid In an anNogous manner to example 879, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(rrifluoromethyl)benzenesulfonamide and tert-butyl 3-bromopropionate were used to prepNe 3-[4-( { [5-(phenylsulfonyl)-2-(trifluoromethy l)phenyl]sulfonyl} amino)piperidin- 1 -yljpropanoic acid. HPLC purity 97.6% at 210-370 nm, 6.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1 .2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CaiHbFaNNN + H+, 521.10224; found (ESI, {M+HJ+), 521.1035. Example 891: 3-[4-({[5-(phenyIsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl] benzole acid To a stirred solution of 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide (0.13 g, 0.29mmol) in methylene chloride (2 mL) under a drying tube was added 3-(tertbutoxycNbonyl)-phenylboronic acid (O.OSg, 0.35 mmol), triethylamine (0.15 mL, 1.0 mmol) and copper II acetate (0.10 g, 0.58 mmol). The resulting solution was stirred room temperature for 2 days. The reaction mixture was washed with ammonium chloride solution (sat.), concentrated, and flash column sepNated using a 0-30% ethyl acetate/hexane gradient. The resulting materiN was dissolved in 4N HC1 in dioxane solution (1 mL) and stirred overnight. The solution was concentrated and trituration with methylene chloride to gNe 3-[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]benzoic acid. (0.026 g, 16%). HPLC purity 100% at 210-370 nm, 9.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C2sH23F3N2O6S2 + H+, 569.10224; found (ESI, [M+Hf), 569.1034. Example 893: 4-({[5-(phenyIsuIfonyI)-2-(trifluoromethyl)phenyl]sulfonyl}amino)butanoic acid Step 1: Following the same procedure described on example 654, 2- trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and 4-amino-N-butyric acid tert-butyl ester hydrochloride were used to prepNe 3-(5-Benzenesulfonyl-2-trifluoromethyl-benzenesulfonylamino)-butyric acid tert-butyl ester. Step 2: Following the same procedure described on example 688, 3-(5- Benzenesulfonyl-2-trifluoromethyl-benzenesulfonylamino)-butyric acid tert-butyl ester was used to prepNe 4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)butanoic acid. HPLC purity 99.1% at 210-370 nm, 8.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for Ci7Hi6F3NO6S2 + H+, 452.04439; found (ESI, [M+H]+), 452.0446. Example 894: 5-oxo-5-[4-({[5-eridin-l-yl}sulfonyl)benzoic acid In an anNogous manner to example 462. 5-(phenylsulfonyl)-N-(piperidin-4-ylmethyl)-2-(trifluoromethyl)benzen.esulfonamide and 3-(cblorosulfonyl)benzoic acid were used to prepNe 3-({4-[({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidin-l-yl}sulfonyl)benzoic acid. MS (ES-H) m/z 646.7; HPLC purity 92.6% at 210-370 nm, 9.3 min.; XterrNPIS, 3.5u, 150 x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for 1 Drain, hold 4min. HUMS: cNcd for C26H25F3N2O8S3 + H+, 647.07979; found (ESI, [M+H]4), 647.0802. Example 905: N-{2-[(2-hydroxyethyI)(methyI)amino]ethyl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide To a stirred suspension of M-[2-(methylamino)ethyl]~5-(phenylsuIfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride (65 mg, 0.14 mmol) from Example 799 in a solution of 2-bromoethanol (1 1 uL, 19 mg, 0.16 mmol) in CHaCN (2 mL) under Na at room temperature was added diisopropylethylamine (49 uL, 36 mg, 0.28 mmol). The mixture was stirred under Na at 74°C for 18 hours. The solvent was evaporated. The residue was pNtitioned with CEfcCk and water and washed twice with water. It was loaded directly onto a silica gel column and eluted with a gradient of hexane and ethyl acetate to gNe 40 mg (61%) of N-{2-{(2-hydroxyemyl)(memyl)ammo]ethyl}-5-(phenylsulfonyl)-2-(trifluoromelhyl)berizenesulfonairudeN MS (ES+) m/z 466.8; HRMS: cNcd for CigH2iF3N2O5S2 + H+, 467.09167; found (ESI, {M+H]+), 467.0922. Example 906: methyl N-methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]glycinate To a stirred suspension of N-[2-(methylamino)ethyll-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride (12 mg, 0.26 mmol) from Example 799 in CHaCla (3.5 mL) under Na at room temperature was added methyl brornoacetate (26 uL, 43 mg, 0.28 mmol) and diisopropylethylamine (83 pL, 62 mg, 0.48 mmol). The mixture was stirred at room temperatue for 2 days. . It was washed twice with water and loaded directly onto a silica gel column and elufed with a gradient of hexane and ethyl acetate to gNe 0.1 1 g (85%) of methyl N-methyl-N-[2-({[5-(phenylsulfonyl)-2--(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]glycinate. MS (ES-) m/z 492.7; HRMS: cNcd for C]9H2iF3N2O6S2 + H+, 495.08659; found (ESI, [M+H]+), 495.0846. Example 907: ethyl N-methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-p-Naninate To a stirred suspension of N-[2-(methylamino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride (0.15 g, 0.33 mmol) from Example 799 in CHCls (15 mL) under Na at room temperature was added ethyl acrylate (48 uL, 44 mg, 0.44' mmol) and diisopropylethylamine (70 uL, 52 mg, 0.40 mmol). The mixture was stirred at 57°C for 18 hours. Ethyl acrylate (46 uL, 42 mg, 0.42 mmol) and diisopropylethylamine (90 p.L, 67 mg, 0.52 mmol) were added. The mixture was stirred at 57°C for 2 days. It was washed with water and concentrated to 5 mL. This was loaded directly onto a Isco silica gel column and eluted with a gradient of hexane and ethyl acetate to gNe 0.15 g (88%) of ethylTV-methyl-.N-p-QfS-NhenylsulfonylNNtrifluoromethytyphenyNsuN MS (ES+) m/z 522.8; HRMS: cNcd for CiiHasFaNaCN + H+, 523.1 1789; found (ESI, [M+H]""), 523.1 188. Example 908: terf-butyl 2-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidine-l-cNboxylate In an anNogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)-benzenesulfonyl chloride and 2-(aminoethyl)-l-N-BOC-pyrrolidine were used to prepNe tert-butyl 2-[2-( { [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyI} amino)ethyl]pyrrolidine- 1 -cNboxylate. MS (ES-) m/z 560.8; HPLC purity 100% at 210-370 nm, 10.3 min.; XterrNPIS, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 909: tert-butyl 4-({[2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate In an anNogous m.., rssr to Example 300: 5-benzenesulfonyl-2-ethyl-benzenesulfonyl chloride and 4-Naino-piperidine-l-carboxylic acid tert-butyl ester were used to prepNe tot-butyl 4-({[2-ethyl~5-(phenylsulfonyl)phenyljsulfonyl} amino)piperidine- 1 -cNboxylate. MS (ES-)/H/z 507.1; HPLC purity 100% at 210-370 nm, 10.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C24H32N2O6S2 + H+, 509.17745; found (ESI, [M+H]+), 509.1793. Example 910: tert-butyl 4-({[2,3-dimethyI-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l -cNboxylate In an anNogous manner to Example 347: 5-Benzenesulfonyl-2,3-dimethyl-benzenesulfonyl chloride and 4-amino-piperidine-l-carboxylic acid tert-butyl ester were used to prepNe to-/-butyl 4-({[2,3-dimethyl-5-(phenylsulfonyl)phenyl]sulfonyl) amino)piperidine- 1 -cNboxylate. MS (ES-)m/z 507.1; HPLC purity 100% at 210-370 nm, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CNNOefe + H+, 509.17745; found (ESI, [M+Hf ), 509.1761 . Example 911: tert-butyl 4-({[2,4-dimethyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate r • In an anNogous manner to Step 3, Example 295: 5-Benzenesulfonyl-2,4-dimethyl-benzenesulfonyl chloride and 4-amino-piperidine-l carboxylic acid tert-butyl ester were used to prepNe tert-butyl 4-({[2,4-dimethyl-5-(pheny Isulfony l)pheny 1] sulfonyl } amino)piperidine- 1 -cNboxylate . MS (ES-)/n/z 507.1; HPLC purity 100% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOrnin, hold 4min. HRMS: cNcd for CNNiOeSa + H+, 509.17745; found (ESI, [M+Hf), 509.1798. Example 912: tert-butyl 4-({[2-isopropyI-5- (phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate In an. anNogous manner to Step 3, Example 295: 5-Benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride and 4-Nnino-piperidine-l-carboxylic acid tert-butyl ester were used to prepNe tert-butyl 4-({[2-isopropyl-5-(phenylsulfonyl)phenyl]sulfonyl} aminojpiperidine- 1 -cNboxylate. MS(ES-)w/z521.1; HPLC purity 100% at 210-370 nm, 10.2 rain.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C25H34N2O6S2 + H+, 523.19310; found (ESI, [M+Hf), 523.1921. Example 913: 5-(phenylsulfonyl)-N-(2-pyrroIidin-2-ylethyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 688, tert-butyl 2-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidine-l -cNboxylate was used to prepNe 5-(phenylsulfonyl)-N-(2-pyrrolidm-2-ylemyl)-2-(txifluoromethyl)benzenesulfonamide. MS (ES+)m/z 462.8; HPLC purity 100% at 210-370 nm, 7.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1 .2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACNH-MeOH) for lOmin, hold 4min. HRMS: cNcd for CirffciFaNzCN + H+, 463.09676; found (ESI, [M+H]+), 463.0961. Example 914: N-{l-[(4-hydroxyphenyl)sulfonyl]piperidin-4-yl}-5-{phenyIsulfonyl)-2-(trifluoromethyl)benzenesulfonamide Step 1 : Following the same procedure described on example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamideand4-methoxybenzene sulfonyl chloride were used to prepNe N-{ l-[(4-m.ethoxyphenyl)sulfonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. Step 2: Following the same procedure described on example 744, N-{l-[(4-methoxyphenyl)sulfonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide was used to prepNe N-{l-[(4-hydroxyphenyl)sulfonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 604.7; MS (ES) m/z 604.7; HPLC purity 100% at 210-370 nm, 9.4 mm.; Xterra RP1S, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C24H23F3N2O7S3 + H+, 605.06922; found (ESI, [M+H]+), 605.0696. Example 915: tert-butyl 4-{[4-({[5-(phenylsuIfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]cNbonyl}piperidine-l-cNboxylate To a stirred solution of 1 -BOC-piperidine-4-carboxylic acid (O.OSg, 0.34 mmol) in methylene chloride (2 mL) was added triethylamine (0.1 mL, 0.7 mmol) and cNbonyldiimidazole (0.06 g, 0.34 mmol). The resulting solution was stirred at room temperature for 20 minutes. To the mixture was added 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide (0.15 g, 0.34 mmol). The resulting solution was stirred Ihr, washed with ammonium chloride solution (sat), and concentrated. Flash column sepNation using 0%-50% ethyl acetate/hexane gradient gave tert-butyl 4-{[4-({[5-(phenylsulfonyl)-2-(trffluoromethyl)phenyl]sulfonyl}ammo)piperidin-l-yl]cNbonyl}piperidme-l-cNboxylate. (0.13 g.70%). MS (ES-) m/z 657.8; HPLC purity 100% at 210-370 nm, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C29H36F3N3O7S2 + H+, 660.20195; found (ESI, [M+H]*), 660.2032. Example 916: N-[l-(A-N-dimethylglycyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trrfluoromethyl)benzenesulfonamide and dimethylaminoaceyl chloride hydrochloride were used to prepNe N-[l -(1H-dimethylglycyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 533.8; HPLC purity 100% at 210-370 nm, 7.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CNHseFaNaCNSa + H+, 534.13387; found (ESI, [M+H]+), 534.1341. Example 917: YV-{l-[4-(dimethylaniino)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfon;!mide In an anNogous manner to example 462, 5-(phenylsulfonyl)-Npiperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 4-(dimethylamino)benzoyl chloride were used to prepNe N-{l-[4-(diraethylamino)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 595.8; HPLC purity 95.8% at 210-370 nm, 9.7 min.; Xterra RP1S, 3.5u, 150 x 4.6 mm column, 1.2 rnL/min, 85/15-5/95 (Nnmon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C27H28F3N3O5S2 + H+, 596.14952; found (ESI, [M+H]*), 596.1509. Example 918: {2-[2-({[5-(phenylsulfonyI)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidin-l-yl}aceticacid In an anNogous manner to example 879, 5-(phenylsulfonyl)-N-(2-pyrrolidin-2-ylethyl)-2-(trifluoromethyl)ben2enesulfonamide and tert-bxitylbromoacetate were used to prepNe {2-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sidfonyl}amino)ethyl]pyrrolidin-l-yl} acetic acid. MS (ES+) m/z 520.8; HPLC purity 100% at 210-370 nm, 7.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 rnL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CaiHNNaOeSa + H+, 521/10224; found (ESI, [M+Hf), 521 .1031 . Example 919: 4-oxo-4-{2-[2-({t5-(phenyIsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidin-l-yl}butanoicacid In an anNogous manner to example 878, 5-(phenylsulfonyl)-N-(2-pyrrolidin-2-ylethyr)-2-(trifluoromethyl)benzenesulfonamide and succinic anhydride were used to prepNe 4-oxo-4-{2-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidin-] yl}butanoic acid. MS (ES+) m/z 562.7; HPLC purity 100% at 210-370 nm, 8.5 min.; Xterra RP18, 3.5u, 150 x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold4min. HRMS: cNcd for CosHNFsNNSo + H+, 563.1 1280; found (ESI, [M+H]'1), 563.1 1 14. Example 920: 3-({2-[2-({[5-(phenyIsulfonyl)-2-(trifltioromethyJ)phenyl]sulfonyl}amino)ethyl]pyrrolidm-l-yI}sulfonyl)benzoic acid In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-(2-pyiTolidin-2-ylethyl)-2-(trifluoromethyl)benzenesulfonamide and and 3~(chlorosulfonyl)benzoic acid were used to prepNe 3-({2-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyn-olidin-l-yl}sulfonyl)benzoic acid. MS (ES+) m/z 646.7; HPLC purity 95.2% at 210-370 nm, 9.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CNHWFsNzOgSs + H+, 647.07979; found (ESI, [M+H]*), 647.0803. Example 921 : 2-ethyl-5-(phenylsulfonyI)-]-N-piperidm-4-yIbenzenesuIfoiiamide Example 909 (550 mg, 1.1 mmol) was dissolved in dry dioxane and a 4M hydrogenechloride solution in dioxane (2 mL) was added and the reaction was stirred at room temperature until the stNting materiN was consumed as evidence by LCMS and . The resulting white precipitate was isolated by suction filtration and then recrystNized in hot ethanol resulting in the isolation of 2-ethyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide (270 mg, 55%) MS (ES+)w/z 408.8; HPLC purity 100% at 210-370 nm, 6.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CNNaCNSz + H+, 409.12502; found (ESI, [M+Hf), 409.1242. Example 922: 2,3-dimethyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide In an anNogous manner to Example 92 1 : Example 910 was treated with a solution of hydrogen chloride in dioxane to provide 2,3-dimethyl-5-(phenylsulfonyl)-N~piperidin-4-ylbenzenesulfonamide. MS (ES+)m/z 408.8; HPLC purity 100% at 210-370 run, 6.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph-3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcdfor Ci9H24N2O4S2 + H+, 409.12502; found (ESI, [M+Hf ); 409.1246. Example 923: 2,4-diinethyl-5-(phenyIsulfonyI)-N-piperidin-4-ylbenzenesuIfonamide In an anNogous manner to Example 921 : Example 91 1 was treated with a solution of hydrogen chloride in dioxane to provide 2,4-dmiethyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide. MS (ES+) m/z 408.8; HPLC purity 100% at 210-370 nm, 6.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for CNNCN + H+, 409.12502; found (ESI, [M+H]+), 409.1241. Example 924: 2-isopropyl-5-(phenylsuIfonyl)-N-piperidin-4-ylbenzenesulfonamide In an anNogous manner to Example 92 1 : Example 912 was treated with a solution of hydrogen chloride in dioxane to provide 2-isopropyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonam.ide. MS (ES+)w/z 422.9; HPLC purity 100% at 210-370 nm, 7.1 min.; Xterra RP18, 3.5u, 150 x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C2oH26N2O4S2 + H+, 423.14067; found (ESI, [M+H]+), 423.1404. Example 925: 5-(phenylsulfonyl)-N-piperidin-4-yl-2-propylbenzenesulfonamide In an anNogous manner as Example 909, 5-benzenesulfonyl-2-propyl- benzenesulfonyl chloride and 4-amino-piperidine-l-carboxylic acid tert-butyl ester were used to prepNe tert-butyl 4-({[2-propyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-cNboxylate. In an anNogous manner to Example 921 : /e/"Nbutyl4-({[2-propyl-5-(phenylsuhconyl)phenyl]sulfonyl}Nnino)piperidine-l-cNboxylate was treated with a solution of hydrogen chloride in dioxane to provide 5-(phenylsulfonyl)-Npiperidin-4-yl-2-propylberizenesulfonamide. MS (ES+) m/z 422.9; HPLC purity 100% at 210-370 nm, 7.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C2oH26N204S2 + H+s 423. 14067; found (ESI, [M+H]+), 423.1412. Example 926: tert-butyl (35)-3-[({methyl[2-({[5-(phenyIsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)amino]pyrrolidine-l- carboxylate Step 1 :In an anNogous manner to Example 866, Step 1, N,N'- cNbonyldiimidazole and (S)-N-BOC-3-aminopyrrolidine were used to prepNe the intermediate tert-butyl (3N-(tert-butyl>2-{[4-({[5-(phenylsulfonyl)-2- (Mfluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]cNbonyl}pyrrolidine-l-cNboxamide. MS (ES+) m/z 644.9; HPLC purity 100.0%at210-370nm, 10.9min.;XterrNP18, 3.5u, 150x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for dtfLigNQfa + H+, 645.20229; found (ESI, [M+H]+), 645.2048. Example 1074: (25)-N-phenyl-2-{[4-({[5-(phenylsulfonyI)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]cNbonyl}pyrrolidine-l- cNboxamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-./V-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and phenylisocyanate were used to prepNe (25)-N-phenyl-2-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl] sulfonyl } amino)piperidin- 1 -yljcNbonyl }pyrrolidine- 1 -carboxamide. MS (ES+)/»/z'664.8; HPLC purity 100.0% at 210-370 run, 9.4 min.; Xterra RP1S, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 1075:/V-{l-[l-(methylsulfonyl)-L-proIyl]piperidin-4-yI}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and methane sulfonyl chloride were used to prepNe N-{l-[l-(methylsulfonyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 623.8; HRMS: cNcd for C24H28F3N3O7S3 + H+, 624.11142; found (ESI, [M+H]+), 624.1116; HPLC purity 100.0% at 210-370 nm, 8.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 1076: N-[l-(l-benzoyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyI)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-(l-L- prblylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and benzoyl chloride were used to prepNe N-[l-(l-benzoyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 649.8; HPLC purity 94.7% at 210-370 nm, 9.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C3oH3oF3N3O6S2 + H+, 650.16009; found (ESI, [M+H]*), 650.1616. Example 1077: N-(l-{l-f4-(dimethylamino)benzoyl]-L-prolyl}piperidin-4-yl)-5-(pheny!sulfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-(l-L-prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and 4-demethylaminobenzoyl chloride were used to prepNe N-(l-{l-[4-(dimethylamino)benzoyl]-L-prolyl}piperidin-4-yl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 692.9; HPLC purity 94.2% at 210-370 nm, 9.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: cNcd for C32H35F3N406S2 + H+, 693.20229; found (ESI, [M+H]+), 693.2034. Example 1078: N-[N( (trifluoromethyl)benzenesulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and isonicotinoyl chloride were used to prepNe N-[l-(l-isonicotinoyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 650.8; HRMS: cNcd for C29H29F3N4O6S2 + H+, 651.15534; found (ESI, [M+H]N), 651.1552; FffLC purity 100.0% at 210-370 nm, 9.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 1079: A"-(l-{l-[(6-chloropyridin-3-yI)cNbonyI]-L-prolyI}piperidin-4-yI)-5-(phenylsuIfonyl)-2-(trifluororaethyl)benzenesulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and 6-chloro-nicotinoyl chloride were used to prepNe N-(l-{ l-[(6-chloropyridin-3-yl)cNbonyl]-L-prolyl}piperidin-4-yl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 684.8; HPLC purity 100.0% at 210-370 nm, 9.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 1080: 4-[((25)-2-{[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]cNbonyl}pyrrolidin-l-yl)sulfonyl] benzole acid In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and 4-(chlorosulfonyl)benzoic acid were used to prepNe 4-[((25)-2-{[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]cNbonyl}pyiTolidin-l- ' yl)sulfonyl]benzole acid. MS (ES+)»z/z 729.8; HPLC purity 100.0% at 210-370 ran, 8.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 1081: N-[l-(N.tN:-dimethylglycyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluororaethyl)benzenesulfonamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and dimethylamino-acetyl chloride were used to prepNe N-[l-(N5Nr-dimethylglycyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethy l)benzenesulfonamide. MS (ES+) m/z 630.9; HPLC purity 87.6% at 210-370 nm, 7.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hokUmin. Example 1082: 2-({[5-(phenylsulfonyl)-2-(trifluoromethyI)phenyl]suIfonyl}amino)indane-5-carboxylic acid Methyl 2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)indane-5-cNboxylate (478.2mg, 0.9 mmol) prepNe in example 1037 was taken up in 25 ml of a solution of 2:2:1 tetrahydrofuran:methanol:water. To the stirring solution 2N sodium hydroxide (880 \iL, 1.76 mmol) was syringed into the reaction flask and Nlowed to stir overnight at room temperature. 2N Hydrochloric acid (900 nL, 1.8 mmol) was syringed into the reaction flask that caused a white solid to crash out of solution. The solid was collected by filtration and the product was transferred onto a 12 g Isco RediSep® NormN Phase column and was purified by automated flash chromatography using a gradient of 20% to 100% hexane/ethyl acetate. Isolation of the main component gave the title compound 2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)indane-5-carboxylicacid (122.2 mg, 26%) as a white solid. MS (ES-) m/z 525.7; HPLC purity 97.2% at 210-370 nm, 9.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 1083: W-methyl-2-[4-({[5-(phenylsuIfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]acetamide In an anNogous manner to example 880, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 2-chloro-N-metliyl-acetamide were used to prepNe N-methyl~2-[4-({ [5-(phenylsulfonyl)-2-(trifluoromethyI)phenyl]sulfonyl}amino)piperidin-1 -yl]acetamide. MS(ES+)m/z519.8; HPLC purity 100.0% at 210-370 nm, 7.2 min.; Xterra RPI 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 1084: N[l-(l-benzyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyI)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 880, 5-(phenylsulfonyl)-A;'-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and benzyl bromide were used to prepNe N-[l-(l-benzyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+)m/z 635.9; HPLC purity 100.0% at 210-370 nm, 8.1 min.; Xterra RPI 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 1085: N-dimethyl-2-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]acetamide In an anNogous manner to example 880, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 2-cWoro-N,N-dimethyl-acetamide were used to prepNe AyV-dimethyl-2-[4-({ [5-(phenylsulfonyl)-2-(trifluoromethyl)pheny 1] sulfonyl} amino)piperidin-1 -y Ijacetamide. MS (ES+) m/z 533.9;HPLC purity 96.6% at 210-370 nm, 6.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph-3.5/ACN+MeOH) for lOmin, hold 4min. Example 1089: N-{l-[l-(3,3-dimethylbutyl)-L-prolyl]piperidin-4-yl}-5-(phenylsuIfonyl)-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 1088, 5-(phenylsulfonyl)-N-(l-L-prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and 3,3-dimethyl-butyrNdehyde were used to prepNe 7>/-{l-[l-(3,3-dimethylbutyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 630.0; HPLC purity 100.0% at 210-370 nm, 8.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 1090: 5-(phenylsulfonyl)-N-[l-(l,3-thiazol-4-ylcNbonyl)piperidin-4-yl]-2-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 1026 step 2, 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and thiazole-4-carboxylic acid were used to prepNe 5-(phenylsulfonyl)-N-[l-(l,3-thiazol-4-ylcNbonyl)piperidin-4-yl]-2-(trifluoromethyl)benzenesulfonamide. MS (ES+)wfe 559.6; HPLC purity 98.5% at 210-370 nm, 8.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 1091: (25)-N-ethyI-2-{[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]cNbonyl}pyrrolidine-l- cNboxamide In an anNogous manner to example 462, 5-(phenylsuhcbnyl)-N-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and ethylisocyanate were used to prepNe (2S)-#-ethyl-2- {[4-( {[5-(phenylsulfonyl)-2- (trifluoromethy l)phenyl] sulfonyl} amino)piperidin-1 -y 1] cNbonyl jpyrrolidine-1 -cNboxamide. MS (ES+)m/z 616.8; HPLC purify 100.0% at 210-370 nm, 8.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 1086:N-isopropyI-2-[4-({[5-(pheny!sulfonyl)-2-(trifluoromethyl)pheiiyl]sulfonyl}am«io)piperidin-l-yl]acetamide In an anNogous manner to example 880, 5-(phenylsiilfonyI)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 2-chloro-N-isopropyl-acetamide were used to prepNe N-isopropyl-2-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyI)phenyl]sulfonyl}amino)piperidm-l-yljacetamide. MS (ES-) m/z 547.8; HPLC purity 95.1% at 210-370 nm, 7.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1 .2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 1087: N-t (trifluoromethyl)benzenesulfonamide In an anNogous manner to example 880, 5-(phenylsulfonyI)-N-piperidin-4-yl-2-(trifluoromethy])benzenesulfonamide and 2-chloro-l-morpholin-4-yl-ethanone were used to prepNe N[l-(2 -morpholin-4-yl-2-oxoethyl)piperidin-4-yl]-5-(phenylsuifonyl)-2-(trifluoromettvy l)benzenesulfonamide . MS (ES+)wfe 575.8; HPLC purity 98.2% at 210-370 nm, 7.0 min.; Xterra RP18, 3,5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 1088: NV-{l-[l-(cyclohexylmethyl)-L-prolyl]piperidin-4-yI}-5-(phenylsulfonyI)-2-(trifluoromethyl)benzenesulfonamide l . N ; To a stirred solution of 5-(phenylsulfonyI)-N-( 1 -L-prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide (0.09 g, 0.16 mmol) and cyclohexanecNbNdehyde (0.02 g, 0. 1 6 mmol) in methanol (1 mL) was added triacetoxy sodium borohydride (0.05 g, 0.22 mmol) and the resulting solution was stirred overnight at room temperature. The crude mixture was concentrated. Flash column sepNation using 0%-10% methanol/methylene chloride gradient gave N- { 1 -[1 -(cyclohexylmethyl)-L-prolyl]piperidin-4-yi} -5-(phenylsulfonyl)-2-(trifluorometliyl)benzenesulfonamide. (0.025 g, 25%). MS (ES+) m/z 64 1.9; HPLC purity 1 00.0% at 2 1 0-370 nm, 8.9 min.; Xterra RP 1 83 3 .5u, 1 50 x 4.6 mm column, 1 .2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4mh. Example 1092: (2N)-NNV-dimethyl-2-{[4-({[5-(phenyIsulfonyI)-2- (trifluoromethyl)pheny]]sulfonyl}amino)piperidin-l-yl]cNbonyl}pyrrolidine-l- cNboxamide In an anNogous manner to example 462, 5-(phenylsulfonyl)-N-(l-L-prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and dimethylaminocNbonyl chloride were used to prepNe (25)-Nr,N-dimethyl-2-{[4-({[5-(phenylsulfonyl)-2-(1rifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]cai'bonyl}pyiTolidine-l-cNboxamide. MS(ES+)w/z616.8; HPLC purity 100.0% at 210-370 nm, 8.7 min.; XterrNPl 8, 3. 5u, 1 50 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 1093: N-flNlIT-imidazol-l-ylacetyOpiperidin-Nyll-S-Cphenylsulfonyl)-!-(trifluoromethyl)benzenesulfonamide In an anNogous manner to example 1026 step 2, 5-(phenylsulfonyl)-N- piperidmN-yl-2Ntrifluoromethyl)benzenesiufonamide and imidazol-1-yl-acetic acid were used to prepNe N-[lNlH-imidazol-l-ylacetyNpiperidinN-S-Cphenylsulfonyl)N-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 556.8; HPLC purity 99.2% at 210-370 nm, 7.3 min.; Xterra RP18, 3.5u, 150 x4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 1094: (trifluoromethyl)benzenesulfonamide To a stirred suspension of 5-bromoindan-2-amine hydrobromide (2.80 g, 9.56 mmol) in a solution of 5-(phenylsulfonyl)-2-(trifiuoromethyl)benzenesulfonyl chloride (3.67 g, 9.54 mmol) from Example 677 in CH-jCk (75 mL) under N2 at room temperature was added diisopropylethylamine (5.00 mL, 3.71 g, 28.7 mmol). The mixture was stirred at room temperature for 1 .5 hours. It was washed once with 2N HC1, twice with water and once with brine. The solvent was evaporated. The residue was dissolved again in CHNCfe (18 mL) The solution was loaded directly onto a silica gel column and eluted with a gradient of hexane and CH2C12 to gNe 4.1 1 g (77%) of N-(5-bromo-233-dihydro-lJ7-inden-2-yl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonNmde. MS (ES-) m/z 557.6. Example 1095: tert-butyl (2.S)-2-{[4-({[5-[(3-cyanoPhenyl)sulfouyl]-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]cNbonyl}pyrroHdine-l-cNboxylate Step 1: In an anNogous manner to example 1026 step 2, 5-[(3- bromophenyl)sulfonyl]-N-piperidin-4-yl-2-(lrifluoromethyl)benzenesulfonamideandN-(re/t-butoxycNbonyl)-L-proline were used to prepNe te/7-butyl (25)-2-{[4-({[5-[(3-bromophenyl)sulfonyl]-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-y 1] cNbonyl} pyrrolidine-1 -cNboxylate. Step 2: In an anNogous manner to example 376, tert-butyl (2S)-2-{[4-({[5-[(3-bromophenyl)sulfonyl]-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidin-1 -yl]cNbonyl}pyrrolidine-l-cNboxylate was used to prepNe tert-butyl (2S)-2-{[4-({[5-[(3-cyanophenyl)sulfonyl]-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidin-1 -yl]cNbonyl}pyrrolidine-l-cNboxylate. MS (ES+)w/z 670.7 HPLC puritys98.8% at 210-370 nm, 11.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 1096: Fluorescence PolNization Binding Assay The Nfinity of test compounds for SFRP-1 was determined using a fluorescence polNization binding assay. According to the assay design, a probe compound was bound to SFRP-1. The fluorescence anisotropy vNue of the probe compound is increased upon binding to SFRP-1. Upon the addition of a test compound, the fluorescence anisotropy vNue for the probe compound decreased due to competitNe displacement of the probe by the test compound. The decrease in anisotropy as a function of increasing concentration of the test compound provides a direct measure of the test compound's binding Nfinity for SFRP-1. To determine IC50 vNues, fluorescence polNization experiments were conducted in a 384-well format according to the following procedures. A 20 mM stock solution of the probe compound was prepNed in 100 % DMSO and dispensed in 10 uL Niquots for long-term storage at -20 °C. The binding assay buffer was prepNed by combining stock solutions of Tris-Cl, NacL, glycerol, and NP40 at finN concentrations of 25 mM Tris-Cl pH 7.4, 0.5 M NaCl, 5% glycerol and 0.002 % NP40. Master stock solutions of the test compounds were prepNed in 100 % DMSO at finN concentrations of 20 mM. TypicNly the working stock solutions of the' test compounds were prepNed by seriNly diluting the 20 mM master stock solution to 5 mM, 2,5 mM, 1.25 mM, 0.625 mM, 0.3125 mM, 0.156 mM, 7-8 uM, 39 uM, 19.5 uM, 9.8 pM, 4.9 |oM, 2.44 jiM, 1.22 uM, 0.31 uM, 76 nM, and 19 nM in DMSO. The working stock solutions of the test compounds were further diluted by combining 6 ul of the solutions with 24 uL of Milli-Q purity water, resulting in working stock solutions (lOx compound stocks) in 20 % DMSO. The assay controls were prepNed as follows. A 2 uL Niquot of the 20 mM fluorescence probe compound was diluted 1000-fold in 100 % DMSO to a finN concentration of 20 |aM. 6 pL of the 20 pM probe was combined with 5.4 mL of the assay buffer, mixed well, and 18 (J.L of the resulting solution was dispensed into 384-well plates. SFRP-1 /probe complex was prepNed by combining 11 uL of 20 pM probe compound with 9.9 mL of the assay buffer and SFRP-1 stock solution to finN concentrations of 22 nM probe compound and 50 nM SFRP-1. 18 pL of the SFRP-1/probe complex was dispensed into the 384-well plates. 2 uL Niquots of the test compounds from the lOx working stock solutions were removed and dispensed into the plate containing the SFRP-1/probe complex and the resultant solutions were mixed by pipetting up and down once. The finN concentratons of SFRP-1 and probe in the assay solutions were 45 nM and 20 nM, respectNely. In a typicN experiment, each plate was used to test 14 compounds. "1 The plate was incubated in the dNk for 15 minutes. The fluorescence of the SFRP-1/probe complexs was read in the Tecan Ultra plate reader at excitation and emission maxima of 485 and 535 nm. The plate reader settings were as follows: Mode: Fluorescence PolNization Plate definition: MatricN3841v.pdf (pdf stands for Plate Definition File) Excitation 485nm (bandwidth 20nm) Emission 535nm (bandwidth 30nm) G-factor: 1.03 # flashes / well: 10 integration time: lOOus time btwn move, flash: 60ms Z-position: 10730 urn AnNysis of Results Fluorescence anisotropy results from the emission of polNized light in the pNNlel and perpendiculN directions when a fluorophore is excited with verticNly polNized light. The anisotropy of the probe in the free and bound state was determined using the following equation: where 1(11) and 1(1) Ne the pNNlel and perpendiculN emission intensities, respectNely. ' Monitoring the anisotropy changes of the probe compound reveNed that it bound saturably to SFRP-1 with a KD of 20-30 nM. The binding Nfinity was independently verified using a tryptophan fluorescence quenching assay. ] The decrease in the anisotropy of the probe upon addition of the competing test compound was fitted to a sigmoidN dose response curve of the equation shown below: where "X" is the logNithm of concentration, "Y" is the anisotropy, and "Bottom" and "Top" correspond to the anisotropy vNues of the free and SFRP-1 -bound probe prior to the addition of the test compound, respectNely. For automated IC50 determinations, the equation shown above was used in the program GraphPad Prism. The "Hillslope" was kept constant at 1. The vNue for "Bottom" was fixed, but was determined by the blank (probe-only) wells in the plate. The vNues for "Top" and "IC50" were determined by the data fit. The vNue for "Top" was typicNly close to 120, equNNent to approximately 50 % bound probe, and the .vNue for "Bottom" was Nound 30, due to free probe. If the test compound interfered with the probe in the fluorescence assay at high concentrations, the range for the fitted data was limited to the lower concentration range. The data obtained from the experiments Ne shown in the table below. (Table Removed) Example 1097: Cell-based Assay for in vitro Measurement of SFRP-1/SNP2 Antagonist ActNity The following cell-based assay can be used to identify inhibitors of SFRP-1. MateriNs and Methods Cells The osteosNcoma cell line, U2OS (ATCC, HTB 96), was passaged twice a week with growth medium (McCoy's 5A medium containing 10% (v/v) fetN cNf serum, 2mM GlutaMAX-1, and 1% (v/v) Penicillin- Streptomycin). The cells were maintained in vented flasks at 37°C inside a 5% CO2/95% humidified air incubator. One day prior to transfection, the cells were plated with growth medium at 25,000 cells/well into 96-well plates and incubated at 37 °C overnight. Routine Co-Transfection The growth medium was removed, and the cells were washed once with OPTIMEMI (Gibco-BRL) medium (100 uL/well) to remove the serum and antibiotics. The wash medium was removed, and the cells were re-fed with OPTI-MEMI medium (100 uL/well). For each well of cells to be transfected, the following DNNs were diluted together in 25 uL OPTI-MEM I medium: 0.1 ug 16x TCF-tk-Luciferase reporter, 0.02 ug Wnt 3, Wnt3A, Wnt 1 or empty vector (Upstate Biotechnology), 0.075 ug hSFRP-1 or empty vector (pcDNAS.l, Invitrogen), and 0.025 jag CMV-(3gN (Clonetech). For each well of cells to be transfected, lul of Lipofectamine 2000 reagent (Invitrogen) was diluted in 25 ul OPTI-MEM I medium and incubated at room temperature for 5 minutes. The diluted DNNs were then combined with the diluted Lipofectamine 2000 (LF2000), and the mixture was incubated at room temperature for 20 minutes. Fifty uL of the DNA-LF 2000 mixture was added to each well, and the plate(s) were incubated at 37 °C in a 5% CO?./95% humidified air incubator for 4 hours. The cells were washed once with 150 uL/well of experimentN medium (phenol red-free RPMI Medium 1640 containing 2% fetN bovine serum, 2mM GlutaMAX-1, and 1% Penicillin-Streptomycin). FinNly, the cells were treated overnight at 37 °C with 200 |uL/well of experimentN medium containing either vehicle (typicNly DMSO) or diluted compound in replicates of 8 wells/compound. Dosing InitiN single dose screening of test compounds was done at 10 jNM . Dose-response experiments were initiNly performed with the compounds in log increases of concentration from 1-10,000 nM. From these dose-response curves, ECso vNues were generated. Assay Nter treatment, the cells were washed twice with 150 uL/well of PBS without cNcium or magnesium and were lysed with 50 uL/well of IX cell culture lysis reagent (Promega Corporation) on a shaker at room temperature for 30 minutes. Thirty uL Niquots of the cell Iysates were transferred to 96-well luminometer plates, and luciferase actNity was measured in a MicroLumat PLUS luminometer (EG&G Berthold), or a Victor (PerkinElmer Life Sciences) using 100 uL/well of luciferase substrate (Promega Corporation). Following the injection of substrate, luciferase actNity was measured for 10 seconds Nter a 1.6 second delay. SimilNly, 10 uL Niquots of the cell Iysates were transferred to sepNate 96-well luminometer plates, and 50 uL of GNacton chemiluminescent substrate (Tropix) was added to each well. The plates were covered and incubated on a rotNy shaker at room temperature for one hour. PgN actNity was measured in a MicroLumat PLUS luminometer or Victor using 100 uL/well of Light Emission Accelerator (Tropix). Following the injection of the accelerator, pgN actNity was measured for 10 seconds Nter a 1.6 second delay. The luciferase and (3gN actNity data were transferred from the luminometer to a PC and anNyzed using the SAS/Excel program. Nter the luciferase actNity was normNized to PgN, the SAS/Excel program was used to determine the mean and standNd deviation of each treatment, to anNyze the data for statisticN significance, and to determine ECso vNues (see the Table below). LNge-ScNe Co-Transfection As an NternatNe to co-transfection in a 96 well plate, the U2OS cells were transfected in T225 flasks and the transfected cells were frozen. The frozen cells were thawed and plated on a 96 well plate and the assay was cNried out as detailed above. The growth medium was removed from the T225 flasks, and the cells were washed once with OPTI-MEMI medium (approx. 25 m1Hlask) to remove the serum and antibiotics. The wash medium was removed, and the cells were re-fed with OPTI-MEM I medium (59 m1Hlask). For each T225 flask of cells to be transfected, the following DNNs were diluted together in 5.9 ml OPTI-MEM I medium: 70.3 u,g 16x TCF-tk-Luciferase reporter, 14.06 u.g WNT3,3A or WntI or empty vector, 52.8 pig hSFRP-1 or empty vector, and 17.58 (.tg CMV-pgN. SepNately, for each flask of cells to be transfected, 354 jiiL of Lipofectamine 2000 reagent (Invitrogen) was diluted in 5.9 mL OPTI-MEM I medium and incubated at room temperature for 5 minutes. The diluted DNNs were then combined with the diluted Lipofectamine 2000 (LF2000), and the mixture was incubated at room temperature for 20 minutes. 11.8 mL of the DNA-LF 2000 mixture was added to each flask, and the flask(s) were incubated at 37 °C in a 5% C02/95% humidified air incubator for 4 hours. The medium was removed, and the cells were washed once with approximately 25 m1Hlask of phenol red-free RPMI Medium 1640, then re-fed with 50 m1Hlask of experimentN medium (phenol red-free RPMI Medium 1640 containing 2% fetN bovine serum, 2 mM GlutaMAX-ls and 1% Penicillin- Streptomycin) and incubated at 37 °C overnight. Freezing Cells The transfected cells were washed twice with 25 m1Hlask/wash of PBS without cNcium or magnesium. Three ml of Trypsin-EDTA (0.05% Trypsin, 0.53 mM EDTA-4Na) was added to each flask, and the flasks were incubated at room temperature for approximately 5 minutes until the cells were rounded and detached from the surface of the flask(s). The cells were resuspended in 10 m1Hlask of phenol red-free RPMI 1640 containing 10% fetN bovine serum and were pipetted up and down severN times until a single cell suspension was formed. The resuspended cells were pooled and a 10 uL Niquot was removed and diluted at 1:10 in PBS. The diluted cells were counted using a hemacytometer to determine the totN number of cells in the pool. The cells were transferred to sterile centrifuge tubes and pellerted at 1500 rpm in a SorvNl RC-3B refrigerated centrifuge at 4 °C for 5 minutes. The supernatant was aspirated and the cells were resuspended in cold, phenol red-free RPMI 1640 medium containing 50% FBS to a cell density of 2.5E+7 cells/ml. An equN volume of cold, 2x freezing medium (phenol red-free RPMI 1640 medium containing 50% FBS and 15% DMSO) was added slowly, dropwise to the resuspended cells with gentle mixing, resulting in a finN cell density of 1.25E+7 cells/mL. The resuspended cells were placed on ice and Niquoted into sterile cryogenic viNs. The viNs were transferred to a NNgene Cryo 1 °C freezing container (NNgene catNog # 5100-0001) containing 250 mL isopropyl Ncohol. The seNed container was placed in a -80 °C freezer overnight to freeze the cells at a cooling rate of-1 °C/minute. The frozen cells were then transferred to a -150 °C freezer for long-term storage. Benchtop Assay for Single Dose Confirmation of HIS Hits Ethy in the morning, a viN of frozen transfected cells was thawed, and the cells were resuspended in phenol red-free RPMI1640 medium to a finN cell density of 150,000 cells/ml. The resuspended cells were then plated in white, 96-well polystyrene tissue culture treated CulturPlatesTM (PackNd cat. # 6005180) at a volume of 100 uL of cell suspension/well (i.e. 15,000 cells/well). The plates were incubated at 37 °C inside a 5% CO2/95% humidified air incubator for 6 hours or until the cells were attached and stNted to spread. Test compounds were then added to the wells (1 well/compound) and the plates were incubated at 37 °C overnight. Nter the overnight incubation, luciferase actNity was measured using the Luc-Screen Luciferase Assay System (Tropix). Fifty uL of Luc-Screen buffer 1, wNmed to room temperature, was added directly to the cells in the 96-well plates. Fifty uL of Luc-Screen buffer 2, wNmed to room temperature, was then added, and the plates were incubated in the dNk, at room temperature, for 10 minutes. The plates were transferred to a PackNd Top Count Microplate Scintillation and Luminescence Counter (PackNd), and the light emission was measured for 10 seconds Nter a 2 minute delay. The luciferase actNity data was transferred to a PC and anNyzed using the SAS/Excel program as described above. AnNysis of Results The luciferase data was anNyzed using the SAS/Excel program. For the initiN single dose experiment, if the compound treatment resulted in increased reporter actNity and was specific to SFRP-1 inhibition, then the results were reported as fold induction over SFRP-1 control (see the Table below). Compounds A known inhibitor of GSK-3{$, a key enzyme involved in the Wnt signNing pathway, served as an internN control for measurement of the cellulN response to Wnt signNing. The inhibition of GSK-3 results in stabilization of p-catenin, leading to up-regulation of LEF/TCF regulated reporter genes. (Table Removed) The entire disclosure of each patent, patent application, and publication cited or described in this document is hereby incorporated by reference. We Claim: 1. A compound of Formula (1): (Formula Removed) or a phNmaceutically acceptable salt thereof, wherein (Formula Removed) and each RI group is optionally substituted with up to three R8 groups; Y is O, S, or NR9; R8 is alkyl, Nylalkyl, perfluoroalkyl, alkenyl, Nylalkenyl, alkynyl, Nylalkynyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, Nyl, alkylNyl, heteroNyl, alkoxy, peliluoroalkoxy, Nylalkoxy, alkylcNbonyl, NylcNbonyl, halogen, cyano, azido, hydroxyl, cNboxy, alkoxycNbonyl, alkylamino, dialkylamino, alkylaminocNbonyl, dialkylanlinocNbonyl, alkylcNbonylamino, alkylcNbonylalkylamino, hydroxyalkylamirlo, nitro, alkylcNbonyloxime, alkylsulfonyl, alkylsulfinyl, alkylthio, perfluoroalkylthio, Nylthio, tertiaiy alkylcNbinol, tertiNy alkylcycloalkylcNbinol, or tertiNy NylalkylcNbinol; R8 is hydrogen, alkyl, Nyl, Nylalkyl, cycloalkylalkyl, heterocycloalkyl, or spirocycloalkyl; X is oxygen or an electron pair; R2 is hydrogen, alkyl, alkoxy, cycloalkyl, perfluoroalkyl, perfluoroalkylalkyl, perfluoroalkoxy, dialkylamino, or halogen; R4 is hydrogen, halogen, alkyl, cycloalkyl, alkoxy, perfluoroalkyl, or perfluoroalkoxy; or Ra and R4, together with the cNbon Noms to which they Ne Ntached, form a cycloallcyl ring of 5 to 7 cNbon Noms thN is optionally substituted with 1 to 3 R groups; each R is, independently, hydrogen, alkyl, Nylalkyl, cyanoalkyl, cycloallcyl, cycloalkylalkyl, heterocycloalkyl, spirocycloalkyl, Nyl, Nylalkyl, or alkoxyalkyl; R5, and Re Ne, independently, hydrogen, alkyl, Nyl, alkoxy, halogen, or perfluoroalkyl; R3 and R7 Ne each, independently, hydrogen or an optionally substituted alkyl, cycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, heteroNylalkyl, alkylNyl, alkylheteroNyl, alkenyl, alkynyl, fused cycloalkylNyl, fused heterocycloalkylNyl, cycloalkylcNbonyl, or heterocycloalkylcNbonyl group; or RS and Ry, together with the nitrogen Nom to which they Ne Ntached, form a five or six membered heterocycloalkyl ring optionally substituted with 1 to 5 substituents selected from alkyl, Nyl, heterocycloalkyl, heterocycloalkylalkyl, alkylamino, dialkylamino, alkoxycNbonyl, alkylcNbonyl, alkylaminocNbonylalkyl, and heterocycloalkylcNbonylalkyl; provided thN the compound is not 2-methyl-N-(2-phenylethyl)-5-(phenylsulfonyl)-benzenesulfonamide; 2-methyi-N-(2-phenyhnethyl)-5-(phenylsulfonyl)-benzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-cyclohexyl-2-m.ethylbenzenesulfonamide; N-benzyl-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide; 5-[(4-cMorophenyl)sulfonyl]-N-(2-furylrnethyl)-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-benzenesulfonamide; 5-[(4-bromophenyl)sulfonyl]-2-methylbenzenesulfonamide; 2-methyl-5-[(4-nitrophenyl)sulfonyl]-benzenesulfonamide; 5-[(2,4-dinitrophenyl)sulfonyl]-2-methyl-benzenesulfonamide; or 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-(3-pyridinylmethyl)-benzenesulfonamide. 2. The compound of claim 1 wherein the alkyl, cycloalkyl, alkylheterocycloalkyl, heteroNylalkyl, alkylNyl, alkylheteroNyl, alkenyl, alkynyl, fused cycloalkylNyl, fused heterocycloalkylNyl, cycloalkylcNbonyl, and heterocycloalkylcNbonyl groups groups of R3 and R7 Ne each independently, optionally substituted with 1 to 5 substituents selected from alkyl, perfluoroalkyl, cycloalkyl, heterocycloallcyl, Nyl, heteroNyl, fused cycloalkylNyl, alkoxy, aminocNbonylalkoxy, alkoxycNbonylalkoxy, cNboxyalkoxy, cycloalkyloxy, Nyloxy, amino, alkylamino, dialkylamino, alkoxycNbonylamino, cNboxy, cyano, halogen, oxo, hydroxyl, alkylcNbonyl, cNboxyalkylcNbonyl, NylaminocNbonyl, heterocycloallcylcNbonyl, allcoxycNbonyl, alkylaminocNbonyl, diallcylaminocNbonyl, fused cycloalkylNylaminocNbonyl, and fused heterocycloalkylNylcNbonyl. 3. The compound of claim 2 wherein the cycloalkyl, heterocycloalkyl, Nyl, and heteroNyl substituents on the alkyl groups of R3 and R7 Ne independently, optionally substituted with 1 to 5 substituents selected from alkyl, cycloalkyl, heterocycloalkyl, spirocycloalkyl, perfluoroalkyl, haloalkyl, cyanoalkyl, cNboxyalkyl, dimethylphosphonNealkyl, phosphonic acid alkyl, Nylalkyl, cycloalkylalkyl, alkoxy, perfluoroalkoxy, Nylalkoxy, benzoxy, Nyl, heteroNyl, cNboxyNyl, NylcNbonyl, alkylcNbonyl, perfluoroalkylcNbonyl, alkoxycNbonyl, cNboxyalkylcNbonyl, NyloxycNbonyl, alkoxythiocNbonyl, NyloxythiocNbonyl, NylcNbonyl, cycloalkylcNbonyl, heterocycloalkylcNbonyl, heterocycloalkylthiocNbonyl, NylthiocNbonyl, alkylaminocNbonyl, dialkylaminocNbonyl, dialkylaminoNylcNbonyl, dialkylaminoalkylcNbonyl, alkylthiocNbonyl, NylaminocNbonyl, heteroNylcNbonyl, heteroNylaminocNbonyl, alkylaminothiocNbonyl, dialkylaminothiocNbonyl, NylaminothiocNbonyl, heteroNylaminothiocNbonyl, aminosulfonyl, alkylsulfonyl, Nylsulfonyl, NylsulfonylNylsulfonyl, cNboxyNylsulfonyl, nitro, amino, dialkylamino, alkylcNbonylamino, alkylsulfonylamino, cNboxyNylsulfonylamino, hydroxy, cNboxy, sulfonamide, alkylthio, halogen, cyano, guanidine, and oxo, and the nitrogen Noms in the heteroNyl substituents Ne optionally substituted with an oxygen Nom. 4. The compound of claim 1 wherein the heterocycloalkyl groups of R3 and R7 Ne independently, optionally substituted with 1 to 5 substituents selected from alkyl, hydroxyalkyl, cyanoalkyl, cNboxyalkyl, aminocNbonylalkyl, alkoxycNbonylalkyl, aminocNbonylalkyl, allcylaminocNbonylalkyl, dialkylaminocNbonylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heterocycloalkylcNbonylalkyl, Nylalkyl, heteroNylalkyl, NylcNbonylalkyl, alkylcNbonyl, cyano, alkylester, alkylamide,.cycloalkylamide, Nyl, aiylester, alkylcNbonyl, perfluoroalkylcNbonyl, aminocNbonyl, NylaminocNbonyl, NylaminothiocNbonyl, cyanoalkoxycNbonyl, cycloalkylcNbonyi, NylcNbonyl, NylthiocNbonyl, alkylaminocNbonyl, dialkylaminocNbonyl, NylaminocNbonyl, alkylaminothiocNbonyl, dialkylaminothiocNbonyl, heteroNylcNbonyl, heterocycloalkylcNbonyl, cyanoNylcNbonyl, NylalkylcNbonyl, alkoxycNbonyl, alkoxyallcylcNbonyl, alkylthioalkylcNbonyl, alkylaminoalkylcNbonyl, dialkylaminoalkylcNbonyl, heterocycloalkylalkylcNbonyl, heterocycloallcylallcylaminothiocNbonyl, NylaminothiocNbonyl, heteroNylaminothiocNbonyl, heteroNylalkylcNbonyl, cNboxyalkylcNbonyl, alkoxycNbonylaminothiocNbonyl, allcoxycNbonylalkylaminothiocNbonyl, alkylthiocNbonylalkylcNbonyl, alkylsulfonyl, Nylsulfonyl, alkylaminoNylsulfonyl, and heteroNylsulfonyl. 5. The compound of claim 4 wherein the cycloalkyl, heterocycloalkyl, Nyl, and heteroNyl substituents on the heterocycloalkyl groups of R3 and R7 Ne independently, optionally substituted with 1 to 5 substituents selected from alkyl, cycloalkyl, heterocycloalkyl, spirocycloalkyL, perfluoroalkyl, haloalkyl, cyanoalkyl, cNboxyalkyl, dimethylphosphonNealkyl, phosphonic acid alkyl, Nylalkyl, cycloalkylalkyl, alkoxy, perfluoroalkoxy, Nylalkoxy, benzoxy, Nyl, heteroNyl, cNboxyNyl, NylcNbonyl, alkylcNbonyl, perfluoroalkylcNbonyl, alkoxycNbonyl, cNboxyalkylcNbonyl, NyloxycNbonyl, alkoxythiocNbonyl, NyloxythiocNbonyl, NylcNbonyl, cycloalkylcNbonyi, heterocycloalkylcNbonyl, heterocycloalkylthiocNbonyl, NylthiocNbonyl, alkylaminocNbonyl, dialkylaminocNbonyl, dialkylaminoNylcNbonyl, dialkylaminoalkylcNbonyl, alkylthiocNbonyl, NylaminocNbonyl, heteroNylcNbonyl, heteroNylaminocNbonyl, alkylaminothiocNbonyl, dialkylaminothiocNbonyl, NylaminothiocNbonyl, heteroNylaminothiocNbonyl, aminosulfonyl, alkylsulfonyl, Nylsulfonyl, NylsulfonylNylsulfonyl, cNboxyNylsulfonyl, nitro, amino, dialkylamino, alkylcNbonylamino, alkylsulfonylamino, cNboxyNylsulfonylamino, hydroxy, cNboxy, sulfonamide, alkylthio, halogen, cyano, guanidine, and oxo, and the nitrogen Noms in the heteroNyl substituents Ne optionally substituted with an oxygen Nom. 6. The compound of claim 2 wherein the amino substituents on the alkyl groups of R3 and R7 Ne independently, optionally substituted with 1 or 2 substituents selected from alkyl, hydroxyalkyl, cNboxyalkyl, cycloalkyl, alkoxycNbonylalkyl, Nyl, alkylcNbonyl, NylcNbonyl, alkylsulfonyl, Nylsulfonyl, alkylcNbonyl, cycloalkylcNbonyi, alkylaminocNbonyl, dialkylaminocNbonyl, alkylamino thiocNbonyl, dialkylaminothiocNbonyl, alkoxycNbonylalkylaminocNbonyl, cNboxyalkylcNbonyl, cNboxyalkylaminocNbonyl, cNboxyalkylcNbonylheterocycloalkylaminocNbonyl, NylaminocNbonyl, NylcNbonyl, heteroNylaminocNbonyl, heterocycloalkylcNbonyl, NylaminothiocNbonyl, heteroNylaminothiocNbonyl, heterocycloallcylaminocNbonyl, heterocycloalkylthiocNbonyl, heteroNylcNbonyl, allcoxycNbonyl, NyloxycNbonyl, alkoxythiocNbonyl, and NyloxythiocNbonyl. 7. The compound of claim 6 wherein the cycloalkyl, heterocycloalkyl, Nyl, and heteroNyl substituents on the amino substituents on the alkyl groups of R3 and R7 Ne independently, optionally substituted with 1 to 5 substituents selected from alkyl, cycloalkyl, heterocycloalkyl, spirocycloalkyl, perfluoroalkyl, haloalkyl, cyanoalkyl, cNboxyalkyl, dimethylphosphonNealkyl, phosphonic acid alkyl, Nylalkyl, cycloalkylalkyl, alkoxy, perfluoroalkoxy, Nylalkoxy, benzoxy, Nyl, heteroNyl, cNboxyNyl, NylcNbonyl, alkylcNbonyl, perfluoroalkylcNbonyl, alkoxycNbonyl, cNboxyalkylcNbonyl, NyloxycNbonyl, alkoxythiocNbonyl, NyloxythiocNbonyl, NylcNbonyl, cycloalkylcNbonyl, heterocycloalkylcNbonyl, heterocycloalkylthiocNbonyl, NylthiocNbonyl, alkylaminocNbonyl, dialkylaminocNbonyl, dialkylaminoNylcNbonyl, dialkylaminoalkylcNbonyl, alkylthiocNbonyl, NylaminocNbonyl, heteroNylcNbonyl, heteroNylaminocNbonyl, alkylaminotbiocNbonyl, dialkylaminothiocNbonyl, NylaminothiocNbonyl, heteroNylaminothiocNbonyl, aminosulfonyl, alkylsulfonyl, Nylsulfonyl, NylsulfonylNylsulfonyl, cNboxyNylsulfonyl, nitro, amino, dialkylamino, alkylcNbonylamino, alkylsulfonylamino, cNboxyNylsulfonylamino, hydroxy, cNboxy, sulfonamide, alkylthio, halogen, cyano, guanidine, and oxo, and the nitrogen Noms in the heteroNyl substituents Ne optionally substituted with an oxygen Nom. 8. The compound of claim 1 wherein the alkyl group substituents on the heterocycloalkyl ring formed from R3 and R7, together with the nitrogen Nom to which they Ne Ntached Ne each independently, optionally substituted with 1 to 5 substituents selected from Nyl, heteroNyl optionally substituted with one to three alkyl groups, aminoalkyl, heterocycloalkyl, fused heterocycloalkylNyl, and heterocycloalkylcNbonyl. 9. The compound of claim 1 wherein RI is Nyl. 10. The compound of claim 1 wherein each R8 is, independently, alkyl, alkylNyl, allcylheteroNyl, alkylamino, dialkylamino, cNboxy, allcylcNbonyl, alkoxy, perfluoroalkoxy, halogen, or cyano. 11. The compound of claim 1 wherein X is oxygen. 12. The compound of claim 1 wherein R4, R5, and R6 Ne each hydrogen. 13. The compound of claim 1 wherein R4 is methyl and R5 and R6 Ne each hydrogen, or R5 is' methyl and R4 and R6 Ne each hydrogen, or R6 is methyl and R4 and R5 Ne each hydrogen. 14. The compound of claim 1 wherein R2 is methyl, ethyl, isopropyl, propyl, Cl, methoxy, trifluoromethyl, or trifluoromethoxy. 15. The compound of claim 14 wherein R2 is methyl, isopropyl, trifluoromethyl, or trifluoromethoxy. 16. The compound of claim 15 wherein R2 is isopropyl or trifluoromethyl. 17. The compound of claim 1 wherein R3 and R7, together with the nitrogen Noms to which they Ne Ntached, form an optionally substituted 5 or 6 membered heterocycloalkyl group. 18. The compound of claim 17 wherein Rs and R?, together with the nitrogen Noms to which they Ne Ntached, form an optionally substituted piperazinyl group. 19. The compound of claim 1 wherein R7 is hydrogen and R3 is alkyl, cycloalkyl, (Figure Removed) wherein the cNbon Noms of each alkyl, cycloalkyl, heterocycloalkyl, Nyl or heteroNyl group Ne optionally substituted with up to four R13 groups; R13 is hydrogen, F, Cl, Br, alkyl, alkoxy, Nyl, nitro, aminosulfonyl, Nylalkoxy, perfluoroalkyl, perfluoroalkoxy, amino, alkylamino, dialkylamino, hydroxy, cNboxy, cycloalkyl, cNboxyalkyl, cNboxyalkoxy, alkoxycNbonyl, aminocNbonylalkyl, alkoxycNbonylalkoxy,aminocNbonylalkoxy, alkylaminocNbonylalkyl, aminocNbonyl, alkylaminocNbonyl, dialkylaminocNbonyl, heterocycloalkylcNbonyl, heterocycloalkylaminocNbonyl, alkylaminocNbonylalkoxy, dialkylaminocNbonylalkyl, dialkylaminocNbonylalkoxy, heterocycloalkylcNbonylalkyl, heterocycloalkylaminocNbonylalkoxy, heterocycloalkylcNbonylalkoxy, cycloalkylaminoalkyl, heterocycloalkylaminoalkyl, aminoalkylaminoalkylNylamionalkyl, heteroNylaminoalkylNylalkylaminoalkyl, heteroNylallcylaminoalkyl, alkylaminoalkylamino, dialkylaminoalkylaminoNylamino, heteroNylNninoNylalkylamino, teheroNylalkylamino, or cyano; each R12 is alkyl, Nyl, alkylamino, dialkylamino, allcoxy, hydroxyl, amino, Nylamino, diNylamino, Nyl(alkyl)amino, or Nyloxy; each R14 is hydrogen, alkyl, Nyl., cycloalkyl, alkylcNbonyl, NylcNbonyl, NyloxycNbonyl, alkylsulfonyl, Nylsulfonyl, alkylaminocNbonyl, dialkylaminocNbonyl, alkylaminothiocNbonyl, dialkylaminothiocNbonyl, NylaminocNbonyl, heteroNylaminocNbonyl, heterocycloalkylcNbonyl, NylaminothiocNbonyl, heteroNylaminothiocNbonyl, heterocycloalkylthiocNbonyl, heteroNylcNbonyl, alkoxycNbonyl, NyloxycNbonyl, alkoxythiocNbonyl, alkoxycNbonylaminothiocNbonyl, cycloalkylcNbonyl, aminocNbonyl, alkoxycNbonyl, cycloalkylaminocNbonyl, heterocycloalkylaminocNbonyl, cycloalkylsulfonyl, heterocycloalkylsulfonyl, heteroNylsulfonyl, or NyloxythiocNbonyl; RIS is hydrogen, alkyl, Nyl, cycloalkyl, alkylcNbonyl, NylcNbonyl, alkylsulfonyl, Nylsulfonyl, alkylcNbonyl, NylcNbonyl, alkylaminocNbonyl, dialkylaminocNbonyl, alkylaminothiocNbonyl, dialkylaminothiocNbonyl, NylaminocNbonyl, heteroNylaminocNbonyl, heterocycloalkylcNbonyl, NylaminothiocNbonyl, heteroNylaminothiocNbonyl, heterocycloalkylthiocNbonyl, heterocycloalkylalkylaminothiocNbonyl, heteroNylcNbonyl, alkoxycNbonyl, NyloxycNbonyl, NylthiocNbonyl, alkoxythiocNbonyl, or NyloxythiocNbonyl; R16, R17 and R18 Ne each, independently, hydrogen, alkyl, Nyl or cycloalkyl; m is 0, 1 , or 2; p is0, 1,or2; q is 1 or 2; s is 1 or 2; and W is NR9, O, or S. 20. The compound of claim 19 wherein the alkyl., Nyl and cycloalkyl groups of R13, R14 and R15 Ne each, independently, optionally substituted with 1 to 5 substituents selected from alkyl, cycloalkyl, heterocycloalkyl, perfiuoroalkyl, Nyl, heteroNyl, alkoxy, Nyloxy, cycloalkyloxy, amino, alkylamino, dialkylamino, cNboxy, cyano, oxo, hydroxyl, alkylcNbonyl, alkoxycNbonyl, NylcNbonyl, alkoxycNbonylamino, allcylcNbonylamino, aminocNbonyl, alkylaminocNbonyl, dialkylaminocNbonyl, alkylthio, alkyloxothio, and alkoxycNbonylalkylamino. 21 . The compound of claim 19 wherein the Nylsulfonyl, NylcNbonyl and heteroNylcNbonyl groups of R13, R14 and R15 Ne each, independently, optionally substituted with 1 to 5 substituents selected from hydrogen, halogen, hydroxyl, alkyl, cycloalkyl, perfluoroalkyl, Nyl, alkoxy, heterocycloalkyl, heteroNyl, cycloalkyloxy, Nyloxy, amino, alkylamino, dialkylamino, alkylthio, alkyloxothio, cNboxy, cyano, oxo, alkylcNbonyl, NylcNbonyl,alkoxycNbonyl, alkylcNbonylamino, aminocNbonyl, alkylaminocNbonyl, and dialkylaminocNbonyl. 22. The compound of claim 19 wherein the heterocycloalkyl groups of R13, R14 and R15 Ne each, independently, optionally substituted with 1 to 5 substituents selected from hydrogen, hydroxyl, alkyl, cycloalkyl, perfluoroalkyl, Nyl, heterocycloalkyl, heteroNyl, heteroNylcNbonyl, heteroNylalkylcNbonyl, alkylcNbonyl, alkylsulfonyl, Nylsulfonyl, alkoxycNbonyl, NylcNbonyl, heteroNylcNbonyl, alkylaminocNbonyl, dialkylaminocNbonyl, alkylaminoalkylcNbonyl, dialkylaminoalkylcNbonyl, alkylaminocNbonylalkyl, dialkylaminocNbonylalkyl, heterocycloalkylcNbonylalkyl, cNboxyalkylcNbonyl, and NylaminocNbonyl. 23. The compound of claim 19 wherein the alkylcNbonyl groups of R13, RH and R15 Ne each, independently, optionally substituted with 1 to 5 substituents selected from amino, alkylamino, dialkylamino, cycloalkyl, heterocycloalkyl., perfluoroalkyl, Nyl, heteroNyl, alkoxy, Nyloxy, cycloalkyloxy, cNboxy, cyano, oxo, hydroxyl, alkylcNbonyl, alkoxycNbonyl, NylcNbonyl, and alkoxy cNbonylamino. 24. The compound of claim 19 wherein the amino groups of the alkylamino and hetercycloalkylamino groups of R13, RH and R15 Ne each, independently, optionally substituted with a substituent selected from hydrogen, alkyl, cycloalkyl, and Nyl. 25. The compound of claim 1 wherein R7 is hydrogen and R3 is heteroNylethyl, heteroNylpropyl, Nylethyl, heterocycloalkyl, heterocycloalkylethyl, heterocycloalkylpropyl, heterocycloalkylmethyl, heterocyclalkylamino, cycloalkyl, fused cycloalkylNyl, aminoalkyl, or alkoxyalkyl. 26. The compound of claim 2S wherein R7 is hydrogen and R3 is heteroNylethyl, heteroNylpropyl, heterocyclalkylamino, fused cycloalkylNyl, or phenylethyl. 27. The compound of claim 26 wherein R7 is hydrogen and R3 is pyridinylethyl, imidazolylethyl, imidazolylpropyl, heterocyclallcylamino, fused cycloalkylNyl, or phenylethyl. 28. The compound of claim 1 which is N-(2-phenylethyl)-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(2-chlorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(2-methoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(3-methoxyphenyl)ethyl]-3-(phenylsuLfonyl)benzenesulfonamide; N-[2-(3,4-dimethoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-bromophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-fluorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-chlorophenyl)ethyl]-3-(phenylsulfonyl)ben2enesulfonamide; N- [2-(4-methoxypheny l)ethy 1] -3 -(pheny lsulfonyl)benzenesulfonamide; N-[2-(4-methylphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-{2-[4-(aminosulfonyl)phenyl]ethyl}-3-(phenylsulfonyl)benzenesulfonamide; N-{2-[3,4-bis(benzyloxy)phenyl]ethyl}-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-nitrophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonaniide; N-[2-(l,3-benzodioxol-5-yl)e11iyl]-3-(phenylsuhcbnyl)benzenesulfonamide; 3-(phenylsulfonyl)-A'-{2-[3-(trifluoromethyl)phenyl]ethyl}benzenesulfonamide; N-[2-(3-chlorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(2,4-dichlorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N- [2-(2,6- dichloropheny l)ethy 1] -3 -(pheny Isulfony l)benzenesulfonamide; N-[2-(2,5-dimethoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N[2-(3,4-dichlorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N--[2-(3,5-dimethoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-ethoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(3-fluorophenyl)ethyl]-3-(plienylsulfonyl)benzenesulfonamide; N-[2-(2-fluorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(3-ethoxy-4-methoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonaniide; N-(4-methoxybenzyl)-3-(phenylsulfonyl)beiozenesulfonamide; N-[2-(2-bromo-4,5-dimethoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N- [2-(5 -bromo -2 -methoxyphenyl)ethy 1] -3 -(pheny lsulfonyl)benzenesulfonamide; N-{[3-(phenylsulfonyl)phenyl]sulfonyl}-beta-alaninamide; methyl N-{ [3-(phenylsulfonyl)phenyl]suIfonyl} -beta-alaninNe; N-(2-cyanoethyl)-3-(phenylsulfonyl)benzenesulfonamide; 3-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide; N-(3-morpholin-4-ylpropyl)-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(l-methylpyrrolidin-2-yl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; 3-(phenylsulfonyl)-N-(2-pyridin-4-ylethyl)benzenesulfonamide; 3-(phenylsulfonyl)-N-(2-piperidin-1 -ylethyl)benzenesulfonamide; N-[2-(lH-imidazol-4-yl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-({[3-(phenylsulfonyl)phenyl]sulfonyl}amino)ethyl]acetamide; N-(2 -morpholin-4-ylethyl)-3 -(phenylsulfonyl)benzenesulfonamide; N-[3-(2-oxopyrrolidin-l-yl)propyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(diethylamino)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(dimethylamino)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-(3-methoxypropyl)-3-(phenylsulfonyl)benzenesulfonamide; N-[3-(dimethylamino)propyl]-3-(phenylsulfonyl)benzenesiilfonamide; N-(2-methoxyethyl)-3-(phenylsulfonyl)benzenesulfonainidc; N-[3-(dietIiylamino)propyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[3 -(1H-imidazol-1 -y l)propy 1] -3 -(pheny lsulfonyl)benzenesulfonamide; 3-(phenylsulfonyl)-N-(3-pyrroljdin-1 -ylpropyl)benzenesulfonamide; N-[3-(4-methylpiperazin-l-yl)propyl]-3-(phenylsulfonyl)benzenesulfonamide; N-{[3-(phenylsulfonyl)phenyl]sulfonyl}-beta-alanine; N-2,3-dihydro-lH-inden-2-yl-3-(phenylsulfonyl)benzenesulfonamide; N-[(lS,2R)-2-phenylcyclopropyl]-3-(phenylsulfonyl)benzenesuIfonamide; N-[(2R)-2-phenylpropyl]-3-(phenylsulfonyl)benzenesuIfonamide; or N-[(2S)-2-phenylpropyl]-3-(phenylsulfonyl)benzenesulfonamide. 29. The compound of claim 1 which is 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(2-phenylethyl)ben2enesulfonamide; N-[2-(2-chlorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-[2-(2-methoxyphenyl)ethyl]-2-methylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-[2-(3-methoxyphenyl)ethyl]-2-methylbenzenesulfonamide; N-[2-(3,4-dimethoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N-[2-(4-bromophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbeiizenesulfonamide; N-[2-(4-fluorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N'-[2-(4-chlorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; 5-[(4-fluorophenyl)suIfonyl]-N-[2-(4-methoxyphenyl)ethyl]-2-methylbenzenesulfonamide; 5-[(4-fluorophenyl)su]fonyl]-2-methyl-N-[2-(4-methylphenyl)ethyl]benzenesulfonamide; N-{2-[4-(aminosulfonyl)phenyl]ethyl}-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide; N-{2-[3,4-bis(benzyloxy)phenyl]ethyl}-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[2-(4-nitrophenyl)ethyl]benzenesulfonamide; N-[2-(13-benzodioxol-5-yl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesiilfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-{2-[3- (trifluoromethyl)phenyl]ethyl}benzenesulfonNaide; N-[2-(3-chlorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N-[2-(2,4-dichlorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N-[2-(2,6-dichlorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N-[2-(2,5-dimethoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N-[2-(3,4-dichlorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonainide; N-[2-(3,5-dimethoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N-[2-(4-ethoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N-[2-(3-fluorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N-[2-(2-fluorophenyl)ethyl]-5-[(4-fluorophenyl)sutfonyl]-2-methylbenzenesulfonamide; N-[2-(3-ethoxy-4-methoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide; N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyi]-N-(4-methox}'benzyl)-2-methylbenzenesulfonamide; N-[2-(2-bromo-4,5-dimethoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide; N-[2-(5-bromo-2-methoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide; 2-Methyl-N- (2-phenylethyl)-5-(phenylsulfonyl) benzene sulfonamide; N-[2-(2-chlorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(2-methoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(3-methoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(3,4-dimethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-bromophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-fluorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N- [2-(4-chlorophenyl)ethyl] -2-methy 1-5 -(phenylsulfony l)benzenesulfonamide; N-[2-(4-naethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-A'-[2-(4-methylphenyl)ethyl]-5-(phenylsulfonyl)beiizenesulfonamide; N-{2-[4-(aminosulfonyl)phenyl]ethyl}-2-methyl-5-(phenylsulfonyl)benzenesiilfonamide; N-{2-[3,4-bis(benzyloxy)phenyl]ethyl}-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; 2-me1iiyl-N-[2-(4-nitrophenyl)ethyl]-5-(phenylsulfonyl)ben2enesulfonamide; N-[2-(13-benzodioxol-5-yl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-{2-[3-(trifluoromethyl)phenyl]ethyl}benzenesulfonamide; N-[2-(3-chlorophenyl)ethyl]-2-raethyl-5-(phenylsulfonyl)benzenesuIfonamide; N-[2-(2,4-dichlorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(2,6-dichlorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(2,5-diniethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(3,4-dichlorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(3,5-dimethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-ethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N- [2-(3 -fluorophenyl)e thyl] -2-methy 1-5 -(phenylsulfonyl)benzenesulfonamide; N-[2-(2~fluorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)beiizenesulfonamide; N[2-(3-ethoxy-4-methoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-(4-methoxybenzyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(2-bromo-4,5-dimethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(5-bromo-2-methoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonNnide; 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-(2-phenylethyl)benzenesulfonamide; N-[2-(2-chlorophenyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N[2-(2-methoxyphenyl)ethyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-[2-(3-methoxyphenyl)ethyl]-2-methylben2;enesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-methylbenzenesulfonamide; N-[2-(4-bromophenyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-[2-(4-fluorophenyl)ethyl]-2-methylbenzenesulfonamide; N-[2-(4-chlorophenyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-[2-(4-methoxyphenyl)ethyl]-2-inethylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-[2-(4-methylphenyl)ethyl]benzenesulfonamide; N-{2-[4-(aminosulfonyl)phenyl]ethyl}-5-[(4-chlorophenyl)sulfonyl]-2- raethylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N:-[2-(4-mtrophenyl)ethyl]benzenesulfonamide; N-[2H13-benzodioxol-5-yl)etiiyl]-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonNaide; 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-{2-[3- (trifluoromethyl)phenyl]ethyl}ben2;enesulfonaniide; N-[2-(3-chlorophenyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-[2-(2,4-dichlorophenyl)ethyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-[2-(2,6-dichlorophenyl)ethyl]-2-methylbenzenesiilfonamide; 5-[(4-cUorophenyl)sulfonyl]-N-[2-(2,5-dimethoxyphenyl)ethyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N:-[2-(3,4-dichlorophenyl)ethyl]-2-methylbenzenesulfonaniide; 5-[(4-cWorophenyl)sulfonyl]-N-[2-(3,5-dimethoxyphenyl)ethyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-[2-(4-ethoxyphenyl)ethyl]-2-methylbenzenesulfonamide; • 5-[(4-chlorophenyl)sulfonyl]-N-[2-(3-fluorophenyl)ethyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-[2-(2-fluorophenyl)ethyl]-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-[2-(3-ethoxy-4-methoxyphenyl)ethyl]-2- methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-2- methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-(4-methoxybenzyl)-2-methylbenzenesulfonamide; N-[2-(2-bromo-4,5-dimethoxyphenyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2- methylbenzenesulfonamide; N-[2-(5-bromo-2-methoxyphenyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2- methylbenzenesulfonamide; 2-metliyl-5-[(4-methylphenyl)sulfonyl]-N-(2-phenylethyl)benzenesulfonamide; N-[2-(2-chlorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(2-methoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(3-methoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(3,4-dimethoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(4-bromophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(4-fluorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonainide; N-[2-(4-chlorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(4-methoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonaniide; 2-methyl-N-[2-(4-me1hylphenyl)ethyl]-5-[(4-methylphenyl)sulfonyl]ben2enesulfonamide; N-{2-[4-(aminosulfonyl)phenyl]ethyl}-2-methyl-5-[(4- methylphenyl)sulfonyl]benzenesulfonamide; 2-methyl-5-[(4-methylphenyl)sulfonyl]-N-[2-(4-nitrophenyl)ethyl]benzenesulfonamide; N-[2-(13-benzodioxol-5-yl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; 2-methyl-5-[(4-methylphenyl)sulfonyl]-N-{2-[3- (trifluoromethyl)phenyl]ethyl}benzEnesulfonamide; N-[2-(3-chlorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(2,4-dichlorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(2,6-dichlorophenyl)ethyl]-2-inethyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(2,5-dimethoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(3,4-dichlorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(3,5-dimethoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(4-ethoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(3-fluorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyrjbenzenesulfonamide; N- [2-(2-fluoropheny l)ethyl] -2-methy 1-5 - [(4-methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(2-bromo-4,5-dimethoxyphenyl)ethyl]-2-methyl-5-[(4- methylphenyl)sulfonyl]benzenesulfonamide; N-[2-(5-bromo-2-methoxyphenyl)ethyl]-2-methyl-5-[(4- methylphenyl)sulfonyl]benzenesulfonamide; 2-ethyl-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-ethyl-N-[2-(2-methoxyphenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide; 2-ethyl-N-[2-(3-methoxyphenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(3,4-dimethoxyphenyl)ethyl]-2-ethyl-5-(phenylsulfonyl)benzenesulfonamide; N-{2-[4-(aminosulfonyl)phenyl]ethyl}-2-ethyl-5-(phenylsulfonyl)benzenesulfonamide; 2-ethyl-N-[2-(3-fluorophenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide; 2-ethyl-N-[2-(2-fluorophenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(3-ethoxy-4-methoxyphenyl)ethyl]-2-ethyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-2-ethyl-5-(phenylsulfonyl)benzenesulfonamide; 2-methoxy-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-methoxy-N-[2-(2-methoxyphenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide; 2-methoxy-N-[2-(3-methoxyphenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(3,4-dimethoxyphenyl)ethyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide; N-{2-[4-(aminosulfonyl)phenyl]ethyl}-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(3-fluorophenyl)ethyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(2-fluorophenyl)ethyl]-2-methoxy-5-(phenylsulfonyl)ben2enesuIfonamide; N-[2-(3-ethoxy-4-methoxyphenyl)ethyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-N-(3-phenylpropyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-ethyl-N-(3-phenylpropyl)-5-(phenylsulfonyl)benzenesulfonamide; N-2,3-dihydro-lH-inden-2-yl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-N-[(1532R)-2-phenylcyclopropyl]-5-(phenylsulfonyl)benzenesulfonamide;' 2-methyl-N-[(2R)-2-phenylpropyl]-5-(phenylsulfonyl)benzenesulfonamide; N-2,3-dihydro-lH'-inden-2-yl-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonaniide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[(lS,2R)-2-phenylcyclopropyl]benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[(2R)-2-phenylpropyl]benzenesulfonamide; N-2,3-dihydro-lH-inden-2-yl-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; 2-methyl-5-[(4-methylphenyl)sulfonyl]-N-[(15,2R)-2-phenylcyclopropyl]benzenesulfonamide; 2-methyl-5-[(4-methylphenyl)sulfonyl]-N-[(2R)-2-phenylpropyl]benzenesidfonamide; 5-[(4-chlorophenyl)sulfonyl]-N-2,3-dihydro-lH-inden-2-yl-2-metliylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-[(1S,2R)-2-phenylcyclopropyl]benzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-[(2R)-2-phenylpropyl]benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[(2S)-2-phenylpropyl]benzenesulfonamide; 2-methyl-N-[(2S)-2-phenylpropyl]-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-5-[(4-methylphenyl)sulfonyl]-N-[(2S)-2-phenylpropyl]benzenesulfonamide; 5 - [(4-chlorophenyl)sulfonyl] -2-methyl-N- [(2S)-2-pheny lpropyl]benzenesulfonamide; N-2,3-dihydro-lH-inden-2-yl-2-ethyl-5-(phenylsulfonyl)benzenesulfonamide; 2-ethyl-N-[(lS',2R)-2-phenylcyclopropyl]-5-(phenylsulfonyl)benzenesulfonamide; 2-ethyl-N-[(2R)-2-phenylpropyl]-5-(phenylsulfonyl)benzenesulfonNnide; N-2,3-dihydro-lH-inden-2-yl-2-methoxy-5-(phenylsulfonyl)benzenesiilfonamide; 2-methoxy-N-[(lS,2R)-2-phenylcyclopropyl]-5-(phenylsulfoiiyl)benzenesulfonamide; 2-methoxy-N-[(2R)-2-phenylpropyl]-5-(phenylsulfonyl)benzenesulfonamide; 2-isopropyl-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-N-(2-phenylethyl)-3-(phenylsulfonyl)benzenesulfonainide; 2-chloro-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-(2-hydroxy-2-methylpropyl)-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide; N-{ [2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl} -L-phenylalaninamide; methyl N-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-D-phenylalaninNe; N-(2,3 -dihydro-1 H-inden-1 -yl)-2-methy l-5-(phenylsulfony l)benzenesulfonamide; N- [2-(2-fluoropheny l)ethy 1] -3 -[(4-methylphenyl)sulfonyl]-5,6,7,8-tetrahydronaphthalene-1 - sulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[(2R)-2-phenylpropyl]benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[(2S)-2-phenylpropyl]benzenesulfonainide; N-(2-phenylethyl)-5-(phenylsulfonyl)-2-propylbenzenesulfonamide; 5-(phenylsulfonyl)-2-propylbenzenesulfonamide; 5-[(4-fluorophenyl)sullfonyl]-N-(2-phenylethyl)-2-propylbenzenesulfonamide; 5- [(4-fluorophenyl)sulfony 1] -2-propylbe nzenesulfonamide; N-(2-phenylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)-ben2enesulfonamide; 2,4-diisopropyl-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide; N-(2,3-dihydro-lH-inden-2-yl)-2,4-diisopropyl-5-(phenylsulfonyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropyl-N-(2-phenylethyl)benzenesulfqnamide; or N-(2,3-dihydro-lH-inden-2-yl)-5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropylbenzenesulfonamide. 30. The compound of claim 1 which is N-(2-hydroxy-2-phenylethyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-phenylethyl)-2-methylbenzenesulfonamide; 2-ethyl-5-[(4-fluorophenyl)sulfonyl]-N(2-hydroxy-2-phenylethyl)benzenesulfonamide; N-(2-hydroxy-2-phenylethyl)-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide; tons-N-(2-hydroxy-l-methyl-2-phenylethyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-[trans-2-hydroxy-l-methyl-2-phenylethyl]-2-methylbenzenesulfonamide; 2-ethyl-5-[(4-fluorophenyl)sulfonyl]-N-[(trans)-2-hydroxy-l-methyl-2-phenylethyl]benzenesulfonamide; N-[(trans)-2-hydroxy-l-methyl-2-phenylethyl]-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide; N-[(lS*,2S*)-2-hydroxycyclohexyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonainideor 5-[(4-fluorophenyl)sulfonyl]-N'-(2-hydroxyethyl)-2-isopropylbenzenesiilfonamide. 31. The compound of claim 1 which is 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(3-morpholin-4-ylpropyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(2-pyridin-4-ylethyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-(2-pyridin-4-ylethyl)benzenesulfonamide; • 2-ethyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-methoxy-5-(phenylsulfonyl)-N(2-pyridin-2-ylethyl)benzenesulfonamide; 2-methoxy-5-(phenylsulfonyl)-N-(2-pyridin-4-ylethyl)benzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2,4-dimethyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonaniide; 5-[(4-fluorophenyl)sulfonyl]-2,4-dimethyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-chloro-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2,3-dimethyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-methyl-5- {[4-(methylamino)phenyl]sulfonyl} -N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-isopropyl-5- {[4-(methylamino)phenyl]sulfonyl} -N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-{ [4-(l -cyclohexyl-1 -hydroxyethyl)phenyl]sulfonyl}-2-methyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide; 5- {[4-( 1 -hydroxy-1 -pheny lethyl)phenyl] sulfony 1} -2-methyl-N-(2-pyridin-2- y lethyl)benzenesulfonamide; 5- {[4-( 1 -hydroxy-1 -methy l-2-phenylethyl)phenyl]sulfonyl} -2-methyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide; 5-[(3-cyanophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-methyl-5-(l-naphthylsulfonyl)-N-(2-pyridin-2-ylethyl)be]izenesulfonamide; 5-[(3-hydroxyphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)ben2enesulfonamide; 5-[(3,5-difluorophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4-ethylphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonainide; 5-[(3-acetylphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(2-ethoxyphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesiilfonamide; 5-[(2,5-dimethoxyphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(23-dimethoxyphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(2,4-dimethoxyphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-yletli3'l)benzenesulfonainide; 2-methyl-N-(2-pyridin-2-ylethyl)-5-(pyridin-3-ylsulfonyl)benzenesulfonamide; 5-(lH-indol-5-ylsulfonyl)-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4-cyanophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5- {[3 -(ethylsulfony l)phenyl] sulfony 1} -2-methy l-N-(2-pyridin-2-ylethy l)benzenesulfonamide; 2-methyl-5-[(2-methylphenyl)sulfonyl]-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(2-ethylphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-(biphenyl-2-ylsulfonyl)-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-(biphenyl-4-ylsulfonyl)-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-(biphenyl-3-ylsulfonyl)-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4-tert-butylphenyl)sulfonyl]-2-isopropyI-N-(2-pyridin-2- yletliyl)benzenesulfonamide; 5-[(4-tert-butylphenyl)su.lfonyl]-2 inethyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(3,5-dimethylphenyl)sulfonyl'l-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(3-chlorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-yletliyl)beiizenesulfonamide; 2-isopropyl-5-[(3-methoxyphenyl)sulfonyl]-N-(2-pyridin-2-ylethy-l)benzenesulfonamide; 2-isopropyl-5-[(2-methoxyphenyl)sulfonyl]-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(3,5-difluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-cyclohexyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)ben2enesulfonamide; 2-cyclohexyl-5-[(4-fluorophenyl)sulfonyl]-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-ter/-butyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2,6-dimethyl-3-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-{ [5-(dimethylamino)-1 -naphthyl]sulfonyl} -2-isopropyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide; 5-[(3-chloro-5-cyanophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide 2-methyl-3-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)ben2enesulfonamide; 5-[(3,5-dichlorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-isopropyl-N-(2-pyridin-2-ylethyl)-5-{[3- (trifluoromethoxy)phenyl]sulfonyl}benzenesulfonamide; 5- {[4-(dimethy lamino)phenyl] sulfony 1} -2-isopropyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide; 2-isopropyl-N-(2-pyridin-2-ylethyl)-5-{[3- (trifluoromethyl)phenyl]sulfonyl}benzenesulfonamide; 5-[(5-chloro-2-methoxyphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2- ylethyObenzenesulfonamide; 2-isopropyl-N-(2-pyridin-2-ylethyl)-5-(quinolin-8-ylsulfonyl)benzenesulfonamide; 5-[(2,5-dichloro-3-thienyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(5-chloro-l,3-dimethyl-lH-pyrazol-4-yl)sulfonyl]-2-isopropyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide; 2-isopropyl-5-[(l-methyl-lH'-imidazol-4-yl)sulfonyl]-N-(2-pyridin-2- ylethyl)benzenesulfonamide; 5-[(3-chloro-2-methylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4,4-dunethyl-2-oxo-l,4~dihydro-2H-3,l-benzoxazin-6-yl)sulfonyl]-2-isopropyl-N-(2-pyridin- 2-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-4-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-3- ylethyl)benzenesulfonamide; 5-[(3-cyanophenyl)sulfonyi]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-( 1H-indol-5-ylsulfonyl)-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-(phenylsulfonyl)-2-propyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-propyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)-2-(trifluoromethyl)benzenesulfonamide; 2-isopropyl-5-(phenylsulfinyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(3-bromo-2-methylpheiiyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(2-chloro-6-methylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-isopropyl-5-[(3-methylphenyl)sulfonyl]-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-isopropyl-5-[(R)-phenylsulfinyl]-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-isopropyl-5-[(S)-phenylsulfinyl]-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-bromo-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesiilfonamide; 5-[(3-cyano-2-methylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonainide; 5-[(3-acetyl-2-methylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(3-cUoro-4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4-fluoro-2-methylphenyl)siilfonyl]-2-isopropyl-N-(2-pyridin-2-yletiiyl)ben2»nesulfonam 2-isopropyl-5-[(l-methyl-lH-indol-5-yl)svilfonyl]-N-(2-pyridin-2-ylethyl)benzenesvdfonamidH 2-isopropyl-5-{[2-methyl-4-(methylamino)phenyl]sulfonyl}-N-(2-pyridin-2- ylethyl)benzenesulfonamide; 5-{[3-chloro-4-(methylamino)phenyl]sulfonyl}-2-isopropyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide; 2,4-diisopropyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2,4-diisopropyl-5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)benzenesulfonamide; 2,4-diisopropyl-5-(phenylsulfonyl)-N-(2-pyridin-4-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropyl-N-(2-pyridin-3-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2S4-diisopropyl-N-(2-pyridin-4-ylethyl)benzenesulfonamide; 2-chloro-5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)benzenesulfonamide; 2-chloro-5-(phenylsulfonyl)-N-(2-pyridin-4-ylethyl)benzenesulfonamide; or 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[2-(l-oxidopyridin-3- yl)ethyi]benzenesulfonamide. 32. The compound of claim 1 which is 5-[(4-fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-4-yl)ethyl]-2-methylbenzenesulfonamide; 5- [(4-fluorophenyl)sulfonyl]-N- [3-( 1 H-imidazol-1 -yl)propyl]-2-methy Ibenzenesulfonamide; N-[2-( 1H'-imidazol-4-yl)ethyl] -2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N- [3 -(1H-imidazol-1 -y l)propy 1] -2-methy 1-5 -(pheny lsulfonyl)benzenesulfonamide; 2-ethyl-N-[2-(lH-imidazol-4-yl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide; 2-ethyl-N-[3-(lH'-imidazol-l-yl)propyl]-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(lH-imidazol-4-yl)ethyl]-2-methoxy-5-(pheiiylsulfonyl)benzenesulfonamide; N-[3-(lH-imidazol-l-yl)propyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide; 5- [(4-chlorophenyl)sulfony 1] -N- [3 -(1 H-imidazol-1 -yl)propyl] -2-methy Ibenzenesulfonamide; 5-[(4-azidophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide; N-[2-(lH-indol-3-yl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[3-(1H-imidazol-l-yl)propyl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide; 2-ethyl-5-[(4-fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-l-yl)ethyl]benzenesiilfonamide; 2-ethyl-5-[(4-fluorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]berizenesulfonamide; 5-({4-[etbyl(me1hyl)amino]phenyl}sulfonyl)-N-[3--(ljy-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide; N-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5-[(4-pyrrolidin-l-ylphenyl)sulfonyl]benzenesulfonamide; N[3-(lH-imidazol-l-yl)propyl]-4-methyl-3-(phenylsulfinyl)benzenesulfonamide; 5- [(4-fluorophenyl)sulfonyl]-N- [2-( 1H-imidazol-1 -yl)ethyl]-2-methy Ibenzenesulfonamide; N-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5-{[4-(methylamino)phenyl]sulfonyl}benzenesulfonamide; 5-{[4-(ethylamino)phenyl]sulfonyl}-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide; N-[3-(lH-imidazol-l -yl)propyl]-2-methyl-5-[(4-piperidin-l -ylphenyl)sulfonyl]benzenesulfonamide; N-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5-[(4-morpholin-4-ylphenyl)sulfonyl]benzenesulfonamide; N-[2-(lH-imidazol-l-yl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[3-(lH-imidazol-l-yl)propyl]-5-[(4-methoxyphenyl)sulfonyl]-2-methylbenzenesurfonamide; N"-[3-(lH-imidazol-l-yl)propyl]-5-[(2-methoxyphenyl)sulfonyl]-2-methylbenzenesulfonamide; N-[3-(lH-imidazoI-l-yl)propyl]-4-methyl-3-(phenylsulfonyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-l-yi)ethyl]-2-isopropylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-isopropylbenzenesulfonamide; N-[3-(lH-imidazol-l-yl)propyl]-5-[(3-methoxyphenyl)sulfonyl]-2-methylbenzenesulfonamide; N-[2-(lH-imidazol-l-yl)ethyl]-2,4-diinethyl-5-(phenylsulfonyl)benzenesulfonamide; N- [3 -(1H-imidazol-1 -yl)propy 1] -2,4-dimethyl-5 -(phenylsulfonyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-l-yl)ethyl]-2,4-dimethylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2,4-dimethylbenzenesulfonamide; 2-chloro-N-[3-(lH-imidazol-l-yl)propyl]-5-(phenylsulfonyl)benzenesulfonamide; N- [3 -(1 H-imidazol-1 -yl)propy 1] -5 - [(4-isopropylpheny l)sulfonyl] -2-methylbenzenesulfonNuide; N-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5-(2-naphthylsulfonyl)benzenesulfonamide; 5-[(3,4-dichlorophenyl)sulfonyl]-N-[3-( 1H-imidazol-1 ~yl)propyl]-2-methylbenzenesulfonamide; 5-[(3-chlorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide; 5-[(3,5-dimethylphenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide; 5-[(355-dichorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide; 5-[(2,5-dichlorophenyl)sulfonyl]-N-[3-(lH-iniidazol-l-yl)propyl]-2-methylbenzenesiilfonamide; N-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5-(phenylsulfinyl)benzenesulfonainide; N-[2-(lH-imidazol-l-yl)ethyl]-23-dimethyl-5-(phenylsulfonyl)benzenesulfonN N-[3-(lH-imidazol-l-yl)propyl]-23-dimethyl-5-(phenylsulfonyl)benzenesulfonamide; 5-{[4-(cyclohexylamino)phenyl]sulfonyl}-N-[3-(lH-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide; 5-({4-[(2-cyanoethyl)amino]phenyl}sulfonyl)-N-[3-(lH-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide; 5-[(4-{[(15r,2S)-l-(hydroxymethyl)-2-methylbutyl]amino}phenyl)sulfonyl]-N-[3-(lH-imidazol- 1 -yl)propy 1] -2-methy Ibenzenesulfonamide; N-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5-({4-[(l- phenylethyl)amino]phenyl}sulfonyl)benzenesulfonamide; 5-[(2,3-dichlorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonajiiiide; N- [3 -(1 H-imidazol-1 -yl)propyl]-2-methy l-5-(2-thienylsulfonyl)benzenesulfonamide; N-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5-[(2-methyl-3-f\iryl)sulfonyl]benzenesulfonamide; N-[3 -(1 H-imidazol-1 -yl)propyl]-2-methyl-5- {[4-(tetrahydro-2H-pyran-4- ylamino)phenyl]sulfonyl}benzenesulfonamide; N-[3-(lH-imidazol-l-yl)propyl]-5-({4-[(3-isopropoxypropyl)amino]phenyl}sulfonyl)-2- methylbenzenesulfonamide; 5-({4-[(cyclopropylmethyl)amino]phenyl}sulfonyl)-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide; 5-({4-[(lR,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]phenyl}sulfonyl)-N-[3-(lH-imidazol-l- yl)propyl]-2-methylbenzenesulfonamide; 5-{[4-(benzylamino)phenyl]sulfonyl}-N-[3-(lH-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide; 5-[(4-{[(1S)-l-cyclohexylethyl]amino}phenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide; 5-[(4- {[(IR)-1 -cyclohexylethyl]ammo}phenyl)sulfonyl]-N-[3-(lH-imidazol-1 -yl)propyl]-2- methylbenzenesulfonamide; 5-( {4-[(2-hydroxybutyl)amino]phenyl} sulfonyl)-N-[3-( lH-imidazol-1 -yl)propyl]-2- methylbenzenesulfonamide; N-[3 -(1H-imidazol-1 -yl)propyl]-2-methyl-5-[(4- {[4- (trifluoromethyl)benzyl]amino}phenyl)sulfonyl]benzenesulfonamide; 5-[(2-chlorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide; N-(tert-butyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; 5-[(4-tert-butylphenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2- isopropylbenzenesulfonamide; 5-[(4-tert-butylphenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide; 5-[(4-fluorophenyl)sidfonyl]-N-[2-(lH-imidazol-4-yl)ethyl]-2-isopropylbenzenesulfonaniide; 5-({4-[(2-cyanoethyl)amino]phenyl}sulfonyl)-N-[2-(lH-imidazol-l-yl)ethyl]-2- isopropylbenzenesulfonamide; N-[2-(lH-imidazol-l-yl)ethyl]-2-isopropyl-5-{[4- (methylamino)phenyl]sulfonyl}benzenesulfonaniide; 5-( {4-[(2-hydroxybutyl)amino]phenyl} sulfonyl)-N- [2-(1H-imidazol-1 -yl)ethyl]-2- isopropylbenzenesulfonamide; 5-[(4- {[(2S)-1 -(hydi-oxymethyl)-2-methylbutyl]amino}phenyl)sulfonyl]-N-[2-( 1H-imidazol-1 - yl)ethyl]-2-isopropylbenzenesulfonamide; N- [3 -(1 H-imidazol-1 -yl)propy 1] -2 -methy 1-3 -(phenylsulfonyl)benzenesulfonamide; N-[3-(lH-Imidazol-l-yl)propyl]-5-(phenylsulfonyl)-2-propylbenzenesulfonamide; 5-[(4-Fluorophenyl)sulfonyl]-N-[3"(1H-imidazol-l-yl)propyl]-2-propylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[2-(2-methyl- 1H-imidazol-1 - yl)ethyl]benzenesulfonamide; N-[2-(2-ethyl-lH-imidazol-l-yl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[2-(2-isopropyl-lH-iinidazol-l- yl)ethyl]benzenesulfonamide or N-[3-(lH-Imidazol-l-yl)propyl]-2,4-diisopropyl-5-(phenylsulfonyl)benzenesulfonamide. 33. The compound of claim 1 which is 5-[(4-fluorophenyl)sulfonyl]-2-metiiyl-N[2-(l-methylpyrroHdin-2-yl)ethyl]benzenesulfonamide; 5-[(4-fluorophenyl)siJfonyl]-2-me1iiyl-N-(2-piperidin-l-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N(2-moipholin-4-ylethyl)benzenesulfonainide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[3-(2-oxopyrrolidin-l-yl)propyl]benzenesulfonamide; N"-[3-(dimethylammo)propyl]-5-[(4-fluorophemyl)sulfonyl]-2-methylbenzenesulfonainide; 5-[(4-fluorophenyl)sulfonyl]-N'-(2-methoxyethyl)-2-methylbenzenesulfonamide; 5-[(4-fluorophenyl)siilfonyl]-2-methyl-N(3-pyrrolidin-l-ylpropyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[3-(4-methylpiperazin-l- yl)propyl]benzenesulfonamide; 2-methyl-H-(3-morpholin-4-ylpropyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-H-[2-(l-methylpyrrolidin-2-yl)ethyl]-5-(phenylsulfonyl)ben2enesulfonainide; 2-methyl-5-(phenylsulfonyl)-N-(2-piperidin-l-ylethyl)benzenesulfonamide; 2-methyl-N:-(2-morpholm-4-ylethyl)-5-(phenylsulfonyl)ben2;enesulfonamide; 2-methyl-N-[3-(2-oxopyrrolidin-l-yl)propyl]-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-(3-pyrrolidin-l-ylpropyl)benzenesulfonamide; 2-methyl-N- [3 - (4-methy Ipiperazin-1 -yl)propyl]-5 -(phenylsulfonyl)benzenesulfonamide; 2-ethyl-H-(2-morpholin-4-ylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-ethyl-5-(phenylsulfonyl)-N-(3-pyrrolidin-l-ylpropyl)benzenesulfonamide; 2-methoxy-N-(2-morpholin-4-ylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-methoxy-5-(phenylsulfonyl)-N-(3-pyiTolidin-l-ylpropyl)benzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-(2-morpholin-4-ylethyl)benzenesulfonamide; 2-methyl-5-(phenyisulfonyl)-N-tetfahydro-2-pyran-4-ylbenzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-(2-tetrahydro-2H-pyran-4-ylethyl)benzenesulfonNnide; 2-etliyl-5-(phenylsulfonyl)-N-tetrahydro-2H-pyran-4-ylbenzenesulfonamide; 2-ethyl-5-(phenylsulfonyl)-H-(2-tetrahydro-2H-pyran-4-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N'-tetrahydro-2ff-pyran-4-ylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N'-(2-tetrahydro-2H-pyran-4-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-H-tetrahydro-2H-pyran-4-yIbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-tetrahydro-2Hf-pyran-4- ylethyl)benzenesulfonamide; 2,4-dimethyl-5-(phenylsulfonyl)-N-tetrahydro-2J:r-pyran-4-ylbenzenesulfonamide; 2,4-dimethyl-5-(phenylsulfonyl)-N-(2-tetrahydro-2H-pyran-4-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2,4Kiimethyl-N(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2,4-dimethyl-N-[2-(tetrahydro-2ff-pyran-4- yl)ethyl]benzenesulfonamide; 2-chloro-H-(2-morpholin-4-ylethyl)-5-(phenylsulfonyl)benzenesvdfonamide; 2,3-dimethyl-5-(phenylsulfonyl)-N(tetrahydro-2/T-pyranH-yl)benzenesulfonamide; 23Himethyl-5-(phenylsulfonyl)-H-[2Htetrahydro-2H-pyran-4-yl)ethyl]benzenesulfonamide; 2-isopropyl-5-{[4-(methylamino)phenyl]sulfonyl}-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide; 2-isopropyl-5- {[4-(methylamino)phenyl] sulfonyl} -N-[2-(tetrahydro-2 jy-pyran-4- yl)ethyl]benzenesiUfonamide; 2-chloro-5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; 5-[(4-bromophenyl)sulfonyl]-2-methyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; 5-[(4-cyanophenyl)sulfonyl]-2-methyl-N1-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; H-H-(lH-imidazol-l-yOpropyyH-methyl-S-CpyridinH-ylsulfonyHbenzenesulfonamide; 5-[(2,4-dicWorophenyl)sulfonyl]-N-[3-(lJy-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide; 5-[(4-acetylphenyl)sulfonyl]-2-methyl-N-(tetrahydro-2N-pyran-4-yl)benzenesulfonaniide; 5-[(4-bromophenyl)sulfonyl]-2 -me\hy\-N-(2 -pyridin-2-ylethyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-(tetrahydro-2Jy'-pyran-4-ylmethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N(tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide; 2-ethyl-5-[(4-fluorophenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4--ylmethyl)benzenesulfonamide; 2,4-dimethyl-5-(phenylsulfonyl)-N'-(tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide; N-(2,2-dimethylpropyl)-2-methyl-5-(phenylsulfonyl)benzenesurfonamide; 5-( {4- [(1 E)-HV-hydroxyethanimidoy l]phenyl} sulfonyl)-2-methyl-N-(tetrahydro-2H"-pyran-4- yl)benzenesulfonamide; 5-[(4-acetylphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5- {[4-(l -hydroxy-1 -methylethyl)phenyl]sulfonyl} -2-methyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)benzenesulfonamide; N-(l-benzylpiperidin-4-yl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-(l-benzylpyrrolidin-3-yl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; ethyl 4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-1 -cNboxylNe; 5-[(4-tert-butylphenyl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; 5-[(4-tert-butylphenyl)sulfonyl]-2-methyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-pyran-4- ylmethyl)benzenesulfonamide; tert-buty 14-( {[2-methyl-5-(phenylsulfony l)pheny IJsulfonyl} amino)piperidine-1 - cNboxylNe; 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesidfonamide; 2-methyl-5-(phenylsulfonyl)-N-[l-(phenylsulfonyl)piperidin-4-yl]benzenesulfonamide; N-[l-(2-fiiroyl)piperidijiH-yl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[l-(2-methoxybenzoyl)piperidin-4-yl]-2-methyl-5-(phenylsidfonyl)ben2enesulfonamide; N-[ 1 -(3-tnethoxybenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide; N-[ 1 -(3,4-dimethoxybenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-{l-[3-(trifluoromethyl)benzoyl]piperidin-4- yl}benzenesulfonamide; N-[l-(4-chlorobenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide; N-[l-(4-methoxybenzoyl)piperidin-4-yl]-2-methyl-5-(phenylsvilfonyl)benzenesulfonamide; 2-methyl-N-[l-(4-methylbenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide; N-[ 1 -(methoxyacetyl)piperidin-4-yl]-2-methy 1-5- (phenylsulfonyl)benzenesulfonamide; 2-methyl-N-[l-(phenylacetyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide; N-[l-(cyclohexylcNbonyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide; 2,6-dimethyl-3-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; N-[l-(cycIopropylcNbonyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide; N-[l-(4-cyanobenzoyl)piperidin-4-yl]-2-methyI-5- (phenylsulfonyl)benzenesulfonamide; N-[l-(3-cyanobenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide; 2-methyl-N-[l-(methylsulfonyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide;; N-(l-acetylpiperidin-4-yl)-2-methyl-5-(phenylsuifonyl)benzenesulfonamide N-(4- {[4-( {[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl} amino)piperidin-1 - yl]cNbonyl}phenyl)acetamide; 2-methyl-N-{l-[(l-methyl-lH-imidazol-4-yl)sulfonyl]piperidin-4-yl}-5- (phenylsulfonyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-[l-(2-thienylsulfonyl)piperidin-4-yl]benzenesulfonamide; N-( 1 - {[5 -(dimethylamino)-1 -naphthy 1] sulfony 1} piper idin-4-y l)-2-methyl-5 - (phenylsulfonyl)benzenesulfonamide; N-[l-(l,3-benzodioxol-5-ylcNbonyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonaniide; N-[l-(isoxazol-5-ylcNbonyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide; N-[l-(N,N-dimethylglycyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide; prop-2-yn-l-yl 4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine- 1- cNboxylNe; methyl 4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l - cNboxylNe; 2-methoxyphenyl 4-( {[2-methyl-5- (phenylsulfonyl)phenyl]sulfonyl) amino)piperidine-1 - cNboxylNe; N-(tert-butyl)-4-({[2-methyl-5-(phenylsidfonyl)phenyl]svilfonyl}ainino)piperidine- 1-cNboxamide; N-cyclohexyl-4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- cNboxamide; 2-methyl-N-(2-morpholin-4-ylethyl)-3-(phenylsulfonyl)benzenesulfonamide; 2-methyl-N-[l-(2-naphthoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-[l-(2-thienylcNbonyl)piperidin-4-yl]benzenesulfonamide; isobutyl 4-({ [2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-1 - cNboxylNe; N-{ 1 -[4-(diniethylamino)benzoyl]piperidin-4-yl} -2-methyl-5- (phenylsulfonyl)benzenesulfonamide;; 4-fluorophenyl4-({[2-methyl-5-(phenylsulfonyl)pheuyl]sulfonyl}amino)piperidine- 1- cNboxylNe N-ethyl-4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-1 - cNboxamide; 2-methyl-N-[l-(morpholin-4-ylcNbonyl)piperidin-4-5- (phenylsulfonyl)benzenesultbnamide; N,N-dimethyl-4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- cNboxamide; N-[l-(3,3-dimethylbutanoyl)piperidin-4-yl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-[l-(pyridin-3-ylcNbonyl)piperidin-4-yl]benzenesulfonamide; tert-butyl 4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidine-1 - cNboxylNe; N-(l-{[5-(diraethylamino)-l-naphthyl]sulfonyl}piperidin-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[l-(methoxyacetyl)piperidin-4- yljbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-piperidin-4-ylbenzenesulfonamide; N-( 1 -benzylpiperidin-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide; ethyl 4-[({ 5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl} snlfonyl)amino]piperidine-1 - cNboxylNe; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-piperidin-l-ylethyl)benzenesulfonamide; tert-butyl 4-{[(2-isopropyl-5-{[4- (methylaniino)phenyl]sulfonyl}phenyl)sulfonyl]amino}piperidine-l-cNboxylNe; N-( 1 -acetylpiperidin-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide; N-[l-(cyclopropylcNbonyl)piperidin-4-yl]-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide; N-[l-(4-cyanobenzoyl)piperidin-4-yl]-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide; 5-[(4-fluorophenyl)siilfonyl]-2-isopropyl-N-(te1rahydrofuran-2-yhTaethyl)berizenesulfonamide; 5-({4-[(2-cyanoethyl)ammo]phenyl}sulfonyl)-2-isopropyl-N'-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide; 5-({4-[(2-cyanoethyl)amino]phenyl}sulfonyl)-2-isopropyl-N'-(tetrahydro-2H-pyran-4- ylmethyl)benzenesulfonamide; 5-({4-[(2-cyanoethyl)amino]phenyl}sulfonyl)-2-isopropyl-N-[2-(tetrahydro-2H-pyran-4- yl)ethyl]benzenesulfonamide; N-(3l,6l-dihydroxy-3-oxo-3H-spiro[2-benzofuran-l,9'-xanthen]-5-yl)-.4-[({5-[(4- fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]piperidine-l-cNbothioamide; 2-isopropyl-5-[(2-methylphenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; 5-[(3-chloro-2-methylphenyl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide; 2-isopropyl-5-{[4-(methylamino)phenyl]sulfonyl}-N-(tetrahydro-2H-pyran-4- y lmethyl)benzenesulfonamide; 5-{[4-(dimethylamino)phenyl]sulfonyl}-2-isopropyl-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide; 5- {[4-(dimethylamino)phenyl]sulfonyl} -2-isopropyl-N-(tetrahydro-2H-pyran-4- ylmethyl)benzenesulfonamide; 5- {[4-(dimethylamino)phenyl]sulfonyl} -2-isopropyl-N-[2-(tetrahydro-2H-pyran-4- yl)ethyl]benzenesulfonamide; 2-isopropyl-5-{[4-(4-methylpiperazin-l-yl)phenyl]sulfonyl}-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide; 2-isopropyl-5-{[4-(4-methylpiperazin-l-yl)phenyl]sulfonyl}-N-(tetrahydro-2-pyran-4- ylmethyl)benzenesulfonamide; 2-isopropyl-5-{[4-(4-methylpipera2in-l-yl)phenyl]sxilfonyl}-H-[2-(tetrahydro-2-pyran-4-yl)ethyl]benzenesulfonamide; 5-(phenylsulfonyl)-2-propyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; 5-(phenylsulfonyl)-2-propyl-N-(tetrahydro-2H-pyranH-ylmethyl)benzenesuIfonainide; 5-(phenylsulfonyl)-2-propyl-N'-[2-(tetrahydro-2H-pyran-4-yl)ethyl]benzenesulfonaniide; ter/-butyl4-({[5-(phenylsulfonyl)-2-propylphenyl]sulfonyl}amino)piperidine-l-cNboxylNe; 5-[(4-fluorophenyl)sulfonyl]-2-propyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-propyl-AKtettH 5-[(4-fluorophenyl)sulfonyl]-2-propyl-N-[2-(tetrahydro-2H-pyran-4- yl)ethyl]benzenesulfonamide; tert-Butyl 4-[({5-[(4-fluorophenyl)sulfonyl]-2-propylphenyl} sulfonyl)amino]piperidine-1 - cNboxylNe; 2-isopropyl-5- {[4-(methylamino)phenyl]sulfonyl} -N-piperidiii-4- ylbenzenesulfonamide; 5-[(5-chloro-l,3-dimethyl-l-pyrazol-4-yl)sulfonyl]-2-isopropyl-N-(tetrahydro-2-pyran-4- yl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[l-(morpholin-4-ylcNbonyl)piperidin- 4- yl]benzenesulfonamide; 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N,N- dimethylpiperidine- 1-cNboxamide; N-( 1 -benzylpiperidin-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-piperidin-4-ylbenzenesulfonamide; 5-({4-[(2-cyanoethyl)(methyl)amino]phenyl}sulfonyl)-2-isopropyl-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide; 5-({4-[(2-cyanoethyl)(methyl)amino]phenyl}sulfonyl)-2-isopropyl-A'-(tetrahydro-2/:f-pyran-4- ylmethyl)benzenesulfonamide; N-(l-acetylpiperidin-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide; N- [ 1 -(4-cyanobenzoyl)piperidin-4-y 1] -5 - [(4-ftuorophenyl)sulfony l]-2- methylbenzenesulfonamide; 4- [({ 5-[(4-fluorophenyl)sulfonyl]-2-methylphenyl} sulfonyl)amino]-N,N- dimethylpiperidine-1 - cNboxamide; 5-[(4-fluorophenyl)sulfonyl]-N-[l-(methoxyacetyI)piperidin-4-yl]-2- methylbenzenesulfonamide; 2-isopropyl-5-[(3-methoxyphenyl)sulfonyl]-N-(tetrahydro-2H-pyranH-yl)berizenesulfonamide; 5-{[4-(dimethylamino)-2-methylphenyl]sulfonyl}-2-isopropyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide; 2-(dime1iiylamino)-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[l-(morpholin-4-ylcNbonyl)piperidin-4- yl]benzenesulfonamide; 2-chloro-5-[(3-methylphenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; 2-cMoro-5-[(3-me1iioxyphenyl)sulfonyl]-N:(tetrahydro-2JH-pyran-4-yl)benzenesulfonamide; 2-chloro-5-[(l-methyl-lH-indol-5-yl)sulfonyl]-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide; 5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-2-(trifluoromethyl)benzenesulfonamide; 2,4-diisopropyl-5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; 2,4-diisopropyl-5-(phenylsulfonyl)-N-(teti-ahydro-2H-pyran-4-ylmethyl)benzenesulfonamide; 2,4-diisopropyl-5-(phenylsulfonyl)-N-[2~(tetrahydi-o-2H"-pyran-4-yl)ethyl]berizenesulfonamide; 5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; 2-chloro-5-[(4-fluorophenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamicle; tert-butyl 4-({[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-1 -cNboxylNe 2-chloro-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide;; ferr-butyl4-[4-({4-isopropyl-3-[(tetrahydro-2H"-pyran-4- ylamino)sulfonyl]phenyl}sulfonyl)phenyl]piperazine-l-cNboxylNe 5-({4-cw-3,5-dimethylpiperazin-l-ylphenyl}sulfonyl)-2-isopropyl-N-(tetrahydro-2H-pyran-4- y l)benzenesulfonamide; 5-({4-/raw-2,5-dimethylpiperazin-l-ylphenyl}sulfonyl)-2-isopropyl-A'-(tetrahydro-2Hf-pyran-4- yl)benzenesulfonamide; 2-isopropyl-5-[(4-piperazin-l-ylphenyl)sulfonyl]-AL(tetrahydro-2J[/'-pyran-4- yl)benzenesulfonamide; 5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyl-A'-(tetrahydro-2H-pyran-4- ylmethyl)benzenesulfonamide; 5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyl-N-[2-(tetrahydro-2H:-pyran-4- yl)ethyl]benzenesulfonamide; 2-cMoro-N"-[3-(4-mefeylpiperazin-l-yl)propyl]-5-(phenylsulfonyl)benzenesulfonamide; 1 - {[2-chloro-5-(phenylsulfonyl)phenyl]suIfonyl} –N-diethylpyrrolidin-3-amine; ethyl 1 -{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}piperidine-3-cNboxylNe; 2-chloro-5-(phenylstilfonyl)-N-[l-(trifluoroacetyl)piperidin-4-yl]benzenesulfonanude; 2-chloro-N-[l-(2,2-dimethylpropanoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide; N-(tert-bvtyY)-4-( {[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl} amino)piperidine-1 - cNboxamide; 2-cUoro-N[l-(morpholin-4-ylcNbonyl)piperidin-4-yl]-5-(phenylsulfonyl)ben2enesiilfonainide; or 2-chloro-]V-(l-cyanopiperidin-4-yl)-5-(phenylsulfonyl)benzenesulfonamide. 34. The compound of claim 1 which is N3-({5-[(4-fluorophenyl)sulfonyl]-2-methylphenyl}sulfonyl)-beta-alaninamide; methyl N'-({5-[(4-fluorophenyl)sulfonyl]-2-methylphenyl}sulfonyl)-beta-alaninNe; HV-(2-cyanoethyl)-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N-{2-[({5-[(4-fluorophenyl)sulfonyl]-2-methylphenyl}sulfonyl)amino]ethyl}acetamide; N"-[2-(diethylamino)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N'-[2-(dimethylamino)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylben.zenesiilfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(3-methoxypropyl)-2-methylbenzenesulfonamide; N-[3-(diethylamino)propyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; N- ({5-[(4-fluorophenyl) sulfonyl]-2-methylphenyl} sulfonyl)-beta-alanine; N3-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-beta-alaninamide; methyl N-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyI}-beta-alaninNe; N-[2-(diethylamino)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(dimethylamino)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-(3-methoxypropyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[3-(dimethylamino)propyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-(2-methoxyethyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[3-(diethylamino)propyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; methyl N-{[2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyl}-beta-alaninNe; 2-ethyl-7\/'-(3-methoxypropyl)-5-(phenylsvilfonyl)benzenesulfonamide; N'-[3-(dimethylamino)propyl]-2-ethyl-5-(phenylsulfonyl)benzenesulfonamide; 2-ethyl-N-(2-methoxyethyl)-5-(phenylsulfonyl)benzenesulfonamide; N- [3-(diethylamino) propyl]-2-ethyl-5- (phenylsulfonyl) benzene sulfonamide; methyl N-{[2-methoxy-5-(phenylsulfonyl)phenyl]sulfonyl}-beta-alaninNe; 2-methoxy-N-(3-methoxypropyl)-5-(phenylsulfonyl)benzenesulfonamide; H-[3-(dimethylamino)propyl]-2-methoxy-5-(phenylsulfonyl)benzenesiilfonamide; 2-methoxy-H-(2-methoxyethyl)-5-(phenylsulfonyl)benzenesulfonamide; NL[3-(diethylamino)propyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-propylbenzenesulfonamide; N-( 1 -ethylpropyl)-2-methyl-5-(phenylsulfony l)benzenesulfonamide; N-cyclobutyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-cyclopentyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-cyclohexyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide; N-(2-hydroxy-14-dimethylethyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-cyclopropyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-cyclopropyl-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide; N-cyclobutyl-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide; N-cyclopentyl-5-[(4-fiuorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide; N-cyclohexyl-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide; N-cyclopentyl~5-(phenylsulfonyl)-2-propylbenzenesulfonamide; N-cyclopentyl-5-[(4-fluorophenyl)sulfonyl]-2-propylbenzenesulfonamide; N-cyclopentyl-2,4-diisopropyl-5-(phenylsulfonyl)benzenesulfonamide; N-cy clopentyl- 5 - [(4-fluorophenyl)sulfonyl] -2,4-diisopropylbenzenesulfonamide; 2-chloro-N-(2-cyanoethyl)-5-(phenylsulfonyl)benzenesulfonamide; or methyl N-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}-2-methylalaninNe. 35. The compound of claim 1 which is N-[2-(3,4-diiTiethoxyplienyl)ethyl]-7H,2-dimethyl-5-(phenylsulfonyl)benzenesulfonamide; N'-allyl-N'-[2-(3,4-dime1iioxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N'-[2-(3,4-dimethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)-N-prop-2- ynylbenzenesulfonamide; N'-[2-(2-fluorophenyl)ethyl]-N2-dimethyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; N-allyl-N- [2-(2-fluorophenyl) ethyl]-2-methyl-5- [(4-methylphenyl) sulfonyl] benzene sulfonamide; N-[2-(2-fluorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]-N-prop-2- ynylbenzenesulfonamide; NH-dimethyl-NH-phenylethyH-S-HhenylsulfonyObenzenesulfonamide; l-{[2-metiiyl-5-(phenylsulfonyl)phenyl3sulfonyl}-4-(2-oxo-2-pyrrolidin-l-ylethyl)piperazine; AyV-diethyl-N-[2-(4-{ [2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-1 -yl)ethyl]amine; 4-[2-(4-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}pipera2dn-l-yl)ethyl]morpholine; l-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-4-(2-pyrrolidin-l-ylethyl)piperazine; 4-[3-(4-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-l-yl)propyl]morpholine; 2-ethyl-N-methyl-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide; l-{[2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyl}-4-(2-oxo-2-pyrrolidin-l-yletliyl)piperazine; N-diethyl-N-[2-(4-{ [2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-1 -yl)ethyl]amine; 4-[2-(4-{[2-ethyl-5-(phenylsulfoayl)phenyl]sulfonyl}piperazin-l-yl)ethyl]morpholine; l-{[2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyl}-4-(2-pyrrolidin-l-ylethyl)piperazine; 4-[3-(4-{[2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-l-yl)propyl]morpholine; N-[l-(cyclopropylcNbonyl)piperidin-4-yl]-N-({5-[(4-fluorophenyl)sulfonyl]-2- methylphenyl}sulfonyl)cyclopropanecNboxamide; 1 -{[2-chloro-5-(pheny IsulfonyDphenyljsulfony 1} -4-pyrrolidin-1 -ylpiperidine; 4-[2-(4-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-l-yl)ethyl]morpholine; l-(l,3-ben2odioxol-5-ylmethyl)-4-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}piperazine; ?ert-butyl(l-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}pyrrolidin-3-yl)cNbamNe; ?eH-butyl(l-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}piperidin-4-yl)cNbamNe; 2-chloro-A'-methyl-5-(phenylsulfonyl)-7\/-(2-pyridin-2-ylethyl)benzenesulfonamide; or 1 -{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl} -4-[(2,5-dimethyl-1 H-pyrrol-1 -yl)methyl]piperidine. 36. The compound of claim 1 which is 2-chloro-N-(2-hydroxy-1,1 -dimethylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-chloro-H-(cyanomethyl)-5-(phenylsulfonyl)benzenesulfonamide; N-(2-cyanoethyl)-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide; 2-methyl-N-(3 -oxo-3-pyrrolidin-1 -y Ipropy l)-5 -(phenylsulfonyl)benzenesulfonamide; N-(reHbutyl)-N-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-p-alaninamide; 7H-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-H-(l,2,3,4-tetrahydronaphthalen-l-yl)-p-alaninamide; N-methyl-N- {[2-methy l-5-(phenylsulfonyl)phenyl] sulfonyl} -N-phenyl-p -alaninamide; 2-methyl-H-[3-(6-methyl-3,4-dihydroquinolin-l(2J:0-yl)-3-oxopropyl]-5-(phenylsulfonyl)benzenesulfonamide; 2-chloro-N-(2-hydroxyethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-chloro-N-(2-hydroxy-l-methylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-cWoro-]V-[2-hydroxy-l-(hydroxymethyl)ethyl]-5-(phenylsulfonyl)benzenesiilfonamide; N-(2-cyanoethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; H-(2-hydroxyethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N'-(2-hydroxy-l-methylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; Af-[(liS)-2-hydroxy-l-methylethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; /i/-[(l/2)-2-hydroxy-l-methylethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N'-(2-hydroxy-l-methylethyl)-2-isopropylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-?V-[l-(hydroxymethyl)-2-methylpropyl]-2-isopropylbenzene.sulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxybutyl)-2-isopropylbenzenesulfonamide; N-(2-cyanoethyl)-5-[(3-methoxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide; 5-[(3-chlorophenyl)sulfonyl]-N-(2-cyanoethyl)-2-(trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)benzenesulfonamide; N-(2-tnorpholin-4-ylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-(3-morpholin-4-ylpropyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-(3-methoxypropyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-[l-(hydroxymethyl)-2-methylpropyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[(lR)-l-(hydroxymethyl)propyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-(2-hydroxyethyl)-5-[(3-methoxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide; N"-(2-cyanoethyl)-5-[(4-methoxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide; N-(2-cyanoethyl)-5-[(4-hydroxyphenyl)sulfonyl]-2-(trifluoromethyl)ben2enesulfonamide; N-[(l-hydroxycyclohexyl)methyl]-5-(phenylsiilfonyl)-2-(trifluoromethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-piperidin-3-ylethyl)benzenesulfonamide; N-{[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}-p-alanine; 4-( {[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl] sulfonyl} amino)butanoic acid; tert-butyl 4-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidine- 1-cNboxylNe; 5-(phenylsulfonyl)-N-(piperidin-4-ylmethyl)-2-(trifluoromethyl)benzenesulfonamide; tert-butyl [/ran5'-4-({[5-(phenylsulfonyl)-2- % (trifluoromethyl)phenyl]sulfonyl}amino)cyclohexyl]cNbamNe; 4-oxo-4-{4-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidiri- l-yl}butanoic acid; 5-oxo-5-{4-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}'amino)methyl]piperidin- l-yl}pentanoic acid; 3-({4-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidin-l- yl}sulfonyl)benzoic acid; terr-butyl 2-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)ethyl]pyrrolidine-1 -cNboxylNe; 5-(phenylsulfonyl)-N-(2-pyrrolidin-2-ylethyl)-2-(trifluoromethyl)benzenesulfonamide; {2-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidin-1 - . yl} acetic acid; 4-oxo-4-{2-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidin- l-yl}butanoicacid; 3-( {2- [2-( {[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)ethyl]pyrrolidin-1 - yl}sulfonyl)benzoic acid; /er/-butyl4-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]piperidine- 1-cNboxylNe; methyl 3-({[2-isopropyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)cyclohexanecNboxylNe; methyl 4-({[2-isopropyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)cyclohexanecNboxy lNe; methyl transA-[{{[2-isopropyl-5- (phenylsulfonyl)phenyl]sulfonyl}amino)methyl]cyclohexanecNboxylNe; 5-(phenylsulfonyl)-N-(2-piperidin-4-ylethyl)-2-(trifluoromethyl)benzenesulfonamide; {4-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidin-l- yl}acetic acid; {4-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]piperidin-l- yl} acetic acid; methyl 3-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)cyclohexanecNboxylNe; methyl 4-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)cyclohexanecNboxylNe; methyl trans-4-[({ [5-(phenylsulfony l)-2- (trifluoromethyl)phenyl]sulfonyl}amino)methyl]cyclohexanecNboxylNe; 3-({[2-isopropyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)cyclohexanecNboxylic acid; 4-({ [2-isopropyl-5-(phenylsulfonyl)phenyl]sulfonyl} amino)cyclohexanecNboxylic acid; trans-4-[( {[2-isopropyl- 5 - (phenylsulfonyl)phenyl]sulfonyl}amino)methyl]cyclohexanecNboxylie acid; 3-{4-[({[5 -(phenylsulfony l)-2-(trifluoromethy l)phenyl] sulfonyl} amino)methy l]piperidin-1 - yl}benzoic acid; 3-{4-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]piperidin-l- yl}benzoic acid; N"-(/ra«H-4-aminocyclohexyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; 3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)cyclohexanecNboxylic acid; 4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)cyclohexanecNboxylic acid; /mw-4-[({[5-(phenylsulfonyl)-2 - (trifluoromethyl)pheDyl]sulfonyl}amino)methyl]cyclohexanecNboxylicacid; N-(frawj-4-hydroxycyclohexyl)-5-(pheny]sulfonyl)-2-(trifluoromethy])benzenesulfonamide; tert-butyl 4-[({[5-(phenylsulfonyI)-2- (trifluoromethyl)pheny]]sulfonyl } amino)cNbonyl]piperidine- 1 -cNboxylNe ; or N-{[5-(pheBylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}piperidine-4-cNboxamide. 37. The compound of claim 1 which is 5 -(phenylsulfonyl)-Af-(tetrahy dro-2H"-pyran-4-yl)-2 -(frifluoromethoxxy )benzenesulfonamide ; 2-isopropyl-5-(phenylsulfonyl)-N-(tetrahydro-2JfiT-pyran-4-yl)benzenesulfonamide; 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide; 2-Methoxy-5-(phenylsulfonyl)-H-(tetrahydro-2/r-pyran-4-yl)bem:enesulfonamide; 5-[(3-methoxyphenyl)sulfonyl]-N-(tetrahydro-2/:f-pyran-4-yl)-2- (triflnoromethyl)benzenesulfonamide; 5-[(3~hydroxyphenyl)sulfonyJJ-N-(tetrahydro-2Hr-pyran-4-yl)-2- (trifluoromethyl)benzenesulfonamide; 5-[(3-chlorophenyl)sidfonyl]-N-(tetrahydro-2H:-pyran-4-yl)-2- (trifluoromethiyl)benzenesulfonNaide; 5-(phenylsulfonyl)rN[(3J?)-pip6ridin-3-yl]-2-(trifluoromethyl)benzenesulfonNaide; 5-f( 1 ,2-dimethyl- 1 H-indol-5-yl)sulfonyl]-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide ; 5-(phenylsulfony])-N-[(3S)-pyrrolidin-3-yl]-2'(trifluoromethy!)benzenesulfonamide; 5-(phenylsulfonyl)-N-[(3R)-pyrrolidin-3-yl]-2-(trifluoromsthyl)benzenesuIfonamide; 2-metliyl-5-(phenylsulfonyl)~N-(tetrahydro-2H-thiopyraiv4-yI)ben2enesuIfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(telxahydro-2H-thiopyran-4-yl)benzeiiesulfonamide; 5-[(4-fIuorophenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)-2- (trifluoromethyljbenzenesulfonamide; 5-[(2-fluorophenyl)sulfonyl]-N-(tetrahydro-2H-pVTan-4-yl)-2- (trifluoromethy])bejizenesujfon;:)mide; 5-(phenylsulfonyl)-N-pyrrolidin-3-yl-2-(trifluoromethyl)benzenesulfonaniide; N-[(2R*,4S*,6S*)-2,6-dimethyltetrahydro»2H-pyran-4-yl]-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide; 5-{[4-(methylamino)phenyl]sulfonyl}-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonainide; 5-{ [4-(dimethylamino)phenyl]sulfonyl} -N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide; 5-({4-[(2-hydroxyethyl)amino]phenyl}sulfonyl)-H-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide; N-( 1,1 -dioxidotetrahydro-2H-thiopyran-4-yl)-5-[(4-fluorophenyl)sulfonyl]--2- isopropylbenzenesulfonamide; 5-{[2-(methylamino)phenyl]sulfonyl}-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide; 5-{[2-(dimethylamino)phenyl]suifonyl}-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide; 5-({2-[(2-hydroxyethyl)Naino]phenyl}sulfonyl)-N:-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide; 2-ethyl-5-(phenylsulfonyl)-N'-piperidin-4-ylben2enesulfonamide; 2S3-dimethyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide; 2,4-dimethyl-5-(phenylsulfonyl)-N:-piperidin-4-ylbenzenesulfonamide; 2-isopropyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide; 5-(phenylsulfonyl)-]V-piperidin-4-yl-2-propylbehzenesulfonamide; 2-isopropyl-5-(phenylsulfonyl)-N'-(2,2,6,6-tetramethylpiperidin-4-yl)benzenesu]fonainide; 5-(phenylsulfonyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-2- (trifluoromethyl)benzenesulfonamide; 5-[(4-methoxyphenyl)s'ulfonyl]-N-piperidin-4-yl-2-(trifluoromethy l)benzenesulfonainide; or 5-[(3-bromophenyl)sulfonyl]-N-piperidin-4-yl-2-(trifluoromethyl)benzenesalfonamide. 38. The compound of claim 1 which Is 2-chloro-A'-[l-(4-fluorobenzoyl)piperidm-4-yl]-5-(phenylsulfonyl)benzene3ulfonamide: 2-chloro-A'-[l-(4-cyanobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide; 2-chloro-5-(phenylsulfonyi)-N-{l-[4-(trifluorpmethyl)benzoyl]pipsridi::i-4- yl} benzenesulfonamide; 5-(phenylsulfonyl)-2-(trifluoromethyl)-N-{l-[4-(trifluoromethyl)benzoyl]piperidin-4-yl} benzenesulfonamide; N-[l-(2-chlorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[l-(2-methoxybenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[l-(3-chlorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[ 1 -(3,4-difluorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N'-[l-(3,5-difluorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; H-[l-(2,6-dimethoxybenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[l-(2,4-dimethoxybenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-{ 1 -[4-(trifluoromethoxy)benzoyl]piperidin-4-yl} -2- (trifluoromethyl)benzenesulfonamide; N- {I -[2-fluoro-4-(trifluoromethyl)benzoyl]piperidin-4-yl} -5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N{l-[3-fluoro-4-(trifluoromethyl)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[i-(3,4-dichlorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide N-[l_(4-chlorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-(l-isonicotinoylpiperidin-4-yl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-[l-(2-chloro-6-methoxyisonicotinoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N"-[l-(2-chloro-4-fluorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethy l)benzenesulfonamide; 5-(phenyisulfonyl)-N-[l-(2,4,6-ti'ifluorobenzoyl)piperidm-4-yl]-2- (trifluoromethyl)benzenesulfonamide; N-[l-(4-HH-butylbeiizoyl)piperidin-4-y]]-5-(phenylsulfonyi)-2-(trifluoromethyl)benzenesulfonami de ; N-(4-{[4-({[5-(phenylsulfonyl)-2-(trifluorornethyl)phenylJsulfonyl}amino)piperidin-l- yl]cNbonyl}phenyl)acetamide; 5-(phenylsuifonyl)-2-(trifluoromethyl)-N-(l-{[4- (trifluoromethyl)phenyl]cNbonothioyl}piperidin-4-yI)ben2enesvilfonamide; J/V-[l-(4-tert-butylbenzoyl}piperidin-4-yl]-5-[(3-methoxyphenyl)sulfonyl]-2- (trifluoromethyl)benzenesulfonamide; N[l-(4-/er/-butylbenzoyl)piperidm-4-yl]-5-[(3-chlorophenyl)sulfonyl]-2- (trifluoromethyl)benzenesulfonamide; S-Hhenylsulfonyl)-H- { 1 -[2-(trifluoromethoxy)benzoyl]piperidin-4-yl } -2- (trifluoromethyl)benzenesiHfonamide; N-(l-benzoylpiperidinH-yl)-5-(phenylsulfonyl)-2Htrifluoromethyl)ben2enesxilfonainide; N[l-(4-/err-butylbenzoyl)pyrrolidin-3-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[l-(4-ferr-butylbenzoyl)piperidiri-4-yl]-5-[(3-hydroxyphenyl)sulfony]]-2- (trifluorometbyl)benzenesulfonamide; (trifluoromethyl)ben2enesulfonamide; N-[l-(3-ben2oylbenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; l-Isopropyl-4-(phenylsulfonyl)benzene; 2-Isopropyl-N-[l-(2-methoxybeazoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesuIfonNiiide; N-[l-(3-Fluoroben2oyl)piperidin-4-yl]-2-isopropyl-5-(pheriylsulforiyt)benzenesulfonamide; HV-[l-(4-Fluorobenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenyIsulfonyl)benzenesulfonamide; Nr-[l-(2-Fluorobenzoyl)piperidin-4-yI]-2-isopropyl-5-(phenyIsulfonyl)ben2enesulfonamide; 2-Isopropyi-5-(phenylsulfonyl)-N- { 1 -[4-(trifluoromethyl)benzoyi Jpiperidin-4- yl} benzenesulfonamide; 2-Isopropyl-N-[l-(l-ziaphthoyl)piperidiii-4-yl]-5-(phenylsulfbriyl)benzenesulfonairiide; 2-Isopropyl-N-[l-(2-naphtlioyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide; N-[l-(3-Cyanobenzoyl)piperidiji-4-yl]-2-isopropyl-5-(phenylsulfony!)benzenesulfonainide; N[l-(4-Cyanobenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide; H-[l-(4-rer/-Butylbenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsuifonyl)benzenesulfonamide; N- [ 1 -(2-Ethoxy-1 -naphthoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonai-aide; N-[l-(2-chloro-6-methyIisonicotinoyl)piperidin-4-y]]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N"-[l-(2,6-dichloroisonicotinoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N- {I -[4-(dimetb.ylamino)benzoy l]piperidin-4-y 1} -5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-{l-[(6-chloropyridin-3-yl)cNbonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluqromethyl)benzenesulfonamide; N- {1 -[(2,5-dichloropyridin-3-yl)cNbonyl]piperidin-4-yl} -5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[l-(2-chloroisonicotinoyl)piperidin-4-yl3-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-{ 1 -[(6-pyrrolidin-1 -ylpyridin-3-yl)cNbonyl]piperidin-4-yl}-2- (trifluoromethyl)benzenesulfonamide; N"-(l-{[6-(dimethylamino)pyridin-3-yl]cNbonyl}piperidin-4-yl)-5-(phenylsulfonyI)-2- (trifluoromethyl)benzenesulfonamide; N- {I -[(6-oxo-1 - {[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl) -1,6-dihydropyridui-3- yl)cNbonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-(trifluoromethyl)beiizenesulfonainide; N-{l-[(6-phenylpyridin-3-yl)cNbonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoroinethyl)benzenesulfonainide; N-{l-[(6-morpholin-4-ylpyridin-3-yl)cNbonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsuIfonyl)-N-[l-(2-pyrrolidin-l-ylisonicotinoyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonNaide; N-{l-[(6-oxo-l,6-dihydropyridin-3-yl)cNbonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesurfonamide; 5-(phenylsulfonyl)-]V-[l-(pyridin-3"ylcNbonyr)pipeL'idin-4-yl]-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-[l-(pyridin-2-yIcNbonyl)piperidini-4-ylJ-2- (trifluoromethyObenzenesulfonamide; H- {1 -[4-(methylthio)benzoy l]piperidin-4-yI} - 5 -(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonNaide; 5-(phenylsulfony I)-2-(trifluoromethy l)-N-( 1 - {[6-(trifluoromethyl)pyridin-3- yl] cNbonyl} piperidin-4-yI)benzenesuIfon.aniide; N-{1 -[4-(methylsuifinyi)benzoyl]piperidin-4-yl}-5-(phenyIsulfonyl)-2- (trifluoromethyl)beBzenesulfonamide; or 5-(pheaylsulfonyl)-AL[l-(l53-tbjazol-4-ylcNbonyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide. 39. The compound of claim 1 which is rert-butyl 4-( {[5-(phenylsulfony I)-2-(trifluoromethyl)phenyl] sulfony 1} amino)piperidine-1 - cNboxylNe; tert-buty 1 (3S)-3-( {[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidine-1 - cNboxylNe; /er/-butyl (3J?)-3-({ [5-(phenylsulfony l)-2-(trifluoromethyl)phenyl]sulfonyl} Naino)piperidine-1 - cNboxylNe; tert-butyl 4-[({5-[(4-fluorophenyI)sulfonyl]-2- methylphenyl}sulfonyl)amino]piperidine-l - cNboxylNe; r€Hbutyl(3iSH3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidine-l- cNboxylNe; tert-butyl (3H)-3-({[5-(pheny}sulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidine-l- cNboxylNe; tert-butyl 4-( {[5-[(4-fluorophenyl)sulfonyl]-2- (trifluoromethyl)phenyl]sulforiyl}amirio)piperidine-l-cNboxylNe; tert-butyl 4-({[2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyI}amino)piperidine-l-cai-boxy lNe; /er?-butyl4-({[2,3-dimethyl-5-(phenylsulfonyl)phenyl]sulfonyl}ammo)piperidine-l-cNboxylNe; /e?f-butyl4-({[2,4-dimethyi-5-(pheiaylsultbnyl)phenyl]sulfonyl}amino}piperidine-l-cNboxylNe; tert-butyl 4-({[2-isopropyl-5-(phenylsiilfonyl)phenyJ]sulfonyl}amino)piperidine-l-cNboxylNe; or 4-{[3-({[l-(Hr/-butoxycNbouyl)piperidm-4-yl]ainino}sulfonyl)-4- (trifluoromethyl)phenyl]s\ilfonyl}benzoic acid. 40. The compound of claim 1 which is 4-oxo-4-[4-({[5-(phenylsulfonyl)-2-(trifluorometliyl)phenyl]sulfonyl}amino)piperidin-l-yl]butanoic acid; 4-oxo-4-[3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidin-l- yljbutanoic acid; 5-oxo-5-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yljpentanoic acid; 5-OXO-5- [3 -({[5 -(pheny Isulfony l)-2-(trifluoromethy l)pheny 1] sulfonyl} amino)pyrrolidin-1 - yljpentanoic acid; HV-[l-(N'.(N-dimethylglycyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethy l)benzenesulfonamide; /er/-buty!4-{2-oxo-2-[4-({[5-(phenylsulfonyl)-2- (trifluQromethyl)phenyl]sulfonyl} amino)piperidin-1 -yl]ethyl}piperidine-1 -cNboxylNe; 5-(phenylsulfonyl)-N[l-(piperidin-4-ylacetyl)piperidmHyl]-2- (trifluoromethyl)benzenesulfonamide; N-[l-(N-methylglycyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-[l -(pyrrolidin-1 -ylacetyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide; N-[l-(morpholin-4-ylacetyl)piperidin-4-yl]-5-(pheny Isulfony l)-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-[l-(piperazin-l-ylacetyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide; N-{l-[3-(methylthio)propanoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-{ 1 -[3-(methylsulfmyl)propanoyl]piperidin-4-yl} -5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; or N-[l -(I H-imidazol-1 -ylacetyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)berizenesulfonamide. 41. The compound of claim 1 which is 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-l-naphthylpiperidine- 1-cNbothioamide; N-(2-fluorophenyl)-4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl} sulfonyl)amino]piperidine-1 -cNbothioamide; 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-(2- methylphenyl)piperidine-1 -cNbothioamide; ethyl ({4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidin-1 - yl}cNbonothioyl)cNbamNe; N-buryl-4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl} sulfony l)amino]piperidine-l- cNbothioamide; 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-(4- methoxyphenyl)piperidine-l-cNbothioamide; methyl 4-[({4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]piperidin-l- yl} cNbonothioyl)amino]benzoNe; methyl N-({4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]piperidin-l- yl}cNbonothioyl)glycinNe; 4-[( {5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl} sulfonyl)amino]-N-(2- morpholin-4- ylethy l)piperidine-1 -cNbothioamide; 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-(3- nitropheny l)piperidine-1 -cNbothioamide; 3-[({4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]piperidin-l- yl}cNbonothioyl)amino]benzoic acid; 4- [({ 5- [(4-fluorophenyl)sulfonyl] -2-isopropy Iphenyl} sulfony l)amino] -N-pyr idin-3 - ylpiperidine- 1 -cNbothioamide; 4- [({5- [(4-fluoropheny l)sulfony 1] -2-isopropy Iphenyl} sulfony l)amino] -N- [4- (trifluoromethyl)phenyl]piperidine-1 -cNbothioamide; N-(4-/er/-buty Ipheny l)-4-( {[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)piperidine-1 -cNboxamide; or 3-({[4-({[5-(phenylsulfonyl)-2-(tiifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yl]cNbonothioyl} amino)benzoic acid. 42. The compound of claim 1 which is tert-butyl4-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}aniino)piperidin-l- yl]cNbonyl}piperidine-1 -cNboxylNe; 5-(phenylsulfonyl)-N-[l-(piperidin-4-ylcNbonyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide; tert-butyl(2S)-2-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin- 1 -yl]cNbonyl}pyrrolidine-1 -cNboxylNe; 5-(phenylsulfonyl)-N'-(l-L-prolylpiperidin-4-yl)-2-(trifluoromethyl)ben2enesulfonamide; tert-butyl(2/?)-2-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin- 1 -yl] cNbonyl} pyrrolidine-1 -cNboxylNe; 5-(phenylsulfonyl)-]V-(l-D-prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide; N-[l-(l-acetyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethy l)benzenesulfonamide; ter/-butyl (5S)-2-oxo-5-{ [4-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]siUfonyl}amino)piperidin-l-yl]cNbonyl}pyrrolidine-l-cNboxylNe; N-[l-(5-oxo-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-[l-(l-methyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethy l)benzenesulfonNnide; /er/-butyl (47?)-4-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin- 1 -yl] cNbonyl} -1,3 -thiazolidine-3-cNboxy lNe; 5-(phenylsulfonyl)-H-{l-[(4J?)-l,3-thiazolidin-4-ylcNbonyl]piperidin-4-yl}-2- (trifluoromethyl)benzenesulfonamide; tert~b\ityl (3/?)-3- {[4-( {[5-(phenylsulfonyl)-2-(trifluoromethyl)pheny 1]sulfonyl) amino)piperidiri- 1 -yl] cNbonyl} pyrrolidine-1 -cNboxylNe; rerf-butyl(3S)-3-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin- 1 -yl] cNbonyl} pyrrolidine-1 -cNboxylNe; 5-(phenylsulfonyl)-N-{l-[(3R)-pyrrolidin-3-ylcNbonyl]piperidin-4-yl}-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N- {1 -[(3.S)-pyrrolidin-3 -ylcNbonyl]piperidin-4-yl} -2- (trifluoromethy l)benzene sulfonamide; tert-butyl (4R)-4-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sultbnyl}amino)piperidir l-yl]cNbonyl}-l,3-thiazolidine-3-cNboxylNe I-oxide; N-(1 -{[(3R)-1 -acetylpyrrolidin-3-yl]cNbonyl}piperidin-4-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesuifonNaide; N-(l-{[(35)-l-acetylpyrrolidin-3-y]3cNbonyl}piperidin-4-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[l-(l-isobutyryl-L-proIyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)ben2enesuifonamide; N-{l-[l-(2,2-dimethylpropanoyl)-L-pro]yl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluororaethyl)benzenes ulfonamide; N-{l-[l-(3,3-dimethylbutanoyl)-L-prolylJpiperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N~{ 1 -[1 -(cyclohexylcNbonyI)-L-proIyl]piperidin-4-yl}-5-(phenylsuIfonyl)-2- (trifluoromethyl)benzenesulfonamide; N~ { 1 - [ 1 -(morpholin-4-ylcNbonyl)-L-prolyl]piperidin-4-yl} -5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; (trifluoromethyl)phenyl]sulfonyl) amino)piperidin- 1 -yl]cNbonyl}pyrrolidine- 1 -cNboxamide; (2S-N-phenyl-2-{[4-({[5-(phenylsulfonyl-2-(trifluoromethyl)phenyl]Hfonyl}am 1 -yl]cNbony 1} pyrrolidine- 1 -cNboxamide; N- { 1 -[ 1 -(methy Isulfony l)-L-prolyl]piperidin-4-yl} -5 -(phenylsu!fonyl)-2- (trifluoromethy l)benzenesulfonamide ; N-[l -( I -benzoyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfony])-2- (trifluoromethyl)benzenesulfonamide; N-(l -{ 1 -romethyl)benzene[4-(dimethylamino)benzoyl]-L-prolyl} piperidin-4-yl)-5-(phenylsu{fonyl)-2- (trifluo sulfonamide; (trifluoromethyl)benzenesulfon.amide; N-(l-{l-[(6-chloropyridin-3-yl)cNbonyl]-L-prolyI}piperidin-4-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 4-[((2S)-2- { [4-( { [5 -(phenylsulfonyl)-2-(trifluoromethy l)phenyl] sulfenyl } amino)piperidin-l - yl]cNbonyl}pyrrolidin-l -yl)sulfonyl]benzoic acid; N-[l-(N',(V-dimetIiyiglycyl-L-proly])piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[l-(l-ben2yl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N- {1 -[1 -(cyclohexylmethyl)-L-prolyl]piperidin-4-yl} -5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; H-{l-[l-(3,3-dimethylbutyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; (2iS)-N-ethyl-2- {[4-( {[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-1 - yl] cNbony 1} pyrrolidine-1 -cNboxamide; (2S)-H5H-dimethyl-2-{[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]cNbonyl}pyrrolidine-l-cNboxamide; or tert-butyl (2S)-2-{[4-({[5-[(3-cyanophenyl)sulfonyl]-2- (trifluoromethyl)phenyl]sulfonyl}ainino)piperidin-l-yl]cNbonyl}pyrrolidine-l-cNboxylNe. 43. The compound of claim 1 which is H-[l-(2-hydroxy-2-methylpropyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 5-(pheny lsulfonyl)-2-(trifluoromethyl)-H- {1 -[4-(trifluoromethyl)benzyl]piperidin-4- yljbenzenesulfonamide; N-[l-(cyanomethyl)piperidm-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; H-[l-(2-oxo-2-phenylethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethy l)benzenesulfonamide; 5-(pheny Isulfony l)-2-(trifluoromethy l)-N- {1 - [4-(trifluoromethyl)pheny l]piperidin-4- yl}benzenesulfonamide; N-[\ -(2-hydroxyethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethy l)benzenesulfonamide; 2-Isopropyl-W- [(1H?* !55*)-8-methyl-8-azabicyclo[3.2. l]oct-3-yl]-5- (phenylsulfonyl)benzenesulfonamide monohydrochloride; [4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]acetic acid; 2-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]acetamide; 5-(phenylsuifonyl)-N'-[l-(2Jc/-tetra2ol-5-ylmethyl)piperidin-4-yl]-2- (trifluoromethy l)benzenesulfbnamide; 3j[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]propaiioic acid; 3-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]berizoic acid; 4-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]beiizoic acid; N-[l-(3-cyanophenyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; 2- [4-( {[5 -(pheny Isulfony l)-2-(tr ifluoromethy l)pheny 1] sulfony 1} amino)piperidin-1 - yl]propanNaide; N"-[l-(2-morpholin-4-ylethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)berrzenesulfonamide; N[(U?*,55*)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; (2H)-2-[4-({[5-(phenylsidfonyl)-2HlTifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yl]propanamide; (2S)-2-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yl]propanamide; methyl [4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-1 - yl]acetNe; N-methyl-2-[4-({[5-(phenylsiilfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yl]acetamide; NH-dimetliyl-2-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yl]acetamide; N-isopropyl-2-[4-( {[5-(phehylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidin-1 - yljacetamide; or N-[l-(2-morpholin-4-yl-2-oxoethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)ben2enesulfonamide. 44. The compound of claim 1 which is N-{l-[(4-rerr-butylphenyl)sulfonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-(trifiuoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N'-[l-(phenylsulfonyl)piperidin-4-ylJ-2-(trifluorometliyl)benzenesulfonaniide; 3-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yl]sulfonyl}benzoic acid; 4- {[4-( {[5-(phenylsulfonyl)-2-(trifluoromethy l)phenyl]sulfonyl} amino)piperidin-1 - yl]sulfonyl}benzole acid; N- {1 -[(4-hydroxyphenyl)sulfonyl]piperidin-4-yl) -5-(phenylsulfony l)-2- (trifluoromethyl)benzenesulfonamide; methyl 3-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-1 - y 1] sulfony 1} benzoNe; N'-{l-[(3-cyanophenyl)sulfonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; or 5-(phenylsiilfonyl)-A'-(l-{[3-(2J:f-tetrazol-5-yl)phenyl]sulfonyl}piperidin-4-yl)-2- (trifluoromethyl)benzenesulfonamide. 45. The compound of claim 1 which is 5-(phenylsulfonyl)-N(2-pyridin-3-ylethyl)-2-(trifluoromethoxy)benzenesulfonaniide; 2-isopropyl-5-(phenylsulfonyl)-N(2-pyridin-2-ylethyl)benzenesulfonainide; 2-isopropyl-5-(phenylsulfonyl)-N'-(2-pyridin-3-ylethyl)benzenesulfonamide; 5-(phenylsulfonyl)-AA(2-pyridm-3-ylethyl)-2-(trifluoromemyl)benzenesulfonamide; 1 -Methoxy-4-(phenylsulfonyl)benzene; N-[2-(l-oxidopyridin-3-yl)e1iiyl]-5-(phenylsulfonyl)-2-(1rifluoromethyl)benzenesiilfonamide; 5-[(4-fluorophenyl)sulfonyl]-N'-(2-hydroxy-2-pyridin-2-ylethyl)-2- isopropylbenzenesulfonamide; N-(2-hydroxy-2-pyridin-2-ylethyl)-2-isopropyl-5-(phenylsulfonyl)berizene-sulfonamide; N-(2-hydroxy-2-pyridin-2-ylethyl)-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-pyridin-3-ylethyl)-2- isopropylbenzenesulfonamide; N"-(2-hydroxy-2-pyridin-3-ylethyl)-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide; N-(2-hydroxy-2-pyridin-3-ylethyl)-2.,4-dimethyl-5-(jphenylsulfonyl)benzenesulfonamide; N-[2-(lH-Imidazol-l-yl)ethyl]-5-(plienyIsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(2-hyclroxy-2-pyridin-3-ylethyl)-2-methylbenzenesulfonamide; N-(2-hydroxy-2-pyridin-3-ylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; 5-[(3-methoxyphenyl)sulfonyl]-N-(2-pyridin-3-ylethyl)-2-(trifluoromethyl)benzenesulfonamide; 5-[(3-chlorophenyl)sulfonyl]-N-(2-pyridin-3-ylethyl)-2-(trifluoromethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-pyridin-2-ylethyl)-2-niethylbenzenesulfonamide; N-(2-hydroxy-2-pyridin-2-ylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)beiizenesulfonamide; 5-(phenylsulfonyl)-N-(2-pyridin-4-ylethyl)-2-(trifluoromethyl)benzenesulfonamide; 5-[(4-hydroxyphenyl)sulfonyl]-N-(2-pyridin-3-ylethyl)-2-(trifluoromethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-l-yl)ethyl]-2- (Uifluoromethyl)benzenesulfonamide; 5-[(2-fluorophenyl)sulfonyl]-N-[2-( IH-imidazol-l -yl)ethyl]-2- (trifluoromethyl)benzenesulfonamide; 5-(Phenylsulfonyl)-2-propyl-A'-(2-pyridin-4-ylethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-[2-(2H-te1razol-5-yl)ethyl]-2-(trifluoromethyl)benzenesulfonamide; 5-[(4-Fluorophenyl)sulfonyl]-2-propyl-N-(2-pyridin-3-ylethyl)benzenesulfonamide; 5-[(4-Fluorophenyl)sulfonyl]-2-propyl-Nr-(2-pyridin-4-ylethyl)benzenesulfonamide; 5-(Phenylsulfonyl)-2-propyl-H-(2-pyridin-3-ylethyl)benzenesulfonamide; 2-isopropyl-5-(phenylsulfonyl)-N(pyridin-4-ylmethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N(pyridinH-ylmethyl)-2-(trifluoromethyl)ben2enesulfonam N-[(6-chloropyridin-3-yl)me1hyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenes\ilfonamide; 5-(phenylsulfonyl)-/l/-[(6-pyrrolidin-l -ylpyridin-3-yl)methyl]-2- (trifluoromethyl)benzenesulfonamide; or N-[(6-morpholin-4-ylpyridin-3-yl)methyl]-5-(phenylsulfonyl)-2- (trifluoromethy l)benzenesulfonamide. 46. The compound of claim 1 which is 2-chloro-N-[( 1R* ,2R* )-2-hydroxy-1 -methyl-2-phenylethyl]-5- (phenylsulfonyl)benzenesulfonamide; AL(2-hydroxy-2-phenylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-[(lJ2*,2J?*)-2-hydroxy-l-methyl-2-phenylethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesuJfonamide; N-[(15,2H)-2-hydroxy-l-methyl-2-phenylethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; (trifluoromethyl)benzenesulfonamide; N-[(15)-l-benzyl-2-hydroxyethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)ben2;enesulfonainide; N-[(15)-2-hydroxy-l-(lH-indol-3-ylmethyl)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)berizenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-phenylethyl)-2-isopropylbenzenesulfonamide; N-(2-hydroxy-2-phenylethyl)-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide; N-[(2R)-2-hydroxy-2-phenylethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-[(2S)-2-hydroxy-2-phenylethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)ben2;enesulfonamide; 4-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzoic acid; 7\r-[2-(4-aminophenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; 7\H[2-(4-methoxyphenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzfinesulfonamide; H-(4-aminobenzyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-[2-(4-hydroxyphenyl)ethyl]-5-Hhenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; methyl 4-[({ [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)methyl]benzoNe; methyl 4-[({ [2-isopropyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)methyl]benzoNe; N-[2-(4-bromophenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonainideH 3-[({4-[({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)methyl]phenyl} amino)sulfonyl]benzoic acid; N"-(4-bromobenzyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)ben2enesulfonamide; N-[2-(4-cyanophenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonainide; methyl 4-[2-({ [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)ethyl]benzoNe; 4'-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]biphenyl-3- cNboxylic acid; 4'-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]biphenyl-4- cNboxylic acid; 5-(phenylsulfonyl)-N-{2-[4-(2H-tetrazol-5-yl)phenyl]ethyl}-2- (trifluoromethyl)benzenesulfonamide; N-(2-{4-[(methylsulfonyl)amino]phenyl}ethyl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-(3-bromobenzyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; 3'-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]biphenyl-3- cNboxylic acid; 3'-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]biphenyl-4- cNboxylic acid; N_[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[4-(dimethylamino)benzyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;or N-(2,4-dimethoxybenzyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonaniide. 47. The compound of claim 1 which is tert-Butyl [2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cNbamNe; N-(2-Ammoethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamidehydrochloride; N-[2-({[5-(Phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide; 4-Methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide; 4-tert-Butyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide; 4-Fluoro-N-[2-({[5-(phenylsulfonyl>2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide; 4-Chloro-N-[2-({[5-(phenylsuIfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide; 4-Bromo-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide; 4-Methoxy-N-[2-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide; N-[2-({[5-(Phenylsulfonyl)-2-(trifiuoromethyl)phenyl]sulfonyl}amino)ethyl]-4- (trifluoromethy l)benzamide; N-[2-({[5-(Phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-4- (trifluoromethoxy)benzamide; N-[2-({[5-(Phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]isonicotinamide; tert-Butyl methyl[2-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cNbaniNe; N-[2-(Methylamino)ethyl]-:5-(phenylsul:fonyl)-2-(trifluoromc;thyl)benzenesulfonamide hydrochloride; N-Methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} aniino)ethyl]benzamide; 4-Methoxy-N-methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide; N- {2-[(anilinocNbonyl)(methyl)amino]ethyl} -5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-(2-{methyl[(pyridin-3-ylamino)cNbonyl]amino}ethyl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N- {2-[{ [(2,4-dimethoxyphenyl)amino]cNbonyl} (methyl)amino]ethyl} -5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N"-{2-[[(/erNbutylamino)cNbonyl](methyl)amino]ethyl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; NL{2-[{[(4-methoxyphenyl)amino]cNbonyl}(methyl)amino]ethyl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide;; N-{2-[[(butylamino)cNbonyl](methyl)amino]ethyl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide N-{2-[{[(2,4-difluorophenyl)amino]cNbonyl}(methyl)aniino]ethyl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-methyl-H-[2-({[5-(phenylsulfonyl)-2- (trifluorome1iiyl)phenyl]siilfonyl}amino)ethyl]pyrrolidine-l-cNboxamide; N-{2-[[(diethylamino)cNbonyl](methyl)amino]ethyl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-methyl-H-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]morpholine-4-cNboxamide; N-[2-(methyl{[methyl(phenyl)amino]cNbonyl}amino)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-Methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluorometlayl)phenyl]sulfonyl}amino)ethyl]-2- foramide; 4-tert-Butyl-N-methyl-N-[2-({ [5-(phenyisulfonyl)-2 - (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]ben2amide; N-Methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-2- (ti'ifluoromethoxy)beiizamide; N-methyl-N-[2-( {[5-(phenyIsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cyclohexanecNboxamide; 3-Fluoro-N-methyl-N-[2-( {[5-(phenylsulfonyl)-2- (trifluoromethyl)plienyl]su}fonyl}amino)ethyl]-4-(trifluoromethyl)benzamide; Methyl 4-({methyl[2-({[5-(phenylsulfony3)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amtno}cNbonyl)ben2oNe; N-Methyl-N-[2-({[5-Cphenylsulfonyl)-2- (trifluoroniethyl)phenyl]sulfonyl}amino)ethyl]nicotinamide; N-Methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]isonicotinamide; 2-Chloro-N-methyl-N-[2-({[5-(phenylsuifonyl)-2- (trifluoromethyl)phenyl]su3fonyl}amino)ethyl]nicotinamide; N,2,2-trimethyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]propanamide; 2-ethyl-N-methyI-N-[2-({[5-(phenyisulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]butanamide; butyl methyl[2-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cNbamNe; tert-bntyl 4-[({methyl[2-({[5-(phenylsulfonyl)-2- (trifluororaethyl)phenyl]sulfonyl}amino)elliyl]amino}cNbonyl)amino]piperidine-l--cNboxylNe; 2,2-dimethylpropyl methyl[2-( {[5-(phenylsulfonyl)-2- (trifluoromethyl)phen.yl]sulfonyl}aniino)ethyl]cNbamNe; isobutyl methyl [2-( {[5-(phenylsulfonyl)~2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cNbamNe; 3-(trifluorometh.yl)phenyl methyl[2-({ [5-(phenylsulfonyl)-2- (txifluoromethyl)phenyl]sulfonyl}amino)ethyl]cNbamNe; 4-fluorophenyl methyl[2-( {[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}aniino)ethyl]cNbamNe; 4-bromophenyl meti«yi[2-({[5-(phenyIsulfonyl)-2- (ti'ifluorornethyi)phenyl]siilfoiiyl};uriino)ethyl]cai'bamNe; N-(2-{methyl[(piperidin-4-ylamuio)cNbonyl]amiQo}ethyl)-5-(phenylsiilfonyl)-2- (trifluoromethyl)ben2enesulfonamlde; ethyl N-( {methyl[2-( {[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}cNbonyl)glycinNe; 3-({methyl[2-( {[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)ethyl]amino}sulfonyl)benzoic acid; tert-butyl 4-({methyl[2-({ [5-(phenylsulfonyl)-2- (trifluoromethy l)pheny 1] sulfonyl} amino) ethyl] amino} cNbony l)piperazine-1 -cNboxylNe; N-({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}cNbonyl)glycine; 4-{methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}-4- oxobutanoic acid; W-methyl-AH2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]piperazine-l-cNboxamide; N- {2-[(2-hydroxyethyl)(methyl)amino]ethyl} -5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; methyl N-methyl-N-[2-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]glycinNe; ethyl N-methy l-N-[2-( {[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)ethyl]- D - alaninNe; ter/-butyl (35)-3-[({methyl[2-({ [5-(phenylsulfonyl)-2- (trffluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}cNbonyl)amino]pyrrolidine-l-cNboxylNe; tert-butyl methyl[3-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)propyl]cNbamNe; N-[3-(methylamino)propyl]-5-(phenylsulfonyl)-2-(lrifluoromethyl)benzenesulfonamide; N-[2-(methyl{[(35)-pyrrolidin-3-ylamino]cNbonyl}amino)ethyl]-5-(phenylsulfbnyl)-2- (trifluoromethyl)benzenesulfonamide; tert-butyl 4-[({methyl[3-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)propyl]amino}cNbonyl)amino]piperidine-l- cNboxylNe; rerf-butylN-methyl-A'-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-(3-alaninNe; ?eH-butylN-methyl-N'-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]glycinNe; N-(3-{methyl[(piperidin-4-ylamino)cNbonyl]amino}propyl)-5-(phenyIsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; tert-butyl 4-( {methyl[3-({ [5-(phenylsulfonyl)-2- (trifluoromethy l)pheny 1] sulfonyl} amino)propy 1] amino} cNbony l)piperazine-1 -cNboxy lNe; N-methyl-N-[3-( {[5 -(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)propyl]piperazine-1 -cNboxamide; 4-{4-[({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)ethyl]amino} cNbonyl)amino]piperidin-1 -yl} -4- oxobutanoic acid; N"-methyl-H-[2-({[5-(phenylsulfonyl)-2-(1xifluoroniethyl)phenyl]sulfonyl}amino)ethyl]glycine; N-methyl-N'-[2-({[5-(phenylsulfonyl)-2-(trifluorome1hyl)phenyl]sulfonyl}amino)ethyl]-p- alanine; 4-(bromomethyl)-H-methyl-N-[2-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide; tert-butyl [3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)propyl]cNbamNe; tert-butyl 4-[methyl({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}cNbonyl)amino]piperidine-l-cNboxylNe; tert-butyl (3JO-3-[({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]stdfonyl}amino)ethyl]amino}cNbonyl)amino]pyrroUdine-l-cNboxylNH 4-{metiiyl[3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}Naino)propyl]amino}-4- oxobutanoic acid; N-(3-aminopropyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; dimethyl [4-({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}cNbonyl)benzyl]phosphonNe; A'"-[2-(methyl{[methyl(piperidin-4-yl)amino]cNbonyl}amino)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-[2-(methyl{[(3J?)-pyrrolidin-3-ylamino]cNbonyl}amino)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; ter/-butyl(3/?)-3-[({methyl[2-({[5-(phenylsulfonyl)-2- (trifluorpmethyl)pheny 1] sulfonyl} amino)ethyl] amino} cNbony l)amino]piperidine-1 -cNboxy lNe; tert-bntyl (35)-3-[({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}cNbonyl)amino]piperidine-l-cNboxy lNe; N-[2-(methyl{[(3H)-piperidin-3-ylamino]cNbonyl}amino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-[2-(methyl{[(35)-piperidin-3-ylamino]cNbonyl}amino)ethyl]-5-(phenylsulfonyl)-2- • (trifluoromethyl)benzenesulfonamide; [4-({methyl[2-({[5-(phenylsulfonyl)-2- (txifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}cNbonyl)benzyl]phosphonicacid; ter/-butyl 4-[methyl( {[2-( {[5-(phenylsulfonyl)-2- (tiifluoromethyl)phenyl]sulfonyl} amino)ethyl]amino} cNbonyl)amino]piperidine-1 -cNboxylNe; or tert-butyl 4-[({ [2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}cNbonyl)amino]piperidine-l-cNboxylNe. 48. The compound of claim 1 which is N-(2,3-dihydrcnlH-inden-2-yl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonainide; N-(2-hydroxy-2,3-dihydro-1 H-inden-1 -yl)-5-(phenylsulfony l)-2- (trifluoromethy l)benzenesulfonamide; N-( 1 •-hydroxy-2,3-dihydro-1 H-inden-2-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-(5-methoxy-2,3-dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; N-(5-hydroxy-2,3-dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; methyl {[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)-2,3-dihydro-lH- inden-5-yl]oxy) acetNe; {[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)-2,3-dihydro-lH-inden-5- yljoxy} acetic acid; methyl 2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulforiyl}ammo)indane-5-cNboxylNe; N-(l-hydroxy-6-methoxy-2,3-dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 2- {[2-({ [5 -(phenylsulfonyl)-2-(trifluoromethy l)pheny l]sulfonyl} amino)-2,3 -dihydro-1 H-inden- yljoxy} acetic acid; methyl 2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulforiyl}ammo)indane-5-cNboxylNe; N-(l-hydroxy-6-methoxy-2,3-dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 2- {[2-({ [5 -(phenylsulfonyl)-2-(trifluoromethy l)pheny l]sulfonyl} amino)-2,3 -dihydro-1 H-inden- 5-yl]oxy} acetamide; alkoxy, perfluoroalkoxy, Nylalkoxy, alkylcNbonyl, NylcNbonyl, halogen, cyano, azido, hydroxyl, cNboxy, alkoxycNbonyl, alkylamino, dialkylamino, alkylaminocNbonyl, dialkylaminocNbonyl, alkylcNbonylamino, allcylcNbonylalkylamino, hydroxyalkylamino, nitro, alkylcNbonyloxime, alkylsulfonyl, alkylsulfmyl, alkylthio, perfluoroalkylthio, Nylthio, tertiNy alkylcNbinol, tertiNy allcylcycloalkylcNbinol, or tertiNy NylalkylcNbinol; Rg is hydrogen, alkyl, Nyl, Nylalkyl, cycloalkylalkyl, heterocycloalkyl, or spirocycloalkyl; X is oxygen or an electron pair; RT is hydrogen, alkyl, alkoxy, cycloalkyl, perfluoroalkyl, perfluoroallcylallcyl, perfluoroalkoxy, dialkylamino, or halogen; R4 is hydrogen, halogen, alkyl, cycloalkyl, alkoxy, perfluoroalkyl, or perfluoroalkoxy; or R2 and R4, together with the cNbon Noms to which they Ne Ntached, form a cycloalkyl ring of 5 to 7 cNbon Noms thN is optionally substituted with 1 to 3 R groups; each R is, independently, hydrogen, alkyl, Nylalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, spirocycloalkyl, Nyl, Nylalkyl, or alkoxyalkyl; Rs, and R6 Ne, independently, hydrogen, alkyl, Nyl, alkoxy, halogen, or perfluoroalkyl; RS and R; Ne each, independently, hydrogen or an optionally substituted alkyl, cycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, heteroNylalkyl, alkylNyl, alkylheteroNyl, alkenyl, alkynyl, fused cycloalkylNyl, fused heterocycloalkylNyl, cycloalkylcNbonyl, or heterocycloalkylcNbonyl group; or Ra and R?, together with the nitrogen Nom to which they Ne Ntached, form a five or six membered heterocycloalkyl ring optionally substituted with 1 to 5 substituents selected from alkyl, Nyl, heterocycloalkyl, heterocycloalkylalkyl, alkylamino, dialkylamino, alkoxycNbonyl, alkylcNbonyl, alkylaminocNbonylalkyl, and heterocycloalkylcNbonylalkyl. 51. The method of claim 50 wherein the pNient suffers from osteoporosis or Nthritis. 52. Use of a compound having Formula (1) (Formula Removed) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4,R5 , R6, R7,and X are as defined in claim 50, in the preparation of a medicament for treating a. patient suffering from osteoporosis, arthritis, chronic obstructive pulmonary disease, cartilage defects:, bone fractures, or leiomyoma. 53. The Invention substanually such as herein before described.